Inogen
Annual Report 2014

Download report
Get a demo

More annual reports from Inogen:

2023 Report
2022 Report
2021 Report
2020 Report
2019 Report

Peers and competitors of Inogen:

Integra LifeSciences
Luminex Corporation
DENTSPLY SIRONA
Hill-Rom Holdings, Inc.
NeuroMetrix Inc.

Plain-text annual report

Inogen, Inc. FISCAL 2014 ANNUAL REPORT [PAGE INTENTIONALLY LEFT BLANK] Dear Stockholders: 2014 was an outstanding year for Inogen, Inc. marked by exceptional growth and operational execution across all areas (cid:101)(cid:92)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:36)(cid:3)(cid:3)(cid:63)(cid:100)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:211)(cid:104)(cid:105)(cid:106)(cid:3)(cid:111)(cid:91)(cid:87)(cid:104)(cid:3)(cid:87)(cid:105)(cid:3)(cid:87)(cid:3)(cid:102)(cid:107)(cid:88)(cid:98)(cid:95)(cid:89)(cid:98)(cid:111)(cid:3)(cid:106)(cid:104)(cid:87)(cid:90)(cid:91)(cid:90)(cid:3)(cid:89)(cid:101)(cid:99)(cid:102)(cid:87)(cid:100)(cid:111)(cid:34)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:90)(cid:95)(cid:92)(cid:92)(cid:91)(cid:104)(cid:91)(cid:100)(cid:106)(cid:95)(cid:87)(cid:106)(cid:91)(cid:90)(cid:3)(cid:99)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106)(cid:3)(cid:105)(cid:106)(cid:104)(cid:87)(cid:106)(cid:91)(cid:93)(cid:111)(cid:34)(cid:3)(cid:95)(cid:100)(cid:100)(cid:101)(cid:108)(cid:87)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:102)(cid:104)(cid:101)(cid:90)(cid:107)(cid:89)(cid:106)(cid:3) portfolio and pipeline, and increased capital base resulted in strong performance that enabled our team to execute on our mission – to increase freedom and independence for oxygen therapy patients. Highlights from 2014: • Successful initial public offering in February and secondary follow-on offering in October. • (cid:74)(cid:101)(cid:106)(cid:87)(cid:98)(cid:3)(cid:104)(cid:91)(cid:108)(cid:91)(cid:100)(cid:107)(cid:91)(cid:105)(cid:3)(cid:101)(cid:92)(cid:3)(cid:26)(cid:39)(cid:39)(cid:40)(cid:36)(cid:43)(cid:3)(cid:99)(cid:95)(cid:98)(cid:98)(cid:95)(cid:101)(cid:100)(cid:3)(cid:197)(cid:3)(cid:100)(cid:91)(cid:87)(cid:104)(cid:98)(cid:111)(cid:3)(cid:43)(cid:38)%(cid:3)(cid:111)(cid:91)(cid:87)(cid:104)(cid:35)(cid:101)(cid:108)(cid:91)(cid:104)(cid:35)(cid:111)(cid:91)(cid:87)(cid:104)(cid:3)(cid:93)(cid:104)(cid:101)(cid:109)(cid:106)(cid:94)(cid:36) • (cid:60)(cid:58)(cid:55)(cid:3)(cid:89)(cid:98)(cid:91)(cid:87)(cid:104)(cid:87)(cid:100)(cid:89)(cid:91)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:104)(cid:91)(cid:98)(cid:91)(cid:87)(cid:105)(cid:91)(cid:3)(cid:106)(cid:101)(cid:3)(cid:99)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106)(cid:3)(cid:101)(cid:92)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:63)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:3)(cid:55)(cid:106)(cid:3)(cid:62)(cid:101)(cid:99)(cid:91)(cid:34)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:98)(cid:95)(cid:93)(cid:94)(cid:106)(cid:91)(cid:105)(cid:106)(cid:3)(cid:211)(cid:108)(cid:91)(cid:3)(cid:98)(cid:95)(cid:106)(cid:91)(cid:104)(cid:3)(cid:102)(cid:91)(cid:104)(cid:3)(cid:99)(cid:95)(cid:100)(cid:107)(cid:106)(cid:91)(cid:3)(cid:89)(cid:101)(cid:100)(cid:106)(cid:95)(cid:100)(cid:107)(cid:101)(cid:107)(cid:105)(cid:3)(cid:212)(cid:101)(cid:109)(cid:3)(cid:3)(cid:101)(cid:110)(cid:111)(cid:93)(cid:91)(cid:100)(cid:3) concentrator on the market today. • (cid:70)(cid:101)(cid:105)(cid:95)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:104)(cid:91)(cid:95)(cid:99)(cid:88)(cid:107)(cid:104)(cid:105)(cid:91)(cid:99)(cid:91)(cid:100)(cid:106)(cid:3)(cid:89)(cid:101)(cid:108)(cid:91)(cid:104)(cid:87)(cid:93)(cid:91)(cid:3)(cid:90)(cid:91)(cid:89)(cid:95)(cid:105)(cid:95)(cid:101)(cid:100)(cid:3)(cid:92)(cid:101)(cid:104)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:63)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:3)(cid:69)(cid:100)(cid:91)(cid:3)(cid:61)(cid:41)(cid:3)(cid:95)(cid:100)(cid:3)(cid:106)(cid:109)(cid:101)(cid:3)(cid:99)(cid:87)(cid:96)(cid:101)(cid:104)(cid:3)(cid:59)(cid:107)(cid:104)(cid:101)(cid:102)(cid:91)(cid:87)(cid:100)(cid:3)(cid:99)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106)(cid:105)(cid:48)(cid:3)(cid:60)(cid:104)(cid:87)(cid:100)(cid:89)(cid:91)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:61)(cid:91)(cid:104)(cid:99)(cid:87)- ny. We currently sell our products in 44 countries outside of the United States. • (cid:59)(cid:110)(cid:102)(cid:87)(cid:100)(cid:105)(cid:95)(cid:101)(cid:100)(cid:3)(cid:101)(cid:92)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:90)(cid:95)(cid:104)(cid:91)(cid:89)(cid:106)(cid:35)(cid:106)(cid:101)(cid:35)(cid:89)(cid:101)(cid:100)(cid:105)(cid:107)(cid:99)(cid:91)(cid:104)(cid:3)(cid:95)(cid:100)(cid:105)(cid:95)(cid:90)(cid:91)(cid:3)(cid:105)(cid:87)(cid:98)(cid:91)(cid:105)(cid:3)(cid:104)(cid:91)(cid:102)(cid:104)(cid:91)(cid:105)(cid:91)(cid:100)(cid:106)(cid:87)(cid:106)(cid:95)(cid:108)(cid:91)(cid:105)(cid:3)(cid:92)(cid:104)(cid:101)(cid:99)(cid:3)(cid:39)(cid:38)(cid:46)(cid:3)(cid:87)(cid:106)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:91)(cid:100)(cid:90)(cid:3)(cid:101)(cid:92)(cid:3)(cid:40)(cid:38)(cid:39)(cid:41)(cid:3)(cid:106)(cid:101)(cid:3)(cid:39)(cid:40)(cid:47)(cid:3)(cid:87)(cid:106)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:91)(cid:100)(cid:90)(cid:3)(cid:101)(cid:92)(cid:3) 2014. (cid:60)(cid:104)(cid:101)(cid:99)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:88)(cid:91)(cid:93)(cid:95)(cid:100)(cid:100)(cid:95)(cid:100)(cid:93)(cid:34)(cid:3)(cid:95)(cid:99)(cid:102)(cid:104)(cid:101)(cid:108)(cid:95)(cid:100)(cid:93)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:98)(cid:95)(cid:108)(cid:91)(cid:105)(cid:3)(cid:101)(cid:92)(cid:3)(cid:101)(cid:110)(cid:111)(cid:93)(cid:91)(cid:100)(cid:3)(cid:106)(cid:94)(cid:91)(cid:104)(cid:87)(cid:102)(cid:111)(cid:3)(cid:102)(cid:87)(cid:106)(cid:95)(cid:91)(cid:100)(cid:106)(cid:105)(cid:3)(cid:94)(cid:87)(cid:105)(cid:3)(cid:88)(cid:91)(cid:91)(cid:100)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:89)(cid:101)(cid:104)(cid:91)(cid:3)(cid:102)(cid:107)(cid:104)(cid:102)(cid:101)(cid:105)(cid:91)(cid:36)(cid:3)(cid:63)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:34)(cid:3)(cid:63)(cid:100)(cid:89)(cid:36)(cid:3)(cid:109)(cid:87)(cid:105)(cid:3)(cid:92)(cid:101)(cid:107)(cid:100)(cid:90)(cid:91)(cid:90)(cid:3) (cid:106)(cid:94)(cid:104)(cid:101)(cid:107)(cid:93)(cid:94)(cid:3)(cid:87)(cid:3)(cid:102)(cid:91)(cid:104)(cid:105)(cid:101)(cid:100)(cid:87)(cid:98)(cid:3)(cid:89)(cid:101)(cid:100)(cid:100)(cid:91)(cid:89)(cid:106)(cid:95)(cid:101)(cid:100)(cid:3)(cid:106)(cid:101)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:98)(cid:95)(cid:99)(cid:95)(cid:106)(cid:87)(cid:106)(cid:95)(cid:101)(cid:100)(cid:105)(cid:3)(cid:101)(cid:92)(cid:3)(cid:106)(cid:104)(cid:87)(cid:90)(cid:95)(cid:106)(cid:95)(cid:101)(cid:100)(cid:87)(cid:98)(cid:3)(cid:101)(cid:110)(cid:111)(cid:93)(cid:91)(cid:100)(cid:3)(cid:106)(cid:94)(cid:91)(cid:104)(cid:87)(cid:102)(cid:111)(cid:49)(cid:3)(cid:95)(cid:99)(cid:102)(cid:104)(cid:101)(cid:108)(cid:95)(cid:100)(cid:93)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:98)(cid:95)(cid:108)(cid:91)(cid:105)(cid:3)(cid:101)(cid:92)(cid:3)(cid:106)(cid:94)(cid:91)(cid:105)(cid:91)(cid:3)(cid:102)(cid:87)(cid:106)(cid:95)(cid:91)(cid:100)(cid:106)(cid:105)(cid:3)(cid:99)(cid:101)- (cid:106)(cid:95)(cid:108)(cid:87)(cid:106)(cid:91)(cid:105)(cid:3)(cid:107)(cid:105)(cid:3)(cid:91)(cid:108)(cid:91)(cid:104)(cid:111)(cid:3)(cid:90)(cid:87)(cid:111)(cid:36)(cid:3)(cid:77)(cid:91)(cid:3)(cid:87)(cid:104)(cid:91)(cid:3)(cid:104)(cid:91)(cid:93)(cid:107)(cid:98)(cid:87)(cid:104)(cid:98)(cid:111)(cid:3)(cid:95)(cid:100)(cid:105)(cid:102)(cid:95)(cid:104)(cid:91)(cid:90)(cid:3)(cid:88)(cid:111)(cid:3)(cid:102)(cid:87)(cid:106)(cid:95)(cid:91)(cid:100)(cid:106)(cid:3)(cid:92)(cid:91)(cid:91)(cid:90)(cid:88)(cid:87)(cid:89)(cid:97)(cid:3)(cid:105)(cid:107)(cid:89)(cid:94)(cid:3)(cid:87)(cid:105)(cid:34)(cid:3)(cid:199)(cid:67)(cid:111)(cid:3)(cid:104)(cid:91)(cid:89)(cid:91)(cid:100)(cid:106)(cid:3)(cid:90)(cid:95)(cid:87)(cid:93)(cid:100)(cid:101)(cid:105)(cid:95)(cid:105)(cid:3)(cid:104)(cid:91)(cid:103)(cid:107)(cid:95)(cid:104)(cid:95)(cid:100)(cid:93)(cid:3)(cid:101)(cid:110)(cid:111)(cid:93)(cid:91)(cid:100)(cid:3)(cid:89)(cid:101)(cid:107)(cid:98)(cid:90)(cid:3) (cid:94)(cid:87)(cid:108)(cid:91)(cid:3)(cid:88)(cid:91)(cid:91)(cid:100)(cid:3)(cid:90)(cid:91)(cid:108)(cid:87)(cid:105)(cid:106)(cid:87)(cid:106)(cid:95)(cid:100)(cid:93)(cid:3)(cid:106)(cid:101)(cid:3)(cid:99)(cid:111)(cid:3)(cid:87)(cid:89)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:98)(cid:95)(cid:92)(cid:91)(cid:105)(cid:106)(cid:111)(cid:98)(cid:91)(cid:34)(cid:3)(cid:88)(cid:107)(cid:106)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:63)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:3)(cid:69)(cid:100)(cid:91)(cid:3)(cid:94)(cid:87)(cid:105)(cid:3)(cid:87)(cid:98)(cid:98)(cid:101)(cid:109)(cid:91)(cid:90)(cid:3)(cid:99)(cid:91)(cid:3)(cid:106)(cid:101)(cid:3)(cid:89)(cid:87)(cid:104)(cid:104)(cid:111)(cid:3)(cid:101)(cid:100)(cid:190)(cid:63)(cid:3)(cid:89)(cid:101)(cid:107)(cid:98)(cid:90)(cid:100)(cid:202)(cid:106)(cid:3)(cid:88)(cid:91)(cid:3)(cid:98)(cid:95)(cid:108)(cid:95)(cid:100)(cid:93)(cid:3)(cid:106)(cid:94)(cid:95)(cid:105)(cid:3)(cid:109)(cid:87)(cid:111)(cid:3) without it!” (cid:57)(cid:101)(cid:100)(cid:105)(cid:107)(cid:99)(cid:91)(cid:104)(cid:105)(cid:3)(cid:100)(cid:101)(cid:106)(cid:3)(cid:101)(cid:100)(cid:98)(cid:111)(cid:3)(cid:88)(cid:91)(cid:100)(cid:91)(cid:211)(cid:106)(cid:3)(cid:92)(cid:104)(cid:101)(cid:99)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:95)(cid:100)(cid:90)(cid:91)(cid:102)(cid:91)(cid:100)(cid:90)(cid:91)(cid:100)(cid:89)(cid:91)(cid:3)(cid:87)(cid:100)(cid:3)(cid:63)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:34)(cid:3)(cid:63)(cid:100)(cid:89)(cid:36)(cid:3)(cid:102)(cid:104)(cid:101)(cid:90)(cid:107)(cid:89)(cid:106)(cid:3)(cid:102)(cid:104)(cid:101)(cid:108)(cid:95)(cid:90)(cid:91)(cid:105)(cid:34)(cid:3)(cid:88)(cid:107)(cid:106)(cid:3)(cid:95)(cid:106)(cid:3)(cid:87)(cid:98)(cid:105)(cid:101)(cid:3)(cid:91)(cid:100)(cid:87)(cid:88)(cid:98)(cid:91)(cid:105)(cid:3)(cid:106)(cid:94)(cid:91)(cid:99)(cid:3)(cid:106)(cid:101)(cid:3)(cid:89)(cid:101)(cid:100)- (cid:106)(cid:95)(cid:100)(cid:107)(cid:91)(cid:3)(cid:106)(cid:101)(cid:3)(cid:88)(cid:91)(cid:3)(cid:87)(cid:89)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:106)(cid:94)(cid:107)(cid:105)(cid:3)(cid:89)(cid:87)(cid:100)(cid:3)(cid:102)(cid:101)(cid:105)(cid:95)(cid:106)(cid:95)(cid:108)(cid:91)(cid:98)(cid:111)(cid:3)(cid:95)(cid:100)(cid:212)(cid:107)(cid:91)(cid:100)(cid:89)(cid:91)(cid:3)(cid:106)(cid:94)(cid:91)(cid:95)(cid:104)(cid:3)(cid:101)(cid:108)(cid:91)(cid:104)(cid:87)(cid:98)(cid:98)(cid:3)(cid:103)(cid:107)(cid:87)(cid:98)(cid:95)(cid:106)(cid:111)(cid:3)(cid:101)(cid:92)(cid:3)(cid:98)(cid:95)(cid:92)(cid:91)(cid:36)(cid:3)(cid:69)(cid:107)(cid:104)(cid:3)(cid:102)(cid:101)(cid:104)(cid:106)(cid:87)(cid:88)(cid:98)(cid:91)(cid:3)(cid:89)(cid:101)(cid:100)(cid:89)(cid:91)(cid:100)(cid:106)(cid:104)(cid:87)(cid:106)(cid:101)(cid:104)(cid:105)(cid:3)(cid:87)(cid:98)(cid:105)(cid:101)(cid:3)(cid:91)(cid:98)(cid:95)(cid:99)(cid:95)(cid:100)(cid:87)(cid:106)(cid:91)(cid:3) (cid:106)(cid:94)(cid:91)(cid:3)(cid:100)(cid:91)(cid:91)(cid:90)(cid:3)(cid:92)(cid:101)(cid:104)(cid:3)(cid:101)(cid:100)(cid:93)(cid:101)(cid:95)(cid:100)(cid:93)(cid:3)(cid:106)(cid:87)(cid:100)(cid:97)(cid:3)(cid:90)(cid:91)(cid:98)(cid:95)(cid:108)(cid:91)(cid:104)(cid:95)(cid:91)(cid:105)(cid:34)(cid:3)(cid:109)(cid:94)(cid:95)(cid:89)(cid:94)(cid:3)(cid:89)(cid:87)(cid:100)(cid:3)(cid:98)(cid:101)(cid:109)(cid:91)(cid:104)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:89)(cid:101)(cid:105)(cid:106)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:104)(cid:91)(cid:90)(cid:107)(cid:89)(cid:91)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:89)(cid:101)(cid:99)(cid:102)(cid:98)(cid:91)(cid:110)(cid:95)(cid:106)(cid:111)(cid:3)(cid:92)(cid:101)(cid:104)(cid:3)(cid:87)(cid:3)(cid:102)(cid:104)(cid:101)(cid:108)(cid:95)(cid:90)(cid:91)(cid:104)(cid:3)(cid:101)(cid:92)(cid:3)(cid:101)(cid:110)(cid:111)(cid:93)(cid:91)(cid:100)(cid:3)(cid:106)(cid:94)(cid:91)(cid:104)(cid:87)- py. (cid:63)(cid:100)(cid:3)(cid:40)(cid:38)(cid:39)(cid:42)(cid:34)(cid:3)(cid:109)(cid:91)(cid:3)(cid:87)(cid:89)(cid:94)(cid:95)(cid:91)(cid:108)(cid:91)(cid:90)(cid:3)(cid:89)(cid:101)(cid:100)(cid:105)(cid:95)(cid:90)(cid:91)(cid:104)(cid:87)(cid:88)(cid:98)(cid:91)(cid:3)(cid:104)(cid:91)(cid:108)(cid:91)(cid:100)(cid:107)(cid:91)(cid:3)(cid:93)(cid:104)(cid:101)(cid:109)(cid:106)(cid:94)(cid:3)(cid:109)(cid:101)(cid:104)(cid:98)(cid:90)(cid:109)(cid:95)(cid:90)(cid:91)(cid:34)(cid:3)(cid:104)(cid:91)(cid:212)(cid:91)(cid:89)(cid:106)(cid:95)(cid:100)(cid:93)(cid:3)(cid:102)(cid:87)(cid:106)(cid:95)(cid:91)(cid:100)(cid:106)(cid:3)(cid:87)(cid:109)(cid:87)(cid:104)(cid:91)(cid:100)(cid:91)(cid:105)(cid:105)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:90)(cid:91)(cid:99)(cid:87)(cid:100)(cid:90)(cid:3)(cid:92)(cid:101)(cid:104)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:95)(cid:100)- (cid:100)(cid:101)(cid:108)(cid:87)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:102)(cid:104)(cid:101)(cid:90)(cid:107)(cid:89)(cid:106)(cid:105)(cid:36)(cid:3)(cid:3)(cid:69)(cid:107)(cid:104)(cid:3)(cid:107)(cid:100)(cid:95)(cid:103)(cid:107)(cid:91)(cid:3)(cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:3)(cid:99)(cid:101)(cid:90)(cid:91)(cid:98)(cid:3)(cid:87)(cid:98)(cid:98)(cid:101)(cid:109)(cid:105)(cid:3)(cid:107)(cid:105)(cid:3)(cid:106)(cid:101)(cid:3)(cid:87)(cid:102)(cid:102)(cid:104)(cid:101)(cid:87)(cid:89)(cid:94)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:99)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106)(cid:3)(cid:90)(cid:95)(cid:92)(cid:92)(cid:91)(cid:104)(cid:91)(cid:100)(cid:106)(cid:98)(cid:111)(cid:3)(cid:106)(cid:94)(cid:87)(cid:100)(cid:3)(cid:87)(cid:98)(cid:98)(cid:3)(cid:101)(cid:106)(cid:94)(cid:91)(cid:104)(cid:3)(cid:90)(cid:101)(cid:99)(cid:91)(cid:105)(cid:106)(cid:95)(cid:89)(cid:3) (cid:89)(cid:101)(cid:99)(cid:102)(cid:91)(cid:106)(cid:95)(cid:106)(cid:101)(cid:104)(cid:105)(cid:3)(cid:95)(cid:100)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:102)(cid:104)(cid:101)(cid:90)(cid:107)(cid:89)(cid:106)(cid:3)(cid:89)(cid:87)(cid:106)(cid:91)(cid:93)(cid:101)(cid:104)(cid:111)(cid:3)(cid:109)(cid:95)(cid:106)(cid:94)(cid:3)(cid:109)(cid:94)(cid:87)(cid:106)(cid:3)(cid:109)(cid:91)(cid:3)(cid:88)(cid:91)(cid:98)(cid:95)(cid:91)(cid:108)(cid:91)(cid:3)(cid:106)(cid:101)(cid:3)(cid:88)(cid:91)(cid:3)(cid:105)(cid:107)(cid:88)(cid:105)(cid:106)(cid:87)(cid:100)(cid:106)(cid:95)(cid:87)(cid:98)(cid:3)(cid:88)(cid:87)(cid:104)(cid:104)(cid:95)(cid:91)(cid:104)(cid:105)(cid:3)(cid:106)(cid:101)(cid:3)(cid:91)(cid:100)(cid:106)(cid:104)(cid:111)(cid:36)(cid:3)(cid:3)(cid:77)(cid:91)(cid:3)(cid:87)(cid:98)(cid:105)(cid:101)(cid:3)(cid:88)(cid:91)(cid:98)(cid:95)(cid:91)(cid:108)(cid:91)(cid:3)(cid:109)(cid:91)(cid:3)(cid:87)(cid:104)(cid:91)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3) only oxygen concentrator manufacturer that employs a direct-to-consumer business model in the United States, which allows us to build strong patient demand and awareness. Not only has our direct-to-consumer channel grown this year, (cid:88)(cid:107)(cid:106)(cid:3)(cid:109)(cid:91)(cid:3)(cid:87)(cid:98)(cid:105)(cid:101)(cid:3)(cid:88)(cid:91)(cid:98)(cid:95)(cid:91)(cid:108)(cid:91)(cid:3)(cid:89)(cid:101)(cid:100)(cid:105)(cid:95)(cid:90)(cid:91)(cid:104)(cid:87)(cid:88)(cid:98)(cid:91)(cid:3)(cid:90)(cid:101)(cid:99)(cid:91)(cid:105)(cid:106)(cid:95)(cid:89)(cid:3)(cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:35)(cid:106)(cid:101)(cid:35)(cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:3)(cid:105)(cid:87)(cid:98)(cid:91)(cid:105)(cid:3)(cid:93)(cid:104)(cid:101)(cid:109)(cid:106)(cid:94)(cid:3)(cid:95)(cid:105)(cid:3)(cid:88)(cid:91)(cid:95)(cid:100)(cid:93)(cid:3)(cid:93)(cid:91)(cid:100)(cid:91)(cid:104)(cid:87)(cid:106)(cid:91)(cid:90)(cid:3)(cid:92)(cid:104)(cid:101)(cid:99)(cid:3)(cid:87)(cid:3)(cid:102)(cid:107)(cid:98)(cid:98)(cid:35)(cid:106)(cid:94)(cid:104)(cid:101)(cid:107)(cid:93)(cid:94)(cid:3)(cid:91)(cid:92)- (cid:92)(cid:91)(cid:89)(cid:106)(cid:3)(cid:87)(cid:105)(cid:3)(cid:89)(cid:101)(cid:100)(cid:105)(cid:107)(cid:99)(cid:91)(cid:104)(cid:105)(cid:3)(cid:88)(cid:91)(cid:89)(cid:101)(cid:99)(cid:91)(cid:3)(cid:99)(cid:101)(cid:104)(cid:91)(cid:3)(cid:87)(cid:109)(cid:87)(cid:104)(cid:91)(cid:3)(cid:101)(cid:92)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:101)(cid:110)(cid:111)(cid:93)(cid:91)(cid:100)(cid:3)(cid:106)(cid:94)(cid:91)(cid:104)(cid:87)(cid:102)(cid:111)(cid:3)(cid:102)(cid:104)(cid:101)(cid:90)(cid:107)(cid:89)(cid:106)(cid:105)(cid:36)(cid:3)(cid:3)(cid:3)(cid:69)(cid:107)(cid:104)(cid:3)(cid:95)(cid:100)(cid:106)(cid:91)(cid:104)(cid:100)(cid:87)(cid:106)(cid:95)(cid:101)(cid:100)(cid:87)(cid:98)(cid:3)(cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:3)(cid:87)(cid:98)(cid:105)(cid:101)(cid:3)(cid:88)(cid:91)(cid:100)(cid:91)(cid:211)(cid:106)(cid:91)(cid:90)(cid:3)(cid:92)(cid:104)(cid:101)(cid:99)(cid:3) (cid:106)(cid:94)(cid:91)(cid:3)(cid:102)(cid:101)(cid:105)(cid:95)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:104)(cid:91)(cid:95)(cid:99)(cid:88)(cid:107)(cid:104)(cid:105)(cid:91)(cid:99)(cid:91)(cid:100)(cid:106)(cid:3)(cid:90)(cid:91)(cid:89)(cid:95)(cid:105)(cid:95)(cid:101)(cid:100)(cid:105)(cid:3)(cid:95)(cid:100)(cid:3)(cid:106)(cid:109)(cid:101)(cid:3)(cid:99)(cid:87)(cid:96)(cid:101)(cid:104)(cid:3)(cid:59)(cid:107)(cid:104)(cid:101)(cid:102)(cid:91)(cid:87)(cid:100)(cid:3)(cid:99)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106)(cid:105)(cid:34)(cid:3)(cid:60)(cid:104)(cid:87)(cid:100)(cid:89)(cid:91)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:61)(cid:91)(cid:104)(cid:99)(cid:87)(cid:100)(cid:111)(cid:34)(cid:3)(cid:92)(cid:101)(cid:104)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:63)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:3)(cid:69)(cid:100)(cid:91)(cid:3)(cid:61)(cid:41)(cid:36) (cid:55)(cid:102)(cid:87)(cid:104)(cid:106)(cid:3)(cid:92)(cid:104)(cid:101)(cid:99)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:90)(cid:95)(cid:92)(cid:92)(cid:91)(cid:104)(cid:91)(cid:100)(cid:106)(cid:95)(cid:87)(cid:106)(cid:91)(cid:90)(cid:3)(cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:3)(cid:99)(cid:101)(cid:90)(cid:91)(cid:98)(cid:34)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:106)(cid:91)(cid:89)(cid:94)(cid:100)(cid:101)(cid:98)(cid:101)(cid:93)(cid:111)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:101)(cid:100)(cid:93)(cid:101)(cid:95)(cid:100)(cid:93)(cid:3)(cid:102)(cid:95)(cid:102)(cid:91)(cid:98)(cid:95)(cid:100)(cid:91)(cid:3)(cid:101)(cid:92)(cid:3)(cid:95)(cid:100)(cid:100)(cid:101)(cid:108)(cid:87)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:102)(cid:104)(cid:101)(cid:90)(cid:107)(cid:89)(cid:106)(cid:105)(cid:3)(cid:87)(cid:104)(cid:91)(cid:3)(cid:95)(cid:99)(cid:102)(cid:101)(cid:104)(cid:106)- ant contributors fueling patient demand. With the Inogen At Home launch in 2014 and future product releases in (cid:106)(cid:94)(cid:91)(cid:3)(cid:109)(cid:101)(cid:104)(cid:97)(cid:105)(cid:34)(cid:3)(cid:105)(cid:107)(cid:89)(cid:94)(cid:3)(cid:87)(cid:105)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:100)(cid:91)(cid:110)(cid:106)(cid:3)(cid:212)(cid:87)(cid:93)(cid:105)(cid:94)(cid:95)(cid:102)(cid:3)(cid:102)(cid:104)(cid:101)(cid:90)(cid:107)(cid:89)(cid:106)(cid:34)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:63)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:3)(cid:69)(cid:100)(cid:91)(cid:3)(cid:61)(cid:42)(cid:34)(cid:3)(cid:109)(cid:91)(cid:3)(cid:88)(cid:91)(cid:98)(cid:95)(cid:91)(cid:108)(cid:91)(cid:3)(cid:109)(cid:91)(cid:3)(cid:87)(cid:104)(cid:91)(cid:3)(cid:105)(cid:106)(cid:87)(cid:111)(cid:95)(cid:100)(cid:93)(cid:3)(cid:87)(cid:106)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:92)(cid:101)(cid:104)(cid:91)(cid:92)(cid:104)(cid:101)(cid:100)(cid:106)(cid:3)(cid:101)(cid:92)(cid:3)(cid:102)(cid:87)(cid:106)(cid:95)(cid:91)(cid:100)(cid:106)(cid:3) (cid:90)(cid:91)(cid:99)(cid:87)(cid:100)(cid:90)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:102)(cid:104)(cid:91)(cid:92)(cid:91)(cid:104)(cid:91)(cid:100)(cid:89)(cid:91)(cid:3)(cid:109)(cid:94)(cid:95)(cid:98)(cid:91)(cid:3)(cid:95)(cid:100)(cid:89)(cid:104)(cid:91)(cid:87)(cid:105)(cid:95)(cid:100)(cid:93)(cid:3)(cid:87)(cid:89)(cid:89)(cid:91)(cid:105)(cid:105)(cid:3)(cid:106)(cid:101)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:102)(cid:104)(cid:101)(cid:90)(cid:107)(cid:89)(cid:106)(cid:105)(cid:3)(cid:106)(cid:101)(cid:3)(cid:90)(cid:104)(cid:95)(cid:108)(cid:91)(cid:3)(cid:92)(cid:107)(cid:106)(cid:107)(cid:104)(cid:91)(cid:3)(cid:93)(cid:104)(cid:101)(cid:109)(cid:106)(cid:94)(cid:36)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3)(cid:3) (cid:69)(cid:107)(cid:104)(cid:3)(cid:105)(cid:107)(cid:89)(cid:89)(cid:91)(cid:105)(cid:105)(cid:92)(cid:107)(cid:98)(cid:3)(cid:63)(cid:70)(cid:69)(cid:3)(cid:95)(cid:100)(cid:3)(cid:40)(cid:38)(cid:39)(cid:42)(cid:3)(cid:102)(cid:104)(cid:101)(cid:108)(cid:95)(cid:90)(cid:91)(cid:90)(cid:3)(cid:107)(cid:105)(cid:3)(cid:109)(cid:95)(cid:106)(cid:94)(cid:3)(cid:87)(cid:3)(cid:105)(cid:101)(cid:98)(cid:95)(cid:90)(cid:3)(cid:211)(cid:100)(cid:87)(cid:100)(cid:89)(cid:95)(cid:87)(cid:98)(cid:3)(cid:88)(cid:87)(cid:105)(cid:91)(cid:3)(cid:106)(cid:101)(cid:3)(cid:91)(cid:110)(cid:91)(cid:89)(cid:107)(cid:106)(cid:91)(cid:3)(cid:101)(cid:100)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:93)(cid:104)(cid:101)(cid:109)(cid:106)(cid:94)(cid:3)(cid:102)(cid:98)(cid:87)(cid:100)(cid:105)(cid:36)(cid:3)(cid:3)(cid:77)(cid:91)(cid:3)(cid:104)(cid:91)(cid:95)(cid:100)(cid:108)(cid:91)(cid:105)(cid:106)(cid:91)(cid:90)(cid:3)(cid:100)(cid:91)(cid:106)(cid:3) (cid:102)(cid:104)(cid:101)(cid:211)(cid:106)(cid:105)(cid:3)(cid:88)(cid:87)(cid:89)(cid:97)(cid:3)(cid:95)(cid:100)(cid:106)(cid:101)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:94)(cid:87)(cid:108)(cid:91)(cid:3)(cid:99)(cid:107)(cid:98)(cid:106)(cid:95)(cid:102)(cid:98)(cid:91)(cid:3)(cid:87)(cid:108)(cid:91)(cid:100)(cid:107)(cid:91)(cid:105)(cid:3)(cid:106)(cid:101)(cid:3)(cid:90)(cid:104)(cid:95)(cid:108)(cid:91)(cid:3)(cid:92)(cid:107)(cid:106)(cid:107)(cid:104)(cid:91)(cid:3)(cid:93)(cid:104)(cid:101)(cid:109)(cid:106)(cid:94)(cid:34)(cid:3)(cid:95)(cid:100)(cid:89)(cid:98)(cid:107)(cid:90)(cid:95)(cid:100)(cid:93)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:89)(cid:101)(cid:100)(cid:106)(cid:95)(cid:100)(cid:107)(cid:91)(cid:90)(cid:3)(cid:91)(cid:110)(cid:102)(cid:87)(cid:100)(cid:105)(cid:95)(cid:101)(cid:100)(cid:3)(cid:101)(cid:92)(cid:3) our direct-to-consumer and physician referral networks; increasing adoption across our domestic and international busi- (cid:100)(cid:91)(cid:105)(cid:105)(cid:35)(cid:106)(cid:101)(cid:35)(cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:3)(cid:89)(cid:94)(cid:87)(cid:100)(cid:100)(cid:91)(cid:98)(cid:105)(cid:49)(cid:3)(cid:87)(cid:90)(cid:90)(cid:95)(cid:106)(cid:95)(cid:101)(cid:100)(cid:87)(cid:98)(cid:3)(cid:102)(cid:104)(cid:95)(cid:108)(cid:87)(cid:106)(cid:91)(cid:3)(cid:102)(cid:87)(cid:111)(cid:101)(cid:104)(cid:3)(cid:89)(cid:101)(cid:100)(cid:106)(cid:104)(cid:87)(cid:89)(cid:106)(cid:105)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:102)(cid:104)(cid:101)(cid:90)(cid:107)(cid:89)(cid:106)(cid:3)(cid:90)(cid:91)(cid:108)(cid:91)(cid:98)(cid:101)(cid:102)(cid:99)(cid:91)(cid:100)(cid:106)(cid:36)(cid:3)(cid:3)(cid:3)(cid:77)(cid:95)(cid:106)(cid:94)(cid:3)(cid:102)(cid:101)(cid:104)(cid:106)(cid:87)(cid:88)(cid:98)(cid:91)(cid:3)(cid:101)(cid:110)(cid:111)(cid:93)(cid:91)(cid:100)(cid:3)(cid:89)(cid:101)(cid:100)(cid:89)(cid:91)(cid:100)- (cid:106)(cid:104)(cid:87)(cid:106)(cid:101)(cid:104)(cid:105)(cid:3)(cid:93)(cid:104)(cid:101)(cid:109)(cid:95)(cid:100)(cid:93)(cid:3)(cid:95)(cid:100)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:99)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106)(cid:102)(cid:98)(cid:87)(cid:89)(cid:91)(cid:34)(cid:3)(cid:88)(cid:107)(cid:106)(cid:3)(cid:105)(cid:106)(cid:95)(cid:98)(cid:98)(cid:3)(cid:101)(cid:100)(cid:98)(cid:111)(cid:3)(cid:104)(cid:91)(cid:102)(cid:104)(cid:91)(cid:105)(cid:91)(cid:100)(cid:106)(cid:95)(cid:100)(cid:93)(cid:3)(cid:87)(cid:102)(cid:102)(cid:104)(cid:101)(cid:110)(cid:95)(cid:99)(cid:87)(cid:106)(cid:91)(cid:98)(cid:111)(cid:3)(cid:43)(cid:35)(cid:45)%(cid:3)(cid:101)(cid:92)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:67)(cid:91)(cid:90)(cid:95)(cid:89)(cid:87)(cid:104)(cid:91)(cid:3)(cid:99)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106)(cid:3)(cid:88)(cid:87)(cid:105)(cid:91)(cid:90)(cid:3)(cid:101)(cid:100)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3) (cid:98)(cid:87)(cid:105)(cid:106)(cid:3)(cid:87)(cid:108)(cid:87)(cid:95)(cid:98)(cid:87)(cid:88)(cid:98)(cid:91)(cid:3)(cid:90)(cid:87)(cid:106)(cid:87)(cid:34)(cid:3)(cid:109)(cid:91)(cid:3)(cid:88)(cid:91)(cid:98)(cid:95)(cid:91)(cid:108)(cid:91)(cid:3)(cid:106)(cid:94)(cid:91)(cid:104)(cid:91)(cid:3)(cid:95)(cid:105)(cid:3)(cid:87)(cid:3)(cid:105)(cid:107)(cid:88)(cid:105)(cid:106)(cid:87)(cid:100)(cid:106)(cid:95)(cid:87)(cid:98)(cid:3)(cid:101)(cid:102)(cid:102)(cid:101)(cid:104)(cid:106)(cid:107)(cid:100)(cid:95)(cid:106)(cid:111)(cid:3)(cid:92)(cid:101)(cid:104)(cid:3)(cid:89)(cid:101)(cid:100)(cid:106)(cid:95)(cid:100)(cid:107)(cid:91)(cid:90)(cid:3)(cid:93)(cid:104)(cid:101)(cid:109)(cid:106)(cid:94)(cid:3)(cid:95)(cid:100)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3)(cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:3)(cid:92)(cid:107)(cid:91)(cid:98)(cid:91)(cid:90)(cid:3)(cid:88)(cid:111)(cid:3)(cid:102)(cid:101)(cid:104)(cid:106)(cid:87)(cid:88)(cid:98)(cid:91)(cid:3) concentrators claiming a larger portion of a growing market. I would like to personally thank you for your continued support of our company and our mission. Sincerely, Raymond Huggenberger (cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:57)(cid:94)(cid:95)(cid:91)(cid:92)(cid:3)(cid:59)(cid:110)(cid:91)(cid:89)(cid:107)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:69)(cid:92)(cid:211)(cid:89)(cid:91)(cid:104) [PAGE INTENTIONALLY LEFT BLANK] UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (cid:95) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2014 OR (cid:133) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From to Commission file number: 001-36309 INOGEN, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation or organization) 326 Bollay Drive Goleta, California (Address of principal executive offices) 33-0989359 (I.R.S. Employer Identification No.) 93117 (Zip Code)) (805) 562-0500 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Common Stock, $0.001 par value Name of each exchange on which registered The NASDAQ Global Select Market Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes (cid:133) No (cid:95) Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes (cid:133) No (cid:95) Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes (cid:95) No (cid:133) Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes (cid:95) No (cid:133) Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of the Registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. (cid:133) Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Large accelerated filer Non-accelerated filer (cid:133) Accelerated filer (cid:95) (Do not check if a smaller reporting company) Smaller reporting company (cid:133) (cid:133) Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes (cid:133) No (cid:95) The aggregate market value of the voting and non-voting stock held by non-affiliates of the Registrant, based on the closing sale price of the Registrant’s common stock on the last business day of its most recently completed second fiscal quarter, as reported on The NASDAQ Global Select Market, was approximately $135,071,367. Shares of common stock held by each executive officer and director and by each person who owns 5% or more of the outstanding common stock, based on filings with the Securities and Exchange Commission, have been excluded from this computation since such persons may be deemed affiliates of the Registrant. The determination of affiliate status for this purpose is not necessarily a conclusive determination for other purposes. As of April 15, 2015, the registrant had 19,282,247 shares of common stock, par value $0.001, outstanding. DOCUMENTS INCORPORATED BY REFERENCE TABLE OF CONTENTS Part I Page Item 1. Business ............................................................................................................................................................................ Item 1A. Risk Factors ...................................................................................................................................................................... Item 1B. Unresolved Staff Comments ............................................................................................................................................. Properties .......................................................................................................................................................................... Item 2. Legal Proceedings ............................................................................................................................................................ Item 3. Mine Safety Disclosures ................................................................................................................................................... Item 4. Part II Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities ....... Item 5. Selected Financial Data .................................................................................................................................................... Item 6. Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations ........................................... Item 7A. Quantitative and Qualitative Disclosures About Market Risk .......................................................................................... Financial Statements and Supplementary Data ................................................................................................................ Item 8. Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure ........................................... Item 9A. Controls and Procedures ................................................................................................................................................... Item 9B. Other Information ............................................................................................................................................................. Part III Item 10. Directors, Executive Officers and Corporate Governance ............................................................................................... Item 11. Executive Compensation .................................................................................................................................................. Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters ......................... Item 13. Certain Relationships and Related Transactions, and Director Independence ................................................................. Item 14. Principal Accountant Fees and Services ........................................................................................................................... Part IV Item 15. Exhibits, Financial Statement Schedules .......................................................................................................................... 2 18 40 40 40 41 42 45 50 72 73 73 73 74 76 82 89 91 94 95 i INOGEN, INC. PART I Forward-Looking Statements The following discussion and analysis should be read together with our financial statements and the notes to those statements included elsewhere in this Form 10-K. This Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or Exchange Act, that are based on our management’s beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained principally in the sections entitled “Business” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include, but are not limited to, statements concerning the following: (cid:120) (cid:120) (cid:120) information concerning our possible or assumed future cash flow, revenue, sources of revenue and results of operations, operating and other expenses; our assessment of the impact from Competitive Bidding and the Centers for Medicare and Medicaid services rules; our ability to develop new products, including our fourth-generation portable oxygen concentrator, improve our existing products and increase the value of our products; (cid:120) market share expectations, unit sales, business strategies, financing plans, expansion of our business, competitive position, industry environment, potential growth opportunities; (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) our expectations regarding the market size, market growth and the growth potential for our business; our ability to sustain and manage growth, including our ability to develop new products and enter new markets; our expectations regarding the average selling price and manufacturing costs of our products; the effects of seasonal trends on our results of operations; our expectations regarding our fourth-generation portable oxygen concentrator product; and the effects of competition. Forward-looking statements include statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would,” or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in Part I, Item 1A, “Risk Factors,” and elsewhere in this Annual Report on Form 10-K. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. You should read this Annual Report on Form 10-K completely and with the understanding that our actual future results may be materially different from what we expect. “Inogen,” “Inogen One,” “Inogen One G2,” “Inogen One G3,” “Oxygenation,” “Live Life in Moments, not Minutes,” “Never Run Out of Oxygen,” “Oxygen Therapy on Your Terms,” “Oxygen.Anytime.Anywhere,” “Reclaim Your Independence,” “Intelligent Delivery Technology,” “Inogen At Home,” and the Inogen design are trademarks or registered trademarks of Inogen, Inc. We have registered the trademark Inogen in Australia, Canada, China, South Korea, Mexico, and in Europe (European Community registration). We have registered the trademark Inogen One in Australia, Canada, China, South Korea, Mexico, and in Europe (European Community registration). We have registered the trademark Satellite Conserver in Canada, and China. We have registered the trademark Inogen At Home in Europe (European Community Registration). Other service marks, trademarks, and trade names referred to in this Annual Report on Form 10-K are the property of their respective owners. In this Form 10-K, “we,” “us” and “our” refer to Inogen, Inc. 1 Unless otherwise specifically indicated, all amounts herein are expressed in thousands, except for share quantity, per share data, and unit counts. The following discussion of our financial condition and results of operations should be read together with our financial statements and the accompanying notes to those statements included elsewhere in this document. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Form 10-K. ITEM 1. BUSINESS General We are a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which we call the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. Our proprietary Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or 7.0 pounds. Our Inogen One G3 and G2 have up to 4.5 and 5 hours of battery life, respectively, with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. Our Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility. Although portable oxygen concentrators represent the fastest-growing segment of the Medicare oxygen therapy market, we estimate based on 2013 Medicare data that patients using portable oxygen concentrators represent approximately 5% to 7% of the total addressable oxygen market in the United States. Based on 2013 industry data, we believe we were the leading worldwide manufacturer of portable oxygen concentrators, as well as the largest provider of portable oxygen concentrators to Medicare patients, as measured by dollar volume. We believe we are the only manufacturer of portable oxygen concentrators that employs a direct-to- consumer strategy in the United States, meaning we market our products to patients, process their physician paperwork, provide clinical support as needed and bill Medicare or insurance on their behalf. To pursue a direct-to-consumer strategy, our manufacturing competitors would need to meet national accreditation and state-by-state licensing requirements and secure Medicare billing privileges, as well as compete with the home medical equipment providers that many rely on across their entire homecare business. Since adopting our direct-to-consumer strategy in 2009 following our acquisition of Comfort Life Medical Supply, LLC, which had an active Medicare billing number but few other assets and limited business activities, we have directly sold or rented our Inogen One systems to more than 66,000 patients, growing our revenue from $10.7 million in 2009 to $112.5 million in 2014. In 2014, 22% of our revenue came from our international markets and 35% of our revenue came from oxygen rentals. Our net loss was $2.6 million in 2009 transitioning to net income of $6.8 million in 2014. Our market Overview of oxygen therapy market We believe the current total addressable oxygen therapy market in the United States is approximately $3 billion to $4 billion, based on 2013 Medicare data and our estimate of the ratio of the Medicare market to the total market. We estimate that there are 2.5 to 3 million patients in the United States and more than 4.5 million patients worldwide use oxygen therapy, and more than 60% of oxygen therapy patients in the United States are covered by Medicare. The number of oxygen therapy patients in the United States is projected to grow by approximately 7% to 10% per year between 2013 and 2019, which we believe is the result of earlier diagnosis of chronic respiratory conditions, demographic trends and longer durations of long-term oxygen therapy. Long-term oxygen therapy has been shown to be a cost-efficient and clinically effective means to treat hypoxemia, a condition in which patients have insufficient oxygen in the blood. Hypoxemic patients are unable to convert oxygen found in the air into the bloodstream in an efficient manner, causing organ damage and poor health. Chronic obstructive pulmonary disease, or COPD, is a leading cause of hypoxemia. Approximately 70% of our patient population has been diagnosed with COPD, which we believe is reflective of the long-term oxygen therapy market in general. Industry sources estimate that 24 million people in the United States suffer from COPD, of which one-half are undiagnosed. 2 According to our analysis of 2013 Medicare data, approximately two-thirds of U.S. oxygen users require ambulatory oxygen and the remaining one-third require only stationary or nocturnal oxygen. Clinical data has shown that ambulatory patients that use oxygen twenty-four hours a day, seven days a week, or 24/7, regardless of whether such patients rely on portable oxygen concentrators or the delivery model, have approximately two times the survival rate and spend at least 60% fewer days annually in the hospital than non-ambulatory 24/7 patients. The cost of one year of oxygen therapy is less than the cost of one day in the hospital. Of the ambulatory patients, we estimate that approximately 85% rely upon the delivery model, which has the following disadvantages: (cid:120) (cid:120) (cid:120) (cid:120) limited flexibility outside the home, dictated by the finite oxygen supply provided by tanks and cylinders and dependence on delivery schedules; restricted mobility and inconvenience within the home, as patients must attach long, cumbersome tubing to a noisy stationary concentrator to move within their homes; products are not cleared for use on commercial aircraft and cannot plug into a vehicle outlet for extended use; and high costs driven by the infrastructure necessary to establish a geographically diverse distribution network to serve patients locally, as well as personnel, fuel and other costs, which have limited economies of scale and generally increase over time. Portable oxygen concentrators were developed in response to many of the limitations associated with traditional oxygen therapy. Portable oxygen concentrators are designed to offer a self-replenishing, unlimited supply of oxygen that is concentrated from the surrounding air and to operate without the need for oxygen tanks or regular oxygen deliveries, enhancing patient independence and mobility. Additionally, because portable oxygen concentrators do not require the physical infrastructure and service intensity of the delivery model, we believe portable oxygen concentrators can provide long-term oxygen therapy with a lower cost structure. Despite the ability of portable oxygen concentrators to address many of the shortcomings of traditional oxygen therapy, we estimate based on 2013 Medicare data that the amount spent by patients with portable oxygen concentrators represents approximately 5% to 7% of total oxygen therapy spend. We believe the following has hindered the market acceptance of portable oxygen concentrators: (cid:120) (cid:120) (cid:120) to obtain portable oxygen concentrators, patients are dependent on home medical equipment providers, which have made significant investments in the physical distribution infrastructure to support the delivery model and which we believe are therefore disincentivized to encourage adoption of portable oxygen concentrators; constrained manufacturing costs of conventional portable oxygen concentrators, driven by home medical equipment provider preference for products that have lower upfront equipment cost; and limitations of conventional portable oxygen concentrators, including bulkiness, poor reliability and lack of suitability beyond intermittent or travel use. Our solution Our Inogen One systems provide patients who require long-term oxygen therapy with a reliable, lightweight single solution product that we believe improves quality-of-life, fosters mobility and eliminates dependence on both oxygen tanks and cylinders as well as stationary concentrators. We believe our direct-to-consumer strategy increases our ability to effectively develop, design and market our Inogen One solutions, as it allows us to: (cid:120) (cid:120) (cid:120) drive patient awareness of our portable oxygen concentrator through direct marketing, sidestepping the home medical equipment channel that other manufacturers rely upon across their homecare businesses, and that is incentivized to continue to service oxygen patients through the delivery model; capture the manufacturer and home medical equipment provider margins, allowing us to focus on the total cost of the solution and to invest in the development of product features instead of being constrained by the price required to attract representation from a distribution channel. For example, we have invested in features that improve patient satisfaction, product durability, reliability and longevity, which increase the cost of our hardware, but reduce the total cost of our solution by reducing our maintenance and repair cost; and access and utilize direct patient feedback in our research and development efforts, allowing us to innovate based on this feedback and stay at the forefront of patient preference. For example, we have integrated a double battery into our product offering based on direct patient feedback. 3 We believe the combination of our direct-to-consumer strategy with our singular focus on designing and developing oxygen concentrator technology has created the best-in-class portfolio of portable oxygen concentrators. Our two current portable product offerings, the Inogen One G3 and Inogen One G2, at approximately 4.8 and 7.0 pounds, respectively, are amongst the most lightweight portable oxygen concentrators on the market. We believe our Inogen One solutions offer the following benefits: (cid:120) Single solution for home, ambulatory, travel (including on commercial aircraft) and nocturnal treatment. We believe our Inogen One solutions are the only portable oxygen concentrators marketed as a single solution, by which we mean a patient can use our Inogen One systems as their only supplemental oxygen source with no need to also use a stationary concentrator regularly. Our compressors are specifically designed to enable our patients to run our portable oxygen concentrators 24/7, whether powered by battery or plugged into an outlet at home or in a car while the battery is recharging. (cid:120) Reliability. We have made product performance a priority and have improved reliability with each generation. For example, we have introduced patented air-dryer and patent-pending user-replaceable sieve beds to our products, which have improved product performance and, as a result, patient satisfaction. Reliability is not only critical to patient satisfaction, but also cost management, as our minimal physical infrastructure makes product exchanges more costly to us than providers with greater local physical infrastructure. (cid:120) Effective for nocturnal use. Our Intelligent Delivery Technology enables our portable oxygen concentrators to provide consistent levels of oxygen during sleep despite decreased respiratory rates. As a result, patients can rely on the Inogen One G3 and Inogen One G2 portable oxygen concentrators overnight while sleeping. (cid:120) Unparalleled flow capacity. Our 4.8 pound Inogen One G3 has at least 50% more flow capacity than other sub-5 pound portable oxygen concentrators, and our 7.0 pound Inogen One G2 has at least 15% more flow capacity than other sub-10 pound portable oxygen concentrators. (cid:120) User friendly features. Our systems are designed with multiple user friendly features, including long battery life and low noise-levels in their respective weight categories. Our Inogen One systems and Inogen At Home system We market our current portable product offerings, the Inogen One G3 and the Inogen One G2, as single solutions for oxygen therapy. This means our solutions can operate on a 24/7 basis for at least 60 months without a stationary concentrator. We believe the technology in our Inogen One G3 and our Inogen One G2 is effective for nocturnal use. Our Inogen One G2 and the Inogen One G3 are sub-5 and sub-10 pound portable oxygen concentrators that can operate reliably and cost-effectively over the long period of time needed to service oxygen therapy patients without supplemental use of a stationary concentrator or a replacement portable oxygen concentrator. The following table summarizes our key product features: Capacity (ml/min) Weight (lbs) Battery run-time Key Product Specifications Inogen One G3 840 4.8 (single battery) 5.8 (double battery) Up to 4.5 hours (single battery) Up to 9.0 hours (double battery) Inogen One G2 1,260 7.0 (single battery) 8.4 (double battery) Up to 5 hours (single battery) Up to 10 hours (double battery) User replaceable oxygen filtration cartridges & battery Air dryer & user replaceable battery Maintenance prevention advantages Technology effective for overnight use Sound Yes 42 dBA Yes 38 dBA We have focused our research and development efforts on creating solutions that we believe have overcome the reputation of portable oxygen concentrators as being limited in durability and reliability as well as unsuitable for nighttime or 24/7 use. We specifically designed our compressors for 24/7 use. We have worked to improve our reliability and reduce service costs by equipping our portable oxygen concentrators with features such as membrane air dryers and user replaceable filtration cartridges. All of our Inogen One systems are equipped with Intelligent Delivery Technology, a form of pulse-dose technology from which the patient receives a bolus of oxygen upon inhalation. Pulse dose technology was developed to extend the number of hours an oxygen tank would last and is generally used on all ambulatory oxygen therapy devices. Our proprietary conserver technology utilizes differentiated triggering sensitivity to quickly detect a breath and ensure oxygen delivery within the first 400 milliseconds of inspiration, the interval when oxygen has the most effect on lung gas exchange. During periods of sleep, respiratory rates typically decrease. Our Inogen One systems actively respond to this changing physiology through the use of proprietary technology that increases bolus size. Our Intelligent Delivery Technology is designed to provide effective levels of blood oxygen saturation during sleep and all other periods of rest and activity that are substantially equivalent to continuous flow systems. 4 The Inogen One G3, our latest portable oxygen concentrator released to market in September 2012, is among the most lightweight products on the market with substantially higher oxygen production capabilities than the other sub-5 pound portable oxygen concentrators on the market. We believe the performance parameters around the Inogen One G3 and Inogen One G2 allow us to serve approximately 95% of the ambulatory oxygen patients and enable us to address a patient’s particular clinical needs, as well as lifestyle and performance preferences. The Inogen At Home stationary oxygen concentrator allows us to access the non-ambulatory patient market and serves as a backup to our Inogen One system for ambulatory patients. We currently provide a backup source of oxygen to our patients who are able to elect either a stationary concentrator or oxygen tank as their backup source. We believe the Inogen At Home concentrator is the lightest five liter per minute continuous flow oxygen concentrator on the market today. At approximately 18 pounds, the Inogen At Home concentrator is lighter than current oxygen concentrators from leading manufacturers with equivalent flow capacity. Additionally, the Inogen At Home product has low power consumption with worldwide electrical compatibility, which should reduce the cost of electricity for oxygen therapy patients, as well as reduces manufacturing and distribution complexities. While the Inogen One product line is clinically validated for 24/7 use, the Inogen At Home represents a compelling solution for nocturnal-only oxygen therapy patients that do not yet require a portable solution, which are estimated to represent greater than 30% of total oxygen patients in the United States. Our direct-to-consumer business model has enabled us to receive direct patient feedback, and we have used this feedback to create portable oxygen concentrators that address the full suite of features and benefits critical to patient preference and retention. Our products prevent patients from having to choose between lightweight size, suitability for 24/7 use, reliability, and key features such as battery life, flow and reduced noise levels. Sales and marketing Our direct-to-consumer sales and marketing efforts are focused on generating awareness and demand for our Inogen One systems and Inogen At Home systems among patients, physicians and other clinicians, and third-party payors. As of December 31, 2014 we employed a marketing team of 6 people, an in-house sales team of 144 people, and a field-based sales force of 17 people, each based in the United States. Of the $88.1 million of our 2014 revenue derived from the United States, approximately 45% represented direct-to-patient rentals, 33% represented cash pay sales to patients and 22% represented sales to third-party home medical equipment providers. Patients who choose to use their Medicare or private insurance benefits rent our systems, while those who purchase our product outright are typically not eligible to use their insurance benefits due to their capped rental status, or chose to purchase because the patient prefers to own the equipment, or the patient has an upcoming trip where they have an immediate need for our product that cannot by processed in time. Our ability to rent to Medicare patients directly, bill Medicare and other third-party payors on their behalf, and service patients in their homes requires that we hold a valid Medicare supplier number, are accredited by an independent agency approved by Medicare, and comply with the differing licensure and process requirements in the 49 states in which we serve patients. 5 We use a variety of direct-to-consumer marketing strategies to generate interest in our solutions among current oxygen therapy patients. After a patient contacts us, we guide them through product selection and insurance eligibility, and, if they choose to move forward, process the necessary reimbursement and physician paperwork on their behalf, as well as coordinate the shipping, instruction, and clinical setup process. In accordance with Medicare regulations, we do not initially contact patients directly and contact them only upon an inbound inquiry or upon receipt on a physician’s order. The below chart describes our United States direct-to-consumer sales and rental process. Consumer Advertising Patient Inquiry and Suitability Review Physician Paperwork Patient Set-up and Clinical Evaluation Mixture of print, TV and internet advertising Advertisements are designed to create awareness of our solutions amongst oxygen patients Review current oxygen needs against lnogen solutions Determine insurance eligibility Review insurance and cash options Obtain qualifying medical record, if necessary Coordinate clinical assessment Schedule patient visit, if necessary Obtain supporting Certificate of Medical Necessity, order, and/or prescription, if necessary Obtain patient paperwork Coordinate removal of current oxygen equipment, if necessary In addition to the direct-to-consumer marketing model, we are increasingly utilizing a physician referral model as a complementary sales method. Under this model, our field sales representatives work with physicians in the representative’s territory to help physicians understand our products and the value these products provide for patients. We believe that by educating physicians on our products, we can cost-effectively supplement our direct-to-consumer sales and rentals and capture a greater number of patients earlier in the course of their oxygen therapy. Concentration of Customers We sell our products to home medical equipment providers in the United States and in foreign countries on a credit basis. No single customer represented more than 10% of our total revenue for 2014 and 2013. In 2012 one customer accounted for 12% of our total revenue. We also rent products directly to patients, which results in a customer concentration relating to Medicare’s service reimbursement programs. Medicare’s service reimbursement programs (net of patient co-insurance obligations) accounted for 76%, 73% and 66% of rental revenue in 2014, 2013 and 2012, respectively, and based on total revenue were 27%, 29% and 27% for 2014, 2013 and 2012, respectively. Accounts receivable balances relating to Medicare’s service reimbursement programs amounted to $4,875 or 25% of total accounts receivable at December 31, 2014, $2,560 or 25% of total accounts receivable at December 31, 2013 and $3,043 or 33% of total accounts receivable at December 31, 2012. We engage in a number of other initiatives to increase awareness, demand, and orders for Inogen One systems and Inogen At Home systems. These include attendance at oxygen therapy support groups, guest speaking arrangements at trade shows, and product demonstrations as requested. Additionally, we are targeting private payors to become an in-network provider of oxygen therapy solutions, which we expect will reduce or eliminate any additional patient co-insurance associated with using our solution. We believe this will result in both increased conversion of our initial leads, as well as direct referrals from insurance companies in some cases. 6 International Approximately 22% of our sales were from outside the United States in 2014. We sell our products in 44 countries outside the United States through distributors or directly to large “house” accounts, which include gas companies and home oxygen providers. In this case, we sell to and bill the distributor or “house” accounts directly, leaving the patient billing, support, and clinical setup to the local provider. As of December 31, 2014, we had 5 people who focused on selling our products to distributors and “house” accounts worldwide. No single international customer represented more than 10% of our total revenue in 2014 or 2013. International sales have been a rapidly growing portion of our business, and we estimate there are 2 million long-term oxygen therapy patients outside of the United States. We believe that the international market is attractive for the following reasons: (cid:120) More favorable reimbursement in certain countries, including France and the United Kingdom, where portable oxygen concentrators receive more favorable reimbursement than in the United States. (cid:120) Less developed oxygen delivery infrastructure in some countries. We believe that some countries outside the United States have less developed oxygen delivery infrastructure than in the United States. As a result, portable oxygen concentrators enable providers to reach and service patients they cannot economically reach with the delivery model. (cid:120) An absence of reimbursement for any ambulatory oxygen therapy modalities in some countries, resulting in patients bearing all of the cost of ambulatory oxygen therapy and therefore becoming more involved in the selection of the modality. In Australia, for example, patients shoulder the burden of all costs associated with ambulatory oxygen therapy. In these cases, they tend to choose products like portable oxygen concentrators that provide a higher level of personal freedom. We will continue to focus on building out our international sales efforts. Customer support and order fulfillment Our procedures enable us to package and ship a system directly to the patient in the patient’s preferred configuration the same day the order is received in most cases. This enables us to minimize the amount of finished goods inventory we keep on hand. Our primary logistics partner is United Parcel Service, or UPS, and FedEx. UPS supports our domestic shipments and provides additional services that support our direct-to-consumer oxygen therapy program. The UPS pick up service is used to retrieve patient paperwork, products requiring repair and systems that are no longer needed by the patient. Additionally, UPS, when necessary and requested by us, will go into a patient’s home to remove a replacement product from the box, box the failed device and return it to us. In this manner, we are able to operate as a remote provider while maintaining the level of customer service of a local oxygen therapy provider. FedEx supports our international shipments. We believe it is important to provide patients with the highest quality customer support to achieve satisfaction with our products and optimal outcomes. As of December 31, 2014, we had a dedicated client service team of 21 people who were trained on our products, a clinical support team of 17 people who were licensed nurses or respiratory therapists, and a dedicated billing services team of 52 people. We provide our patients with a dedicated 24/7 hotline that is only given to our patients and is not published publicly. Via the hotline, patients have direct access to our client services representatives, who can handle product-related questions. Additionally, clinical staff is on call 24/7 and available to patients whenever either the patient or the client services representative deems appropriate. Our dedicated billing services team is available to answer patient questions regarding invoicing, reimbursement, and account status during normal business hours. We receive no additional reimbursement for patient support, but provide high-quality customer service to enhance patient comfort, satisfaction, compliance, and safety with our products. We believe our focus on providing the highest level of customer service has helped drive our sustained patient satisfaction rating of approximately 95%. Third-party reimbursement Medicare or private insurance rentals represented approximately 35% of our revenue in 2014. In cases where we rent our oxygen therapy solutions directly to patients, we bill third-party payors, such as Medicare or private insurance, for monthly rentals on behalf of our patients. We process and coordinate all physician paperwork necessary for reimbursement of our solutions. A common medical criterion for oxygen therapy reimbursement is insufficient blood oxygen saturation level. Our team in sales and sales administration are trained on how to verify benefits, review medical records and process physician paperwork. Additionally, an independent internal review is performed and our products are not deployed until after physician paperwork is processed and reimbursement eligibility is verified and communicated to the patient. As of December 31, 2014, our direct to consumer inside sales administration groups consisted of 144 people. 7 We are authorized by Medicare to bill for oxygen therapy, and we believe that more than 60% of oxygen therapy patients have Medicare coverage. Our Inogen One systems are reimbursed under HCPCS codes E1390 and E1392. Our Inogen At Home system is reimbursed under HCPCS code E1390. E1390 covers stationary/nocturnal oxygen therapy systems, while E1392 provides additional reimbursement for portable oxygen concentrators for the treatment of ambulatory patients. Even though E1390 is a stationary oxygen code, we bill under both the E1390 and E1392 codes for our portable oxygen concentrators, assuming that the patient qualifies for portable oxygen, as well as stationary oxygen. Only in the event the patient solely qualifies for portable oxygen would we exclusively bill under the E1392 code, which is not typical. Currently, Medicare reimburses oxygen therapy as a monthly rental for up to 36 months. We retain equipment ownership at all times. After 36 months, payment is “capped,” meaning the monthly payment amounts are discontinued. After two additional years or another qualifying event, the patient is eligible for replacement equipment and a new capped rental period. As of January 1, 2011, Medicare has phased in a program called competitive bidding. Competitive bidding impacts the amount Medicare pays suppliers for durable medical equipment, including portable oxygen concentrators. The program is defined geographically, with suppliers submitting bids to provide medical equipment for a specific product category within that geography. Once bids have been placed, an individual company’s bids across products within the category are aggregated and weighted by each product’s market share in the category. The weighted average price is then indexed against competitors. Medicare determines a “clearing price” out of these weighted average prices at which sufficient suppliers have indicated they will support patients in the category, and this threshold is typically designed to have theoretical supply two times greater than expected demand. Bids for each modality among the suppliers that made the cut are then arrayed to determine what Medicare will reimburse for each product category. The program has strict anti-collusion guidelines to ensure bidding is truly competitive. Competitive bidding contracts last up to three years once implemented, after which they are subject to re-bidding. The competitive bidding program effectively reduces the number of oxygen suppliers that can participate in the Medicare program. We believe that more than 75% of existing oxygen suppliers were eliminated in round one of competitive bidding implemented January 1, 2011 in 9 U.S. Metropolitan Statistical Areas. Round two of competitive bidding was implemented July 1, 2013 in 91 U.S. Metropolitan Statistical Areas and we believe the impact on the number of oxygen suppliers will be similar when released. Combined with the round one of competitive bidding, we believe that approximately 59% of the market was covered by round one and two. The following table sets forth the current standard Medicare reimbursement rates and the weighted average of reimbursement rates applicable in Metropolitan Statistical Areas covered by rounds one and two of competitive bidding. The round one re-compete was completed in the same Metropolitan Statistical Areas as round one for the next three year period starting January 1, 2014 when the original contracts expire. Reimbursement rates under the Medicare competitive bidding program have been in the mid $130s per month since mid-2013. Round one re-compete Medicare Round one Round two standard weighted average allowable 1/1/11- effective 12/31/13 1/1/15 weighted weighted average 1/1/14- 12/31/16 average 7/1/13- 6/30/16 116.16 $ 41.89 158.05 $ 68% 93.07 $ 42.72 135.79 $ 58 % 95.74 38.08 133.82 58% E1390 .............................................................................. $ 180.92 $ E1392 .............................................................................. 51.63 Total ................................................................................ $ 232.55 $ % of standard .................................................................. 8 In October 2014, the Centers for Medicare and Medicaid services released a ruling that sets forth methodologies to adjust the fee schedule amounts for items subject to competitive bidding in areas where competitive bidding is not implemented. The ruling applies rate reductions to all un-bid areas instead of doing an additional bidding process. The fee schedules in the un-bid areas will be adjusted based on regional averages of the single payment amounts for areas already under competitive bidding. The regional prices would be limited by a national ceiling (110% of the average of the regional prices) and a floor (90% of the average regional prices). The regions are defined as follows: States Covered Region Name Far West ......................................................... CA, NV, OR, WA Great Lakes .................................................... Mideast .......................................................... DC, DE, MD, NJ, NY, PA New England ................................................. CT, MA, NH, RI Plains ............................................................. Rocky Mountain ............................................ CO, ID, UT Southeast ........................................................ AL, AR, FL, GA, KY, LA, NC, SC, TN, VA Southwest ....................................................... AZ, NM, OK, TX IA, KS, MN, MO, NE IL, IN, MI, OH, WI The Centers for Medicare and Medicaid defines frontier states as states where more than 50% of the counties in the state have a population density of 6 people or less per square mile and rural states are defined as states where more than 50% of the population lives in rural areas per census data. Current frontier states include MT, ND, SD and WY; rural states include ME, MS, VT and WV; and non-contiguous United States areas include AK, HI, Guam and Puerto Rico. For frontier and rural states, and frontier and rural zip codes in non-frontier/rural states, the single payment amount will be the national ceiling (110% of the average of the regional prices) to account for higher servicing costs in these areas. For non-contiguous United States areas, single payment amounts will be the higher of the national ceiling, or the average of competitive bidding pricing from these areas, if the areas had been bid through competitive bidding. While we are monitoring the implementation of this ruling, we believe that the net effect of the ruling would be an approximately 3-4% headwind to 2016 total revenue since this pricing will be applied partially from January 1, 2016 to June 30, 2016 and completely starting July 1, 2016. The Centers for Medicare and Medicaid Services accepted bids through March 26, 2015 for competitive bidding round two re- compete, associated with approximately 50% of the market with contracts set to begin July 1, 2016 and continue through December 31, 2018. The Centers for Medicare and Medicaid Services updated the product categories and the competitive bidding areas. Respiratory equipment includes oxygen, oxygen equipment, continuous positive airway pressure devices, respiratory assist devices and related supplies and accessories. Nebulizers are now their own separate product category instead of being included in the respiratory equipment category. Round two re-compete is in the same geographic areas that were included in the original round two. However, as a result of the Office of Management and Budget’s updates to the original 91 round two metropolitan statistical areas, there are now 90 metropolitan statistical areas for round two re-compete and 117 competitive bidding areas (CBAs). Any CBA that was previously located in multi-state metropolitan statistical areas was redefined so that no CBA is included in more than one state. The round two re-compete competitive bidding areas have nearly the same ZIP codes as the round two competitive bidding areas; the associated changes in the zip codes since competitive bidding was implemented are reflective in this round two re-compete. On March 17, 2015 the House of Representatives approved the Medicare DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics and Supplies) Competitive Bidding Improvement Act of 2015 which would require Medicare suppliers that bid under the DMEPOS competitive bidding program to obtain a $50,000 to $100,000 bid surety bond for each competitive bidding area (CBA). The bill is intended to prevent suppliers from submitting not-binding, “low-ball” bids that artificially drive down prices and jeopardize beneficiary access to equipment. If the supplier bids lower than the median composite bid rate and does not accept a contract for a CBA, the bid bond would be forfeited. The bill also would codify that competitive bidding contracts can only be awarded to suppliers that meet applicable state licensure requirements. On April 14, 2015, this bill was passed by the Senate and then signed by President Obama into law on April 16, 2015, thus we will incur additional expense to obtain the appropriate surety bonds in the CBAs where we win contracts. There are currently 9 CBAs under contract in round 1 re-compete and 117 CBAs under contract in round 2 re- compete. CBAs are defined by Medicare and are subject to change at each new bidding period. This cost is not expected to be material to our financial results. As of December 31, 2014, we had contracts with 63 non-Medicare payors. These contracts enable us to become an in-network provider for these payors, which enables patients to use our systems at the same cost as other in-network solutions, including the delivery model. Based on our patient population, we believe non-Medicare payors represent at least 30% of all oxygen therapy 9 patients. We believe that private payor reimbursement levels will generally be reset in accordance with Medicare reimbursement level determined by competitive bidding. We cannot predict the extent to which reimbursement for our products will be affected by competitive bidding or by initiatives to reduce costs for private payors. The unavailability of third-party coverage or inadequacy of reimbursement for our current or future products would adversely affect our business, financial conditions, and results of operations. Manufacturing We have been developing and refining the manufacturing of our Inogen One systems over the past ten years. While nearly all of our manufacturing and assembly process was originally outsourced, assembly of the manifold, compressor, sieve bed and concentrator is now conducted in-house in order to improve quality control and reduce cost. Additionally, we use lean manufacturing practices to maximize our manufacturing efficiency. Bringing manufacturing and assembly largely in-house, combined with improvements in our manufacturing processes, has enabled us to reduce our cost of revenue per system by 40% from 2009 to 2014. We rely on third party manufacturers to supply several components of our Inogen One systems and Inogen At Home systems. We typically enter into supply agreements for these components that specify quantity, quality requirements, and delivery terms, which, in certain cases, can be terminated by either party upon relatively short notice. We have elected to source certain key components from single sources of supply, including our batteries, bearings, carry bags, motors, pistons, valves, and molded plastic components. While alternative sources of supply are readily available for these components, we believe that maintaining a single- source of supply allows us to control production costs and inventory levels, and to manage component quality. In order to mitigate against the risks related to a single-source of supply, we qualify alternative suppliers and develop contingency plans for responding to disruptions. If any single-source supplier were no longer able to supply a component, we believe we would be able to promptly and cost-effectively switch to an alternative supplier without a significant disruption to our business and operations. We have adopted additional contingency plans to protect against an immediate disruption in supply of our battery and motor components, and any potential delay that may result from a switch to a new supplier. These contingency plans include our own inventory management, along with a requirement that each supplier maintain specified quantities of inventory in multiple locations, and our maintenance of back-up tooling that can easily be transferred to a new supplier. We believe that these contingency plans would limit any disruption to our business in the event of an immediate termination of either our battery or motor supply. We currently manufacture in two leased buildings in Goleta, California and Richardson, Texas, that we have registered with the Federal Drug and Administration, or FDA, and for which we have obtained International Standards Organization, or ISO, 13485 certification. The Goleta, California facility is approximately 39,000 square feet. A subset is used for manufacturing activities in the Goleta facility. The Richardson, Texas manufacturing facility is approximately 24,000 square feet. Because we have two separate manufacturing facilities, in the event one facility is incapacitated, the other facility will enable us to continue manufacturing our products to meet our current level of demand. We believe we have sufficient capacity to meet anticipated demand. Our entire organization is responsible for quality management. Our Quality Assurance department oversees this by tracking component, device and organization performance and by training team members outside the Quality Assurance department to become competent users of our Quality Management system. By measuring component performance, communicating daily with the production group and our suppliers, and reviewing customer complaints, our Quality Assurance department, through the use of our corrective action program, drives and documents continuous performance improvement of our suppliers and internal departments. Our Quality Assurance department also trains internal auditors to audit our adherence to the Quality Management system. Our Quality Management system has been certified to International Standards Organization, or ISO, 13485:2012 by Intertek, a Notified Body to ISO. As a medical device manufacturer, our manufacturing facilities are subject to periodic inspection by the FDA and certain corresponding state agencies. We have been audited three times since April 2012 by the FDA and found to be in compliance with Good Manufacturing Practices guidelines. We have completed three surveillance audits and one certification audit by our notifying body over the same period and identified one minor non-conformance, which was addressed through implementation of new training software. As of December 31, 2014, we had 93 employees in operations, manufacturing, quality assurance and repair. Research and development We are committed to ongoing research and development to stay at the forefront of patient preference in the oxygen concentrator field. As of December 31, 2014, our research and development staff included 19 engineers and scientists with expertise in air 10 separation, compressors, pneumatics, electronics, embedded software, mechanical design, sensors and manufacturing technologies. Our current research and development efforts are focused primarily on increasing functionality, improving design for ease-of-use, and reducing production costs of our Inogen One systems and Inogen At Home systems, as well as development of our next-generation oxygen concentrators. Over the last 3 fiscal years, Inogen has invested over $7.7 million to efficiently bring two new generations of portable oxygen concentrators and the first generation stationary oxygen concentrator to market ($3.0, $2.4 and $2.3 million for the years ended 2014, 2013 and 2012), leveraging our 27 issued U.S. patents and one Canadian patent while also reducing the product manufacturing costs 40% from 2009 to 2014. Utilizing lean product development methodologies, we have released four products over the last 10 years, including our Inogen One G1 in October 2004, our Inogen One G2 in March 2010, and our Inogen One G3 in September 2012 and our Inogen At Home system in October 2014. Our dedication to continuous improvement has also resulted in three mid-cycle product updates and numerous incremental improvements. Development projects utilize a combination of rapid prototyping and accelerated life testing methods to ensure products are taken from concept to commercialization in a fast and capital efficient manner. We leverage our direct patient expertise to rapidly gain insight from end users and to identify areas of innovation that we believe will lead to higher-quality products and lower total cost of ownership for its products. Our product pipeline consists of our fourth generation, ultra-lightweight portable oxygen concentrator. Our fourth-generation portable oxygen concentrator will be smaller and lighter and less expensive to manufacture than our Inogen One G3 and we expect to commercialize this product in 2016. Additionally, we continue to focus our efforts on other design and functionality improvements that enhance patient quality of life. Competition The oxygen therapy market is a highly competitive industry. We compete with a number of manufacturers and distributors of portable oxygen concentrators, as well as providers of other oxygen therapy solutions such as home delivery of oxygen tanks, or cylinders. Our significant manufacturing competitors are Invacare Corporation, Respironics (a subsidiary of Koninklijke Philips N.V.), AirSep Corporation and SeQual Technologies (subsidiaries of Chart Industries, Inc.), Inova Labs, Inc. and DeVilbiss Healthcare. Given the relatively low barriers to entry in the oxygen therapy device manufacturing market, we expect that the industry will become increasingly competitive in the future. Manufacturing companies compete for sales to providers primarily on the basis of product features, service and price. We believe that we compete favorably with respect to these factors, due to our manufacturing competitors’ complete reliance on home medical equipment distribution, which compresses their margins and limits their ability to invest in product features that address consumer preferences. To pursue a direct-to-consumer strategy, our manufacturing competitors would need to meet national accreditation and state-by-state licensing requirements and secure Medicare billing privileges, as well as compete directly with the home medical equipment providers that many rely on across their entire homecare businesses. For our two largest medical device competitors, the entire oxygen business for each, including stationary and transfilling concentrators, represents less than 14% percent of each of their billion-dollar plus homecare businesses in 2013. Lincare Inc., Apria Healthcare, Inc. Rotech Healthcare, Inc. and American HomePatient, Inc. have been among the market leaders in providing oxygen therapy for many years, while the remaining oxygen therapy market is serviced by local providers. Because many oxygen therapy providers were either excluded from contracts in the Medicare competitive bidding process, or will have difficulty providing service at the prevailing Medicare reimbursement rates, we expect more industry consolidation. Oxygen therapy providers compete primarily on the basis of product features and service, rather than price, since reimbursement levels are established by Medicare and Medicaid, or by the individual determinations of private payors. We believe that the investment made by oxygen therapy providers in the physical distribution required for oxygen delivery limits their ability to easily switch their business model and employ a solution directly competitive to Inogen. Some of our competitors are large, well-capitalized companies with significantly greater resources than we have. As a consequence, they are able to spend more aggressively on product development, marketing, sales and other product initiatives than we can. Some of these competitors have: (cid:120) (cid:120) (cid:120) (cid:120) significantly greater name recognition; established relations with healthcare professionals, customers and third-party payors; established distribution networks; additional lines of products, and the ability to offer rebates or bundle products to offer higher discounts or other incentives to gain a competitive advantage; 11 (cid:120) (cid:120) greater history in conducting research and development, manufacturing, marketing and obtaining regulatory approval for oxygen device products; and greater financial and human resources for product development, sales and marketing, patent litigation and customer financing. As a result, our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standards or customer requirements. In light of these advantages that our competitors maintain, even if our technology and direct-to-consumer distribution strategy is more effective than the technology and distribution strategy of our competitors, current or potential customers might accept competitor products and services in lieu of purchasing our products. We anticipate that we will face increased competition in the future as existing companies and competitors develop new or improved products and distribution strategies and as new companies enter the market with new technologies and distribution strategies. We may not be able to compete effectively against these organizations. Our ability to compete successfully and to increase our market share is dependent upon our reputation for providing responsive, professional and high-quality products and services and achieving strong customer satisfaction. Increased competition in the future could adversely affect our revenue, revenue growth rate, if any, margins and market share. Government regulation Inogen One systems, Inogen At Home systems and related accessories are medical devices subject to extensive and ongoing regulation by the FDA, as well as other federal and state regulatory bodies in the United States and comparable authorities in other countries. The FDA regulations govern the following activities that we perform, or that are performed on our behalf, to ensure that medical products distributed domestically or exported internationally are safe and effective for their intended uses: product design and development, pre-clinical and clinical testing, manufacturing, labeling, storage, pre-market clearance or approval, record keeping, product marketing, advertising and promotion, sales and distribution, and post-marketing surveillance. FDA’s pre-market clearance and approval requirements Unless an exemption applies, each medical device we seek to commercially distribute in the United States will require either a prior Section 510(k) of the Food, Drug and Cosmetic Act, or 501(k) clearance or a pre-market approval from the FDA. Medical devices are classified into one of three classes—Class I, Class II or Class III—depending on the degree of risk associated with each medical device and the extent of control needed to ensure safety and effectiveness. Devices deemed to pose lower risks are placed in either Class I or II, which requires the manufacturer to submit to the FDA a premarket notification requesting permission to commercially distribute the device. This process is generally known as 510(k) clearance. Some low risk devices are exempted from this requirement. Devices deemed by the FDA to pose the greatest risk, such as life-sustaining, life-supporting or implantable devices, or devices deemed not substantially equivalent to a previously cleared 510(k) device, are placed in Class III, requiring premarket approval. 510(k) clearance pathway When a 510(k) clearance is required, we must submit a premarket notification to the FDA demonstrating that our proposed device is substantially equivalent to a previously cleared and legally marketed 510(k) device or a device that was in commercial distribution before May 28, 1976 for which the FDA has not yet called for the submission of a pre-market approval application. By regulation, the FDA is required to clear or deny a 510(k) premarket notification within 90 days of submission of the application. As a practical matter, clearance often takes significantly longer. The FDA may require further information, including clinical data, to make a determination regarding substantial equivalence. If the FDA determines that the device, or its intended use, is not substantially equivalent to a previously-cleared device or use, the FDA will place the device, or the particular use, into Class III. We obtained 510(k) clearance for the original Inogen One system on May 13, 2004. We market the Inogen One G2 and G3 systems pursuant to the original Inogen One 510(k) clearance. We obtained 510(k) clearance for the Inogen At Home system on June 20, 2014. Pre-market approval pathway A pre-market approval application must be submitted to the FDA if the device cannot be cleared through the 510(k) process. The pre-market approval application process is much more demanding than the 510(k) premarket notification process. A pre-market approval application must be supported by extensive data, including but not limited to technical, preclinical, clinical trials, manufacturing and labeling to demonstrate to the FDA’s satisfaction reasonable evidence of safety and effectiveness of the device. After a pre-market approval application is submitted and the FDA determines that the application is sufficiently complete to permit a substantive review, the FDA will accept the application for review. The FDA has 180 days to review an “accepted” pre- market approval application, although the review of an application generally occurs over a significantly longer period of time and can 12 take up to several years. During this review period, the FDA may request additional information or clarification of the information already provided. Also, an advisory panel of experts from outside the FDA may be convened to review and evaluate the application and provide recommendations to the FDA as to the approvability of the device. In addition, the FDA will conduct a preapproval inspection of the manufacturing facility to ensure compliance with quality system regulations. Clinical trials Clinical trials are almost always required to support pre-market approval and are sometimes required for 510(k) clearance. In the United States, these trials generally require submission of an application for an Investigational Device Exemption, or IDE, to the FDA. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing it is safe to test the device in humans and that the testing protocol is scientifically sound. The IDE must be approved in advance by the FDA for a specific number of patients unless the product is deemed a non-significant risk device eligible for more abbreviated IDE requirements. Clinical trials for significant risk devices may not begin until the IDE application is approved by the FDA and the appropriate institutional review boards, or IRBs, at the clinical trial sites. We, the FDA or the IRB at each site at which a clinical trial is being performed may suspend a clinical trial at any time for various reasons, including a belief that the risks to study subjects outweigh the benefits. Even if a trial is completed, the results of clinical testing may not demonstrate the safety and efficacy of the device, may be equivocal or may otherwise not be sufficient to obtain approval or clearance of the product. Pervasive and ongoing regulation by the FDA Even after a device receives clearance or approval and is placed on the market, numerous regulatory requirements apply. These include: (cid:120) (cid:120) (cid:120) establishment registration and device listing; quality system regulation, which requires manufacturers, including third-party manufacturers, to follow stringent design, testing, control, documentation and other quality assurance procedures during all aspects of the manufacturing process; labeling regulations and the FDA prohibitions against the promotion of products for un-cleared, unapproved or “off-label” uses, and other requirements related to promotional activities; (cid:120) medical device reporting regulations, which require that manufacturers report to the FDA if their device may have caused or contributed to a death or serious injury or malfunctioned in a way that would likely cause or contribute to a death or serious injury if the malfunction were to recur; (cid:120) (cid:120) corrections and removals reporting regulations, which require that manufacturers report to the FDA field corrections and product recalls or removals if undertaken to reduce a risk to health posed by the device or to remedy a violation of the Federal Food, Drug and Cosmetic Act that may present a risk to health; and post-market surveillance regulations, which apply when necessary to protect the public health or to provide additional safety and effectiveness data for the device. After a device receives 510(k) clearance or a pre-market approval, any modification that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, will require a new clearance or approval. The FDA requires each manufacturer to make this determination initially, but the FDA can review any such decision and can disagree with a manufacturer’s determination. We have modified various aspects of our Inogen One systems since receiving regulatory clearance, but we believe that new 510(k) clearances are not required for these modifications. If the FDA disagrees with our determination not to seek a new 510(k) clearance, the FDA may retroactively require us to seek 510(k) clearance or pre-market approval. The FDA could also require us to cease marketing and distribution and/or recall the modified device until 510(k) clearance or pre-market approval is obtained. Also, in these circumstances, we may be subject to significant regulatory fines and penalties. Failure to comply with applicable regulatory requirements can result in enforcement action by the FDA, which may include any of the following sanctions: warning letters, fines, injunctions, civil or criminal penalties, recall or seizure of our products, operating restrictions, partial suspension or total shutdown of production, refusing our request for 510(k) clearance or pre-market approval of new products, rescinding previously granted 510(k) clearances or withdrawing previously granted pre-market approvals. As a medical device manufacturer, our manufacturing facilities are subject to periodic inspection by the FDA and certain corresponding state agencies. We have been audited three times since April 2012 by the FDA and found to be in compliance with Good Manufacturing Practices guidelines. We have completed three surveillance audits and one certification audit by our notifying body over the same period and identified one minor non-conformance, which was addressed through implementation of new training software. 13 International sales of medical devices are subject to foreign government regulations, which may vary substantially from country to country. The time required to obtain approval by a foreign country may be longer or shorter than that required for FDA approval, and the requirements may differ. There is a trend towards harmonization of quality system standards among the European Union, United States, Canada and various other industrialized countries. Licensure In April 2009, we became a Durable, Medical Equipment, Prosthetics, Orthotics, and Supplies accredited Medicare supplier by Accreditation Commission for Health Care for our Goleta, California facility for Home/Durable Medical Equipment Services for oxygen equipment and supplies. Our Medicare accreditation must be renewed every three years through passage of an on-site inspection. Our current accreditation with Medicare is due to expire in May 2015. Several states require that durable medical equipment providers be licensed in order to sell products to patients in that state. Certain of these states require that durable medical equipment providers maintain an in-state location. Most of our state licenses are renewed on an annual or bi-annual basis. Although we believe we are in compliance with all applicable state regulations regarding licensure requirements, if we were found to be noncompliant, we could lose our licensure in that state, which could prohibit us from selling our current or future products to patients in that state. In addition, we are subject to certain state laws regarding professional licensure. We believe that our certified clinicians are in compliance with all such state laws. If our clinicians were to be found non-compliant in a given state, we would need to modify our approach to providing education, clinical support and customer service in such state. Federal anti-kickback and self-referral laws The Federal Anti-Kickback Statute prohibits the knowing and willful offer, payment, solicitation or receipt of any form of remuneration in return for, or to induce the: (cid:120) (cid:120) (cid:120) referral of a person; furnishing or arranging for the furnishing of items or services reimbursable under Medicare, Medicaid or other governmental programs; or purchase, lease, or order of, or the arrangement or recommendation of the purchasing, leasing, or ordering of any item or service reimbursable under Medicare, Medicaid or other governmental programs. The Federal Anti-Kickback Statute applies to our arrangements with sales representatives, customers and health care providers, as well as certain coding and billing information that we may provide to purchasers of our Inogen One and Inogen At Home systems. Although we believe that we have structured such arrangements to be in compliance with the Anti-Kickback Statute and other applicable laws, regulatory authorities may determine otherwise. Noncompliance with the federal anti-kickback statute can result in exclusion from Medicare, Medicaid or other governmental programs, restrictions on our ability to operate in certain jurisdictions, as well as civil and criminal penalties, any of which could have an adverse effect on our business and results of operations. Federal law also includes a provision commonly known as the “Stark Law,” which prohibits a physician from referring Medicare or Medicaid patients to an entity providing “designated health services,” including a company that furnishes durable medical equipment, in which the physician has an ownership or investment interest or with which the physician has entered into a compensation arrangement. Violation of the Stark Law could result in denial of payment, disgorgement of reimbursements received under a noncompliant arrangement, civil penalties, and exclusion from Medicare, Medicaid or other governmental programs. Although we believe that we have structured our provider arrangements to comply with current Stark Law requirements, these arrangements may not expressly meet the requirements for applicable exceptions from the law. Additionally, as some of these laws are still evolving, we lack definitive guidance as to the application of certain key aspects of these laws as they relate to our arrangements with providers with respect to patient training. We cannot predict the final form that these regulations will take or the effect that the final regulations will have on us. As a result, our provider arrangements may ultimately be found to be not in compliance with applicable federal law. Federal False Claims Act The Federal False Claims Act provides, in part, that the federal government may bring a lawsuit against any person whom it believes has knowingly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim approved. In addition, amendments in 1986 to the Federal False Claims Act have made it easier for private parties to bring “qui tam” whistleblower lawsuits against companies. Although we believe that we are in compliance with the federal government’s laws and regulations, if we are found in violation of these laws, penalties include fines ranging from $5,500 to $11,000 for each false claim, plus three times the amount of damages that the federal government 14 sustained because of the act. We believe that we are in compliance with the federal government’s laws and regulations concerning the filing of reimbursement claims. Civil monetary penalties law The Federal Civil Monetary Penalties Law prohibits the offering or transferring of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary’s selection of a particular supplier of Medicare or Medicaid payable items or services. We sometimes offer customers various discounts and other financial incentives in connection with the sales of our products. While it is our intent to comply with all applicable laws, the government may find that our marketing activities violate the Civil Monetary Penalties Law. If we are found to be in noncompliance, we could be subject to civil monetary penalties of up to $10,000 for each wrongful act, assessment of three times the amount claimed for each item or service and exclusion from the Federal healthcare programs. In addition, to the extent we are found to not be in compliance, we may be required to curtail or restructure our operations. Any penalties, damages, fines, exclusions, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. State fraud and abuse provisions Many states have also adopted some form of anti-kickback and anti-referral laws and false claims act that may apply to all payors. We believe that we are in compliance with such laws. Nevertheless, a determination of liability under such laws could result in fines and penalties and restrictions on our ability to operate in these jurisdictions. HIPAA In addition to creating the two new federal healthcare crimes, regulations implementing HIPAA also establish uniform standards governing the conduct of certain electronic healthcare transactions and protecting the security and privacy of individually identifiable health information maintained or transmitted by healthcare providers, health plans and healthcare clearinghouses, which are referred to as covered entities. Three standards have been promulgated under HIPAA’s regulations: the Standards for Privacy of Individually Identifiable Health Information, which restrict the use and disclosure of certain individually identifiable health information, the Standards for Electronic Transactions, which establish standards for common healthcare transactions, such as claims information, plan eligibility, payment information and the use of electronic signatures, and the Security Standards, which require covered entities to implement and maintain certain security measures to safeguard certain electronic health information, including the adoption of administrative, physical and technical safeguards to protect such information. In 2009, Congress passed the American Recovery and Reinvestment Act of 2009, or ARRA, which included sweeping changes to HIPAA, including an expansion of HIPAA’s privacy and security standards. ARRA includes HITECH, which, among other things, made HIPAA’s privacy and security standards directly applicable to business associates of covered entities effective February 17, 2010. A business associate is a person or entity that performs certain functions or activities on behalf of a covered entity that involve the use or disclosure of protected health information in connection with recognized health care operations activities. As a result, business associates are now subject to significant civil and criminal penalties for failure to comply with applicable standards. Moreover, HITECH creates a new requirement to report certain breaches of unsecured, individually identifiable health information and imposes penalties on entities that fail to do so. HITECH also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney fees and costs associated with pursuing federal civil actions. The 2013 final HITECH omnibus rule modifies the breach reporting standard in a manner that will likely make more data security incidents qualify as reportable breaches. In addition to federal regulations issued under HIPAA, some states have enacted privacy and security statutes or regulations that, in some cases, are more stringent than those issued under HIPAA. In those cases, it may be necessary to modify our planned operations and procedures to comply with the more stringent state laws. If we fail to comply with applicable state laws and regulations, we could be subject to additional sanctions. Any liability from failure to comply with the requirements of HIPAA, HITECH or state privacy and security statutes or regulations could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our results or operations. 15 International regulation International sales of medical devices are subject to foreign governmental regulations, which vary substantially from country to country. The time required to obtain clearance or approval by a foreign country may be longer or shorter than that required for FDA clearance or approval, and the requirements may be different. The primary regulatory body in Europe is the European Union, which has adopted numerous directives and has promulgated voluntary standards regulating the design, manufacture, clinical trials, labeling and adverse event reporting for medical devices. Devices that comply with the requirements of a relevant directive will be entitled to bear the CE conformity marking, indicating that the device conforms to the essential requirements of the applicable directives and, accordingly, can be commercially distributed throughout the member states of the European Union, and other countries that comply with or mirror these directives. The method of assessing conformity varies depending on the type and class of the product, but normally involves a combination of self-assessment by the manufacturer and a third-party assessment by a notified body, an independent and neutral institution appointed by a country to conduct the conformity assessment. This third-party assessment may consist of an audit of the manufacturer’s quality system and specific testing of the manufacturer’s device. Such an assessment may be required in order for a manufacturer to commercially distribute the product throughout these countries. ISO 9001 and ISO 13485 certifications are voluntary standards. Compliance establishes the presumption of conformity with the essential requirements for a CE Marking. We have the authorization to affix the CE Mark to our products and to commercialize our devices in the European Union. Our ISO 13485 certification was issued on April 21, 2005 and our EC-Certificate was issued on March 16, 2007. Before we can sell our devices in Canada we must submit a license application and obtain clearance, implement and comply with ISO Standard 13485, and undergo an audit by a registrar accredited by Health Canada. On January 25, 2006, we received our Medical Device License in Canada. In Australia, we must appoint an agent sponsor who will interact on our behalf with the Therapeutics Goods Administration (TGA). We must also prepare a technical file and declaration of conformity to essential requirements under Australian law, provide evidence of CE Marking of the device and submit this information via our agent sponsor to the TGA in a Medical Device Application. On June 4, 2007, we received our Certificate for Inclusion of a Medical Device in Australia. Intellectual property We believe that to maintain a competitive advantage, we must develop and preserve the proprietary aspect of our technologies. We rely on a combination of patent, trademark, trade secret and other intellectual property laws, non-disclosure agreements and other measures to protect our proprietary rights. Currently, we require our employees, consultants and advisors to execute non-disclosure agreements in connection with their employment, consulting or advisory relationships with us, where appropriate. We also require our employees, consultants and advisors with whom we expect to work on our current or future products to agree to disclose and assign to us all inventions conceived during the work day, developed using our property or related to our business. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our Inogen One systems or to obtain and use information that we regard as proprietary. Patents As of December 31, 2014, we had 27 issued U.S. patents, one issued Canadian patent and 5 additional pending U.S. patent applications relating to design and construction of our oxygen concentrators and our Intelligent Delivery Technology. We anticipate it will take several years for the most recent of these U.S. patent applications to result in issued patents, if successful. Our patent portfolio contains three principal sets of patents and patent applications. The first set relates to the construction and design of specific Inogen products. For example, U.S. Patent Nos. 8,440,004; 8,366,815; 8,377,181; and 8,568,519 are directed to design elements of the Inogen One G2 portable oxygen concentrator. These patents expire in 2031 (without taking into account any patent term adjustments) and may serve to deter competitors from reverse engineering or copying our design elements. This set of patents and patent applications also contains a pending U.S. patent application that relates to the design of the Inogen One G3 portable oxygen concentrator. The second set of patents and patent applications within our portfolio pertains to operating algorithms and design optimization techniques. U.S. Patent Nos. 7,841,343; 7,585,351; 7,857,894; 8,142,544; and 6,605,136 are directed toward optimization of the Pressure Swing Adsorption oxygen generating system and the oxygen conserving technology used across all of our products. These patents expire in 2027, 2026, 2027, 2026 and 2022 respectively (without taking into account any patent term adjustments). These algorithms and optimization techniques are developed to facilitate the design and manufacturing of our products. These patents may prevent competitors from achieving the same levels of optimization as found in our products. 16 The third set of patents and patent applications includes system component designs that may be incorporated into our products. For example, U.S. Patent No. 8,580,015, which expires in 2027 (without taking into account any patent term adjustments), is directed to product improvements that have been utilized in the Inogen One and Inogen One G2 products. Also within this class of patents are U.S. Patent Nos. 7,686,870 and 7,922,789 that are directed to designs that may be utilized in future Inogen products to improve performance over current product offerings. These patents expire in 2027 and 2023 respectively (without taking into account any patent term adjustments). Trademarks We have registered the trademarks Inogen; Inogen One; Inogen One G2; Inogen One G3; Oxygenation; Live Life in Moments, not Minutes; Never Run Out of Oxygen; Oxygen Therapy on Your Terms; Oxygen. Anytime. Anywhere; Reclaim Your Independence; Intelligent Delivery Technology; Inogen At Home; and the Inogen design with the United States Patent and Trademark Office. We have registered the trademark Inogen in Australia, Canada, China, South Korea, Mexico, and in Europe (European Community Registration). We have registered the trademark Inogen One in Australia, Canada, China, South Korea, Mexico, and in Europe (European Community Registration). We have registered the trademark Satellite Conserver in Canada, and China. We have registered the trademark Inogen At Home in Europe (European Community Registration). Employees As of December 31, 2014, we had 411 full and part-time employees, including 205 in sales, marketing, clinical and client services, 93 in operations, manufacturing, quality assurance and repair, 94 in general administration and 19 in research and development. None of our employees is represented by a collective bargaining agreement. We believe that our employee relations are good. Corporate and available information We were incorporated in Delaware in November 2001. Our principal executive offices are located at 326 Bollay Drive, Goleta, California 93117. Our telephone number is (805) 562-0500. Our website address is www.inogen.com. We make available on our website, free of charge, our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports, as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission, or SEC. Our SEC reports can be accessed through the investor relations page of our website located at http://investor.inogen.com/sec.cfm. The SEC also maintains a website that contains our SEC filings. The address of the site is www.sec.gov. Additionally, a copy of this Annual Report on Form 10-K and other materials that we file with the SEC are available at the SEC’s Public Reference Room at 100 F Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the SEC at 1-800-SEC-0330. We webcast our earnings calls and certain events we participate in or host with members of the investment community on our investor relations page of our website. Corporate governance information, including our board committee charters, code of ethics, and corporate governance principles, is also available on our investor relations page of our website located at http://investor.inogen.com/. The contents of our website are not incorporated by reference into this Annual Report on Form 10-K or in any other report or document we file with the SEC, and any references to our website are intended to be inactive textual references only. Environmental matters Our research and development and manufacturing processes involve the controlled use of hazardous materials, including flammables, toxics, and corrosives. Our research and manufacturing operations produce hazardous chemical waste products. We seek to comply with applicable laws regarding the handling and disposal of such materials. Given the small volume of such materials used or generated at our facilities, we do not expect our compliance efforts to have a material effect on our capital expenditures, earnings, and competitive position. However, we cannot eliminate the risk of accidental contamination or discharge and any resultant injury from these materials. We do not currently maintain separate environmental liability coverage and any such contamination or discharge could result in significant cost to us in penalties, damages, and suspension of our operations. Backlog We have no material backlog of orders. 17 Geographic information During the years ended 2014, 2013 and 2012, all of our long-lived assets were located within the United States. Approximately 22% of our 2014 revenue, 22% of our 2013 revenue, and 27% of our 2012 revenue came from international markets. Please see Note 2 to our audited financial statements included elsewhere in this Annual Report on Form 10-K for additional information related to our U.S. and non-U.S. revenue. Seasonality We believe our sales may be impacted by seasonal factors. For example, we typically experience higher sales in the second quarter, as a result of consumers traveling, vacationing during the summer months, and warmer weather. ITEM 1A. RISK FACTORS We operate in a rapidly changing environment that involves numerous uncertainties and risks. The following risks and uncertainties may have a material and adverse effect on our business, financial condition or results of operations. You should consider these risks and uncertainties carefully, together with all of the other information included or incorporated by reference in this report on Form 10-K. If any of the risks or uncertainties we face were to occur, the trading price of our securities could decline, and you may lose all or part of your investment. This report on Form 10-K also contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in the forward-looking statements as a result of factors that are described below and elsewhere in this report. Risks related to our business and strategy A significant majority of our customers have health coverage under the Medicare program, and recently enacted and future changes in the reimbursement rates or payment methodologies under Medicare and other government programs have affected and could continue to materially and adversely affect our business and operating results. As a provider of oxygen product rentals, we have historically depended heavily on Medicare reimbursement as a result of the higher proportion of elderly persons suffering from chronic respiratory conditions. Medicare Part B, or Supplementary Medical Insurance Benefits, provides coverage to eligible beneficiaries that include items of durable medical equipment for use in the home, such as oxygen equipment and other respiratory devices. We believe that more than 60% of oxygen therapy patients in the United States have primary coverage under Medicare Part B. For the years ended December 31, 2014 and 2013, we derived approximately 26.5% and 29.4%, respectively, of our total revenue from Medicare’s program or beneficiaries (including patient co-insurance obligations). There are increasing pressures on Medicare to control healthcare costs and to reduce or limit reimbursement rates for home medical products. Legislation, including the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, the Deficit Reduction Act of 2005, the Medicare Improvements for Patients and Providers Act of 2008, and the Patient Protection and Affordable Care Act, contain provisions that directly impact reimbursement for the durable medical equipment products provided by us: (cid:120) The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 significantly reduced reimbursement for inhalation drug therapies beginning in 2005, reduced payment amounts for certain durable medical equipment, including oxygen, beginning in 2005, froze payment amounts for other covered home medical equipment items through 2008, established a competitive bidding program for home medical equipment and implemented quality standards and accreditation requirements for durable medical equipment suppliers. (cid:120) The Deficit Reduction Act of 2005 limited the total number of continuous rental months for which Medicare will pay for oxygen equipment to 36 months, after which time there is generally no additional reimbursement to the supplier (other than for periodic, in-home maintenance and servicing). The Deficit Reduction Act of 2005 also provided that title of the equipment would transfer to the beneficiary, which was later repealed by the Medicare Improvements for Patients and Providers Act of 2008. For purposes of the rental cap, the Deficit Reduction Act of 2005 provided for a new 36-month rental period that began January 1, 2006 for all oxygen equipment. After the 36th continuous month during which payment is made for the oxygen equipment, the supplier is generally required to continue to furnish the equipment during the period of medical need for the remainder of the useful lifetime of the equipment, provided there are no breaks in service due to medical necessity that exceed 60 days. The reasonable useful lifetime for portable oxygen equipment is 60 months. After 60 months, if the patient requests, the rental cycle starts over and a new 36-month capped rental period begins. There are no limits on the number of 60-month cycles over which a Medicare patient may receive benefits and an oxygen therapy provider may receive reimbursement, so long as such equipment continues to be medically necessary for the patient. We anticipate that the Deficit Reduction Act of 2005 oxygen payment rules will continue to negatively affect our net revenue 18 on an ongoing basis, as each month additional customers reach the 36-month capped service period, resulting in potentially two or more years without rental income from these customers. We cannot state with certainty the number of patients in the capped rental period or the potential impact to revenue associated with patients in the capped rental period. (cid:120) The Medicare Improvements for Patients and Providers Act of 2008 retroactively delayed the implementation of competitive bidding for 18 months from previously established dates and decreased the 2009 fee schedule payment amounts by 9.5% for product categories included in competitive bidding. In addition to the 9.5% reduction under Medicare Improvements for Patients and Providers Act of 2008, the Centers for Medicare & Medicaid Services implemented a reduction to the monthly payment amount for stationary oxygen equipment. The monthly payment rate for non-delivery ambulatory oxygen in the relevant period was flat at $51.63. The table below summarizes the increases and decreases in the monthly payment amounts for stationary oxygen equipment. (dollars in dollars) Stationary oxygen percentage rate changes........ 0.10% Stationary oxygen monthly payment amounts ... $ 175.79 $ 173.17 $ 173.31 $ -2.30% -1.50% 2009 2010 2011 2012 2013 2014 2015 1.60% 1.50% 176.06 $ 177.36 $ 178.24 $ 180.92 0.70 % 0.50% (cid:120) The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, includes, among other things, a deductible excise tax on any entity that manufactures or imports medical devices offered for sale in the United States, with limited exceptions including oxygen products such as ours, which began in 2013, new face- to-face physician encounter requirements for durable medical equipment and home health services, and a requirement that by 2016, the competitive bidding process must be nationalized or prices in non-competitive bidding areas must be adjusted to match competitive bidding prices. These legislative provisions, as currently in effect and when fully implemented, have had and will continue to have a material and adverse effect on our business, financial condition and operating results. Due to budgetary shortfalls, many states are considering, or have enacted, cuts to their Medicaid programs. These cuts have included, or may include, elimination or reduction of coverage for our products, amounts eligible for payment under co-insurance arrangements, or payment rates for covered items. Continued state budgetary pressures could lead to further reductions in funding for the reimbursement for our products which, in turn, would adversely affect our business, financial condition and results of operations. The implementation of the competitive bidding process under Medicare could negatively affect our business and financial condition. The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 requires the Secretary of Health and Human Services to establish and implement programs under which competitive acquisition areas are established throughout the United States for purposes of awarding contracts for the furnishing of competitively priced items of durable medical equipment, including oxygen equipment. In October 2014, the Centers for Medicare and Medicaid services released a ruling that sets forth methodologies to adjust the fee schedule amounts for items subject to competitive bidding in areas where competitive bidding is not implemented. The ruling applies rate reductions to all un-bid areas instead of doing an additional bidding process. The fee schedules in the un-bid areas will be adjusted based on regional averages of the single payment amounts for areas already under competitive bidding. The regional prices would be limited by a national ceiling (110% of the average of the regional prices) and a floor (90% of the average regional prices). The regions are defined as follows: States Covered Region Name Far West ......................................................... CA, NV, OR, WA Great Lakes .................................................... Mideast .......................................................... DC, DE, MD, NJ, NY, PA New England ................................................. CT, MA, NH, RI Plains ............................................................. Rocky Mountain ............................................ CO, ID, UT Southeast ........................................................ AL, AR, FL, GA, KY, LA, NC, SC, TN, VA Southwest ....................................................... AZ, NM, OK, TX IA, KS, MN, MO, NE IL, IN, MI, OH, WI The Centers for Medicare and Medicaid defines frontier states as states where more than 50% of the counties in the state have a population density of 6 people or less per square mile and rural states are defined as states where more than 50% of the population lives in rural areas per census data. Current frontier states include MT, ND, SD and WY; rural states include ME, MS, VT and WV; 19 and non-contiguous United States areas include AK, HI, Guam and Puerto Rico. For frontier and rural states, and frontier and rural zip codes in non-frontier/rural states, the single payment amount will be the national ceiling (110% of the average of the regional prices) to account for higher servicing costs in these areas. For non-contiguous United States areas, single payment amounts will be the higher of the national ceiling, or the average of competitive bidding pricing from these areas, if the areas had been bid through competitive bidding. While we are monitoring the implementation of this ruling, we believe that the net effect of the ruling would be an approximately 3-4% decrease in 2016 revenue since this pricing will be applied partially from January 1, 2016 to June 30, 2016 and completely starting July 1, 2016. The Centers for Medicare and Medicaid Services accepted bids through March 26, 2015 for competitive bidding round two re- compete, associated with approximately 50% of the market with contracts set to begin July 1, 2016 and continue through December 31, 2018. The Centers for Medicare and Medicaid Services updated the product categories and the competitive bidding areas. Respiratory equipment includes oxygen, oxygen equipment, continuous positive airway pressure devices, respiratory assist devices and related supplies and accessories. Nebulizers are now their own separate product category instead of being included in the respiratory equipment category. Round two re-compete is in the same geographic areas that were included in the original round two. However, as a result of the Office of Management and Budget’s updates to the original 91 round two metropolitan statistical areas, there are now 90 metropolitan statistical areas for round two re-compete and 117 competitive bidding areas (CBAs). Any CBA that was previously located in multi-state metropolitan statistical areas was redefined so that no CBA is included in more than one state. The round two re-compete competitive bidding areas have nearly the same ZIP codes as the round two competitive bidding areas; the associated changes in the zip codes since competitive bidding was implemented are reflective in this round two re-compete. On March 17, 2015 the House of Representatives approved the Medicare DMEPOS (Durable Medical Equipment, Prosthetics, Orthotics and Supplies) Competitive Bidding Improvement Act of 2015 which would require Medicare suppliers that bid under DMEPOS competitive bidding program to obtain a $50,000 to $100,000 bid surety bond for each competitive bidding area (CBA). The bill is intended to prevent suppliers from submitting not-binding, “low-ball” bids that artificially drive down prices and jeopardize beneficiary access to equipment. If the supplier bids lower than the median composite bid rate and does not accept a contract for a CBA, the bid bond would be forfeited. The bill also would codify that competitive bidding contracts can only be awarded to suppliers that meet applicable state licensure requirements. On April 14, 2015, this bill was passed by the Senate and then signed by President Obama into law on April 16, 2015, thus we will incur additional expense to obtain the appropriate surety bonds in the CBAs where we win contracts. There are currently 9 CBAs under contract in round 1 re-compete and 117 CBAs under contract in round 2 re- compete. CBAs are defined by Medicare and are subject to change at each new bidding period. This cost is not expected to be material to our financial results. Although we continue to monitor developments regarding the implementation of the competitive bidding program, we cannot predict the outcome of the competitive bidding program on our business when fully implemented, nor the Medicare payment rates that will be in effect in future years for the items subject to competitive bidding, including our products. We expect that the stationary oxygen and non-delivery ambulatory oxygen payment rates will continue to fluctuate and a large negative payment adjustment could adversely affect our business, financial conditions and results of operations. We face intense national, regional and local competition and if we are unable to compete successfully, it could have an adverse effect on our revenue, revenue growth rate, if any, and market share. The oxygen therapy market is a highly competitive industry. We compete with a number of manufacturers and distributors of portable oxygen concentrators, as well as providers of other oxygen therapy solutions such as home delivery of oxygen tanks or cylinders. Our significant manufacturing competitors are Invacare Corporation, Respironics (a subsidiary of Koninklijke Philips N.V.), AirSep Corporation and SeQual Technologies (subsidiaries of Chart Industries, Inc.), Inova Labs, Inc. and DeVilbiss Healthcare. Given the relatively straightforward regulatory path in the oxygen therapy device manufacturing market, we expect that the industry will become increasingly competitive in the future. Manufacturing companies compete for sales to providers primarily on the basis of product features, service and price. For many years, Lincare Inc., Apria Healthcare, Inc. Rotech Healthcare, Inc. and American HomePatient, Inc. have been among the market leaders in providing oxygen therapy, while the remaining oxygen therapy market is serviced by local providers. Because many oxygen therapy providers were either excluded from contracts in the Medicare competitive bidding process, or will have difficulty providing service at the prevailing Medicare reimbursement rates, we expect more industry consolidation. Oxygen therapy providers compete primarily on the basis of product features and service, rather than price, since reimbursement levels are established by Medicare and Medicaid, or by the individual determinations of private payors. 20 Some of our competitors are large, well-capitalized companies with greater resources than we have. As a consequence, they are able to spend more aggressively on product development, marketing, sales and other product initiatives than we can. Some of these competitors have: (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) significantly greater name recognition; established relations with healthcare professionals, customers and third-party payors; established distribution networks; additional lines of products, and the ability to offer rebates or bundle products to offer higher discounts or other incentives to gain a competitive advantage; greater history in conducting research and development, manufacturing, marketing and obtaining regulatory approval for oxygen device products; and greater financial and human resources for product development, sales and marketing, patent litigation and customer financing. As a result, our competitors may be able to respond more quickly and effectively than we can to new or changing opportunities, technologies, standard regulatory and reimbursement development and customer requirements. In light of these advantages that our competitors maintain, even if our technology and direct-to-consumer distribution strategy is more effective than the technology and distribution strategy of our competitors, current or potential customers might accept competitor products and services in lieu of purchasing our products. We anticipate that we will face increased competition in the future as existing companies and competitors develop new or improved products and distribution strategies and as new companies enter the market with new technologies and distribution strategies. We may not be able to compete effectively against these organizations. Our ability to compete successfully and to increase our market share is dependent upon our reputation for providing responsive, professional and high-quality products and services and achieving strong customer satisfaction. Increased competition in the future could adversely affect our revenue, revenue growth rate, margins and market share. Healthcare reform measures may have a material adverse effect on our business and results of operations. In the United States, the legislative landscape, particularly as it relates to healthcare regulation and reimbursement coverage, continues to evolve. In March 2010, the Patient Protection and Affordable Care Act was passed, which has the potential to substantially change healthcare financing by both governmental and private insurers, and significantly impact the U.S. medical device industry. In addition, as discussed above, the Patient Protection and Affordable Care Act also expands the round two of competitive bidding to a total of 117 competitive bidding areas, and by 2016, the process must be nationalized or prices in non-competitive bidding areas must be adjusted to match competitive bidding prices. In addition, other legislative changes have been proposed and adopted in the United States since the Patient Protection and Affordable Care Act was enacted. On August 2, 2011, the Budget Control Act of 2011 among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which went into effect on April 1, 2013, and will remain in effect through 2024 unless additional Congressional action is taken. On January 2, 2013, President Obama signed into law the American Taxpayer Relief Act of 2012 which, among other things, further reduced Medicare payments to certain providers, including physicians, hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures. If we are unable to continue to enhance our existing products and develop and market new products that respond to customer needs and preferences and achieve market acceptance, we may experience a decrease in demand for our products and our business could suffer. We may not be able to compete as effectively with our competitors, and ultimately satisfy the needs and preferences of our customers, unless we can continue to enhance existing products and develop new innovative products. Product development requires significant financial, technological and other resources. While we expended $3.0 million, $2.4 million and $2.3 million for research and development efforts for the twelve months ended December 31, 2014, December 31, 2013 and December 31, 2012, respectively, we cannot assure you that this level of investment in research and development will be sufficient to maintain a competitive advantage 21 in product innovation, which could cause our business to suffer. Product improvements and new product introductions also require significant planning, design, development, and testing at the technological, product, and manufacturing process levels and we may not be able to timely develop product improvements or new products. Our competitors’ new products may enter the market before our new products reach market, be more effective with more features, obtain better market acceptance, or render our products obsolete. Any new products that we develop may not receive market acceptance or otherwise generate any meaningful sales or profits for us relative to our expectations based on, among other things, existing and anticipated investments in manufacturing capacity and commitments to fund advertising, marketing, promotional programs and research and development. We depend upon reimbursement from Medicare, private payors and Medicaid for a significant portion of our revenue, and if we fail to manage the complex and lengthy reimbursement process, our business and operating results could suffer. A significant portion of our revenue is derived from reimbursement by third-party payors. We accept assignment of insurance benefits from customers and, in a majority of cases, invoice and collect payments directly from Medicare, private payors and Medicaid, as well as from customers under co-insurance provisions. For the twelve months ended December 31, 2014 and December 31, 2013, approximately 35.0% and 40.5% of our total revenue was derived from Medicare, private payors, Medicaid, and individual customers who directly receive reimbursement from third-party payors. Our financial condition and results of operations may be affected by the healthcare industry’s reimbursement process, which is complex and can involve lengthy delays between the time that a product is delivered to the consumer and the time that the reimbursement amounts are settled. Depending on the payor, we may be required to obtain certain payor-specific documentation from physicians and other healthcare providers before submitting claims for reimbursement. Certain payors have filing deadlines and they will not pay claims submitted after such time. We are also subject to extensive pre-payment and post-payment audits by governmental and private payors that could result in material delays, refunds of monies received or denials of claims submitted for payment under such third-party payor programs and contracts. We cannot ensure that we will be able to continue to effectively manage the reimbursement process and collect payments for our products promptly. If we fail to manage the complex and lengthy reimbursement process, it would adversely affect our business, financial conditions and results of operations. Failure to obtain private payor contracts and future reductions in reimbursement rates from private payors could have a material adverse effect on our financial condition and operating results. A portion of our revenue is derived from private payors. Based on our patient population, we estimate at least 30% of potential customers have non-Medicare insurance coverage, and we believe these patients represent a younger and more active patient population that will be drawn to the quality-of-life benefits of our solution. Failing to maintain and obtain private payor contracts from private insurance companies and employers and secure in-network provider status could have a material adverse effect on our financial condition and operating results. In addition, private payors are under pressure to increase profitability and reduce costs. In response, certain private payors are limiting coverage or reducing reimbursement rates for the products we provide. We believe that private payor reimbursement levels will generally be reset in accordance with the Medicare payment amounts determined by competitive bidding. We cannot predict the extent to which reimbursement for our products will be affected by competitive bidding or by initiatives to reduce costs for private payors. Failure to obtain or maintain private payor contracts or the unavailability of third- party coverage or inadequacy of reimbursement for our products would adversely affect our business, financial conditions and results of operations. We obtain some of the components, subassemblies and completed products included in our Inogen One systems and our Inogen At Home from a single source or a limited group of manufacturers or suppliers, and the partial or complete loss of one of these manufacturers or suppliers could cause significant production delays, an inability to meet customer demand and a substantial loss in revenue. We utilize single source suppliers for some of the components and subassemblies we use in our Inogen One systems and our Inogen At Home system. We have qualified alternate sources of supply sufficient to support future needs and we have taken other mitigating steps to reduce the impact of a change in supplier; however, there may be delays in switching to these alternative suppliers if our primary source is terminated without notice. Our dependence on single source suppliers of components may expose us to several risks, including, among other things: (cid:120) Our suppliers may encounter financial hardships as a result of unfavorable economic and market conditions unrelated to our demand for components, which could inhibit their ability to fulfill our orders and meet our requirements; (cid:120) Suppliers may fail to comply with regulatory requirements, be subject to lengthy compliance, validation or qualification periods, or make errors in manufacturing components that could negatively affect the efficacy or safety of our products or cause delays in supplying of our products to our customers; 22 (cid:120) Newly identified suppliers may not qualify under the stringent regulatory standards to which our business is subject; (cid:120) We or our suppliers may not be able to respond to unanticipated changes in customer orders, and if orders do not match forecasts, we or our suppliers may have excess or inadequate inventory of materials and components; (cid:120) We may be subject to price fluctuations due to a lack of long-term supply arrangements for key components; (cid:120) We may experience delays in delivery by our suppliers due to changes in demand from us or their other customers; (cid:120) We or our suppliers may lose access to critical services and components, resulting in an interruption in the manufacture, assembly and shipment of our systems; (cid:120) Our suppliers may be subject to allegations by other parties of misappropriation of proprietary information in connection with their supply of products to us, which could inhibit their ability to fulfill our orders and meet our requirements; (cid:120) Fluctuations in demand for products that our suppliers manufacture for others may affect their ability or willingness to deliver components to us in a timely manner; (cid:120) Our suppliers may wish to discontinue supplying components or services to us; and (cid:120) We may not be able to find new or alternative components or reconfigure our system and manufacturing processes in a timely manner if the necessary components become unavailable. In addition, we may be deemed to manufacture or contract to manufacture products that contain certain minerals that have been designated as “conflict minerals” under the Dodd-Frank Wall Street Reform and Consumer Protection Act. As a result, in future periods, we may be required to perform due diligence to determine the origin of such minerals, and disclose and report whether or not such minerals originated in the Democratic Republic of the Congo or adjoining countries. The implementation of these new requirements could adversely affect the sourcing, availability, and pricing of minerals used in the manufacture of our products. In addition, we may incur additional costs to comply with the disclosure requirements, including costs related to determining the source of any of the relevant minerals and metals used in our products. If any of these risks materialize, costs could significantly increase and our ability to meet demand for our products could be impacted. If we are unable to satisfy commercial demand for our Inogen One systems and Inogen At Home systems in a timely manner, our ability to generate revenue would be impaired, market acceptance of our products could be adversely affected, and customers may instead purchase or use alternative products. In addition, we could be forced to secure new or alternative components and subassemblies through a replacement supplier. Finding alternative sources for these components and subassemblies could be difficult in certain cases and may entail a significant amount of time and disruption. In some cases, we would need to change the components or subassemblies if we sourced them from an alternative supplier. This, in turn, could require a redesign of our Inogen One systems and Inogen At Home systems and, potentially, require additional FDA clearance or approval before we could use any redesigned product with new components or subassemblies, thereby causing further costs and delays that could adversely affect our business, financial condition and operating results. We do not have long-term supply contracts with many of our third-party suppliers. We purchase components and subassemblies from third-party suppliers, including some of our single source suppliers, through purchase orders and do not have long-term supply contracts with many of these third-party suppliers. Many of our third-party suppliers, therefore, are not obligated to perform services or supply products to us for any specific period, in any specific quantity or at any specific price, except as may be provided in a particular purchase order. We do not maintain large volumes of inventory from most of these suppliers. If we inaccurately forecast demand for components or subassemblies, our ability to manufacture and commercialize our Inogen One systems and Inogen At Home systems could be delayed and our competitive position and reputation could be harmed. In addition, if we fail to effectively manage our relationships with these suppliers, we may be required to change suppliers which would be time consuming and disruptive and could adversely affect our business, financial condition and operating results. If we fail to comply with U.S. export control and economic sanctions or fail to expand and maintain an effective sales force or successfully develop our international distribution network, our business, financial condition and operating results may be adversely affected. We currently derive the majority of our revenue from rentals or sales generated from our own direct sales force. Failure to maintain or expand our direct sales force could adversely impact our financial and operating performance. Additionally, we use international distributors to augment our sales efforts, certain of which are exclusive distributors in certain foreign countries. We cannot assure you that we will be able to successfully develop our relationships with third-party distributors internationally. In addition, we are subject to United States export control and economic sanctions laws relating to the sale of our products, the violation of which could result in substantial penalties being imposed against us. In particular, we have secured annual export licenses from the 23 U.S. Treasury Department’s Office of Foreign Assets Control to sell our products to a distributor and hospital and clinic end-users in Iran. The use of this license requires us to observe strict conditions with respect to products sold, end-user limitations and payment requirements. Although we believe we have maintained compliance with license requirements, there can be no assurance that the license will not be revoked, be renewed in the future or that we will remain in compliance. More broadly, if we fail to comply with export control laws or successfully develop our relationship with international distributors, our sales could fail to grow or could decline, and our ability to grow our business could be adversely affected. Distributors that are in the business of selling other medical products may not devote a sufficient level of resources and support required to generate awareness of our products and grow or maintain product sales. If our distributors are unwilling or unable to market and sell our products, or if they do not perform to our expectations, we could experience delayed or reduced market acceptance and sales of our products. We may be subject to substantial warranty or product liability claims or other litigation in the ordinary course of business that may adversely affect our business, financial condition and operating results. As manufacturers of medical devices, we may be subject to substantial warranty or product liability claims or other litigation in the ordinary course of business that may require us to make significant expenditures to defend these claims or pay damage awards. For example, our Inogen One systems contain lithium ion batteries, which, under certain circumstances, can be a fire hazard. We, as well as our key suppliers, maintain product liability insurance, but this insurance is limited in amount and subject to significant deductibles. There is no guarantee that insurance will be available or adequate to protect against all claims. Our insurance policies are subject to annual renewal and we may not be able to obtain liability insurance in the future on acceptable terms or at all. In addition, our insurance premiums could be subject to increases in the future, which may be material. If the coverage limits are inadequate to cover our liabilities or our insurance costs continue to increase as a result of warranty or product liability claims or other litigation, then our business, financial condition and operating results may be adversely affected. Increases in our operating costs could have a material adverse effect on our business, financial condition and operating results. Reimbursement rates are established by fee schedules mandated by Medicare, private payors and Medicaid, and are likely to remain constant or decrease due, in part, to federal and state government budgetary constraints. As a result, with respect to Medicare and Medicaid related revenue, we are not able to offset the effects of general inflation on our operating costs through increases in prices for our products. In particular, labor and related costs account for a significant portion of our operating costs and we compete with other healthcare providers to attract and retain qualified or skilled personnel and with various industries for administrative and service employees. This competitive environment could result in increased labor costs. As such, we must control our operating costs, particularly labor and related costs and failing to do so could adversely affect our financial conditions and results of operations. We depend on the services of our senior executives and other key technical personnel, the loss of whom could negatively affect our business. Our success depends upon the skills, experience and efforts of our senior executives and other key technical personnel, including certain members of our engineering staff and our sales and marketing executives. Much of our corporate expertise is concentrated in relatively few employees, the loss of which for any reason could negatively affect our business. Competition for our highly skilled employees is intense and we cannot prevent the resignation of any employee. We do not maintain “key man” life insurance on any of our senior executives. None of our senior executive team is bound by written employment contracts to remain with us for a specified period. In addition, we have not entered into non-compete agreements with members of our senior management team. The loss of any member of our senior management team could harm our ability to implement our business strategy and respond to the market conditions in which we operate. We rely on information technology, and if we are unable to protect against service interruptions, data corruption, cyber-based attacks or network security breaches, our operations could be disrupted and our business could be negatively affected. We rely on information technology networks and systems to process, transmit and store electronic and financial information; to coordinate our business; and to communicate within our company and with customers, suppliers, partners and other third-parties. These information technology systems may be susceptible to damage, disruptions or shutdowns, hardware or software failures, power outages, computer viruses, cyber-attacks, telecommunication failures, user errors or catastrophic events. If our information technology systems suffer severe damage, disruption or shutdown, and our business continuity plans do not effectively resolve the issues in a timely manner, our operations could be disrupted and our business could be negatively affected. In addition, cyber-attacks could lead to potential unauthorized access and disclosure of confidential information (including patient-identifiable health information), and data loss and corruption. There is no assurance that we will not experience these service interruptions or cyber-attacks in the future. 24 We incurred losses from inception until fiscal year 2012, and we have only recently achieved profitability. We have a limited operating history and incurred significant net losses in each fiscal year until fiscal year 2012, when we achieved positive net income. As of December 31, 2014, we had an accumulated deficit of $56.7 million. These net losses have resulted principally from costs incurred from our selling, general and administrative expenses and to a lesser extent in our research and development programs. We expect to incur significant expansion of our sales and marketing expenses and increases in expenses for research and development to a lesser extent. Additionally, since completing our initial public offering, we expect that our general and administrative expenses will increase due to the additional operational and reporting costs associated with being a public company. Because of the numerous risks and uncertainties associated with our commercialization efforts and future product development, we are unable to predict if we will maintain or increase our net income. Our financial results may vary significantly from quarter-to-quarter due to a number of factors, which may lead to volatility in our stock price. Our quarterly revenue and results of operations have varied in the past and may continue to vary significantly from quarter-to- quarter. This variability may lead to volatility in our stock price as research analysts and investors respond to these quarterly fluctuations. These fluctuations are due to numerous factors, including: fluctuations in consumer demand for our products; seasonal cycles in consumer spending; our ability to design, manufacture and deliver products to our consumers in a timely and cost-effective manner; quality control problems in our manufacturing operations; our ability to timely obtain adequate quantities of the components used in our products; new product introductions and enhancements by us and our competitors; unanticipated increases in costs or expenses; and fluctuations in foreign currency exchange rates. For example, we typically experience higher sales in the second quarter, as a result of consumers traveling and vacationing during the summer months. The foregoing factors are difficult to forecast, and these, as well as other factors, could materially and adversely affect our quarterly and annual results of operations. In addition, a significant amount of our operating expenses are relatively fixed due to our manufacturing, research and development and sales and general administrative efforts. Any failure to adjust spending quickly enough to compensate for a revenue shortfall could magnify the adverse impact of such revenue shortfall on our results of operations. Our results of operations may not meet the expectations of research analysts or investors, in which case the price of our common stock could decrease significantly. If the market opportunities for our products are smaller than we believe they are, our revenues maybe adversely affected and our business may suffer. Our projections regarding (i) the size of the oxygen therapy market, both in the United States and internationally, (ii) the number of oxygen therapy patients, (iii) the number of patients requiring ambulatory and stationary oxygen, (iv) the number of patients who rely on the delivery model, and (v) the share of portable oxygen concentrators as a percentage of the total oxygen therapy spend, are based on estimates that we believe are reliable. These estimates may prove to be incorrect, new data or studies may change the estimated incidence or prevalence of patients requiring oxygen therapy, or the type of oxygen therapy patients. The number of patients in the United States and internationally may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our products, or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. The terms of our revolving credit agreement may restrict our current and future operations, and could affect our ability to respond to changes in our business and to manage our operations. On November 7, 2014, we entered into a revolving credit agreement with JPMorgan Chase Bank, N.A., which we refer to as our revolving credit agreement. The agreement provides for a revolving credit facility in an aggregate principal amount of $15.0 million with a sublimit of $1.0 million for the issuance of letters of credit on our behalf. The agreement is secured by all or substantially all of our assets. Pursuant to the revolving credit agreement, we are subject to certain financial covenants relating to our net worth and EBITDA. Tangible net worth under the revolving credit agreement is calculated by subtracting the sum of intangible assets and total liabilities from total assets. EBITDA is defined in the revolving credit agreement as our net income plus interest expense, plus depreciation expense, plus amortization expense, plus income tax expense, plus non-cash expense, plus extraordinary losses, minus non-cash income, and minus extraordinary gains, as computed during certain test periods provided in the revolving credit agreement. We are required to maintain at all times a tangible net worth of $90 million and EBITDA (i) of $10.0 million for any period of four consecutive quarters commencing with the four-quarter test period ending September 30, 2014 through the four-quarter test period ending March 31, 2016 and (ii) of $12.5 million for any four-quarter test period commencing with the four-quarter test period ending June 30, 2016 and continuing thereafter. 25 The agreement contains events of default customary for transactions of this type, including nonpayment, misrepresentation, breach of covenants, and bankruptcy. In the event we fail to satisfy our covenants, or otherwise go into default, JPMorgan Chase Bank, N.A. has a number of remedies, including sale of our assets and acceleration of all outstanding indebtedness. Certain of these remedies would likely have a material adverse effect on our business. As of December 31, 2014, in order to be in compliance with the EBITDA and tangible net worth requirements, we were required to maintain $10 million in EBITDA for the preceding test period, and we had $24 million in EBITDA for that period, and we were required to maintain a tangible net worth of $90.0 million and we had a tangible net worth of $117.8 million. An adverse outcome of a sales and use tax audit could have a material adverse effect on our results of operations and financial condition. The California State Board of Equalization conducted a sales and use tax audit of our operations in California in 2008. As a result of the audit, the California State Board of Equalization confirmed that our sales are not subject to California sales and use tax. We believe that our sales in other states should not be subject to sales and use tax. There can be no assurance, however, that other states may agree with our position and we may be subject to an audit that may not be resolved in our favor. Such an audit could be expensive and time-consuming and result in substantial management distraction. If the matter were to be resolved in a manner adverse to us, it could have a material adverse effect on our results of operations and financial position. Our ability to use net operating losses to offset future taxable income may be subject to certain limitations. As of December 31, 2014, we had federal and state net operating loss carryforwards, or NOLs, of approximately $59.3 and $46.4 million, which expire in various years beginning in 2023 and 2015, respectively, if not utilized. Our existing NOLs are subject to limitations arising from an ownership change in the current period subject to the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, or the Code. If we undergo one or more future ownership changes our ability to utilize NOLs could be further limited. In general, under Section 382 of the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. In general, an “ownership change” occurs if there is a cumulative change in ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period. Even after factoring in the limitations of the current period ownership change, the Company was able to determine that, based upon future projections of income, it is more likely than not that all of its federal NOLs will be utilized before they expire. However, the Company determined that some of its California NOLs will expire unused and therefore has a valuation allowance of $2.9 million relating to these NOLs. In the current period, the Company released (or reversed) $1.2 million of the California NOLs valuation allowance due to expiration of California NOL’s and changes in estimates of future projections of income, resulting in a determination that it is more likely than not that all but $32.8 million ($2.9 million tax effect) of the California NOLs will be utilized. Risks related to the regulatory environment We are subject to extensive Federal and state regulation, and if we fail to comply with applicable regulations, we could suffer severe criminal or civil sanctions or be required to make significant changes to our operations that could adversely affect our business, financial condition and operating results. The federal government and all states in which we currently operate regulate various aspects of our business. In particular, our sales and customer service centers are subject to federal laws that regulate interstate motor-carrier transportation. Our operations also are subject to state laws governing, among other things, distribution of medical equipment and certain types of home health activities, and we are required to obtain and maintain licenses in each state to act as a durable medical equipment supplier. Certain of our employees are subject to state laws and regulations governing the professional practices of respiratory therapy. As a healthcare provider participating in governmental healthcare programs, we are subject to laws directed at preventing fraud and abuse, which subject our marketing, billing, documentation and other practices to government scrutiny. To ensure compliance with Medicare, Medicaid and other regulations, government agencies or their contractors often conduct routine audits and request customer records and other documents to support our claims submitted for payment of services rendered. Government agencies or their contractors also periodically open investigations and obtain information from healthcare providers. Violations of federal and state regulations can result in severe criminal, civil and administrative penalties and sanctions, including debarment, suspension or exclusion from Medicare, Medicaid and other government reimbursement programs, any of which would have a material adverse effect on our business. Changes in healthcare laws and regulations and new interpretations of existing laws and regulations may affect permissible activities, the relative costs associated with doing business, and reimbursement amounts paid by federal, state and other third-party payors. There have been and will continue to be regulatory initiatives affecting our business and we cannot predict the extent to which future legislation and regulatory changes could have a material adverse effect on our business. 26 We are subject to burdensome and complex billing and record-keeping requirements in order to substantiate our claims for payment under federal, state and commercial healthcare reimbursement programs, and our failure to comply with existing requirements, or changes in those requirements or interpretations thereof, could adversely affect our business, financial condition and operating results. We are subject to burdensome and complex billing and record-keeping requirements in order to substantiate our claims for payment under federal, state and commercial healthcare reimbursement programs. Our records also are subject to routine and other reviews by third-party payors, which can result in delays in payments or refunds of paid claims. For example, we have also experienced a significant increase in pre-payment reviews of our claims by the Durable Medical Equipment Medicare Administrative Contractors, which has caused substantial delays in the collection of our Medicare accounts receivable as well as related amounts due under supplemental insurance plans. Current law provides for a significant expansion of the government’s auditing and oversight of suppliers who care for patients covered by various government healthcare programs. Examples of this expansion include audit programs being implemented by the Durable Medical Equipment Medicare Administrative Contractors, the Zone Program Integrity Contractors, the Recovery Audit Contractors, and the Comprehensive Error Rate Testing contractors, operating under the direction of the Centers for Medicare & Medicaid Services. We have been informed by these auditors that healthcare providers and suppliers of certain durable medical equipment product categories are expected to experience further increased scrutiny from these audit programs. When a government auditor ascribes a high billing error rate to one or more of our locations, it generally results in protracted pre-payment claims review, payment delays, refunds and other payments to the government and/or our need to request more documentation from providers than has historically been required. It may also result in additional audit activity in other company locations in that state or Durable Medical Equipment Medicare Administrative Contractors jurisdiction. We cannot currently predict the adverse impact that these audits, methodologies and interpretations might have on our business, financial condition or operating results, but such impact could be material. We are subject to significant regulation by numerous government agencies, including the U.S. Food and Drug Administration, or FDA. We cannot market or commercially distribute our products without obtaining and maintaining necessary regulatory clearances or approvals. Our Inogen concentrators are medical devices subject to extensive regulation in the United States and in the foreign markets where we distribute our products. The FDA and other U.S. and foreign governmental agencies regulate, among other things, with respect to medical devices: (cid:120) (cid:120) (cid:120) (cid:120) design, development and manufacturing; testing, labeling, content and language of instructions for use and storage; clinical trials; product safety; (cid:120) marketing, sales and distribution; (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) pre-market clearance and approval; record keeping procedures; advertising and promotion; recalls and field safety corrective actions; post-market surveillance, including reporting of deaths or serious injuries and malfunctions that, if they were to recur, could lead to death or serious injury; post-market approval studies; and product import and export. Before we can market or sell a medical device in the United States, we must obtain either clearance from the FDA under Section 510(k) of the Federal Food, Drug, and Cosmetic Act, or the FDCA, or approval of a pre-market approval application from the FDA, unless an exemption from pre-market review applies. In the 510(k) clearance process, the FDA must determine that a proposed device is “substantially equivalent” to a device legally on the market, known as a “predicate” device, with respect to intended use, technology and safety and effectiveness, in order to clear the proposed device for marketing. Clinical data is sometimes required to 27 support substantial equivalence. The pre-market approval pathway requires an applicant to demonstrate the safety and effectiveness of the device based, in part, on extensive data, including, but not limited to, technical, preclinical, clinical trial, manufacturing and labeling data. The pre-market approval process is typically required for devices that are deemed to pose the greatest risk, such as life- sustaining, life-supporting or implantable devices. Products that are approved through a pre-market approval application generally need FDA approval before they can be modified. Similarly, some modifications made to products cleared through a 510(k) may require a new 510(k). Both the 510(k) and pre-market approval processes can be expensive and lengthy and require the payment of significant fees, unless an exemption applies. The FDA’s 510(k) clearance process usually takes from three to twelve months, but may take longer. The process of obtaining a pre-market approval is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or longer, from the time the application is submitted to the FDA until an approval is obtained. The process of obtaining regulatory clearances or approvals to market a medical device can be costly and time consuming, and we may not be able to obtain these clearances or approvals on a timely basis, if at all. In the United States, our currently commercialized products are marketed pursuant to pre-market clearance under Section 510(k) of the FDCA. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, our product introductions or modifications could be delayed or canceled, which could cause our sales to decline. In addition, the FDA may determine that future products will require the more costly, lengthy and uncertain pre- market approval process. Although we do not currently market any devices under a pre-market approval, the FDA may demand that we obtain a pre-market approval prior to marketing certain of our future products. In addition, if the FDA disagrees with our determination that a product we currently market is subject to an exemption from pre-market review, the FDA may require us to submit a 510(k) or pre-market approval application in order to continue marketing the product. Further, even with respect to those future products where a pre-market approval is not required, we cannot assure you that we will be able to obtain the 510(k) clearances with respect to those products. The FDA can delay, limit or deny clearance or approval of a device for many reasons, including: (cid:120) we may not be able to demonstrate to the FDA’s satisfaction that our products are safe and effective for their intended users; (cid:120) the data from our pre-clinical studies and clinical trials may be insufficient to support clearance or approval, where required; and (cid:120) the manufacturing process or facilities we use may not meet applicable requirements. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions which may prevent or delay approval or clearance of our products under development or impact our ability to modify our currently approved or cleared products on a timely basis. For example, in response to industry and healthcare provider concerns regarding the predictability, consistency and rigor of the 510(k) regulatory pathway, the FDA initiated an evaluation of the program, and in January 2011, announced several proposed actions intended to reform the review process governing the clearance of medical devices. The FDA intends these reform actions to improve the efficiency and transparency of the clearance process, as well as bolster patient safety. Some of these proposals, if enacted, could impose additional regulatory requirements upon us which could delay our ability to obtain new 510(k) clearances, increase the costs of compliance or restrict our ability to maintain our current clearances. In addition, as part of the Food and Drug Administration Safety and Innovation Act, Congress reauthorized the Medical Device User Fee Amendments with various FDA performance goal commitments and enacted several “Medical Device Regulatory Improvements” and miscellaneous reforms which are further intended to clarify and improve medical device regulation both pre- and post-market. Medical devices may only be promoted and sold for the indications for which they are approved or cleared. In addition, even if the FDA has approved or cleared a product, it can take action affecting such product approvals or clearances if serious safety or other problems develop in the marketplace. Delays in obtaining clearances or approvals could adversely affect our ability to introduce new products or modifications to our existing products in a timely manner, which would delay or prevent commercial sales of our products. Additionally, the FDA and other regulatory authorities have broad enforcement powers. Regulatory enforcement or inquiries, or other increased scrutiny on us, could affect the perceived safety and efficacy of our products and dissuade our customers from using our products. If we modify our FDA cleared devices, we may need to seek additional clearances or approvals, which, if not granted, would prevent us from selling our modified products. Our Inogen One systems and Inogen At Home system have received pre-market clearance under Section 510(k) of the FDCA. The modifications made to our Inogen One G2 and Inogen One G3 systems represent non-significant modifications to the original Inogen One system, have the same indications for use, and are covered under our initial Inogen One 510(k) clearance. Any modifications to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or would constitute a major change 28 in its intended use, manufacture, design, components, or technology requires the submission and clearance of a new 510(k) pre-market notification or, possibly, pre-market approval. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer’s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. We have modified some of our 510(k) cleared products, and have determined based on our review of the applicable FDA guidance that in certain instances new 510(k) clearances or pre-market approval are not required. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or pre-market approval for modifications to our previously cleared products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. Furthermore, the FDA’s ongoing review of the 510(k) program may make it more difficult for us to make modifications to our previously cleared products, either by imposing more strict requirements on when a manufacturer must submit a new 510(k) for a modification to a previously cleared product, or by applying more onerous review criteria to such submissions. Specifically, pursuant to the Food and Drug Administration Safety and Innovation Act, which was signed into law in July 2012, the FDA was obligated to prepare a report for Congress on the FDA’s approach for determining when a new 510(k) will be required for modifications or changes to a previously cleared device. The FDA issued this report in 2014 and indicated that manufacturers should continue to adhere to the FDA’s 1997 Guidance on this topic when making a determination as to whether or not a new 510(k) is required for a change or modification to a device. However, the practical impact of the FDA’s continuing scrutiny of these issues remains unclear. If we fail to comply with FDA or state regulatory requirements, we can be subject to enforcement action. The regulations to which we are subject are complex and have become more stringent over time. Regulatory changes could result in restrictions on our ability to continue or expand our operations, higher than anticipated costs or lower than anticipated sales. Even after we have obtained the proper regulatory clearance or approval to market a product, we have ongoing responsibilities under FDA regulations. The FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by the FDA or state agencies, which may include any of the following sanctions: (cid:120) warning letters, fines, injunctions, consent decrees and civil penalties; (cid:120) (cid:120) (cid:120) (cid:120) recalls, termination of distribution, or seizure of our products; operating restrictions or partial suspension or total shutdown of production; delays in the introduction of products into the market; refusal to grant our requests for future 510(k) clearances or approvals of new products, new intended uses, or modifications to exiting products; (cid:120) withdrawals or suspensions of current 510(k) clearances or approvals, resulting in prohibitions on sales of our products; and (cid:120) criminal prosecution. Any of these sanctions could result in higher than anticipated costs or lower than anticipated sales and have a material adverse effect on our reputation, business, results of operations and financial condition. A recall of our products, either voluntarily or at the direction of the FDA or another governmental authority, or the discovery of serious safety issues with our products that leads to corrective actions, could have a significant adverse impact on us. Medical devices, such as our Inogen concentrators, can experience performance problems in the field that require review and possible corrective action by us or the product manufacturer. We cannot provide assurance that component failures, manufacturing errors, design defects and/or labeling inadequacies, which could result in an unsafe condition or injury to the operator or the patient will not occur. The FDA and similar foreign governmental authorities have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. Manufacturers may also, under their own initiative, recall a product if any material deficiency in a device is found or withdraw a product to improve device performance or for other reasons. A government-mandated or voluntary recall by us or one of our distributors could occur as a result of an unacceptable risk to health, component failures, manufacturing errors, design or labeling defects or other deficiencies and issues. Similar regulatory agencies in other countries have similar authority to recall devices because of material deficiencies or defects in design or manufacture that could endanger health. Any recall would divert management attention and financial resources, could cause the price of our stock to decline and expose us to product liability or other claims and harm our reputation with customers. A recall involving our Inogen concentrators could be particularly harmful to our business, financial and operating results. 29 In addition, under the FDA’s medical device reporting regulations, we are required to report to the FDA any incident in which our product may have caused or contributed to a death or serious injury or in which our product malfunctioned and, if the malfunction were to recur, would likely cause or contribute to death or serious injury. Repeated product malfunctions may result in a voluntary or involuntary product recall. Depending on the corrective action we take to redress a product’s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new approvals or clearances for the device before we may market or distribute the corrected device. Seeking such approvals or clearances may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties, or civil or criminal fines. We may also be required to bear other costs or take other actions that may have a negative impact on our sales as well as face significant adverse publicity or regulatory consequences, which could harm our business, including our ability to market our products in the future. Any adverse event involving our products, whether in the United States or abroad, could result in future voluntary corrective actions, such as recalls or customer notifications, or agency action, such as inspection, mandatory recall or other enforcement action. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, distract management from operating our business and may harm our reputation and financial results. If we or our component manufacturers fail to comply with the FDA’s Quality System Regulation, our manufacturing operations could be interrupted, and our product sales and operating results could suffer. We and our component manufacturers are required to comply with the FDA’s Quality System Regulation, or QSR, which covers the procedures and documentation of the design, testing, production, control, quality assurance, labeling, packaging, sterilization, storage and shipping of our devices. The FDA audits compliance with the QSR through periodic announced and unannounced inspections of manufacturing and other facilities. We and our component manufacturers have been, and anticipate in the future being, subject to such inspections. Although we believe our manufacturing facilities and those of our component manufacturers are in compliance with the QSR, we cannot provide assurance that any future inspection will not result in adverse findings. If our manufacturing facilities or those of any of our component manufacturers or suppliers are found to be in violation of applicable laws and regulations, or we or our manufacturers or suppliers fail to take satisfactory corrective action in response to an adverse inspection, the FDA could take enforcement action, including any of the following sanctions: (cid:120) (cid:120) (cid:120) (cid:120) untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties; customer notifications or repair, replacement, refunds, recall, detention or seizure of our products; operating restrictions or partial suspension or total shutdown of production; refusing or delaying our requests for 510(k) clearance or pre-market approval of new products or modified products; (cid:120) withdrawing 510(k) clearances or pre-market approvals that have already been granted; (cid:120) (cid:120) refusal to grant export approval for our products; or criminal prosecution. Any of these sanctions could adversely affect our business, financial conditions and operating results. Outside the United States, our products and operations are also often required to comply with standards set by industrial standards bodies, such as the International Organization for Standardization, or ISO. Foreign regulatory bodies may evaluate our products or the testing that our products undergo against these standards. The specific standards, types of evaluation and scope of review differ among foreign regulatory bodies. If we fail to adequately comply with any of these standards, a foreign regulatory body may take adverse actions similar to those within the power of the FDA. Any such action may harm our reputation and could have an adverse effect on our business, results of operations and financial condition. If we fail to obtain and maintain regulatory approval in foreign jurisdictions, our market opportunities will be limited. Approximately 22% and 22% of our revenue was from sales outside of the United States for the twelve months ended December 31, 2014 and December 31, 2013, respectively. As of December 31, 2014, we sold our products in 44 countries outside of the United States through distributors or directly to large “house” accounts. In order to market our products in the European Union or other foreign jurisdictions, we must obtain and maintain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies from country to country and can involve additional testing. The time required to obtain approval abroad may be longer than the time required to obtain FDA clearance. The foreign regulatory approval process includes many of the risks associated with obtaining FDA clearance and we may not obtain foreign regulatory approvals on a timely basis, if at all. FDA clearance does not ensure approval by regulatory authorities in other countries, and approval by one foreign 30 regulatory authority does not ensure approval by regulatory authorities in other foreign countries. However, the failure to obtain clearance or approval in one jurisdiction may have a negative impact on our ability to obtain clearance or approval elsewhere. If we do not obtain or maintain necessary approvals to commercialize our products in markets outside the United States, it would negatively affect our overall market penetration. We may be subject to fines, penalties or injunctions if we are determined to be promoting the use of our products for unapproved or “off-label” uses, resulting in damage to our reputation and business. Our promotional materials and training methods must comply with the FDA and other applicable laws and regulations, including the prohibition of the promotion of a medical device for a use that has not been cleared or approved by the FDA. Use of a device outside its cleared or approved indications is known as “off-label” use. Physicians may use our products off-label, as the FDA does not restrict or regulate a physician’s choice of treatment within the practice of medicine. If the FDA determines that our promotional materials or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, which could have an adverse impact on our reputation and financial results. Failure to comply with the Federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, the Health Information Technology for Economic and Clinical Health Act, or HITECH Act, and implementing regulations (including the final omnibus rule published on January 25, 2013) affecting the transmission, security and privacy of health information could result in significant penalties. Numerous federal and state laws and regulations, including HIPAA and the HITECH Act, govern the collection, dissemination, security, use and confidentiality of patient-identifiable health information. HIPAA and the HITECH Act require us to comply with standards for the use and disclosure of health information within our company and with third parties. The Privacy Standards and Security Standards under HIPAA establish a set of basic national privacy and security standards for the protection of individually identifiable health information by health plans, healthcare clearinghouses and certain healthcare providers, referred to as covered entities, and the business associates with whom such covered entities contract for services. Notably, whereas HIPAA previously directly regulated only these covered entities, the HITECH Act, which was signed into law as part of the stimulus package in February 2009, makes certain of HIPAA’s privacy and security standards also directly applicable to covered entities’ business associates. As a result, both covered entities and business associates are now subject to significant civil and criminal penalties for failure to comply with Privacy Standards and Security Standards. HIPAA and the HITECH Act also include standards for common healthcare electronic transactions and code sets, such as claims information, plan eligibility, payment information and the use of electronic signatures, and privacy and electronic security of individually identifiable health information. Covered entities, such as healthcare providers, are required to conform to such transaction set standards pursuant to HIPAA. HIPAA requires healthcare providers like us to develop and maintain policies and procedures with respect to protected health information that is used or disclosed, including the adoption of administrative, physical and technical safeguards to protect such information. The HITECH Act expands the notification requirement for breaches of patient-identifiable health information, restricts certain disclosures and sales of patient-identifiable health information and provides a tiered system for civil monetary penalties for HIPAA violations. The HITECH Act also increased the civil and criminal penalties that may be imposed against covered entities, business associates and possibly other persons and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney fees and costs associated with pursuing federal civil actions. Additionally, certain states have adopted comparable privacy and security laws and regulations, some of which may be more stringent than HIPAA. If we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions. New health information standards, whether implemented pursuant to HIPAA, the HITECH Act, congressional action or otherwise, could have a significant effect on the manner in which we handle healthcare related data and communicate with payors, and the cost of complying with these standards could be significant. The 2013 final HITECH omnibus rule modifies the breach reporting standard in a manner that will likely make more data security incidents qualify as reportable breaches. Any liability from a failure to comply with the requirements of HIPAA or the HITECH Act could adversely affect our financial condition. The costs of complying with privacy and security related legal and regulatory requirements are burdensome and could have a material adverse effect on our results of operations. These new provisions, as modified, will be subject to interpretation by various courts and other governmental authorities, thus creating potentially complex compliance issues for us, as well as our clients and strategic partners. In addition, we are unable to predict what changes to the HIPAA Privacy Standards and Security Standards might be made in the future or how those changes could affect our business. Any new 31 legislation or regulation in the area of privacy and security of personal information, including personal health information, could also adversely affect our business operations. Regulations requiring the use of “standard transactions” for healthcare services issued under HIPAA may negatively impact our profitability and cash flows. Pursuant to HIPAA, final regulations have been implemented to improve the efficiency and effectiveness of the healthcare system by facilitating the electronic exchange of information in certain financial and administrative transactions while protecting the privacy and security of the information exchanged. The HIPAA transaction standards are complex, and subject to differences in interpretation by third-party payors. For instance, some third-party payors may interpret the standards to require us to provide certain types of information, including demographic information not usually provided to us by physicians. As a result of inconsistent application of transaction standards by third-party payors or our inability to obtain certain billing information not usually provided to us by physicians, we could face increased costs and complexity, a temporary disruption in accounts receivable and ongoing reductions in reimbursements and net revenue. In addition, requirements for additional standard transactions, such as claims attachments or use of a national provider identifier, could prove technically difficult, time-consuming or expensive to implement, all of which could harm our business. If we fail to comply with state and federal fraud and above laws, including anti-kickback, false claims and anti-inducement laws, we could face substantial penalties and our business, operations, and financial condition could be adversely affected. The federal anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce or in return for purchasing, leasing, ordering, or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid, or other federal financed healthcare programs. Although there are a number of statutory exceptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and any remuneration to or from a prescriber or purchaser of healthcare products or services may be subject to scrutiny if they do not qualify for an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Federal false claims laws prohibit any person from knowingly presenting or causing to be presented a false claim for payment to the federal government, or knowingly making or causing to be made a false statement to get a false claim paid. The majority of states also have statutes or regulations similar to the federal anti-kickback law and false claims laws, which apply to items or services, reimbursed under Medicaid and other state programs, or, in several states, apply regardless of payor. These false claims statutes allow any person to bring suit in the name of the government alleging false and fraudulent claims presented to or paid by the government (or other violations of the statutes) and to share in any amounts paid by the entity to the government in fines or settlement. Such suits, known as qui tam actions, have increased significantly in the healthcare industry in recent years. Sanctions under these federal and state laws may include civil monetary penalties, exclusion of a manufacturer’s products from reimbursement under government programs, criminal fines and imprisonment. In addition, the recently enacted Patient Protection and Affordable Care Act, among other things, amends the intent requirement of the federal anti-kickback and criminal healthcare fraud statutes. A person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Patient Protection and Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal anti- kickback statute constitutes a false or fraudulent claim for purposes of the false claims statutes. Because of the breadth of these laws and the narrowness of the safe harbors and exceptions, it is possible that some of our business activities could be subject to challenge under one or more of such laws. Such a challenge, regardless of the outcome, could have a material adverse effect on our business, business relationships, reputation, financial condition and results of operations. The Patient Protection and Affordable Care Act also imposes new reporting and disclosure requirements on device and drug manufacturers for any “transfer of value” made or distributed to prescribers and other healthcare providers. Device and drug manufacturers will also be required to report and disclose any investment interests held by physicians and their immediate family members during the preceding calendar year. Failure to submit required information may result in civil monetary penalties of up to an aggregate of $150,000 per year (and up to an aggregate of $1 million per year for “knowing failures”), for all payments, transfers of value or ownership or investment interests not reported in an annual submission. As of August 1, 2013, manufacturers are required to collect data, and were required to submit their first data reports to the Centers for Medicare & Medicaid Services by March 31, 2014 and by the 90th day of each calendar year thereafter. In addition, there has been a recent trend of increased federal and state regulation of payments made to physicians. Certain states, mandate implementation of compliance programs and/or the tracking and reporting of gifts, compensation and other remuneration to physicians. The shifting compliance environment and the need to build and maintain robust and expandable systems 32 to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that a healthcare company many violate one or more of the requirements. The Federal Civil Monetary Penalties Law prohibits the offering or giving of remuneration to a Medicare or Medicaid beneficiary that the person knows or should know is likely to influence the beneficiary’s selection of a particular supplier of items or services reimbursable by a Federal or state governmental healthcare program. We sometimes offer customers various discounts and other financial incentives in connection with the sales of our products. While it is our intent to comply with all applicable laws, the government may find that our marketing activities violate the Civil Monetary Penalties Law. If we are found to be in noncompliance, we could be subject to civil money penalties of up to $10,000 for each wrongful act, assessment of three times the amount claimed for each item or service and exclusion from the federal or state healthcare programs. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restricting of our operations. Any penalties, damages, fines, curtailment or restructuring or our operations could harm our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state fraud laws may prove costly. Foreign governments tend to impose strict price controls, which may adversely affect our future profitability. As of December 31, 2014 we sold our products in 44 countries outside the United States through distributors or directly to large “house” accounts. In some foreign countries, particularly in the European Union, the pricing of medical devices is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to supply data that compares the cost-effectiveness of our Inogen One systems and our Inogen At Home to other available oxygen therapies. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, it may not be profitable to sell our products in certain foreign countries, which would negatively affect the long-term growth of our business. Our business activities involve the use of hazardous materials, which require compliance with environmental and occupational safety laws regulating the use of such materials. If we violate these laws, we could be subject to significant fines, liabilities or other adverse consequences. Our research and development programs as well as our manufacturing operations involve the controlled use of hazardous materials. Accordingly, we are subject to federal, state and local laws governing the use, handling and disposal of these materials. Although we believe that our safety procedures for handling and disposing of these materials comply in all material respects with the standards prescribed by state and federal regulations, we cannot completely eliminate the risk of accidental contamination or injury from these materials. In the event of an accident or failure to comply with environmental laws, we could be held liable for resulting damages, and any such liability could exceed our insurance coverage. Risks related to our intellectual property If we are unable to secure and maintain patent or other intellectual property protection for the intellectual property used in our products, we will lose a significant competitive advantage, which may adversely affect our future profitability. Our commercial success depends, in part, on obtaining and maintaining patent and other intellectual property protection for the technologies used in our products. The patent positions of medical device companies, including ours, can be highly uncertain and involve complex and evolving legal and factual questions. Furthermore, we might in the future opt to license intellectual property from other parties. If we, or the other parties from whom we would license intellectual property, fail to obtain and maintain adequate patent or other intellectual property protection for intellectual property used in our products, or if any protection is reduced or eliminated, others could use the intellectual property used in our products, resulting in harm to our competitive business position. In addition, patent and other intellectual property protection may not: (cid:120) (cid:120) (cid:120) prevent our competitors from duplicating our products; prevent our competitors from gaining access to our proprietary information and technology; or permit us to gain or maintain a competitive advantage. 33 Any of our patents may be challenged, invalidated, circumvented or rendered unenforceable. We cannot provide assurance that we will be successful should one or more of our patents be challenged for any reason. If our patent claims are rendered invalid or unenforceable, or narrowed in scope, the patent coverage afforded our products could be impaired, which could make our products less competitive. As of December 31, 2014, we had five pending U.S. patent applications, 27 issued U.S. patents and one issued Canadian patent relating to the design and construction of our oxygen concentrators and our intelligent delivery technology. We cannot specify which of these patents individually or as a group will permit us to gain or maintain a competitive advantage. U.S. patents and patent applications may be subject to interference proceedings, and U.S. patents may be subject to re-examination, inter partes review, post- grant review, and derivation proceedings in the U.S. Patent and Trademark Office. Foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent offices. Any of these proceedings could result in loss of the patent or denial of the patent application, or loss or reduction in the scope of one or more of the claims of the patent or patent application. Changes in either patent laws or in interpretations of patent laws may also diminish the value of our intellectual property or narrow the scope of our protection. Interference, re-examination, inter partes review, and opposition proceedings may be costly and time consuming, and we, or the other parties from whom we might potentially license intellectual property, may be unsuccessful in defending against such proceedings. Thus, any patents that we own or might license may provide limited or no protection against competitors. In addition, our pending patent applications and those we may file in the future may have claims narrowed during prosecution or may not result in patents being issued. Even if any of our pending or future applications are issued, they may not provide us with adequate protection or any competitive advantages. Our patents and patent applications are directed to particular aspects of our products. Other parties may develop and obtain patent protection for more effective technologies, designs or methods for oxygen therapy. If these developments were to occur, it would likely have an adverse effect on our sales. Our ability to develop additional patentable technology is also uncertain. Non-payment or delay in payment of patent fees or annuities, whether intentional or unintentional, may also result in the loss of patents or patent rights important to our business. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to other parties. In addition, many countries limit the enforceability of patents against other parties, including government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as do the laws of the United States, particularly in the field of medical products and procedures. Our products could infringe the intellectual property rights of others, which may lead to patent and other intellectual property litigation that could itself be costly, could result in the payment of substantial damages or royalties, prevent us from using technology that is essential to our products, and/or force us to discontinue selling our products. The medical device industry in general has been characterized by extensive litigation and administrative proceedings regarding patent infringement and intellectual property rights. Our competitors hold a significant number of patents relating to oxygen therapy devices and products. From time to time, we have commenced litigation to enforce our intellectual property rights. For example, we have pursued litigation against Inova Labs Inc. for infringement of two of our patents seeking damages, injunctive relief, costs, and attorneys’ fees. An adverse decision in this action or in any other legal action could limit our ability to assert our intellectual property rights, limit the value of our technology or otherwise negatively impact our business, financial condition and results of operations. Monitoring unauthorized use of our intellectual property is difficult and costly. Unauthorized use of our intellectual property may have occurred or may occur in the future. Although we have taken steps to minimize the risk of this occurring, any such failure to identify unauthorized use and otherwise adequately protect our intellectual property would adversely affect our business. Moreover, if we are required to commence litigation, whether as a plaintiff or defendant as has occurred with Inova Labs Inc., not only will this be time-consuming, but we will also be forced to incur significant costs and divert our attention and efforts of our employees, which could, in turn, result in lower revenue and higher expenses. We cannot provide assurance that our products or methods do not infringe the patents or other intellectual property rights of third parties and if our business is successful, the possibility may increase that others will assert infringement claims against us. Determining whether a product infringes a patent involves complex legal and factual issues, and the outcome of a patent litigation action is often uncertain. We have not conducted an extensive search of patents issued or assigned to other parties, including our competitors, and no assurance can be given that patents containing claims covering our products, parts of our products, technology or methods do not exist, have not been filed or could not be filed or issued. Because of the number of patents issued and patent applications filed in our technical areas, our competitors or other parties may assert that our products and the methods we employ in the use of our products are covered by U.S. or foreign patents held by them. In addition, because patent applications can take many years to issue and because publication schedules for pending applications vary by jurisdiction and some companies opt not to publish 34 their patent applications, there may be applications now pending of which we are unaware and which may result in issued patents that our current or future products infringe. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. There could also be existing patents that one or more of our products or parts may infringe and of which we are unaware. As the number of competitors in the market for oxygen products and as the number of patents issued in this area grows, the possibility of patent infringement claims against us increases. In certain situations, we may determine that it is in our best interests to voluntarily challenge a party’s products or patents in litigation or other proceedings, including patent re-examinations, or inter partes reviews. As a result, we may become involved in unwanted litigation that could be costly, result in diversion of management’s attention, require us to pay damages and force us to discontinue selling our products. Infringement and other intellectual property claims and proceedings brought against us, whether successful or not, could result in substantial costs and harm to our reputation. Such claims and proceedings can also distract and divert management and key personnel from other tasks important to the success of the business. We cannot be certain that we will successfully defend against allegations of infringement of patents and intellectual property rights of others. In the event that we become subject to a patent infringement or other intellectual property lawsuit and if the other party’s patents or other intellectual property were upheld as valid and enforceable and we were found to infringe the other party’s patents or violate the terms of a license to which we are a party, we could be required to do one or more of the following: (cid:120) (cid:120) (cid:120) (cid:120) cease selling or using any of our products that incorporate the asserted intellectual property, which would adversely affect our revenue; pay damages for past use of the asserted intellectual property, which may be substantial; obtain a license from the holder of the asserted intellectual property, which license may not be available on reasonable terms, if at all, and which could reduce profitability; and redesign or rename, in the case of trademark claims, our products to avoid infringing the intellectual property rights of third parties, which may not be possible and could be costly and time-consuming if it is possible to do so. If we are unable to prevent unauthorized use or disclosure of trade secrets, unpatented know-how and other proprietary information, our ability to compete will be harmed. We rely on a combination of trade secrets, copyrights, trademarks, confidentiality agreements and other contractual provisions and technical security measures to protect certain aspects of our technology, especially where we do not believe that patent protection is appropriate or obtainable. We require our employees and consultants to execute confidentiality agreements in connection with their employment or consulting relationships with us. We also require our employees and consultants to disclose and assign to us all inventions conceived during the term of their employment or engagement while using our property or that relate to our business. We also require our corporate partners, outside scientific collaborators and sponsored researchers, advisors and others with access to our confidential information to sign confidentiality agreements. We also have taken precautions to initiate reasonable safeguards to protect our information technology systems. However, these measures may not be adequate to safeguard our proprietary intellectual property and conflicts may, nonetheless, arise regarding ownership of inventions. Such conflicts may lead to the loss or impairment of our intellectual property or to expensive litigation to defend our rights against competitors who may be better funded and have superior resources. Our employees, consultants, contractors, outside clinical collaborators and other advisors may unintentionally or willfully disclose our confidential information to competitors. In addition, confidentiality agreements may be unenforceable or may not provide an adequate remedy in the event of unauthorized disclosure. Enforcing a claim that a third party illegally obtained and is using our trade secrets is expensive and time-consuming, and the outcome is unpredictable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Unauthorized parties may also attempt to copy or reverse engineer certain aspects of our products that we consider proprietary, and in such cases we could not assert any trade secret rights against such party. As a result, other parties may be able to use our proprietary technology or information, and our ability to compete in the market would be harmed. We have registered the trademarks Inogen; Inogen One; Inogen One G2; Oxygenation; Live Life in Moments, not Minutes; Never Run Out of Oxygen; Oxygen Therapy on Your Terms; Oxygen. Anytime. Anywhere; Reclaim Your Independence; Intelligent Delivery Technology; and the Inogen design with the United States Patent and Trademark Office. We have applied with the United States Patent and Trademark Office to register the trademark Inogen at Home. We have registered the trademark Inogen in Australia, Canada, China, South Korea, Mexico, and in Europe (European Community registration). We have registered the trademark Inogen One in Australia, Canada, China, South Korea, Mexico, and in Europe (European Community registration). We have registered the trademark Satellite Conserver in Canada, and China. We have registered the trademark Inogen At Home in Europe (European Community Registration). 35 We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of other companies. Many of our employees were previously employed at other medical device companies focused on the development of oxygen therapy products, including our competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Even if we are successful in defending against these claims, litigation could result in substantial costs, damage to our reputation and be a distraction to management. Risks related to being a public company We will incur increased costs as a result of operating as a public company and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices. On February 20, 2014 we completed our initial public offering. As a public company, and increasingly after we are no longer an “emerging growth company,” we will incur significant legal, accounting and other expenses that we did not incur as a private company. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and the NASDAQ Global Select Market impose numerous requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Also, the Securities Exchange Act of 1934, as amended, or the Exchange Act, requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating results. Our management and other personnel will need to devote a substantial amount of time to compliance with these laws and regulations. These requirements have increased and will continue to increase our legal, accounting, and financial compliance costs and have made and will continue to make some activities more time consuming and costly. For example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors or our board committees or as executive officers. Overall, we estimate that our incremental costs resulting from operating as a public company, including compliance with these rules and regulations, may be between $1.5 million and $3.0 million per year. However, these rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Additionally, we are involved in a securities class action lawsuit as discussed in “Item 3 – Legal Proceedings.” The Sarbanes-Oxley Act requires, among other things, that we assess the effectiveness of our internal control over financial reporting annually and the effectiveness of our disclosure controls and procedures quarterly. In particular, Section 404(a) of the Sarbanes-Oxley Act, or Section 404(a), will require us to perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal control over financial reporting. Section 404(b) of Sarbanes-Oxley Act, or Section 404(b), also requires our independent registered public accounting firm to attest to the effectiveness of our internal control over financial reporting. As an “emerging growth company” we expect to avail ourselves of the exemption from the requirement that our independent registered public accounting firm attest to the effectiveness of our internal control over financial reporting under Section 404(b). However, we may no longer avail ourselves of this exemption when we are no longer an “emerging growth company.” When our independent registered public accounting firm is required to undertake an assessment of our internal control over financial reporting, the cost of our compliance with Section 404(b) will correspondingly increase. Our compliance with applicable provisions of Section 404 will require that we incur substantial accounting expense and expend significant management time on compliance-related issues as we implement additional corporate governance practices and comply with reporting requirements. Furthermore, investor perceptions of our company may suffer if deficiencies are found, and this could cause a decline in the market price of our stock. Irrespective of compliance with Section 404, any failure of our internal control over financial reporting could have a material adverse effect on our stated operating results and harm our reputation. If we are unable to implement these requirements effectively or efficiently, it could harm our operations, financial reporting, or financial results and could result in an adverse opinion on our internal controls from our independent registered public accounting firm. 36 We have identified a material weakness in our internal control over financial reporting. If we do not remediate the material weakness in our internal control over financial reporting, we may not be able to accurately report our financial results or file our periodic reports in a timely manner, which may cause investors to lose confidence in our reported financial information and may lead to a decline in the market price of our stock. Effective internal control over financial reporting is necessary for us to provide reliable financial reports in a timely manner. In connection with the audit of our financial statements for the year ended December 31, 2014, we concluded that there was a material weakness with respect to internal control over the review of sales order documentation supporting our direct-to-customer sales and rentals prior to revenue recognition. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We identified a material weakness with respect to internal control over the review of sales documentation related to our direct-to-customer sales and rentals prior to revenue recognition. The primary factors contributing to this material weakness were the improper use of technology to simulate medical documentation and absence of sufficient monitoring controls over illegitimate delivery of medical documentation. We are in the process of implementing a remediation plan to supplement control over financial reporting to address this material weakness. Steps we are taking to remediate the material weakness in our internal control over financial reporting of revenue include: implementation of a combination of new and revised control procedures in our order review process and compliance program, supplemented document retention policies on sales documentation, additional quarterly screening through data analytics to confirm compliance with our policies, and improved processes and controls in our customer relationship management software system. If one or more material weaknesses persist or if we fail to establish and maintain effective internal controls over financial reporting, our ability to timely and accurately report our financial results could be adversely affected. Although remediation efforts are still in progress, management is taking steps to remediate the material weakness in our internal control over financial reporting of revenue, including the implementation of new control procedures in our order review process and compliance audit program, thereby strengthening our control environment. However, we cannot assure you that these efforts will remediate our material weakness in a timely manner, or at all, or that our registered public accounting firm will be able to attest that such internal controls are effective when they are required to do so. Although we believe these controls, once properly designed and implemented, will be effective, our management, internal audit department and independent registered public accounting firm did not perform an evaluation of our internal control over financial reporting during any period in accordance with the provisions of the Sarbanes-Oxley Act. Had management, the internal audit department and our independent registered public accounting firm performed an evaluation of our internal control over financial reporting in accordance with the provisions of the Sarbanes-Oxley Act, additional control deficiencies amounting to material weaknesses may have been identified. As long as we qualify as an “emerging growth company” as defined by the Jumpstart our Business Startups Act of 2012, we will not be required to obtain an auditor’s attestation report on our internal controls in future annual reports on Form 10-K as otherwise required by Section 404(b) of the Sarbanes-Oxley Act. Our qualification as an emerging growth company may last for up to five years following our February 2014 IPO. If our efforts to remediate this material weakness are not successful or if other deficiencies occur, our ability to accurately and timely report our financial position, results of operations, cash flows or key operating metrics could be impaired, which could result in late filings of our annual and quarterly reports under the Exchange Act, restatements of our financial statements or other corrective disclosures. Additional impacts could include a decline in our stock price, suspension of trading or delisting of our common stock by NASDAQ Global Select Market, or other material adverse effects on our business, reputation, results of operations, financial condition or liquidity. Furthermore, if we continue to have this existing material weakness or other material weaknesses or significant deficiencies in the future, it could create a perception that our financial results do not fairly state our financial condition or results of operations. Any of the foregoing could have an adverse effect on the value of our stock. We are an “emerging growth company” and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors. We are an “emerging growth company,” as defined in the 2012 Jumpstart Our Business Startups (JOBS) Act, and we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced financial disclosure obligations, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any golden parachute payments not previously approved. We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging growth company upon the earliest to occur of: the last day of the fiscal year in which we have more than $1.0 billion in 37 annual revenue; the date we qualify as a large accelerated filer, with at least $700 million of equity securities held by non-affiliates; the issuance, in any three-year period, by us of more than $1.0 billion in non-convertible debt securities; and the last day of the fiscal year ending after the fifth anniversary of our initial public offering. We may choose to take advantage of some but not all of these reduced reporting burdens. If we take advantage of any of these reduced reporting burdens in future filings, the information that we provide our security holders may be different than you might get from other public companies in which you hold equity interests. In addition, the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. We have elected to avail ourselves of this exemption and, as a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. Risks related to our common stock We expect that our stock price will fluctuate significantly, and you may have difficulty selling your shares. Prior to our initial public offering, there was no public market for shares of our common stock. We cannot predict the extent to which investor interest in our company will lead to the development of an active trading market on the NASDAQ Global Select Market or otherwise or how liquid that market might become. If an active trading market does not develop, you may have difficulty selling any of our shares of common stock that you buy. In addition, the trading price of our common stock may be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control. These factors include: (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) actual or anticipated quarterly variation in our results of operations or the results of our competitors; announcements of secondary offerings; announcements by us or our competitors of new commercial products, significant contracts, commercial relationships or capital commitments; issuance of new or changed securities analysts’ reports or recommendations for our stock; developments or disputes concerning our intellectual property or other proprietary rights; commencement of, or our involvement in, litigation; (cid:120) market conditions in the oxygen therapy market; (cid:120) (cid:120) reimbursement or legislative changes in the oxygen therapy market; failure to complete significant sales; (cid:120) manufacturing disruptions that could occur if we were unable to successfully expand our production in our current or an alternative facility; any future sales of our common stock or other securities; any major change to the composition of our board of directors or management; and general economic conditions and slow or negative growth of our markets. (cid:120) (cid:120) (cid:120) The stock market in general and market prices for the securities of technology-based companies like ours in particular, have from time to time experienced volatility that often has been unrelated to the operating performance of the underlying companies. A certain degree of stock price volatility can be attributed to being a newly public company. These broad market and industry fluctuations may adversely affect the market price of our common stock, regardless of our operating performance. In several recent situations where the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders were to bring a lawsuit against us, the defense and disposition of the lawsuit could be costly and divert the time and attention of our management and harm our operating results. If securities or industry analysts do not publish research or publish unfavorable research about our business, our stock price and trading volume could decline. The trading market for our common stock will rely in part on the research and reports that equity research analysts publish about us and our business. We will not have any control of the analysts or the content and opinions included in their reports. The price of our stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If 38 one or more equity research analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock price or trading volume to decline. Future sales of shares could cause our stock price to decline. Our stock price could decline as a result of sales of a large number of shares of our common stock or the perception that these sales could occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Holders of approximately 8.1 million shares (including shares underlying outstanding warrants), or approximately 42.5%, of our outstanding shares, have rights, subject to some conditions, to require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also registered the offer and sale of all shares of common stock that we may issue under our equity compensation plans. In addition, in the future, we may issue additional shares of common stock or other equity or debt securities convertible into common stock in connection with a financing, acquisition, litigation settlement, and employee arrangements or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause our stock price to decline. Our directors, executive officers and principal stockholders will continue to have substantial control over us and could limit your ability to influence the outcome of key transactions, including changes of control. As of December 31, 2014, our executive officers, directors and stockholders who owned more than 5% of our outstanding common stock and their respective affiliates beneficially owned or controlled approximately 42.3% of the outstanding shares of our common stock. Accordingly, these executive officers, directors and stockholders who owned more than 5% of our outstanding common stock and their respective affiliates, acting as a group, have substantial influence over the outcome of corporate actions requiring stockholder approval, including the election of directors, any merger, consolidation or sale of all or substantially all of our assets or any other significant corporate transactions. These stockholders may also delay or prevent a change of control of us, even if such a change of control would benefit our other stockholders. The significant concentration of stock ownership may adversely affect the trading price of our common stock due to investors’ perception that conflicts of interest may exist or arise. Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management and limit the market price of our common stock. Provisions in our certificate of incorporation and bylaws may have the effect of delaying or preventing a change of control or changes in our management. Our amended and restated certificate of incorporation and amended and restated bylaws include provisions that: (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) authorize our board of directors to issue, without further action by the stockholders, up to 10,000,000 shares of undesignated preferred stock; require that any action to be taken by our stockholders be effected at a duly called annual or special meeting and not by written consent; specify that special meetings of our stockholders can be called only by our board of directors, the Chairman of the board of directors, or the Chief Executive Officer; establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors; establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three year terms; provide that our directors may be removed only for cause; provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum; specify that no stockholder is permitted to cumulate votes at any election of directors; and require a super-majority of votes to amend certain of the above-mentioned provisions. 39 These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. We continue to retain broad discretion in the use of the net proceeds from our initial public offering and may not use them effectively. We continue to retain broad discretion in the application of the net proceeds from our initial public offering and could spend the proceeds in ways that do not improve our results of operations or enhance the value of our common stock. We might not be able to yield a significant return, if any, on any investment of these net proceeds from the initial public offering. Stockholders will not have the opportunity to influence our management’s decisions on how to use the net proceeds, and our failure to apply these funds effectively could have a material adverse effect on our business and cause the price of our common stock to decline. We have never paid dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable future. We have paid no cash dividends on any of our classes of capital stock to date, have contractual restrictions against paying cash dividends and currently intend to retain our future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future. ITEM 1B. UNRESOLVED STAFF COMMENTS None. ITEM 2. PROPERTIES We lease approximately 39,000 square feet of manufacturing and office space at our corporate headquarters in Goleta, California under a lease that expires in October 2020, and approximately 31,000 square feet of manufacturing and office space in Richardson, Texas under a lease that expires in December 2019. We have leased an additional 24,000 square foot facility in Richardson, Texas to move our manufacturing to allow for capacity expansion. This move occurred in the first half of 2015, and will require registration with the FDA and ISO certification. Operations continued in our current facilities until this facility was ready. We believe that our existing facilities are adequate to meet our business requirements for the near-term and that additional space will be available on commercially reasonable terms, if required. ITEM 3. LEGAL PROCEEDINGS Inova Labs Litigation On November 4, 2011, we filed a lawsuit in the United States District Court for the Central District of California against Inova Labs Inc., or Defendant, for infringement of two of our patents. The case, Inogen Inc. v. Inova Labs Inc., Case No. 8:11-cv-01692- JST-AN, or the Lawsuit, involves U.S. Patent Nos. 7,841,343, entitled “Systems and Methods For Delivering Therapeutic Gas to Patients,” or the ’343 patent, and 6,605,136 entitled “Pressure Swing Adsorption Process Operation And Optimization,” or the ’136 patent. We alleged in the Lawsuit that certain of Defendant’s oxygen concentrators infringe various claims of the ’343 and ’136 patents. The Lawsuit seeks damages, injunctive relief, costs and attorneys’ fees. The Defendant has answered the complaint, denying infringement and asserting various sets of defenses including non- infringement, invalidity and unenforceability, patent misuse, unclean hands, laches and estoppel. The Defendant also filed counterclaims against us alleging patent invalidity, non-infringement and inequitable conduct. We denied the allegations in the Defendant’s counterclaims and filed a motion to dismiss Defendant’s inequitable conduct counterclaim. The Defendant filed a request with the U.S. Patent and Trademark Office seeking an inter partes reexamination of the ’343 and ’136 patents. The Defendant also filed a motion to stay the Lawsuit pending outcome of the reexamination. On March 20, 2012, the Court granted the Defendant’s motion to stay the Lawsuit pending outcome of the reexamination and also granted our motion to dismiss the Defendant’s inequitable conduct counterclaim. 40 Securities class action lawsuit On March 13 and March 19, 2015, plaintiffs Brad Christi and Roger D. Holford each filed, respectively, a lawsuit against Inogen, Raymond Huggenberger, Inogen’s President and Chief Executive Officer, and Alison Bauerlein, Inogen’s Executive Vice President and Chief Financial Officer, in the United States District Court for the Central District of California on behalf of a purported class of purchasers of our securities between November 12, 2014 and March 11, 2015. The complaints allege that Inogen, Mr. Huggenberger and Ms. Bauerlein violated Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, and that Mr. Huggenberger and Ms. Bauerlein violated Section 20(a) of the Securities Exchange Act of 1934. Specifically, the complaints allege that during the purported class period our financial statements and disclosures concerning internal controls over financial reporting were materially false and misleading. The complaints seek compensatory damages in an unspecified amount, costs and expenses, including attorneys’ fees and expert fees, prejudgment and post-judgment interest and such other relief as the court deems proper. The deadline for motions for appointment as lead plaintiff is May 12, 2015. We intend to vigorously defend ourselves against these allegations. We are currently unable to predict the outcome of these lawsuits and therefore cannot determine the likelihood of loss nor estimate a range of possible loss. Other litigation We are party to various legal proceedings arising in the normal course of business. We carry insurance, subject to specified deductibles under the policies, to protect against losses from certain types of legal claims. At this time, we do not anticipate that any of these proceedings will have a material adverse effect on our business. ITEM 4. MINE SAFETY DISCLOSURES None. 41 PART II ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES Market Information and Holders Our common stock has been publicly traded on the NASDAQ Global Select Market under the symbol “INGN” since February 14, 2014. Prior to that time, there was no public market for our common stock. The following table sets forth, for the periods indicated, the high and low sales prices for our common stock as reported on The NASDAQ Global Select Market. Year ended December 31, 2014 First quarter (beginning February 14, 2014) ........................ $ Second quarter ..................................................................... $ Third quarter ........................................................................ $ Fourth quarter ...................................................................... $ High Low 21.00 $ 22.62 $ 24.50 $ 32.19 $ 14.78 13.12 17.72 19.16 On April 15, 2015, the closing price for our common stock as reported on the NASDAQ Global Select Market was $35.36 per share. 42 Stock Performance Graph The following graph compares the performance of our common stock for the periods indicated with the performance of the S & P Healthcare and Supplies Index, the Russell 2000 Index, and the NASDAQ Composite Index. This graph assumes an investment of $100 on February 14, 2014 in each of our common stock, the NASDAQ Composite Index and the S & P Healthcare Equipment and Supplies, the Russell 2000 and assumes reinvestment of dividends, if any. The stock price performance shown on the graph below is not necessarily indicative of future stock price performance. SHAREHOLDER RETURN PERFORMANCE GRAPH COMPARISON OF THE YEARS CUMULATIVE TOTAL RETURN SINCE FEBRUARY 14, 2014 Among Inogen, Inc., the S & P Healthcare Equipment and Supplies Index, the Russell 2000 Index and the NASDAQ Composite Index $250.00(cid:3) $200.00(cid:3) $150.00(cid:3) $100.00(cid:3) $50.00(cid:3) $50.00 $(cid:882) 2/14/2014 3/31/14 4/30/14 5/31/14 6/30/14 7/31/14 8/31/14 9/30/14 10/31/14 11/30/14 12/31/14 Inogen,(cid:3)Inc. S(cid:3)&(cid:3)P(cid:3)Healthcare(cid:3)Equipment(cid:3)&(cid:3)Supplies^(1) Russell(cid:3)2000^(2) Nasdaq(cid:3)Composite^(3) Month(cid:3)Ending 2/14/2014 3/31/14 4/30/14 5/31/14 6/30/14 7/31/14 8/31/14 9/30/14 10/31/14 11/30/14 12/31/14 Inogen, Inc. .......................... $ 100.00 $ 108.98 $ 93.14 $110.76 $148.91 $132.01 $ 136.30 $136.04 $ 155.84 $ 160.33 $ 207.06 S & P Healthcare Equipment & Supplies^(1) .... (cid:3) 100.00 99.30 92.16 96.38 99.87 98.38 97.74 95.71 104.74 109.15 112.13 Russell 2000^(2) .................... (cid:3) 100.00 102.07 98.06 98.72 103.81 97.46 102.19 95.86 102.11 102.09 104.83 Nasdaq Composite^(3) .......... (cid:3) 100.00 98.94 96.95 99.97 103.87 102.96 107.92 105.88 109.11 112.90 111.59 (1) The S&P Healthcare Equipment and Supplies Index is a capitalization weighted average index compiled of healthcare companies in the S&P 500 Index. (2) The Russell 2000 Index is a small-cap stock market index of the bottom 2,000 stocks in the Russell 3000 Index (3) The Nasdaq Composite is a market-value weighted index of all common stocks listed on the NASDAQ. 43 Stockholders As of April 15, 2015, there were 37 registered stockholders of record for our common stock. The actual number of stockholders is greater than this number of record holders and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities. Dividend Policy We have never declared or paid any cash dividends on our common stock or any other securities. We anticipate that we will retain all available funds and any future earnings, if any, for use in the operation of our business and do not anticipate paying cash dividends in the foreseeable future. In addition, our revolving credit agreement materially restricts, and future debt instruments we issue may materially restrict, our ability to pay dividends on our common stock. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including our financial condition, operating results, current and anticipated cash needs, the requirements of current or then-existing debt instruments and other factors our board of directors deems relevant. Recent Sales of Unregistered Securities The following list sets forth information regarding all unregistered securities sold by us since January 1, 2014. Between January 1, 2014 and December 31, 2014, we sold securities in transactions that were not registered under the Securities Act as set forth below. Between January 1, 2014 and February 18, 2014 (the date of the filing of our registration statement on Form S-8, File No. 333- 194016), we issued and sold the following stock: (cid:120) we issued 2,093 shares of our common stock to officers, employees and consultants upon the exercise of options, at exercise prices ranging from $0.60 to $8.70 per share, for an aggregate exercise price of $5,235 pursuant to our 2002 Stock Incentive Plan. Between January 1, 2014 and December 31, 2014 we issued and sold the following warrants: (cid:120) we issued 218,174 shares of our common stock, upon the conversion of 218,393 common stock warrants (of which 16,206 common stock warrants were exercised via cashless exercise into 15,987 shares of common stock) to investors upon the exercise of warrants at an exercise price of $0.30 per warrant for an aggregate exercise price of $60,656, (cid:120) we issued 11,056 shares of our common stock, upon the conversion of 11,459 Series C redeemable convertible preferred stock warrants (of which 631 shares were exercised via a cashless exercise into 228 shares of common stock) to investors upon the exercise warrants at an exercise price of $17.58 per Series C warrant for an aggregate exercise price of $195,033, (cid:120) we issued 11,415 share of our common stock, upon the conversion of 11,415 Series D redeemable convertible preferred stock warrants an exercise price of $21.90 per Series D warrant for an aggregate exercise price of $249,989, and (cid:120) we issued 4,053 shares of our common stock, upon the conversion of 4,222 Series E redeemable convertible preferred stock warrants convertible into 11,367 shares of common stock via a cashless exercise of such warrants. None of the foregoing transactions involved any underwriters, underwriting discounts or commissions, or any public offering. We believe the offers, sales and issuances of the above securities were exempt from registration under the Securities Act by virtue of Section 4(2) of the Securities Act because the issuance of securities to the recipients did not involve a public offering, or in reliance on Rule 701 because the transactions were pursuant to compensatory benefit plans or contracts relating to compensation as provided under such rule. The recipients of the securities in each of these transactions represented their intentions to acquire the securities for investment only and not with a view to or for sale in connection with any distribution thereof, and appropriate legends were placed upon the stock certificates issued in these transactions. All recipients had adequate access, through their relationships with us, to information about us. The sales of these securities were made without any general solicitation or advertising. 44 Use of Proceeds from Initial Public Offering of Common Stock On February 12, 2014, our Registration Statement on Form S-1, as amended (Reg. No. 333- 192605) was declared effective in connection with the IPO of our common stock, pursuant to which we sold 3,529,411 shares at a price to the public of $16.00 per share. Additionally, the selling stockholders sold 981,902 shares of common stock (882,352 upon the IPO, and 99,550 of which were sold pursuant to a 30-day option granted to the underwriters). The offering closed on February 20, 2014, as a result of which we received net proceeds of approximately $52.5 million after underwriting discounts of approximately $3.9 million, but before offering expenses of approximately $2.7 million. We did not receive any proceeds from the shares sold by the selling stockholders. J.P. Morgan acted as sole book-running manager for the offering, Leerink Partners acted as lead manager, and William Blair and Stifel acted as co- managers. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities, or (iii) any of our affiliates. There has been no material change in the planned use of proceeds from our initial public offering as described in our final prospectus filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on February 14, 2014. ITEM 6. SELECTED FINANCIAL DATA The following selected historical financial data should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, our financial statements and the related notes included in Item 8, “Financial Statements and Supplementary Data” of this Annual Report on Form 10-K. The statements of operations data for the years ended December 31, 2014, 2013, 2012 and 2011 and the balance sheet data as of December 31, 2014, 2013, 2012 and 2011 are derived from our audited financial statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in this Annual Report on Form 10-K. The balance sheet data as of December 31, 2012 and 2011 are derived from our audited financial statements not included in this Annual Report on Form 10-K. Our historical results are not necessarily indicative of the results that may be expected in the future and our interim results are not necessarily indicative of results to be expected for the full fiscal year. (amounts in thousands, except share and per share amounts) Revenue Year ended December 31, 2014 2013 2012 2011 Sales revenue ................................................................... $ Rental revenue ................................................................. Total revenue .............................................................. 73,096 $ 39,441 112,537 44,905 $ 30,538 75,443 28,704 $ 19,872 48,576 Cost of revenue Cost of sales revenue ....................................................... Cost of rental revenue ...................................................... Total cost of revenue .................................................. Gross profit ............................................................................ Operating expenses Research and development .............................................. Sales and marketing ......................................................... General and administrative .............................................. Total operating expenses ............................................ Income (loss) from operations ............................................... Other expense, net ................................................................. Income (loss) before provision for income taxes .................. Provision (benefit) for income taxes ................................ Net income (loss) .................................................................. $ 38,693 18,327 57,020 55,517 2,977 24,087 17,942 45,006 10,511 (459) 10,052 3,226 6,826 $ 24,306 12,146 36,452 38,991 17,384 7,243 24,627 23,949 2,398 18,375 13,754 34,527 4,464 (616) 3,848 (21,587) 25,435 $ 2,262 12,569 8,289 23,120 829 (247 ) 582 18 564 $ 19,657 10,977 30,634 12,147 3,783 15,930 14,704 1,789 9,014 5,623 16,426 (1,722) (267) (1,989) 13 (2,002) 45 (amounts in thousands, except share and per share amounts) Reconciliation of net income to net income (loss) to common stockholders - basic and diluted Numerator-basic and diluted: Net income (loss) ....................................................................... $ Less deemed dividend on redeemable preferred stock ............... Net income (loss) after deemed dividend ................................... Less preferred rights dividend .................................................... Less: undistributed earnings to preferred stock - basic .............. Net income (loss) attributable to common stockholders - basic .... $ Numerator-diluted Net income (loss) ....................................................................... $ Less deemed dividend on redeemable preferred stock ............... Net income (loss) after deemed dividend ................................... Less preferred rights dividend .................................................... Less: undistributed earnings to preferred stock - diluted ........... Net income (loss) attributable to common stockholders - diluted ........................................................................................ $ Year ended December 31, 2014 2013 2012 2011 6,826 $ (987) 5,839 — (567) 5,272 $ 6,826 $ (987) 5,839 — (514) 25,435 $ (7,278) 18,157 (7,165) (10,781) 211 $ 25,435 $ (7,278) 18,157 (7,165) (9,625) 564 $ (5,781 ) (5,217 ) — — (5,217 ) $ 564 $ (5,781 ) (5,217 ) — — (2,002) (3,027) (5,029) — — (5,029) (2,002) (3,027) (5,029) — — 5,325 $ 1,367 $ (5,217 ) $ (5,029) Denominator: Weighted-average common shares-basic common stock ................. 16,182,569 Weighted-average common shares-diluted common stock .............. 18,037,498 0.33 $ Net income (loss) per share-basic common stock ............................ $ Net income (loss) per share-diluted common stock ......................... $ 0.30 $ Shares excluded from diluted net income (loss) Common stock warrants ............................................................ Preferred convertible stock ........................................................ Stock options ............................................................................. Shares excluded from diluted net income (loss)......................... — — 546,142 546,142 276,535 2,008,156 0.76 $ 0.68 $ 261,268 261,268 (19.97 ) $ (19.97 ) $ 249,519 249,519 (20.15) (20.15) — 233,611 — 14,057,509 — 1,646,223 — 15,937,343 250,997 10,899,820 1,425,624 12,576,441 (1) See note 2 to each of our audited financial statements included elsewhere in this Annual Report on Form 10-K for an explanation of the calculations of our basic and diluted net loss per share attributable to common stockholders and pro forma net loss per share attributable to common stockholders. (2) For a discussion of our use of EBITDA, Adjusted EBITDA and Adjusted net income (loss) and their calculations, please see “Non GAAP financial measures.” (amounts in thousands) Balance sheet data: Cash and cash equivalents ..................................................... $ Working capital ..................................................................... Total assets ............................................................................ Total indebtedness ................................................................. Deferred revenue ................................................................... Total liabilities....................................................................... Redeemable convertible preferred stock ............................... Total stockholders' equity (deficit) ........................................ Year ended December 31, 2014 2013 2012 2011 56,836 $ 73,808 140,085 614 4,492 21,935 — 118,150 13,521 $ 14,003 82,397 10,649 2,263 26,098 118,671 (62,372) 15,112 $ 13,077 47,586 8,936 1,094 19,011 109,345 (80,770 ) 3,906 1,302 24,131 9,629 594 16,575 83,122 (75,566) 46 Non-GAAP financial measures EBITDA, Adjusted EBITDA, and Adjusted net income (loss) are financial measures that are not calculated in accordance with generally accepted accounting principles in the United States, or GAAP. We define EBITDA as net income or loss excluding interest income, interest expense, taxes and depreciation and amortization. Adjusted EBITDA also excludes the change in the fair value of our preferred stock warrant liability and stock-based compensation. Below, we have provided a reconciliation of EBITDA, Adjusted EBITDA, and Adjusted net income (loss) to our net income or loss, the most directly comparable financial measure calculated and presented in accordance with GAAP. EBITDA, Adjusted EBITDA, and Adjusted net income (loss) should not be considered alternatives to net income or loss or any other measure of financial performance calculated and presented in accordance with GAAP. Our EBITDA, and Adjusted EBITDA, and Adjusted net income (loss) may not be comparable to similarly titled measures of other organizations because other organizations may not calculate EBITDA, Adjusted EBITDA, and Adjusted net income (loss) in the same manner as we calculate these measures. We include EBITDA, Adjusted EBITDA and Adjusted net income (loss) in this 10-K because they are important measures upon which our management assesses our operating performance. We use EBITDA, Adjusted EBITDA and Adjusted net income (loss) as key performance measures because we believe they facilitate operating performance comparisons from period to period by excluding potential differences primarily caused by variations in capital structures, tax positions, the impact of depreciation and amortization expense on our fixed assets, changes related to the fair value re-measurements of our preferred stock warrant, and the impact of stock- based compensation expense. Because EBITDA, Adjusted EBITDA and Adjusted net income (loss) facilitate internal comparisons of our historical operating performance on a more consistent basis, we also use EBITDA, Adjusted EBITDA and Adjusted net income (loss) for business planning purposes, to incentivize and compensate our management personnel, and in evaluating acquisition opportunities. In addition, we believe EBITDA, Adjusted EBITDA and Adjusted net income (loss) and similar measures are widely used by investors, securities analysts, ratings agencies, and other parties in evaluating companies in our industry as a measure of financial performance and debt-service capabilities. Our use of EBITDA, Adjusted EBITDA and Adjusted net income (loss) have limitations as analytical tools, and you should not consider them in isolation or as a substitute for analysis of our results as reported under GAAP. Some of these limitations are: (cid:120) EBITDA, Adjusted EBITDA and Adjusted net income (loss) do not reflect our cash expenditures for capital equipment or other contractual commitments; (cid:120) Although depreciation and amortization are non-cash charges, the assets being depreciated and amortized may have to be replaced in the future, and EBITDA, Adjusted EBITDA and Adjusted net income (loss) do not reflect capital expenditure requirements for such replacements; (cid:120) EBITDA, Adjusted EBITDA and Adjusted net income (loss) do not reflect changes in, or cash requirements for, our working capital needs; (cid:120) EBITDA, Adjusted EBITDA, and Adjusted net income (loss) do not reflect the interest expense or the cash requirements necessary to service interest or principal payments on our indebtedness; and (cid:120) Other companies, including companies in our industry, may calculate EBITDA, Adjusted EBITDA and Adjusted net income (loss) measures differently, which reduces their usefulness as a comparative measure. In evaluating EBITDA, Adjusted EBITDA, and Adjusted net income (loss) you should be aware that in the future we will incur expenses similar to the adjustments in this presentation. Our presentation of EBITDA, Adjusted EBITDA and Adjusted net income (loss) should not be construed as an inference that our future results will be unaffected by these expenses or any unusual or non- recurring items. When evaluating our performance, you should consider EBITDA, Adjusted EBITDA and Adjusted net income (loss) alongside other financial performance measures, including other GAAP results. 47 The following table presents a reconciliation of EBITDA and Adjusted EBITDA to our net income (loss), the most comparable GAAP measure, for each of the periods indicated: Year ended December 31, EBITDA Net income (loss) (GAAP) ............................................................................. $ 2014 2013 2012 2011 6,826 $ 25,435 $ 564 $ (2,002) Non-GAAP adjustments: Interest expense ........................................................................................ Interest income ......................................................................................... Provision (benefit) for income taxes ........................................................ Depreciation and amortization ................................................................. EBITDA ..................................................................................... Change in fair value of preferred stock warrant liability ........................ Stock-based compensation ....................................................................... Adjusted EBITDA (Non-GAAP) ............................................... $ 449 (42 ) 3,226 12,080 22,539 (36 ) 1,451 23,954 $ 562 (12 ) (21,587) 8,544 12,942 262 230 13,434 $ 493 (88 ) 18 4,984 5,971 (148 ) 60 5,883 $ 261 (113) 13 3,198 1,357 119 144 1,620 Net income (loss) (GAAP) ............................................................................. $ 6,826 $ 25,435 $ 564 $ (2,002) Non-GAAP adjustments: One-time benefit from reversal of deferred tax valuation and other tax adjustments ........................................ Adjusted net income (loss) (non-GAAP) ................................... $ (258) 6,568 $ (21,807) 3,628 $ — 564 $ — (2,002) Pro-forma non-GAAP results of EPS calculation (1) (2) Net income after preferred rights dividend ....................................................... $ Add back deemed dividend on redeemable preferred stock ...................... Pro-forma net income attributable to common stockholders ............................ $ Pro-forma net income per share - basic common stock .................................... $ Pro-forma net income per share - diluted common stock ................................. $ Year ended December 31, 2013 2012 2014 5,839 $ 987 6,826 $ 0.38 $ 0.35 $ 18,157 $ 7,278 25,435 $ 1.74 $ 1.55 $ 564 — 564 0.04 0.04 Denominator: Pro-forma weighted-average common shares - basic common stock .............. Pro-forma weighted-average common shares - diluted common stock ........... 17,924,357 19,779,291 14,636,950 16,368,571 14,601,861 15,486,487 (1) The pro-forma non-GAAP EPS calculations give effect to: (1) the automatic conversion of the outstanding convertible preferred stock into a weighted-average of 14,219,001 and 14,057,509 for the years ended December 31, 2014 and 2013, respectively, (2) the cash exercise of warrants to purchase an aggregate of 46,042 and 142,495 shares of common stock for the years ended December 31, 2014 and 2013, respectively. (2) See note 2 to our financial statements included elsewhere in this Annual Report on Form 10-K for an explanation of the calculations of our basic and diluted net income per share attributable to common stockholders and pro-forma net income per share attributable to common stockholders. 48 GAAP results of EPS Calculation (amounts in thousands, except share and per share amounts) Reconciliation of net income to net income (loss) to common stockholders - basic and diluted Numerator-basic and diluted: Net income (loss) ....................................................................... $ Less deemed dividend on redeemable preferred stock ............... Net income (loss) after deemed dividend ................................... Less preferred rights dividend .................................................... Less: undistributed earnings to preferred stock - basic .............. Net income (loss) attributable to common stockholders - basic ....... $ Numerator-diluted Net income (loss) ....................................................................... $ Less deemed dividend on redeemable preferred stock ............... Net income (loss) after deemed dividend ................................... Less preferred rights dividend .................................................... Less: undistributed earnings to preferred stock - diluted ........... Net income (loss) attributable to common stockholders – diluted ..................................................................................... $ Year ended December 31, 2014 2013 2012 2011 6,826 $ (987) 5,839 — (567) 5,272 $ 6,826 $ (987) 5,839 — (514) 25,435 $ (7,278) 18,157 (7,165) (10,781) 211 $ 25,435 $ (7,278) 18,157 (7,165) (9,625) 564 $ (5,781 ) (5,217 ) — — (5,217 ) $ 564 $ (5,781 ) (5,217 ) — — (2,002) (3,027) (5,029) — — (5,029) (2,002) (3,027) (5,029) — — 5,325 $ 1,367 $ (5,217 ) $ (5,029) Denominator: Weighted-average common shares-basic common stock ................. 16,182,569 Weighted-average common shares-diluted common stock .............. 18,037,498 0.33 $ Net income (loss) per share-basic common stock ............................ $ Net income (loss) per share-diluted common stock ......................... $ 0.30 $ Shares excluded from diluted net income (loss) Common stock warrants ............................................................ Preferred convertible stock ........................................................ Stock options ............................................................................. Shares excluded from diluted net income (loss)......................... — — 546,142 546,142 276,535 2,008,156 0.76 $ 0.68 $ 261,268 261,268 (19.97 ) $ (19.97 ) $ 249,519 249,519 (20.15) (20.15) — 233,611 — 14,057,509 — 1,646,223 — 15,937,343 250,997 10,899,820 1,425,624 12,576,441 49 ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following discussion and analysis of the financial condition and results of our operations should be read in conjunction with the financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those discussed below. Factors that could cause or contribute to such differences include, but are not limited to, those identified below, and those discussed in the section titled “Risk Factors” included elsewhere in this Annual Report on Form 10-K. Audit Committee Investigation As previously disclosed, during the first quarter of 2015, management discovered certain potential accounting matters, prompting the Audit Committee, with the assistance of independent advisors, to commence an internal investigation. Specifically, management found that certain direct-to-consumer sales representatives submitted modified documentation in violation of Inogen policies. The Audit Committee’s investigation is now complete. Its principal finding is that five Inogen direct-to-consumer sales representatives falsified or improperly modified sales and rental order documentation and circumvented Inogen’s order entry process. Revenue in the fourth quarter of 2014 was reduced by $0.3 million including prior period adjustments. The net income impact was a reduction of $0.1 million in the fourth quarter of 2014. Substantially all of this revenue will be recognized when the corrected documentation is finalized in 2015. The employees responsible for this conduct have been terminated. The investigation found that the Company’s senior executives did not know of or participate in this conduct. The Audit Committee’s investigation did not reveal systemic falsification or alteration of sales and rental order documentation by other sales representatives. The Company expects additional general and administrative costs due to the audit committee investigation of approximately $1.0 to $1.5 million, primarily in the first quarter of 2015 Overview We are a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which limits patient mobility and requires patients to plan activities outside of their homes around delivery schedules. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. We refer to this traditional delivery approach as the delivery model. Our proprietary Inogen One systems are devices that concentrate the air around them to offer a single source of supplemental oxygen anytime, anywhere. Using our portable systems, patients can eliminate their dependence on stationary concentrators and tank and cylinder deliveries, thereby improving quality-of-life and fostering mobility. In May 2004, we received 510(k) clearance from the U.S. Food and Drug Administration, or the FDA, for our Inogen One G1. From our launch of the Inogen One G1 in 2004, through 2008, we derived our revenue almost exclusively from sales to healthcare providers and distributors. In December 2008, we acquired Comfort Life Medical Supply, LLC in order to secure access to the Medicare rental market and began accepting Medicare reimbursement for our oxygen solutions in certain states. At the time of the acquisition, Comfort Life Medical Supply, LLC had an active Medicare billing number but few other assets and limited business activities. In January 2009, following the acquisition of Comfort Life Medical Supply, LLC, we initiated our direct-to-consumer marketing strategy and began selling Inogen One systems directly to patients and building our Medicare rental business in the United States. In April 2009, we became a Durable, Medical Equipment, Prosthetics, Orthotics, and Supplies accredited Medicare supplier by the Accreditation Commission for Health Care for our Goleta, California facility for Home/Durable Medical Equipment Services for oxygen equipment and supplies. We believe we are the only portable oxygen concentrator manufacturer that employs a direct-to- consumer marketing strategy in the United States, meaning we advertise directly to patients, process their physician paperwork, provide clinical support as needed and bill Medicare or insurance on their behalf. Revenue We derive a majority of our revenue from the sale and rental of our Inogen One systems and related accessories to patients, insurance carriers, home healthcare providers and distributors. We sell multiple configurations of our Inogen One systems with various batteries, accessories, warranties, power cords, and language settings. We also rent our products to Medicare beneficiaries and patients with other insurance coverage to support their oxygen needs as prescribed by a physician as part of a care plan. Our goal is to 50 design, build and market oxygen solutions that redefine how oxygen therapy is delivered. To accomplish this goal and to grow our revenue, we intend to continue to: (cid:121) Expand our sales and marketing channels. We will continue to hire additional internal sales representatives to drive our direct-to-consumer marketing efforts. During the year ended December 31, 2014, we increased our internal sales representatives from 108 to 129. In 2014, we experienced headcount turnover of our internal sales team of 22.1%. Typically, we expect new sales representatives to take 4-6 months to reach full productivity. Additionally, we are building a physician referral channel that currently consists of twelve sales representatives up from eleven as of December 31, 2013. Lastly, we are focused on building our international distribution capabilities. (cid:121) Invest in our product offerings to develop innovative products. We expended $3.0 million, $2.4 million and $2.3 million in 2014, 2013 and 2012, respectively, in research and development expenses, and we intend to continue to make such investments in the foreseeable future. (cid:121) Secure contracts with healthcare payors and insurers. Based on our patient population, we estimate that at least 30% of oxygen therapy patients are covered by non-Medicare payors, and that these patients often represent a younger, more active patient segment. By becoming an in-network provider with more insurance companies, we can reduce the co-insurance for patients, which we believe will allow us to attract additional patients to our Inogen One solutions. We have been developing and refining the manufacturing of our Inogen One systems over the past ten years. While nearly all of our manufacturing and assembly processes were originally outsourced, assembly of the manifold, compressor, sieve bed and concentrator is now conducted in-house in order to improve quality control and reduce cost. Additionally, we use lean manufacturing practices to maximize manufacturing efficiency. We rely on third-party manufacturers to supply several components of our Inogen One systems and Inogen At Home systems. We typically enter into supply agreements for these components that specify quantity, quality requirements and delivery terms. In certain cases, these agreements can be terminated by either party upon relatively short notice. We have elected to source certain key components from single sources of supply, including our batteries, bearings, carry bags, motors, pistons, valves, and molded plastic components. While alternative sources of supply are readily available for these components, we believe that maintaining a single-source of supply allows us to control production costs and inventory levels, and to manage component quality. Historically, we have generated a majority of our revenue from sales and rentals to customers in the United States. In 2014, 2013 and 2012, approximately 22%, 22% and 27%, respectively, of our total revenue was from customers outside the United States, primarily in Europe. To date, most of our revenue has been denominated in United States dollars. As of December 31, 2014, we sold our products in 44 countries outside the United States through distributors or directly to large “house” accounts, which include gas companies and home oxygen providers. In those instances, we sell to and bill the distributor or “house” accounts directly, leaving responsibility for the patient billing, support and clinical setup to the local provider. As of December 31, 2014, we had five employees who focused on selling our products to distributors and “house” accounts worldwide. Our total revenue increased $37.1 million to $112.5 million in 2014 from $75.4 million in 2013, due to growth in rental revenue associated with an increase in the number of patients using Medicare or private payors to rent our products, and growth in sales revenue associated with the increases in business-to-business sales and direct-to-consumer cash sales of our Inogen One systems and new product launches. We generated net income of $6.8 million in 2014 and net income of $25.4 million in 2013. We generated Adjusted EBITDA of $24.0 million and $13.4 million in 2014 and 2013, respectively. Adjusted net income was $6.6 million for 2014, compared to adjusted net income of $3.6 million in 2013. As of December 31, 2014, our accumulated deficit was $56.7 million. The vast majority of our revenue consists of sales revenue and rental revenue. Sales revenue Our future financial performance will be driven in part by the growth in sales of our Inogen One systems, and, to a lesser extent, sales of batteries, other accessories, and sales of our Inogen At Home stationary oxygen concentrator. We plan to grow our system sales in the coming years through multiple strategies, including: expanding our direct-to-consumer sales efforts through hiring additional sales representatives, investing in consumer awareness, expanding our sales infrastructure and efforts outside of the United States, and enhancing our product offerings through additional product launches. As our product offerings grow, we solicit feedback from our customers and focus our research and development efforts on continuing to improve patient preference and reduce the total cost of the product, in order to further drive sales of our products. Our direct-to-consumer sales process involves numerous interactions with the individual patient, the physician and the physician’s staff, and includes an in-depth analysis and review of our product, the patient’s diagnosis and prescribed oxygen therapy, including procuring an oxygen prescription, and assessing the patient’s available insurance benefits. The patient may consider whether 51 to finance the product through an Inogen-approved third party or whether to purchase the equipment. Product is not deployed until both the prescription and payment are received. Once product is deployed, the patient has 30 days to return the product, subject to the payment of a minimal processing and handling fee. Approximately 5% to 10% of patients who purchase a system for cash return the system during this 30-day trial period. Our business-to-business efforts are focused on selling to home medical equipment distributors, oxygen providers and resellers who are based inside and outside of the United States. This process involves interactions with various key customer stakeholders, including sales, purchasing, product testing, and clinical personnel. Businesses that have patient demand that can be met with our portable oxygen concentrator systems place purchase orders to secure product deployment. This may be influenced based on outside factors, including the result of tender offerings, changes in insurance plan coverage, and overall changes in the net oxygen therapy patient population. Products are shipped FOB Inogen domestically, and based on financial history and profile, businesses may either prepay or receive extended terms. Products are shipped both FOB (Freight on Board) Inogen dock and DDP (Delivery Duty Paid) for international shipments depending on the shipper used. DDP shipments are Inogen’s property until title has changed which is upon duty being paid. As a result of these factors, product purchases can be subject to changes in demand by customers. We sold approximately 33,200 systems in 2014, approximately 19,200 systems in 2013 and approximately 11,900 in 2012. Management focuses on system sales as an indicator of current business success. Rental revenue Our rental process involves numerous interactions with the individual patient, the physician and the physician’s staff. The process includes an in-depth analysis and review of our product, the patient’s diagnosis and oxygen needs, and their medical history to confirm the appropriateness of our product for the patient’s oxygen therapy and compliance with Medicare and private payor billing requirements, which often necessitates additional physician evaluation and/or testing as well as a Certificate of Medical Necessity. Once the product is deployed, the patient receives direction on product use and receives a clinical titration from our licensed staff to confirm the product meets the patient’s needs prior to billing. As a result, the time from initial contact with a customer to billing can vary significantly and be up to one month or longer. We plan to grow our rental revenue in the coming years through multiple strategies, including expanding our direct-to-consumer marketing efforts through hiring additional sales representatives and investing in patient awareness and physician-based sales, securing additional insurance contracts and continuing to enhance our product offerings through additional product launches. In addition, patients may come off of our services due to death, a change in their condition, a change in location, a change in provider or other factors. In each case, we maintain asset ownership and can redeploy assets as appropriate following such events. Given the length and uncertainty of our patient acquisition cycle and potential returns we have in the past experienced, and likely will in the future experience, there may be fluctuations in our net new patient setups on a period-to-period basis. As the rental patient base increases, this rental model generates recurring revenue with minimal additional sales and general and administrative expenses. A portion of rentals include a capped rental period when no additional reimbursement will be allowed unless additional criteria are met. In this scenario, the ratio of billable patients to patients on service is critical to maintaining rental revenue growth as patients on service increases. Medicare has noted that a small percentage of beneficiaries, approximately 25%, based on their review of Medicare claims, reach the 36th-month and enter the capped rental period. As of December 31, 2014, in our patient population approximately 13.5% of patients on service were capped. We were unable to calculate the number of capped patients as of December 31, 2013 or for other prior periods. As the rental base expands, we expect our rental revenue to increase, partially offset by declining reimbursement rates. Over time, we believe that our rental revenue should be subject to less period-to-period fluctuation than our sales revenue. As of December 31, 2014, we had over 28,400 oxygen rental patients, an increase from approximately 21,300 oxygen rental patients as of December 31, 2013 and approximately 13,500 in 2012. Management focuses on rental revenue as an indicator of current business success and a leading indicator of likely future rental revenue; however, actual rental revenue recognized is subject to a variety of other factors, including reimbursement levels by patient zip code, the number of capped patients, and adjustments for patients in transition. Reimbursement We rely heavily on reimbursement from Medicare, and secondarily from private payors and Medicaid, for our rental revenue. For the year ended December 31, 2014, approximately 75.6% of our rental revenue was derived from Medicare. The U.S. list price for our stationary oxygen rentals (HCPCS E1390) is $260 per month and for our oxygen generating portable equipment (OGPE) rentals (HCPCS E1392) is $70 per month. The current standard Medicare allowable effective January 1, 2015 for stationary oxygen rentals 52 (E1390) is $180.92 per month and for OGPE rentals (E1392) is $51.63 per month. These are the two primary codes that we bill to Medicare and other payors for our product rentals. As of January 1, 2011, Medicare has phased in a program called competitive bidding. Competitive bidding impacts the amount Medicare pays suppliers of durable medical equipment, including portable oxygen concentrators. The program is defined geographically, with suppliers submitting bids to provide medical equipment for a specific product category within that geography. Once bids have been placed, an individual company’s bids across products within the category are aggregated and weighted by each product’s market share in the category. The weighted average price is then indexed against competitors. Medicare determines a “clearing price” out of these weighted average prices at which sufficient suppliers have indicated they will support patients in the category, and this threshold is typically designed to generate theoretical supply that is twice the expected demand. Bids for each modality among the suppliers that made the cut are then arrayed to determine what Medicare will reimburse for each product category. The program has strict anti-collusion guidelines to ensure bidding is truly competitive. Competitive bidding contracts last up to three years once implemented, after which they are subject to a new round of bidding. Discounts off the standard Medicare allowable occur in competitive bidding Metropolitan Statistical Areas where contracts have been awarded as well as in cases where private payors pay less than this allowable. Current Medicare payment rates in competitive bidding areas are at 48-64% of the standard Medicare allowable for stationary oxygen rentals (average of $93.29 per month) and OGPE rentals are at 70-92% of the standard Medicare allowable (average of $42.33 per month). Competitive bidding rates are based on the zip code where the patient resides. Rental revenue includes payments for product, disposables, and customer service/support. Medicare has not announced specific plans for the plan to implement competitive bidding nationwide, but by 2016 Medicare must implement competitive bidding or competitive bidding pricing for included items to non-competitive bidding areas. In February 2014, Medicare solicited public comment on the methodology it would use to comply with statute. The following table sets forth the current Medicare standard allowable reimbursement rates and the weighted average reimbursement rates applicable in Metropolitan Statistical Areas covered by rounds one and two of competitive bidding. The round one re-compete was completed in the same Metropolitan Statistical Areas as round one for the next three year period starting 1/1/14 when the original contracts expire. E1390 .............................................................................. $ 180.92 $ E1392 .............................................................................. 51.63 Total ................................................................................ $ 232.55 $ % of standard .................................................................. Round one re-compete Medicare Round one Round two standard weighted average allowable effective 1/1/11- 12/31/13 1/1/15 weighted weighted average 1/1/14- 12/31/16 average 7/1/13- 6/30/16 $ 116.16 41.89 158.05 $ 68% 93.07 $ 42.72 135.79 $ 58 % 95.74 38.08 133.82 58% In addition to reducing the Medicare reimbursement rates in the Metropolitan Statistical Areas, the competitive bidding program has effectively reduced the number of oxygen suppliers that can participate in the Medicare program. We believe that more than 75% of existing oxygen suppliers were eliminated in round one of competitive bidding, which was implemented January 1, 2011 in 9 Metropolitan Statistical Areas. Round two of competitive bidding was implemented July 1, 2013 in 91 Metropolitan Statistical Areas and we believe the impact on the number of oxygen suppliers was similar to round one. We believe that 59% of the market was covered by round one and round two of competitive bidding. Cumulatively in rounds one, two and round one re-compete, we were offered contracts for a substantial majority of the competitive bidding areas and products for which we submitted bids. However, there is no guarantee that we will garner additional market share as a result of these contracts. The contracts include products that may require us to subcontract certain services or products to third parties, which must be approved by the Centers for Medicare & Medicaid Services. Following round one of competitive bidding, we were excluded from the Kansas City-MO-KS, Miami-Fort Lauderdale-Pompano- FL, and Orlando-Kissimmee-FL competitive bidding areas and Honolulu-Hawaii, where we have never maintained a license. After round one re-compete, we gained access to Kansas City-MO-KS and were excluded from the following competitive bidding areas: Cleveland- Elyria-Mentor-OH, Cincinnati-Middletown-OH, Miami-Fort Lauderdale-Pompano-FL, Orlando-Kissimmee-FL, Pittsburg-PA, and Riverside-San Bernardino-Ontario-CA. After round two of competitive bidding, we were excluded from an additional 10 competitive bidding areas, including Akron-OH, Cape Coral-Fort Myers-FL, Deltona-Daytona Beach-Ormond Beach-FL, Jacksonville-FL, Lakeland- Winter Haven-FL, North Port-Bradenton-Sarasota-FL, Ocala, Palm Bay-Melbourne-Titusville-FL, Tampa-St. Petersburg-Clearwater-FL and Toledo-OH. Collectively, we have incrementally lost access to approximately seven percent of the Medicare market as of July 1, 53 2013. As a result, on a going forward basis we will continue to have access to approximately 90% of the Medicare market based on our analysis of the 92 competitive bidding areas that we have won out of the 109 competitive bidding areas, representing 59% of the market, with the remaining 41% of the market not subject to competitive bidding. The incremental loss of access to approximately seven percent of the Medicare market is not expected to have a material adverse impact on our rental business, which represented approximately 27% of our total revenue in the year ended December 31, 2014. We expect the decline in total revenue resulting from the loss of competitive bidding contract in the areas that we were excluded from to be partially offset by the grandfathering of existing Medicare patients and direct sales to former Medicare patients with third party insurance coverage or who pay cash. Our revenue from Medicare in the 17 competitive bidding areas where we were not offered contracts was approximately $1.0 million in 2014 and $1.7 million in 2013. Under the Medicare competitive bidding program, oxygen therapy providers may “grandfather” existing patients on service up to the implementation date of the competitive bidding program. This means oxygen therapy providers may retain all existing patients and continue to receive reimbursement for them so long as the new reimbursement rate is accepted and the applicable beneficiary chooses to continue to receive equipment from the provider. Providers must either keep or release all patients under this “grandfathering” arrangement in each competitive bidding area; specific individual selection of patients for retention or release is not allowed. Providers can continue to sell equipment in competitive bid areas where they were not awarded contracts to patients paying with cash or third-party insurance coverage. We have elected to grandfather and retain all patients in competitive bid areas where contracts were not awarded to us. In addition, we plan to continue to accept patients in competitive bidding areas where we did not receive contracts through private insurance. We will also pursue retail sales of our equipment to patients in those areas. For rental equipment, Medicare reimbursement for oxygen equipment is limited to a maximum of 36 months; the equipment is always owned by the home oxygen provider. The provider that billed Medicare for the 36th month continues to be responsible for the patient’s care for months 37 through 60, and there is generally no additional reimbursement for oxygen generating portable equipment for these later months. The Centers for Medicare & Medicaid Services does not reimburse suppliers for oxygen tubing, cannulas and supplies that may be required for the patient. The provider is required to keep the equipment provided in working order and in some cases the Centers for Medicare & Medicaid Services will reimburse for repair costs. After the five year useful life is reached, the patient may request replacement equipment and, if he or she can be re-qualified for the Medicare benefit, a new maximum 36-month rental period would begin. The supplier may not arbitrarily issue new equipment. We cannot state with certainty the potential impact to revenue associated with patients in the capped rental period. Our obligations to service assigned Medicare patients over the contract rental period include supplying working equipment that meets the patient’s oxygen needs pursuant to their doctor’s prescription and certificate of medical necessity form and supplying all disposables required for the patient to operate the equipment, including cannulas, filters, replacement batteries, carts and carry bags, as needed. If the equipment malfunctions, we must repair or replace the equipment. We determine what equipment the patient receives, and we can deploy existing used assets as long as the doctor’s requirements are met. We must also procure a recertification certificate of medical necessity from the patient’s doctor to confirm the patient’s need for oxygen therapy one year after first receiving oxygen therapy and one year after each new 36-month reimbursement period begins. These contracts are cancellable by the patient at any time and by the provider at any time as long as the patient can transition to another provider. In addition to the adoption of the competitive bidding program, reimbursable fees for oxygen rental services in non-competitive bidding areas were eligible to receive mandatory annual Consumer Price Index for all Urban Consumers, or CPI-U, updates beginning in 2010. The CPI-U for 2012 was +3.6%, but the “multi-factor productivity adjustment” remained -1.2%, so the net result was a 2.4% increase in fee schedule payments in 2012 for items and services not included in an area subject to competitive bidding. For 2013, the CPI-U is +1.7%, but the adjustment is -0.9%, so the net result is a 0.8% increase in fee schedule payments in 2013. For 2014, the CPI- U is +1.8%, but the adjustment is -0.8%, so the net result is a 1.0% increase in fee schedule payments in 2014. However, the stationary oxygen equipment codes payment amounts, as required by statute, must be adjusted on an annual basis, as necessary, to ensure budget neutrality of the new payment class for oxygen generating portable equipment. Thus, the increase in allowable payment amounts for stationary oxygen equipment codes increased 0.5% from 2013 to 2014. For 2015, the CPI-U is +2.1%, but the adjustment is -0.6%, so the net result is a 1.5% increase in fee schedule payments in 2015 for stationary oxygen equipment. As of December 31, 2014, we had 63 contracts with Medicaid and private payors. These contracts qualify us an in-network provider for these payors. As a result, patients can use our systems at the same cost as other in-network oxygen therapy solutions, including those utilizing the delivery model. Based on our patient population, we believe at least 30% of all oxygen therapy patients are covered by private payors. Private payors typically provide reimbursement at 60% to 100% of Medicare allowables for in-network plans, and private payor plans can have 36-month caps similar to Medicare. We anticipate that private payor reimbursement levels will generally be reset in accordance with Medicare payment amounts established through competitive bidding. 54 We cannot predict the full extent to which reimbursement for our products will be affected by competitive bidding or by initiatives to reduce costs for private payors. We believe that we are well positioned to respond to the changing reimbursement environment because our product offerings are innovative, patient-focused and cost-effective. We have historically been able to reduce our costs through scalable manufacturing, better sourcing, continuous innovation, and reliability improvements, as well as innovations that reduce our product service costs by minimizing exchanges, such as user replaceable batteries and oxygen filtration cartridges. As a result of bringing manufacturing and assembly largely in-house and our commitment to driving efficient manufacturing processes, we have reduced our overall system cost by 40% from 2009-2013. We intend to continue to seek ways to reduce our cost of revenue through manufacturing and design improvements. Basis of presentation The following describes the line items set forth in our statements of operations. Revenue We classify our revenue in two main categories: sales revenue and rental revenue. There will be fluctuations in mix between business-to-business sales, direct-to-consumer sales and rentals from period to period. In addition, we expect both the average selling price and the manufacturing cost of our products to decrease following the introduction of future generations of our Inogen One systems. Inogen One system and Inogen At Home system selling prices and gross margins for our systems may fluctuate as we introduce new products and reduce our product costs. For example, the gross margin for our Inogen One G3 is higher than our Inogen One G2. Thus, to the extent our sales of our Inogen One G3 systems are higher than sales of our Inogen One G2 systems, our overall gross margins should improve and, conversely, to the extent our sales of our Inogen One G2 systems are higher than sales of our Inogen One G3 systems, our overall gross margins should decline. Sales revenue. Our sales revenue is derived from the sale of our Inogen One systems, Inogen At Home systems, and related accessories to patients in the United States and to home healthcare providers, distributors and resellers worldwide. Sales revenue is classified into two areas: business-to-business sales and direct-to-consumer sales. For the years ended December 31, 2014, 2013 and 2012, business-to-business sales as a percentage of sales revenue were 60%, 60% and 68%, respectively. Generally, our direct-to- consumer sales have higher margins than our business-to-business sales. We also offer a lifetime warranty for direct-to-consumer sales. For a fixed price, we agree to provide a fully functional oxygen concentrator for the remaining life of the patient. Lifetime warranties are only offered to patients upon the initial sale of oxygen equipment by us, and are non-transferable. Product sales with lifetime warranties are considered to be multiple element arrangements within the scope of ASC 605-25. There are two deliverables when a product that includes a lifetime warranty is sold. The first deliverable is the oxygen concentrator equipment which comes with a standard warranty of three years. The second deliverable is the lifetime warranty that provides for a functional oxygen concentrator for the remaining lifetime of the patient. These two deliverables qualify as separate units of accounting. The revenue is allocated to the two deliverables on a relative selling price method. We have vendor-specific objective evidence of selling price for the equipment. To determine the selling price of the lifetime warranty, we use our best estimate of the selling price for that deliverable as the lifetime warranty is neither separately priced nor is selling price available through third-party evidence. To calculate the selling price associated with the lifetime warranties, management considered the profit margins of the overall business, the average estimated cost of lifetime warranties and the price of extended warranties. A significant estimate used to calculate the price and expense of lifetime warranties is the life expectancy of patients. Based on clinical studies, we estimate that 60% of patients will succumb to their disease within three years. Given the approximate mortality rate of 20% per year, we estimate on average all patients will succumb to their disease within five years. We have taken into consideration that when patients decide to buy an Inogen portable oxygen concentrator with a lifetime warranty, they typically have already been on oxygen for a period of time, which can have a large impact on their life expectancy from the time our product is deployed. After applying the relative selling price method, revenue from equipment sales is recognized when all other revenue recognition criteria for product sales are met. Lifetime warranty revenue is recognized using the straight-line method during the fourth and fifth year after the delivery of the equipment which is the estimated usage period of the contract based on the average patient life expectancy. Freight revenue consists of fees associated with the deployment of products internationally or domestically, when expedited freight options or minimum order quantities are not met. Freight revenue is a percentage markup of freight costs. 55 Rental revenue. Our rental revenue is derived from the rental of our Inogen One systems and Inogen At Home systems to patients through reimbursement from Medicare, private payors and Medicaid, which typically also includes a patient responsibility component for patient co-insurance and deductibles. Generally, our product rentals have higher gross margins than our product sales. The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, per ASC 840 — Leases. The Company has separate contracts with each patient that are not subject to a master lease agreement with any payor. The lease term begins on the date products are shipped to patients and are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private payors, and Medicaid. Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. Amounts billed but not earned due to the timing of the billing cycle are deferred and recognized in income on a straight-line basis over the monthly billing period. For example, if the first day of the billing period does not fall on the first of the month, then a portion of the monthly billing period will fall in the subsequent month and the related revenue and cost would be deferred based on the service days in the following month. Included in rental revenue are unbilled amounts for which the revenue recognition criteria had been met as of period-end but were not billed. The estimate of unbilled rental revenue accrual is based on historical trends and estimates of future collectability. Cost of revenue Cost of sales revenue and cost of used rental equipment sales consists primarily of costs incurred in the production process, including costs of component materials, assembly labor and overhead, warranty, provisions for slow-moving and obsolete inventory and delivery costs for items sold. We provide a three-year or lifetime warranty on Inogen One systems sold and Inogen At Home systems sold, and we established a reserve for warranty repairs based on historical warranty repair costs incurred. Provisions for warranty obligations, which are included in cost of sales revenue, are provided for at the time of shipment. Cost of rental revenue consists primarily of depreciation expense and service costs for rental assets, including material, labor, freight, consumable disposables and logistics costs. We expect the average unit costs of our Inogen One systems and Inogen At Home systems to decline in future periods as a result of our ongoing efforts to develop lower-cost systems and to improve our manufacturing processes, reduced rental service costs and expected increases in production volume and yields. Operating expenses Research and development Research and development expenses consist primarily of personnel-related expenses, including salaries, benefits and stock- based compensation, allocated facility costs, laboratory supplies, consulting fees and related costs, costs associated with patent amortization costs, and testing costs for new product launches. We have made substantial investments in research and development since our inception. Our research and development efforts have focused primarily on the tasks required to enhance our technologies and to support development and commercialization of new and existing products. We expect to have moderate increases in research and development expense over time. Sales and marketing Our sales and marketing expenses primarily support our direct-to-consumer strategy. Our sales and marketing expenses consist primarily of personnel-related expenses, including salaries, commissions, benefits, and stock-based compensation, for employees, and allocated facilities costs. They also include expenses for media and advertising, informational kits, public relations and other promotional and marketing activities, including travel and entertainment expenses, as well as customer service and clinical services. Sales and marketing expenses increased throughout 2014 primarily due to an increase in the sales force and the increasing number of rental patients and we expect a further increase in 2015 as we continue to increase sales and marketing activities. General and administrative General and administrative expenses consist primarily of personnel-related expenses, including salaries, benefits, and stock- based compensation for employees in our compliance, finance, medical billing, human resources, information technology, business development and general management functions, and allocated facilities costs. In addition, general and administrative expenses include professional services, such as legal, patent legal fees including defense costs, consulting and accounting services. We expect general and administrative expenses to increase in future periods as the number of administrative personnel grows and we continue to 56 introduce new products, broaden our customer base and grow our business. We also expect legal, accounting and compliance costs to increase due to costs associated with being a public company. Other income (expense), net Other income (expense), net consists primarily of interest expense related to our revolving credit and term loan agreement and interest income driven by the interest accruing on cash and cash equivalents and on past due customer balances. Other income (expense) also includes the change in valuation of warrant liability based on the Monte Carlo valuation model as well as currency translation gains and losses. Result of operations Comparison of years ended December 31, 2014 and 2013 Revenue Year ended December 31, Change 2014 vs. 2013 2014 2013 $ % % of Revenue 2014 2013 Revenue: 73,096 Sales revenue ..................................... $ 39,441 Rental revenue ................................... Total revenue ..................................... $ 112,537 $ $ 44,905 30,538 75,443 $ $ 28,191 8,903 37,094 62.8 % 29.2 % 49.2 % 65.0% 35.0% 100.0% 59.5% 40.5% 100.0% Sales revenue increased $28.2 million for the year ended December 31, 2014 from $44.9 million for the year ended December 31, 2013 to $73.1 million for the year ended December 31, 2014, or an increase of 62.8% over the comparable year. The increase was attributable to an increase in the number of systems sold primarily related to expansion of the Inogen One G3 product line, an increase in direct-to-consumer sales in the United States due to increased sales and marketing efforts, and an increase in business-to-business sales worldwide as the adoption of portable oxygen concentrators improved. As we expected, the growth in sales revenue was not materially impacted by the reduced reimbursement rates resulting from competitive bidding. Rental revenue increased $8.9 million for the year ended December 31, 2014 from $30.5 million for the year ended December 31, 2013 to $39.4 million for the year ended December 31, 2014, or an increase of 29.2% over the comparable year. The increase was attributable to the increase in rental patients from over 21,300 as of December 31, 2013 to over 28,400 as of December 31, 2014 due to additional marketing efforts and increased sales personnel. This increase was partially offset by the reduced reimbursement rates resulting from round two competitive bidding that became effective on July 1, 2013 and round one re-compete competitive bidding that became effective January 1, 2014. Cost of revenue and gross profit Year ended December 31, Change 2014 vs. 2013 2014 2013 Cost of sales revenue .......................... $ Cost of rental revenue ........................ Total cost of revenue .......................... $ 38,693 18,327 57,020 Gross profit - sales revenue ................ $ Gross profit - rental revenue .............. Total gross profit ................................ $ 34,403 21,114 55,517 $ $ $ $ 24,306 12,146 36,452 20,599 18,392 38,991 $ $ $ $ $ 14,387 6,181 20,568 13,804 2,722 16,526 Gross margin percentage – sales revenue ............................................ Gross margin percentage- rental revenue ............................................ Total gross margin percentage ........... 47.1 % 45.9% 53.5 % 49.3 % 60.2% 51.7% 57 % % of Revenue 2014 2013 59.2 % 50.9 % 56.4 % 67.0 % 14.8 % 42.4 % 34.4% 16.3% 50.7% 30.6% 18.8% 49.3% 32.2% 16.1% 48.3% 27.3% 24.4% 51.7% We manufacture our products in our Goleta, California and Richardson, Texas facilities. Our manufacturing process includes final assembly, testing, and packaging to customer specifications. The cost of sales revenue increased $14.4 million from $24.3 million for the year ended December 31, 2013 to $38.7 million for the year ended December 31, 2014, or an increase of 59.2% over the comparable year. The increase in cost of sales revenue was attributable to an increase in the number of systems sold, partially offset by reduced bill of material and labor and overhead costs for our products associated with better sourcing and increased volumes. We expect the cost of sales as a percentage of sales revenue to fluctuate based on customer mix, product mix, and changes in sales prices and cost of goods sold. The cost of rental revenue increased from $12.1 million for the year ended December 31, 2013 to $18.3 million for the year ended December 31, 2014, or an increase of 50.9% over the comparable year. The increase in cost of rental revenue was attributable to an increase of rental patients and related rental assets, depreciation and product exchange and logistics costs. Cost of rental revenue includes $10.3 million of rental asset depreciation for year ended December 31, 2014 versus $7.1 million for the year ended December 31, 2013. Gross margin is defined as revenue less costs of revenue divided by revenue. Sales gross margin increased from 45.9% for the year ended December 31, 2013 to 47.1% for the year ended December 31, 2014. The increase in sales gross margin is partially due to our higher margin Inogen One G3 as compared to our Inogen One G2, and the continued shift towards direct-to-consumer sales revenue in our revenue mix. Rental revenue gross margin decreased from 60.2% for the year ended December 31, 2013 to 53.5% for the year ended December 31, 2014 primarily due to lower rental reimbursement rates resulting from round two competitive bidding that became effective July 1, 2013 and round one re-compete competitive bidding that became effective January 1, 2014. The overall gross margin decreased from 51.7% for the year ended December 31, 2013 to 49.3% for the year ended December 31, 2014. This decline is consistent with the mix in sales gross margin and the decline in rental revenue gross margin. Research and development expense Research and development expense .... $ 2,977 $ 2,398 $ 579 24.1 % 2.6% 3.2% Year ended December 31, Change 2014 vs. 2013 2014 2013 $ % % of Revenue 2014 2013 Research and development expense increased $0.6 million from $2.4 million for the year ended December 31, 2013 to $3.0 million for the year ended December 31, 2014, or an increase of 24.1% over the comparable year. The increase was primarily attributable to a $0.7 million increase in personnel related expenses which includes $0.3 million additional bonus accrual and $0.2 million additional stock compensation expense, partially offset by a decrease of $0.1 million in other research and development related costs. Sales and marketing expense Year ended December 31, Change 2014 vs. 2013 Sales and marketing expense ............. $ 24,087 $ 18,375 $ 2014 2013 $ 5,712 % % of Revenue 2014 2013 31.1 % 21.4% 24.4% Sales and marketing expenses increased $5.7 million from $18.4 million for the year ended December 31, 2013 to $24.1 million for the year ended December 31, 2014, or an increase of 31.1% over the comparable year. The increase was primarily attributable to $2.9 million of personnel-related expenses as a result of increased sales and marketing headcount to support the growth of our business, $1.3 million of media-related marketing and software licensing costs, $0.5 million of personnel-related and outside services expenses for customer care and clinical services to support our increased rental patient base, $0.4 million of sales incentives and giveaways, $0.3 million of higher credit card processing fees, and $0.3 million of higher facilities costs allocated to sales and marketing as well as other general expenses. General and administrative expense Year ended December 31, Change 2014 vs. 2013 General and administrative expense .... $ 2014 17,942 $ 2013 13,754 $ $ 4,188 58 % % of Revenue 2014 2013 30.4 % 15.9% 18.2% General and administrative expenses increased $4.2 million from $13.8 million for the year ended December 31, 2013 to $17.9 million for the year ended December 31, 2014, or an increase of 30.4% over the comparable year. The increase was primarily attributable to $1.7 million of personnel-related expenses as a result of increased headcount in billing, finance, information technology, human resources and compliance, $0.8 million of costs associated with being a public company in 2014, $0.4 million of legal costs, $0.4 million of licenses and fees, $0.3 million of depreciation, $0.2 million of bank charges, $0.2 million of patent defense costs, $0.2 million of information technology professional fees, and $0.2 million of state franchise taxes. These increases were partially offset by a decrease in bad debt expense of $0.4 million. The provision for doubtful accounts, expressed as a percentage of total revenue, was 1.5% and 2.7% in the year ended December 31, 2014 and December 31, 2013, respectively. We expect to incur additional expenses of approximately $1.0 - $1.5 million, primarily in the first quarter of 2015, as a result of our recently completed audit committee investigation. Additionally, we expect to incur additional costs in future periods in connection with the recent securities class action lawsuits filed against us and certain of our executive officers. We are currently unable to predict the outcome of these lawsuits and therefore cannot determine the likelihood of loss nor estimate a range of possible loss. Other income (expense), net Year ended December 31, Change 2014 vs. 2013 2014 2013 $ % % of Revenue 2014 2013 Interest expense .................................. $ Interest income ................................... Revaluation of preferred stock warrant liability ............................... Other income (expense) ..................... Total other expense, net ................ $ (449 ) $ 42 36 (88 ) (459 ) $ (562) $ 12 (262) 196 (616) $ 113 30 298 (284) 157 -20.1 % 250.0 % -113.7 % * -25.5 % -0.4% 0.0% 0.0% -0.1% -0.4% -0.7% 0.0% -0.3% 0.3% -0.8% * not measured Other income (expense), net, decreased $0.1 million from $0.6 million for the year ended December 31, 2013 to $0.5 million for the year ended December 31, 2014, or a decrease of 25.5% over the comparable year. The decrease is due to interest expense in 2014 was driven by the decrease in average debt balances under our revolving credit and term loan agreement compared to the prior year. Other income, net, in 2013 was primarily associated with investment income received in connection with the sale of our interest in our former product liability insurance company. This other income is not expected to recur in future periods. Other income (expense) in 2014, net consists primarily of loss on foreign currency transactions related to the import of our goods into the European Union. Value added tax (VAT) is paid upon import, reclaimed, and reimbursed in EURO. Fluctuations in the EURO to US Dollar exchange rate resulted in a net expense. The increase in preferred stock warrant liability was due to the revaluation of our preferred stock warrants outstanding through a Monte Carlo valuation model due to higher enterprise value and the increased likelihood of an initial public offering as of December 31, 2014 compared to December 31, 2013. Comparison of years ended December 31, 2013 and 2012 Revenue Year ended December 31, Change 2013 vs. 2012 2013 2012 $ % % of Revenue 2013 2012 Revenue: Sales revenue ..................................... $ Rental revenue ................................... Total revenue ..................................... $ 44,905 30,538 75,443 $ $ 28,704 19,872 48,576 $ $ 16,201 10,666 26,867 56.4 % 53.7 % 55.3 % 59.5% 40.5% 100.0% 59.1% 40.9% 100.0% The increase in sales revenue was attributable to an increase in the number of systems sold, related to an increase in business-to- business sales and an increase in direct-to-consumer sales in the United States and worldwide due to increased sales and marketing efforts and the adoption of portable oxygen concentrators. We experienced a price erosion of 4% in business-to-business sales, which was partially offset by the shift towards direct-to-consumer sales, which experienced a 2% increase in the average selling price. This resulted in a 4% decrease in the average selling price of our products. The increase in rental revenue was related to our increased rental patients from over 13,500 as of December 31, 2012 to over 21,300 as of December 31, 2013 due to additional marketing efforts and increased sales personnel. 59 Cost of revenue and gross profit Year ended December 31, Change 2013 vs. 2012 2013 2012 Cost of sales revenue .......................... $ Cost of rental revenue ........................ Total cost of revenue .......................... $ 24,306 12,146 36,452 Gross profit - sales revenue ................ $ Gross profit - rental revenue .............. Total gross profit ................................ $ 20,599 18,392 38,991 $ $ $ $ 17,384 7,243 24,627 11,320 12,629 23,949 $ $ $ $ $ 6,922 4,903 11,825 9,279 5,763 15,042 Gross margin percentage – sales revenue ............................................ Gross margin percentage- rental revenue ............................................ Total gross margin percentage ........... 45.9 % 39.4% 60.2 % 51.7 % 63.6% 49.3% % % of Revenue 2013 2012 39.8 % 67.7 % 48.0 % 82.0 % 45.6 % 62.8 % 32.2% 16.1% 48.3% 27.3% 24.4% 51.7% 35.8% 14.9% 50.7% 23.3% 26.0% 49.3% The increase in cost of revenue was attributable to an increase in the number of systems sold and increased bill of material costs for our products associated with the sales shift to the direct-to-consumer channel where system packages include higher accessories per order. Cost of revenue includes depreciation of our rental assets of $7.1 million for the year ended December 31, 2013 versus $4.1 million for the year ended December 31, 2012. The continued shift towards rental revenue in our revenue mix, along with the initial launch of our higher margin Inogen One G3 in September 2012, accounted for the gross margin improvement from 49% to 51%. The gross margin on our rental revenue was 60% in the year ended December 31, 2013 versus 64% in the year ended December 31, 2012 due to lower reimbursement levels. The gross margin on our sales revenue including sales of used rental equipment was 45% in the year ended December 31, 2013 versus 39% in the year ended December 31, 2012 due to the improved revenue mix towards direct-to-consumer sales. Research and development expense Research and development expense .... $ 2,398 $ 2,262 $ 136 6.0 % 3.2% 4.7% Year ended December 31, Change 2013 vs. 2012 2013 2012 $ % % of Revenue 2013 2012 The increase was primarily attributable to a $0.3 million increase in personnel related expenses as a result of increased headcount, a $0.3 million increase in patent and patent defense costs, and $0.1 million in additional research and development spend on new product development. Research and development expenses were $2.4 million, or 3.2% of total revenue, for the year ending 2013 compared to $2.3 million, or 4.7% of total revenue, for the year ending 2012. Sales and marketing expense Year ended December 31, Change 2013 vs. 2012 Sales and marketing expense ............. $ 18,375 $ 12,569 $ 2013 2012 $ 5,806 % % of Revenue 2013 2012 46.2 % 24.4% 25.9% The increase was primarily attributable to a $4.1 million increase in personnel-related expenses as a result of increased sales and marketing headcount to support the growth of our business, $1.0 million in primarily media-related marketing costs to continue to grow our rental patient base and consumer cash sales, and a $0.6 million increase in personnel-related expenses for customer service and clinical services to support our increased number of rental patients. Sales and marketing expenses were $18.4 million, or 24.4% of total revenue, for the year ending 2013 compared to $12.6 million, or 25.9% of total revenue, for the year ending 2012. 60 General and administrative expense Year ended December 31, Change 2013 vs. 2012 General and administrative expense .... $ 2013 13,754 2012 $ 8,289 $ $ 5,465 % % of Revenue 2013 2012 65.9 % 18.2% 17.1% The increase was primarily attributable to a $1.9 million increase in personnel-related expenses as a result of increased administrative headcount in billing, finance, information technology and compliance to support the growth of our business. In addition, we incurred $0.7 million more in company-wide bonus expense as a result of our higher headcount and better than planned results. To accommodate the higher headcount in 2013, we incurred higher facility costs of $0.2 million for rent, utilities, property taxes and maintenance. In addition, we incurred $0.4 million of general and administrative cost associated with the preparation of an initial public offering that were not capitalizable. In addition, bad debt expense increased $1.1 million due to the growth of our patient population and associated rental revenue bad debt as well as increased bad debt from our business-to-business channel due to a single customer write off. The provision for doubtful accounts, expressed as a percentage of total revenue, was 2.7% and 2.2% in the year ended December 31, 2013 and December 31, 2012, respectively. General and administrative expenses were $13.8 million, or 18.2% of total revenue, for the year ending 2013 compared to $8.3 million, or 17.1% of total revenue, for the year ending 2012. Other income (expense), net Year ended December 31, Change 2013 vs. 2012 2013 2012 $ % % of Revenue 2013 2012 Interest expense .................................. $ Interest income ................................... $ Revaluation of preferred stock warrant liability ............................... $ Other income ...................................... $ Total other expense, net ................ $ (562 ) $ $ 12 (262 ) $ 196 $ (616 ) $ (493) $ 88 148 10 (247) $ (69) (76) 14.0 % -86.4 % (410) 186 (369) -277.0 % 1860.0 % 149.4 % -0.7% 0.0% -0.3% 0.3% -0.8% -1.0% 0.2% 0.3% 0.0% -0.5% The higher interest income in 2012 was associated with interest accruing on a past due customer balance that was not relevant in 2013. The increase in interest expense in 2013 was driven by the increase in average debt balances under our revolving credit and term loan agreement compared to the prior year. Other income, net, in 2013 was primarily associated with investment income received in connection with the sale of our interest in our former product liability insurance company. This other income is not expected to recur in future periods. The increase in preferred stock warrant liability was due to the revaluation of our preferred stock warrants outstanding through a Monte Carlo valuation model due to higher enterprise value and the increased likelihood of an initial public offering as of December 31, 2013 compared to December 31, 2012. Liquidity and capital resources As of December 31, 2014, we had cash and cash equivalents of $56.8 million, which consisted of highly-liquid investments with an original maturity of three months or less. Since inception, we have financed our operations primarily through cash from operations, the sale of equity securities and, to a lesser extent, from borrowings. As of December 31, 2014, we had $0.6 million debt outstanding in patent licensing debt. Since inception, we have received net proceeds of $91.7 million from the issuance of redeemable convertible preferred stock and $52.5 million in net proceeds in connection with the sale of common stock in our initial public offering. As of December 31, 2014, we had $15.0 million in available debt capacity under the revolving facility. Our principal uses of cash are funding our capital expenditures including additional rental assets. We believe that our current cash and cash equivalents together with our short-term investments and available borrowings under our revolving credit agreement and the cash to be generated from expected product sales and rentals, will be sufficient to meet our projected operating and investing requirements for at least the next 12 months. 61 The following table shows a summary of our cash flows for the periods indicated: Cash provided by operating activities ............................. $ Cash used in investing activities ..................................... Cash provided by financing activities ............................. 15,697 $ (16,254) 43,872 13,467 $ (18,142 ) 3,084 4,004 (12,475) 19,677 Year ended December 31, 2013 2012 2014 Operating activities We derive operating cash flows from cash collected from the sale of our products and services. These cash flows received are partially offset by our use of cash for operating expenses to support the growth of our business. Net income in each period has increased associated with increased sales associated with product mix and lower costs. In addition, operating expense leverage has increased as expenses have not grown as quickly as sales due to improved operating efficiencies. The changes in cash related to operating assets and liabilities discussed below were primarily due to the following factors that occurred across all periods: an increase in cash used related to inventory and rental assets as we increased inventory and rental assets to support our growth in revenue; an increase in cash used by accounts receivable resulting from growth in rental receivables which typically have a longer collection cycle; and an increase in cash related to accounts payable resulting from the higher level of operating expenses needed to support the higher sales level. Net cash provided by operating activities for 2014 consisted of our net income of $6.8 million and non-cash expense items such as depreciation and amortization of our equipment and leasehold improvements of $12.1 million, provision for rental revenue adjustments of $7.9 million, provision for sales returns of $3.5 million, loss on disposal of rental units and other fixed assets of $1.9 million, provision for excess and obsolete inventory and inventory losses of $0.2 million, provision for doubtful accounts of $1.7 million, stock-based compensation expense of $1.5 million, ($1.6) million in excess tax benefits from stock-based compensation arrangements and a net change of $1.6 million in our deferred tax asset. These items were partially offset by net changes in our operating assets and liabilities of ($19.9) million. Net cash provided by operating activities for 2013 consisted of our net income of $25.4 million and non-cash expense items such as depreciation and amortization of our equipment and leasehold improvements of $8.5 million, provision for rental revenue adjustments of $6.6 million, provision for doubtful accounts of $2.0 million, provision for sales returns of $1.8 million, loss on disposal of rental units and other fixed assets of $0.3 million, loss on change in fair value of warrants of $0.3 million and stock-based compensation of $0.2 million. These items were partially offset by the reversal of the valuation allowance against our deferred tax assets of $21.8 million and by net changes in our operating assets and liabilities of $10.0 million. Net cash provided by operating activities for 2012 consisted of our net income of $0.6 million and non-cash expense items such as depreciation and amortization of our equipment and leasehold improvements of $5.0 million, provision for rental revenue adjustments of $3.1 million, provision for doubtful accounts of $1.1 million, provision for sales returns of $0.6 million, and loss on rental units of $0.3 million, These items were partially offset by net changes in our operating assets and liabilities of $6.6 million. Investing activities Net cash used in investing activities for each of the periods presented was primarily for the purchase of rental assets, research and development laboratory, manufacturing and computer equipment and software to support our expanding business. In the year ended December 31, 2014, we invested $14.5 million in rental assets and $1.6 million in other property and equipment and $0.2 million in intangible assets. In 2013, we invested $15.1 million in rental assets and $3.0 million in other property and equipment. In 2012, we invested $10.4 million in rental assets deployed and $2.0 million in other property and equipment. We expect to continue investing in property and equipment as we expand our operations. Our operations are inherently capital intensive due to our portions of revenue derived from our rental business model; investments will continue to be required in order to grow and maintain our rental revenue. Financing activities Historically, we have funded our operations through the issuance of stock, the incurrence of indebtedness, as well as cash flows from operations. 62 For the year ended December 31, 2014, net cash provided by financing activities consisted of gross proceeds of approximately $56.5 million (before total offering expenses and broker discounts of approximately $6.0 million) in connection with our IPO, $6.0 million of new debt issuance under our revolving credit and term loan agreement entered into in October 2012, $1.9 million received upon exercise of convertible preferred stock warrants, common stock options and employee stock purchase, and $1.6 million from excess tax benefits from stock-based compensation arrangements on the exercise of employee stock options. This was partially offset by repayments of borrowings under our revolving credit and term loan agreement of $15.9 million and $0.2 million on our contractual obligation. For the year ended December 31, 2013, net cash provided by financing activities consisted of $1.9 million received upon exercise of series D convertible preferred stock warrants and common stock options and $6.0 million of new debt issuance under our revolving credit and term loan agreement entered into in October 2012. This was partially offset by repayments of borrowings under our revolving credit and term loan agreement of $4.0 million. In addition, the Company incurred $0.6 million in costs associated with the IPO completed in February 2014. For the year ended December 31, 2012, net cash provided by financing activities consisted of the issuance of 2,840,260 shares of series G convertible preferred stock which generated net proceeds of $19.9 million in March 2012, the incurrence of an aggregate of $6.0 million of borrowings under our revolving credit and term loan agreement, and the exercise of series B convertible and series C convertible preferred stock warrants for $0.4 million. This was partially offset by repayment of $6.5 million of borrowings under our revolving credit and term loan agreement. Accounts receivable Accounts receivable before allowance for doubtful accounts, rental adjustments and sales returns increased $9.5 million, or 70%, from $13.6 million at December 31, 2013 to $23.1 million at December 31, 2014. Included in accounts receivable are earned but unbilled receivables of $3.7 million at December 31, 2014 and $1.4 million at December 31, 2013. Delays, ranging from a day to several weeks between the date of service, and billing can occur due to delays in obtaining certain required payor-specific documentation from internal and external sources. Earned but unbilled receivables are aged from the date of service and are considered in our analysis of historical performance and collectability. Due to the nature of the industry and the reimbursement environment in which we operate, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for services from some payors may result in adjustments to amounts originally recorded. These adjustments are typically identified and recorded at the point of cash application, claim denial or account review. Management performs analyses to evaluate the net realizable value of accounts receivable. Specifically, management considers historical realization data, accounts receivable aging trends, other operating trends and relevant business conditions. Because of continuing changes in the healthcare industry and third-party reimbursement, it is possible that management’s estimates could change, which could have an impact on operations and cash flows. We derive a significant portion of our rental revenue from Medicare. Revenue is recognized at net realizable amounts estimated to be paid by payors and patients. Our billing system contains payor-specific price tables that reflect the fee schedule amounts in effect or contractually agreed upon by various government and commercial payors for each item of equipment or supply provided to a customer. For Medicare and Medicaid revenue, as well as most other third-party payors, final payment is subject to administrative review and audit. We make estimated provisions for adjustments, including adjustments from administrative review and audit, based on historical experience. We closely monitor our historical collection rates as well as changes in applicable laws, rules and regulations and contract terms in an attempt to use the most accurate information available in determining these provisions. However, due to the complexities involved in these estimates, actual payments we receive could be different from the amounts we estimate and record. Collection of rental receivables from third-party payors and patients is a significant source of cash and is critical to our operating performance. Our primary collection risks relate to patient accounts for which the primary insurance payor has paid, but patient responsibility amounts (generally deductibles and co-insurance) remain outstanding. We record bad debt expense based on a percentage of revenue using historical data specific to us. The percentage and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods including current and historical cash collections, bad debt write- offs and aging of accounts receivable. We write-off accounts receivable against the allowance when all collection efforts (including payor appeals processes) have been exhausted. We routinely review accounts receivable balances in conjunction with our historical contractual adjustments and bad debt rates and other economic conditions that might ultimately affect the collectability of patient accounts when we consider the adequacy of the amounts we record as provision for doubtful accounts. 63 Accounts receivable balance concentrations by major category as of December 31, 2014 and December 31, 2013 were as follows: Percentage of accounts receivable outstanding: Medicare .................................................................................. Medicaid/other government ..................................................... Private insurance ...................................................................... Patient responsibility ................................................................ Business to business sales ........................................................ Total ................................................................................... As of December 31, 2014 2013 27% 11% 25% 7% 30% 100% 26 % 3 % 29 % 18 % 24 % 100 % The following table sets forth the percentage breakdown of our accounts receivable by aging category by invoice date as of December 31, 2014 and December 31, 2013. Accounts receivable by aging category: Unbilled ................................................................................... Aged 0-90 days ........................................................................ Aged 91-180 days .................................................................... Aged 181-365 days .................................................................. Aged over 365 days ................................................................. Total ................................................................................... As of December 31, 2014 2013 16% 48% 8% 12% 16% 100% 11 % 56 % 13 % 16 % 4 % 100 % The following table sets forth the percentage breakdown of our allowances to accounts receivable as of December 31, 2014 and December 31, 2013. Percentage of allowance to accounts receivable Bad debt reserve ....................................................................... Rental adjustments & write-offs reserve .................................. Direct to consumer sales returns reserve .................................. Total percentage of allowance to accounts receivable ........ As of December 31, 2014 2013 5% 10% 1% 16% 8 % 16 % 1 % 25 % The decrease in total percentage of our allowances to accounts receivable from 25% as of December 31, 2013 to 16% as of December 31, 2014 was primarily related to our increasing portion of sales receivables in our total receivables, which have lower adjustment and bad debt allowances. These balances aged over 365 days have increased from 4% to 16% in the periods presented primarily related to our rental business and patient co-pay balances. We have implemented new collection procedures with third party collection agencies to achieve higher collectability rates, as well as timelier payment processing from Medicare, Medicaid and third party, payors whereby they assist with the follow-up and completion of additional requests from these payors to expedite payment. We believe our reserves are adequate and properly present the collectability of our outstanding accounts receivable balances based on our analysis of these balances. We review the accounts receivables on a monthly basis to assess the allowance for doubtful accounts, and adjust the reserves accordingly. The ultimate collection of accounts receivable may not be known for several months because the third party collection firm started collection efforts in 2014. We record bad debt expense based on a percentage of revenue using historical data specific to us. The percentage and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, bad debt write-offs, aged accounts receivable and consideration of any payor-specific concerns. The ultimate write-off of an accounts receivable occurs once collection is considered to be unlikely. 64 We do not use an aging threshold for account receivable write-offs. However, the age of an account balance may provide an indication that collection procedures have been exhausted, and would be considered in the review and approval of an account balance write-off. Sources of funds Our cash provided in operations in the year ended December 31, 2014 was $15.7 million compared to $13.5 million in the year ended December 31, 2013. As of December 31, 2014 we had cash and cash equivalents of $56.8 million and available borrowing capacity under our working capital revolving line of credit of $15 million. We believe, based on our current operating plan, that our existing cash and cash equivalents, cash generated from operating activities and available borrowings under our borrowing arrangements will be sufficient to fund capital expenditures, operating expenses and other cash requirements for at least the next 12 months. In the future, we may make material investments in, or acquisitions of, complementary businesses, which could require us to seek additional equity or debt financing. Additional funds may not be available on terms favorable to us, or at all. Amended and restated revolving credit and term loan agreement In October 2012, we entered into an amended and restated revolving credit and term loan agreement with Comerica Bank as the administrative agent, which we refer to as our Comerica revolving credit and term loan agreement. This agreement incorporated amounts outstanding under one prior loan agreement whereby the existing balances and the payback terms were not changed. This transaction did not result in any debt extinguishment losses or gains. We did not incur or defer any financing cost directly related to the amended loan and security agreement. The revolving credit and term loan agreement also provided for a pre-existing term loan facility for rental assets amounting to up to $3.0 million, which we refer to as Term Loan A, a pre-existing term loan facility for rental assets amounting to up to $8.0 million, which we refer to as Term Loan B, a new term loan facility for rental assets amounting to up to $12.0 million, which we refer to as Term Loan C, and an accounts receivable revolving line of credit amounting to up to $1.0 million based on 80% of eligible accounts receivable, which we refer to as the revolver. We had borrowings of $0, $0.4 million and $1.4 million outstanding under Term Loan A as of December 31, 2014, 2013 and 2012, respectively. We had borrowings of $0, $3.8 million and $6.4 million outstanding under Term Loan B, as of December 31, 2014, 2013 and 2012, respectively. There were borrowings of $0, $5.7 million and $0 outstanding under Term Loan C as of December 31, 2014, 2013 and 2012, respectively. There were no borrowings under the revolver during 2014, 2013, or 2012. The revolver expired on October 13, 2013 and we have no plans to renew or replace it. Payments of interest for the Term Loan were generally payable monthly. Payment of principal is payable monthly. Each term loan bears interest at the base rate, which is a rate equal to the applicable margin plus the greater of (i) the prime rate, (ii) the federal funds effective rate, as defined in the agreement, plus 1%, and (iii) the daily adjusting LIBOR rate, plus 1%. The applicable margins for Term Loans A, B and C are 1.25%, 2.50% and 2.25%, respectively. Upon the closing of an acquisition or initial public offering during the term of the revolving credit and term loan agreement, the lenders were entitled to a fee equal to $120,000. This fee was initiated upon the close of the IPO that occurred in February, 2014, and was subsequently paid in March, 2014 and is recorded as other finance and bank fees in 2014. In November 2014, we secured a primary banking relationship that provides access to a $15 million working capital revolving line of credit, and treasury and cash management services through commercial banking with JP Morgan Chase. This agreement is a three year working capital revolving line of credit which replaces the previous loan facility we maintained with Comerica. The interest rate on outstanding debt balances will be LIBOR plus 1.25%. We are required to maintain a tangible net worth not less than $90 million and EBITDA of $10 million for any period of four consecutive quarters commencing with the four-quarter test period ending September 30, 2014. We were in compliance as of December 31, 2014, and no outstanding debt balances were outstanding on the credit facility. The revolving credit and term loan agreement contains customary conditions to borrowing, events of default and covenants, including covenants that restrict our ability to dispose of assets, merge with or acquire other entities, incur indebtedness, incur encumbrances, make distributions to holders of our capital stock, make investments, engage in transactions with our affiliates. In addition, we must comply with certain financial covenants relating to liquidity, debt service, and leverage ratios. We were in compliance with all covenants as of December 31, 2014 and December 31, 2013. As of December 31, 2013, in order to be in compliance with the liquidity requirements, debt service ratios, and leverage ratios of existing debt obligations, we were required to 65 maintain $2.5 million of Adjusted EBITDA in the previous six months, and we had $6.5 million in Adjusted EBITDA, and $18.7 million of cash and qualified accounts receivable, and we had $13.5 million of actual cash. Our obligations under the revolving credit and term loan agreement were secured by substantially all of our assets, including intellectual property. We may from time to time, depending upon market conditions and financing needs, seek to refinance or repurchase our debt securities or loans in privately negotiated or open market transactions, by tender offer or otherwise. Use of funds Our principal uses of cash are funding our new rental asset deployments and other capital purchases, operations, satisfaction of our obligations under our debt instruments, and other working capital requirements. Over the past several years, our revenue has increased significantly from year to year and, as a result, our cash flows from customer collections have increased as have our profits. As a result, our cash provided by operating activities has increased over time and now is a source of capital to the business. We expect operating activities to continue to be a source of capital to the business in the future. Due to the portion of our business that drives rental revenue, which needs continuing asset deployments to new patients, our cash used in investing activities has increased over time. We expect our investment cash requirements to increase in the future as we increase our rental patient base and deploy rental assets among Medicare and private payors. We may need to raise additional funds to support our investing operations, and such funding may not be available to us on acceptable terms, or at all. If we are unable to raise additional funds when needed, our operations and ability to execute our business strategy could be adversely affected. We may seek to raise additional funds through equity, equity-linked or debt financings. If we raise additional funds through the incurrence of indebtedness, such indebtedness would have rights that are senior to holders of our equity securities and could contain covenants that restrict our operations. Any additional equity financing may be dilutive to our stockholders. Contractual obligations The following table reflects a summary of our contractual obligations as of December 31, 2014. Contractual obligations (in thousands) Operating leases-properties (1) .............................................. $ Operating leases-equipment and other (2).............................. Long-term debt obligations (3) .............................................. Total .................................................................................. $ Payments due by period 1-3 years Less than 1 year 3-5 years More than 5 years Total $ 2,957 101 614 3,672 $ 829 $ 41 299 1,169 $ 904 $ 56 315 1,275 $ 910 $ 4 — 914 $ 314 — — 314 (1) We lease manufacturing and office space in both Richardson, TX and Goleta, CA with terms that expire between 2019 and 2022. (2) This consist of multiple miscellaneous office and processing equipment in both Texas and California with terms expiring within 3 months to 5 years. (3) In 2011, we entered into an amendment of a licensing agreement whereby we were assigned the entire right, title and interest in a portfolio of patents in exchange for an imputed promissory note calculated via prime plus 2 points for $0.7 million, in addition to a $0.8 million existing obligation to the original licensor, for a total of $1.5 million due to the original licensor in installments starting May 22, 2011, and ending October 31, 2016. Critical accounting policies and significant estimates Our discussion and analysis of our financial condition and results of operations are based upon our financial statements which have been prepared in accordance with GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets and liabilities and related disclosure of contingent assets and liabilities, revenue and expenses at the date of the financial statements. Generally, we base our estimates on historical experience and on various other assumptions in accordance with GAAP that we believe to be reasonable under the circumstances. Actual results may differ from these estimates and such differences could be material to the financial position and results of operations. 66 Critical accounting policies and estimates are those that we consider the most important to the portrayal of our financial condition and results of operations because they require our most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our critical accounting policies and estimates include those related to: (cid:121) (cid:121) (cid:121) (cid:121) (cid:121) (cid:121) revenue recognition; stock-based compensation; inventory and rental asset valuation; accounts receivables and allowance for bad debts, returns and adjustments; fair value measurements; and income taxes. Revenue recognition We generate revenue primarily from sales and rentals of our products. Our products consist of our proprietary line of oxygen concentrators and related accessories. A small portion of our revenue comes from extended service contracts and freight revenue for product shipments. Revenue from product sales is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price to the customer is fixed or determinable; and (4) collectability is reasonable assured. Revenue from product sales is recognized upon shipment of the product. Provisions for estimated returns and discounts are made at the time of shipment. Provisions for warranty obligations, which are included in cost of sales revenue, are also provided for at the time of shipment. Accruals for estimated warranty expenses are made at the time that the associated revenue is recognized. We use judgment to estimate these accruals and, if we were to experience an increase in warranty claims or if costs of servicing our products under warranty were greater than our estimates, our cost of revenue could be adversely affected in future periods. The provisions for estimated returns, discounts and warranty obligations are made based on known claims and discount commitments and estimates of additional returns and warranty obligations based on historical data and future expectations. We accrued $1.1 million and $0.8 million to provide for future warranty costs at December 31, 2014 and 2013, respectively. Revenue from the sale of used rental equipment is recognized upon delivery and when collectability is reasonably assured and other revenue recognition criteria are met. When a rental unit is sold, the related cost and accumulated depreciation are removed from their respective accounts, and any gains or losses are included in gross profit. Revenue from the sales of our services is recognized when no significant obligations remain undelivered and collection of the receivables is reasonably assured, which is generally when shipment as occurred. We offer extended service contracts on our Inogen One systems for periods ranging from 12 to 24 months after the end of the standard warranty period. Revenue from extended service contracts and lifetime warranty is deferred and recognized in income over the contract period. To calculate the value associated with the lifetime warranties, management considered the profit margins of the overall company, the average cost of lifetime warranties and the price of extended warranties and created a best estimate. Lifetime warranty revenue is deferred and recognized after the standard three year warranty period, on a straight-line basis, in year four and five. Under the lifetime warranty, the company will provide replacement equipment without any additional cost to the consumer for the duration of the patient’s life. Lifetime warranties are non-transferable. We recognize equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, per ASC 840—Leases. We have separate contracts with each patient that are not subject to a master lease agreement with any payor. We evaluate the individual lease contracts at lease inception and the start of each monthly renewal period to determine if there is reasonable assurance that the bargain renewal option associated with the potential capped free rental period would be exercised. Historically, the exercise of such bargain renewal option is not reasonably assured at lease inception and most subsequent monthly lease renewal periods. If we determine that the reasonable assurance threshold for an individual patient is met at lease inception or at a monthly lease renewal period, such determination would impact the bargain renewal period for an individual lease. We would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term, which may include a portion of the capped rental period. To date, we have not deferred any amounts associated with the capped rental period. Amounts related to the capped rental period have not been material in the periods presented. 67 The lease term begins on the date products are shipped to patients and are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private payors, and Medicaid. Due to the nature of the industry and the reimbursement environment in which we operate, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such adjustments are typically identified and recorded at the point of cash application, claim denial or account review. Accounts receivable are reduced by an allowance for doubtful accounts which provides for those accounts from which payment is not expected to be received, although product was delivered and revenue was earned. Upon determination that an account is uncollectible, it is written- off and charged to the allowance. Amounts billed but not earned due to the timing of the billing cycle are deferred and recognized in income on a straight-line basis over the monthly billing period. For example, if the first day of the billing period does not fall on the first of the month, then a portion of the monthly billing period will fall in the subsequent month and the related revenue and cost would be deferred based on the service days in the following month. Rental revenue is recognized as earned, less estimated adjustments. Revenue not billed at the end of the period is reviewed for the likelihood of collections and accrued. The rental revenue stream is not guaranteed and payment will cease if the patient no longer needs oxygen or returns the equipment. Revenue recognized is at full estimated allowable; transfers to secondary insurances / patient responsibility have no net effect on revenue. Rental revenue is earned for that month if the patient is on service on the first day of the 30-day period commencing on the recurring date of service for a particular claim, regardless if there is a change in condition/death after that date. There is no refund for revenue collected in the 3 year period if the patient does not reach the end of the 5 year capped period. In the event that a third-party payor does not accept the claim for payment, the consumer is ultimately responsible for payment for the products and services. We have determined that the balances are collectable at the time of revenue recognition because the patient signs a notice of financial responsibility outlining their obligations. Included in rental revenue are unbilled amounts that were earned but not able to be billed for various reasons. The criteria for recognizing revenue had been met as of period-end, but there were specific reasons why we were unable to bill Medicare and private insurance for these amounts. As a result, we create an unbilled rental revenue accrual based on these earned revenues not billed based on a percentage of unbilled amounts and historical trends and estimates of future collectability. Stock-based compensation Stock-based compensation is measured at the grant date based on the fair value of the award and is recognized as expense, net of estimated forfeitures, over the requisite service period, which is generally the vesting period of the award. Determining the fair value of stock-based awards at the grant date represents management’s best estimates, but the estimates involve inherent uncertainties and the application of management’s judgment. We use the Black-Scholes option pricing model to determine the fair value of stock options. The determination of the grant date fair value of options using an option pricing model is affected by our estimated common stock fair value, prior to the IPO, as well as assumptions regarding a number of other complex and subjective variables. These variables include the fair value of our common stock, our expected stock price volatility over the expected term of the options, stock option exercise and cancellation behaviors, risk-free interest rates and expected dividends, which are estimated as follows: (cid:121) Fair Value of Our Common Stock. Prior to the IPO our common stock was not publicly traded and we estimated the fair value of the common stock as discussed in “Pre-IPO Common Stock Valuations” below. Following our IPO, we established a policy of using the closing sale price per share of our common stock as quoted on the NASDAQ Global Select Market on the date of grant for purposes of determining the exercise price per share of our options to purchase common stock. (cid:121) Expected Term. The expected term for stock options granted to employees (including members of our board of directors) was estimated using the simplified method allowed under SEC guidance. For grants to nonemployees, the expected term is equal to the contractual term, which have ranged from seven to ten years. (cid:121) Expected Volatility. Given the limited trading history for our common stock, the expected stock price volatility for our common stock was estimated by taking the average historical price volatility for industry peers, which we have designated, based on daily price observations over a period equivalent to the expected term of the stock option grants. Industry peers, which we have designated, consist of several public companies in the industry similar in size, stage of life cycle and financial leverage. We intend to continue to consistently apply this process using the same or similar public companies until a sufficient amount of historical information regarding the volatility of our own common stock share price becomes available, or unless circumstances change such that the identified companies are no longer similar to us, in which case more suitable companies whose share prices are publicly available would be used in the calculation. 68 (cid:121) Risk-free Interest Rate. The risk-free interest rate is based on the yields of U.S. Treasury securities with maturities similar to the expected term of the options for each option group. (cid:121) Expected Dividend Yield. We have never declared or paid any cash dividends to common stockholders and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero. Pre-IPO Common Stock Valuations Prior to the IPO, the fair value of the common stock underlying our stock options was approved by our board of directors, which intended all options granted to be exercisable at a price per share equal to the per-share fair value of our common stock underlying those options on the date of grant. The valuations of our common stock were determined in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Because there had been no public market for our common stock, the board of directors with input from management exercised significant judgment and considered numerous objective and subjective factors to determine the fair value of common stock as of the date of each option grant, including the following factors: (cid:121) (cid:121) (cid:121) (cid:121) contemporaneous third-party valuations of our common stock; the prices, rights, preferences and privileges of preferred stock relative to the common stock; the prices of preferred stock sold to third-party investors in arms-length transactions; the prices of common stock sold to third-party investors in secondary transactions or repurchased by us in arms-length transactions; (cid:121) our operating and financial performance; (cid:121) current business conditions and projections; (cid:121) our stage of development; (cid:121) (cid:121) (cid:121) (cid:121) the likelihood of achieving a liquidity event for the shares of common stock underlying these stock options, such as an initial public offering or sale of the company, given prevailing market conditions; any adjustment necessary to recognize a lack of marketability for common stock; the market performance of comparable publicly traded companies; and the U.S. and global capital market conditions. In order to determine the fair value of our common stock underlying option grants issued, we determined the enterprise value, added net cash, then allocated the equity value to each class of equity securities outstanding (preferred stock, common stock and options). Inventory and rental asset valuation Inventory consists of raw materials, certain component parts to be used in manufacturing our products and finished goods. Inventory is stated at the lower of cost or market. Cost is determined using a standard cost method, including material, labor, and manufacturing overhead, whereby the standard costs are updated at least quarterly to approximate actual costs using the first-in, first- out (“FIFO”) method and market represents the lower of replacement cost or estimated net realizable value. We record adjustments to inventory for potentially excess, obsolete, slow-moving or impaired items. The business environment in which we operate is subject to changes in technology and customer demand. We review inventory for excess and obsolete products and components at least quarterly, taking into account product life cycle and development plans, product expiration and quality issues, historical experience and our current inventory levels. If actual market conditions are less favorable than anticipated, additional inventory adjustments could be required. Rental assets are valued at standard cost to manufacture or purchase the product, including appropriate labor and overhead. Costs are reviewed at least quarterly to confirm standard costs approximate actual costs using the first-in, first-out (“FIFO”) method. Rental assets are depreciated over the life of the asset, typically 18 months to 60 months. Rental asset disposals or losses are recorded at net book value in cost of revenue. 69 Accounts receivable and allowance for bad debts, returns, and adjustments Accounts receivable are customer obligations due under normal sales and rental terms. We perform continuing credit evaluations of the customers’ financial condition and generally do not require collateral. The allowance for doubtful accounts is maintained at a level that, in our opinion, is adequate to absorb potential losses related to account receivables and is based upon our continuous evaluation of the collectability of outstanding balances. Our evaluation takes into consideration such factors as past bad debt experience, economic conditions, and information about specific receivables. Our evaluation also considers the age and composition of the outstanding amount in determining their net realizable values. The allowance is based on estimates and ultimate losses may vary from current estimates. As adjustments to these estimates become necessary, they are reported in earnings in the periods that they become known. The allowance is increased by bad debt provisions charged to operating expense and reduced by direct write-offs, net of recoveries. In the event that a third-party payor does not accept the claim for payment, the consumer is ultimately responsible for payment for the products and services. In general, our allowance for doubtful accounts is higher for our rental revenue compared to our sales revenue. The nature of our rental business necessitates a larger bad debt reserve against billings, as a higher percentage of our billed revenue may never be collected as a result of the failure of some patients to pay their co-insurance and deductible obligations and some billing disputes with payors. Provision for sales returns applies to direct-to-consumer sales only. We do not allow returns from providers. This reserve is calculated based on actual historical return rates under our 30-day return program and is applied to the current period’s sales revenue for direct to consumer sales. We have experienced a small increase in the historical returns rate during the period, primarily due to increased competition among other providers and resellers and a slight increase in product failures in the relevant periods. We also record an allowance for rental revenue adjustments and write-offs, which is recorded as a reduction of rental revenue and rental accounts receivable balances. These adjustments and write offs result from contractual adjustments, audit adjustments, or billing not paid due to another provider performing same or similar functions for the patient in the same period, all of which prevent billed revenue to become realizable. The reserve is based on historical revenue adjustments as a percentage of rental revenue billed during the related period. Included in accounts receivable are earned but unbilled receivables of $3.7 million in December 31, 2014 and $1.4 million at December 31, 2013. Delays in billing can occur between the date revenue is earned and when billing occurs due to delays in receiving the appropriate paperwork for each payor. Earned but unbilled receivables are aged from the date of service and are considered in our analysis of historical performance and collectability. A portion of revenue and related costs are deferred each month for monthly rental revenue based on the timing of the recurring billing and then recorded as revenue in the subsequent month. Fair value measurements Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, creates a single definition of fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement, and states that a fair value measurement should be determined based on assumptions that market participants would use in pricing the asset or liability. Assets and liabilities adjusted to fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. The warrant liability is marked to market each reporting date until the warrants are settled. The fair value of the warrant liability is estimated using a Monte Carlo option pricing model, which takes into consideration the market values of comparable public companies, considering among other factors, the use of multiples of earnings, and adjusted to reflect the restrictions on the ability of the company’s securities to trade in an active market. Income taxes We use the liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to be in effect when such assets and liabilities are recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the year that includes the enactment date. We determine deferred tax assets including net operating losses and liabilities, based on temporary differences between the book and tax bases of assets and liabilities. 70 We utilize a two-step approach for evaluating uncertain tax positions. Step one, recognition, requires us to determine if the weight of available evidence indicates that a tax position is more likely than not to be sustained upon audit, including resolution of related appeals or litigation processes, if any. If a tax position is not considered “more likely than not” to be sustained, no benefits of the position are recognized. If we determine that a position is “more likely than not” to be sustained, then we proceed to step two, measurement, which is based on the largest amount of benefit which is more likely than not to be realized on effective settlement. This process involves estimating our actual current tax exposure, including assessing the risks associated with tax audits, together with assessing temporary differences resulting from the different treatment of items for tax and financial reporting purposes. If actual results differ from our estimates, our net operating loss and credit carryforwards could be materially impacted. At December 31, 2014, we had federal net operating loss carryforwards, or NOLs, of approximately $59.3 million and federal research and experimentation credit carryforwards of approximately $1.2 million, which may be used to reduce future taxable income or offset income taxes due. These NOL carryforwards expire during the period 2023 through 2031. Our realization of the benefits of the NOLs and credit carryforwards is dependent upon sufficient taxable income in future fiscal years. Our utilization of NOLs to offset future income subject to taxes is subject to annual limitations due to a current period “change in ownership” pursuant to the provisions section 382 of the Code and similar state provisions and may be further limited in the future. Even after factoring in the limitations of the current period ownership change, the Company was able to determine, based upon future projections of income, that it is more likely than not that all of its federal NOLs and credit carryforwards will be utilized before they expire. However, the Company determined that some of its California NOLs will expire unused and therefore has a valuation allowance of $2.9 million relating to these NOLs. In the current period, the Company released (or reversed) $1.2 million of the California NOLs valuation allowance due to expiration of California NOL’s and changes in estimates of future projections of income, resulting in a determination that it is more likely than not that all but $32.8 million ($2.9 million tax effect) of the California NOLs will be utilized. We recognize interest and penalties on taxes, if any, within operations as income tax expense. No significant interest or penalties were recognized during the periods presented. We operate in multiple states. The statute of limitations has expired for all tax years prior to 2010 for federal and 2010 to 2011 for various state tax purposes. However, the net operating losses generated on the federal and state tax returns in prior years may be subject to adjustments by the federal and state tax authorities. We do not anticipate that the amount of our existing unrecognized tax benefits will significantly increase or decrease within the next 12 months. Due to the presence of NOLs in most jurisdictions, our tax years remain open for examination by taxing authorities back to the inception of the company. Recent accounting pronouncements Revenue from contracts with customers In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of the Company’s pending adoption of ASU 2014-09 on the Company’s financial statements and has not yet determined the method by which the Company will adopt the standard in 2017. We have reviewed other recent accounting pronouncements and concluded that other than ASU 2014-09 discussed above they are either not applicable to our business or that no material effect is expected on the financial statements as a result of future adoption. As an “emerging growth company” the JOBS Act allows us to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. As a result, our financial 71 statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies. We will be required, pursuant to Section 404(a) of the Sarbanes-Oxley Act, to furnish a report by management on, among other things, the effectiveness of our internal control over financial reporting for the year following our first annual report required to be filed with the SEC. This assessment will need to include disclosure of any material weaknesses identified by management over our internal control over financial reporting. However, our independent registered public accounting firm will not be required to report on the effectiveness of our internal control over financial reporting pursuant to Section 404(b) until the later of the year following our first annual report required to be filed with the SEC, or the date we are no longer an “emerging growth company” if we take advantage of the exemptions contained in the JOBS Act. We are in the very early stages of the costly and challenging process of compiling the system and processing documentation necessary to perform the evaluation needed to comply with Section 404. We may not be able to complete our evaluation, testing or any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal controls are designed and operating effectively, which could result in a loss of investor confidence in the accuracy and completeness of our financial reports. This could cause the price of our common stock to decline, and we may be subject to investigation or sanctions by the SEC. Off-balance sheet arrangements We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or for any other contractually narrow or limited purpose. However, from time to time we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims including certain real estate leases, supply purchase agreements, and directors and officers. The terms of such obligations vary by contract and in most instances a maximum dollar amount is not explicitly stated therein. Generally, amounts under these contracts cannot by reasonably estimated until a specific claim is asserted thus no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented. Inflation We experience pricing pressures in the form of continued reductions in reimbursement rates, particularly from governmental payors such as Medicare or Medicaid but also private payors. We can also be impacted by rising costs for certain inflation-sensitive operating expenses such as labor and employee benefits. However, we do not believe that inflation has had a material effect on our business, financial condition or results of operations. If our costs were to become subject to significant inflationary pressures, we may not be able to fully offset such higher costs through price increases, especially in contracts where pricing is fixed over a specific period. Our inability or failure to do so could adversely affect our business, financial condition and results of operations. ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK We are exposed to various market risks, including fluctuation in interest rates and foreign currency exchange rates. Market risk is the potential loss arising from adverse changes in market rates and prices. We do not hold or issue financial instruments for trading purposes. Interest rate fluctuation risk The principal market risk we face is interest rate risk. We had cash and cash equivalents of $56.8 million as of December 31, 2014, which consisted of highly-liquid investments with an original maturity of three months or less. The primary goals of our investment policy are liquidity and capital preservation. We do not enter into investments for trading or speculative purposes. We believe that we do not have any material exposure to changes in the fair value of these assets as a result of changes in interest rates due to the short-term nature of our cash and cash equivalents. Declines in interest rates, however, would reduce future investment income. If overall interest rates had decreased by 10% during the periods presented, our interest income would not have been materially affected. As of December 31, 2014, we did not have any outstanding term loan agreements. We paid off all outstanding bank debt and accrued interest under the amended and restated revolving credit and term loan agreement with Comerica Bank on August 22, 2014 in the amount of $11.6 million. 72 In November 2014, the Company secured a primary banking relationship that provides access to a $15.0 million working capital revolving line of credit, and treasury and cash management services through commercial banking with JP Morgan Chase. This agreement is a three year working capital revolving line of credit which replaces the previous loan facility the Company maintained with Comerica. The interest rate on outstanding debt balances will be LIBOR plus 1.25%. The Company is required to maintain a tangible net worth not less than $90 million and EBITDA of $10 million for any period of four consecutive quarters commencing with the four-quarter test period ending September 30, 2014. The Company was in compliance as of December 31, 2014, and no outstanding debt balances were outstanding on the credit facility. Foreign currency exchange risk Prior to the fourth quarter of 2014, our international customer and distributor agreements have been denominated almost exclusively in U.S. dollars. In the last quarter of 2014, the Company began accepting payment in Euros, and had an exchange translation loss of $0.1 million. The effect of a 10% adverse change in exchange rates on foreign denominated cash, receivables and payables as of December 31, 2014 and December 31, 2013 would not have been material. As our operations in countries outside of the United States grow, our results of operations and cash flows will be subject to fluctuations due to changes in foreign currency exchange rates, which could harm our business in the future. To date, we have not entered into any material foreign currency hedging contracts although we may do so in the future. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA The financial statements and supplementary data required by this item are included in Part IV, Item 15 of this Report. ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE None ITEM 9A. CONTROLS AND PROCEDURES Limitations on effectiveness of controls In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs. Evaluation of disclosure controls and procedures The Company maintains a system of disclosure controls and procedures (defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) which are designed to provide reasonable assurance that information required to be disclosed in the reports that the Company files or submits under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. These disclosure controls and procedures include, among other processes, controls and procedures designed to ensure that information required to be disclosed in the reports that the Company files or submits under the Exchange Act is accumulated and communicated to management, including the principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. Due to inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Further, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that degree of compliance with the policies and procedures may deteriorate. Accordingly, even effective disclosure controls and procedures can only provide reasonable assurance of achieving their control objectives. The Company carried out an evaluation, under the supervision and with the participation of management, including the principal executive officer and the principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2014. Based on such evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were not effective as of December 31, 2014 due to the existence of a material weakness over the perfection of compliance documentation for direct-to-consumer sales and rental which could affect the financial reporting described below. Notwithstanding the existence of the material weakness discussed below, our management, including our principal executive officer and principal financial officer, has concluded that the financial statements included in this Annual Report 73 on Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with accounting principles generally accepted in the United States of America. Management’s report on internal control over financial reporting Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our management, including our principal executive officer and principal financial officer, conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria set forth in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (“COSO”). Based on our evaluation under the COSO framework, our management concluded that our internal control over financial reporting was not effective as of December 31, 2014 due to the material weakness described below. The Company was not required to adopt the COSO 2013 framework as of December 31, 2014 A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. We identified a material weakness with respect to internal control over the review of sales order documentation supporting our direct-to-consumer sales and rentals prior to revenue recognition. The primary factors contributing to this material weakness were the improper use of technology to simulate medical documentation and absence of sufficient monitoring controls over illegitimate delivery of medical documentation related to direct-to-customer sales and rentals. Plan for Remediation of Material Weakness in Internal Control over Financial Reporting We are in the process of implementing a remediation plan to supplement control over financial reporting to address this material weakness. Steps we are taking to remediate the material weakness in our internal control over financial reporting of revenue include: implementation of a combination of new and revised control procedures in our sales order review process and compliance audit program, supplemented document retention policies on sales documentation, additional quarterly screening through data analytics to confirm compliance with our policies, and improved processes and controls in our customer relationship management software system. These actions are subject to ongoing review by our senior management, as well as oversight by the audit committee of our board of directors. Although we plan to complete this remediation process as quickly as possible, we cannot, at this time, estimate when such remediation may occur, and our initiatives may not prove successful in remediating this material weakness. As long as we qualify as an “emerging growth company” as defined by the Jumpstart our Business Startups Act of 2012, we will not be required to obtain an auditor’s attestation report on our internal controls in future annual reports on Form 10-K as otherwise required by Section 404(b) of the Sarbanes-Oxley Act. Accordingly, our independent registered public accounting firm did not perform an audit of our internal control over financial reporting for the fiscal year ended December 31, 2014. Had our independent registered public accounting firm performed an audit of our internal control over financial reporting, material weaknesses and/or significant deficiencies, in addition to the material weakness discussed above, may have been identified. Our qualification as an emerging growth company may last for up to five years following our IPO. Changes in internal controls over financial reporting During the three months ended December 31, 2014, we identified a material weakness in our internal control over the review of sales order documentation supporting our direct-to-customer sales and rentals prior to revenue recognition. As described above under “Plan for Remediation of Material Weaknesses in Internal Control over Financial Reporting,” we have been taking steps to remediate the material weakness identified above and plan to take additional actions to remediate the underlying cause of the material weakness. ITEM 9B. OTHER INFORMATION Compensatory Arrangements of Certain Officers On April 24, 2015, our compensation, nominating and governance committee met to determine bonus compensation to our named executive officers under our 2014 Bonus Plan. For 2014, our corporate-level goals included achieving specified Adjusted EBITDA targets for the year. For Adjusted EBITDA achievement at the target level, each named executive officer would receive 100% of his or her 2014 target award opportunity. Performance above 100% of our Adjusted EBITDA target entitles each named executive officer to an increase to his or her incentive award payment based on the extent of the achievement above target. For our 2014 Bonus Plan, our adjusted EBITDA target was $18.3 million at 100% of our Adjusted EBITDA, and $20.7 million at 150% of our 74 Adjusted EBITDA, excluding expenses incurred in connection with our initial public offering and follow on offering costs. The compensation, nominating and governance committee approved bonuses to our NEO’s as follows: Name and principal position Raymond Huggenberger .............................................. $ President and Chief Executive Officer Scott Wilkinson ............................................................ Executive Vice President, Sales and Marketing Alison Bauerlein .......................................................... Executive Vice President, Finance and Chief Financial Officer Target award opportunity ($) Actual award amount ($) 264,000 $ 396,000 103,200 154,800 108,000 162,000 Annual Meeting The Company has postponed its 2015 Annual Meeting of Stockholders scheduled to be held at 10:00 a.m. Pacific Time on Thursday, May 14, 2015. The Annual Meeting will be rescheduled at a later date to be determined by the Company’s Board of Directors. The Company is also resetting the record date for the Annual Meeting, as postponed. As soon as practicable upon determining the date of the Annual Meeting, the Company will provide additional information with respect to the Annual Meeting, including the date, time and place of the rescheduled Annual Meeting and the new record date for the Annual Meeting. 75 PART III ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE Executive Officers and Directors The following table identifies certain information about our directors and executive officers as of March 31, 2015. Each executive officer serves at the discretion of our board of directors and holds office until his or her successor is duly elected and qualified or until his or her earlier resignation or removal. There are no family relationships among any of our directors or executive officers. Name Raymond Huggenberger .......................................................... Scott Wilkinson ........................................................................ Alison Bauerlein ...................................................................... Age 56 50 33 Matthew Scribner ..................................................................... Brenton Taylor ......................................................................... Byron Myers ............................................................................ Heath Lukatch, Ph.D.(2) .......................................................... Timothy Petersen(1)(2) ............................................................ Benjamin Anderson-Ray(1) ..................................................... Loren McFarland(1) ................................................................. Heather Rider(2) ...................................................................... 47 33 35 47 51 60 56 55 Position(s) President, Chief Executive Officer and Director Executive Vice President, Sales and Marketing Executive Vice President, Finance and Chief Financial Officer, Corporate Secretary and Corporate Treasurer Executive Vice President, Operations Executive Vice President, Engineering Vice President, Marketing Chairman of the Board Director Director Director Director (1) Member of our audit committee. (2) Member of our compensation, nominating and governance committee. Executive Officers Raymond Huggenberger has served as our President, Chief Executive Officer and as a member of the board of directors of Inogen since 2008. Prior to joining our company, Mr. Huggenberger held various management positions with Sunrise Medical Inc., a global manufacturer and distributor of durable medical equipment, including: Vice President of Marketing for Sunrise’s German subsidiary from 1994 to 1996, President of Sunrise’s German division from 1998 until 2000, President of the European Operating Group from 2000 to 2002, President and Chief Operating Officer from 2002 until 2004, and President of European Operations 2006 to 2007. Mr. Huggenberger also held various management positions with McDermott and Bull Inc., an executive search firm, from 2005 to 2006 and in the healthcare division of TA Triumph Adler AG, a document process management firm, from 1996 to 1998. Mr. Huggenberger currently serves on the board of directors of Wellfount Corporation, a pharmacy services company, and previously served on the board of IYIA Technologies, a healthcare company. Mr. Huggenberger graduated from AKAD University in Rendsburg, Germany in Economics and completed the Advanced Marketing Strategies Program at INSEAD, Fontainebleau, France. The board of directors believes that he is qualified to serve as a director of Inogen because of his deep understanding of our business, operations and strategy. Scott Wilkinson has served as our Executive Vice President, Sales and Marketing since 2008 and in this role currently oversees Inogen’s global operations in sales, marketing, customer service, product management, medical billing, and clinical services. Previously, he served as our Director of Product Management from 2005 to 2006 and Vice President, Product Management from 2006 to 2008. From 2000 to 2005, Mr. Wilkinson worked for Invacare Corporation, a designer and manufacturer of oxygen products, as a Group Product Manager and helped launch their $100 million oxygen product line segment. From 1999 to 2000, Mr. Wilkinson served as a Product Line Director with Johnson & Johnson, a healthcare company. From 1988 to 1999, Mr. Wilkinson worked as a Research Scientist, Product Manager, and Project Leader at Kimberly Clark, a consumer products company. Mr. Wilkinson received a Bachelor’s degree in Chemical Engineering from the University of Akron and an MBA from University of Wisconsin, Oshkosh. Alison Bauerlein is a co-founder of Inogen and has served as our Chief Financial Officer since 2009 and Executive Vice President, Finance since March 2014. Ms. Bauerlein has also served as Corporate Secretary and Corporate Treasurer since 2002. Ms. Bauerlein previously served as our Vice President, Finance from 2008 until March 2014. Prior to serving in these positions, Ms. Bauerlein also served as Controller with our company from 2008 to 2009 and 2001 to 2004, and the Director of Financial Planning and Analysis from 2004 to 2008. During her time with our company, Ms. Bauerlein has helped the company raise approximately $91 million in venture capital funding. Ms. Bauerlein currently serves on the board of directors of Active Life Scientific, Inc. Ms. Bauerlein received a Bachelor of Arts degree in Economics/Mathematics with high honors from the University of California, Santa Barbara. 76 Matthew Scribner has served as our Executive Vice President, Operations since March 2014. Prior to serving this position, Mr. Scribner served as our Vice President, Operations from 2008 until March 2014, the Director of Manufacturing from 2007 to 2008 and the Director of Supply Chain from 2004 to 2007. From 1998 to 2004, Mr. Scribner worked for Computer Motion, a manufacturer of surgical robots that was acquired by Intuitive Surgical, in various executive capacities, including as a Manufacturing Manager and as a Project Manager. From 1989 to 2013, Mr. Scribner served in the United States Navy as a helicopter pilot, on both active duty and as a reservist. He was mobilized and deployed to Iraq in 2003 to fly in support of Operation Iraqi Freedom. He achieved the rank of Commander and retired from the U.S. Navy in July 2013. Mr. Scribner received a Bachelor of Science degree in Ocean Engineering from the United States Naval Academy. Mr. Scribner also received an MBA from the University of San Diego. Brenton Taylor is a co-founder of Inogen and has served as our Executive Vice President, Engineering since March 2014. Prior to serving in this position, Mr. Taylor served as our Vice President, Engineering from 2008 until March 2014 and as the Director of Technology with our company from 2003 to 2008. Mr. Taylor is listed as an inventor on more than 20 of the company’s U.S. patents related to portable oxygen concentrator development. Mr. Taylor received a Bachelor of Science degree in Microbiology from the University of California, Santa Barbara. Byron Myers is a co-founder of Inogen and has served as our Vice President, Marketing since 2011. In this role, Mr. Myers leads Inogen’s Marketing Department and Direct to Consumer sales channel. Prior to serving in this position, Mr. Myers held various roles with our company, including: Product Manager from 2002 to 2006, Director of Marketing from 2006 to 2007 and 2008 to 2011, International Product Manager during 2007, and Director of International Product Management from 2007 to 2008. Mr. Myers received a Bachelor’s degree in Economics/Mathematics from the University of California, Santa Barbara and an MBA from the Rady School of Management at the University of California, San Diego. Directors Raymond Huggenberger. See “Directors, Executive Officers and Corporate Governance — Executive Officers” included elsewhere in this Annual Report on Form 10-K for Mr. Huggenberger’s biographical information. Heath Lukatch, Ph.D. has served as chairman of our board of directors since 2008, and as a director since 2006. Dr. Lukatch is employed as a Partner at Novo Ventures (US) Inc., which provides certain consultancy services to Novo A/S. Dr. Lukatch joined Novo Ventures (US) Inc. in 2006. As of April 30, 2015, Mr. Lukatch will no longer be employed by Novo Ventures (us) Inc. Prior to joining Novo Ventures (US) Inc., Dr. Lukatch was a Managing Director responsible for biotechnology venture investments at Piper Jaffray Ventures and SightLine Partners, a private equity firm and spin off of Piper Jaffray Ventures, from 2001 to 2006. Prior to joining Piper Jaffray Ventures, Dr. Lukatch worked as a strategy consultant with McKinsey & Company, a consulting firm, from 1997 to 2000. Dr. Lukatch also served as co-founder and chief executive officer of AutoMate Scientific, a biotechnology instrumentation company from 1991 to 1997, and held scientific positions with Chiron Corporation, a biotechnology company, from 1990 to 1991, Roche Bioscience, a healthcare company, from 1996 to 1997, and Cetus Corporation, a biotechnology company, in 1987. He currently serves on the boards of directors of AnaptysBio, Inc., Cianna Medical, Inc., Flexion Therapeutics, Inc., Nora Therapeutics, Inc., Panmira Pharmaceuticals LLC., and Spinifex, Inc. Dr. Lukatch previously served on the boards of directors of Amira Pharmaceuticals, Elevation Pharmaceuticals, Inc., FoldRx Pharmaceuticals, Inc., InSound Medical, Inc., NeuroTherapeutics Pharma, Inc., Synosia Therapeutics, Inc., and Verax Biomedical, Inc. Dr. Lukatch received his Ph.D. in Neuroscience from Stanford University where he was a DOD USAF Fellow, and his B.A. in Biochemistry from the University of California at Berkeley. The board of directors believes that he is qualified to serve as a director of Inogen because of his extensive industry experience and experience as a venture capital investor and a board member for several venture-backed healthcare companies Timothy Petersen has served as a member of the board of directors of Inogen since 2010. He has been a managing director at Arboretum Ventures, a venture capital firm, since 2002. Prior to joining Arboretum, he was the managing director of the Zell Lurie Institute for Entrepreneurial Studies at the University of Michigan from 1999 to 2002. During his tenure at the University of Michigan, he also directed the Wolverine Venture Fund, the Institute’s venture capital fund focusing on early-stage life science and technology investments. Prior to the University of Michigan, Mr. Petersen was a manager in the investment banking practice at Plante Moran Corporate Finance, a professional services and consulting firm, and served as a management consultant at Industrial Economics, Inc., a consulting firm. He currently serves on the boards of Advanced ICU Care, Inc., IntelliCyt Corp., Fidelis SeniorCare, Inc., Tangent Medical Technologies, Inc., My Health Direct, Inc., KFx Medical Corp., and CerviLenz, Inc. Previously, Mr. Petersen served on the boards of HealthMedia, Inc. (sold to Johnson & Johnson), PathCentral, Inc., and Accuri Cytometers, Inc. (sold to Becton, Dickinson and Company). Mr. Petersen earned a BA in Economics from Williams College. He also holds an MS in Economics from the University of Wisconsin-Madison, and an MBA from the Ross School of Business at the University of Michigan. The board of directors believes that he is qualified to serve as a director of Inogen because of his extensive experience as an investor and board member for various healthcare companies. 77 Benjamin Anderson-Ray has served as a member of the board of directors since 2013. He has been a partner and advisor with Trinitas Advisors, a consulting firm, since 2009. Prior to joining Trinitas Advisors, he served as the chief executive officer of three manufacturing companies: Hubbardton Forge, LLC from 2008 to 2009, Chromcraft Revington, Inc. from 2005 to 2008 and Gravograph New Hermes from 2002 to 2004. Prior to that, Mr. Anderson-Ray held various senior leadership roles at Sunrise Medical, a medical equipment manufacturer, including president of the Global Business Group in 2001, president of the Continuing Care Group from 1998 to 2000, and president of the Mobility Products Division from 1996 to 2001. Earlier in his career, Mr. Anderson-Ray held management and marketing roles at GE Lighting, a lighting solutions company, from 1984 to 1993, Black & Decker Home Products, a product manufacturing company, from 1993 to 1994, and Rubbermaid Home Products, a manufacturer and distributor of household items, from 1994 to 1996. He currently serves on the boards of Sommetrics. Inc., the Episcopal Church Foundation, and the Addison County Economic Development Corporation. Mr. Anderson-Ray has Bachelor’s degrees in Marketing and Horticulture from Michigan State University, an MBA from the University of Michigan, and is a Certified Advisor with The CEO Advantage. The board of directors believes that he is qualified to serve as a director of Inogen because of his leadership experience and his extensive industry experience. Loren McFarland has served as a member of the board of directors of Inogen since 2013. He has been president and managing member of Santa Barbara Financial Services, LLC since 2008. Prior to founding Santa Barbara Financial Services, he served as the chief financial officer and treasurer of Mentor Corporation, a medical equipment company (now a division of Ethicon, Inc., a Johnson & Johnson company), from 2004 to 2007. Prior to that, Mr. McFarland fulfilled various finance and accounting roles at Mentor from 1985 to 2004. He worked as a certified public accountant and audit supervisor with Touche Ross & Co., an accounting firm, from 1981 to 1985 and served in the North Dakota Army National Guard from 1978 to 1984. He currently serves on the board of Cure Medical, LLC, a privately held manufacturer of disposable urology products, and on the board and executive committee of the MIT Enterprise Forum of the Central Coast. Previously, Mr. McFarland served on the board of directors of Patient Safety Technologies, Inc. (PSTX) as the financial expert on the audit committee and as a member of the compensation committee. Mr. McFarland has a Bachelor’s degree in accounting from the University of North Dakota and an MBA from the University of California, Los Angeles. He completed an ISS Director Certification Program in October 2008 at the University of California, Los Angeles’ Anderson School. The board of directors believes that he is qualified to serve as a director of Inogen because of his leadership experience and his extensive experience in finance and accounting. Heather Rider has served as a member of the board of directors of Inogen since 2014. From 2012 to 2013, Ms. Rider served as Vice President, Global Human Resources of Cymer, Inc., a publicly-traded supplier of light sources for semiconductor manufacturing that was acquired by ASML Holding NV in 2013. From October 2010 to September 2012, Ms. Rider served as Senior Vice President, Global Human Resources of Alphatec Holdings, Inc., a publicly-traded medical device company focused on surgical treatment of spine disorders, and from 2006 to 2010, she served as Vice President, Human Resources of Intuitive Surgical, Inc., a publicly-traded manufacturer of robotic surgical systems. From 2001 to 2005, Ms. Rider served as Senior Vice President of Global Human Resources of Sunrise Medical, Inc., a global manufacturer and distributor of durable medical equipment. From 1998 to 2001, Ms. Rider served as Vice President of Human Resources of Biosense Webster, a member of the J & J family of companies, and a medical device manufacturer of intracardiac catheters and location technology. Prior to 1998, Ms. Rider served as Head of Human Resources for City of Hope, a leading research and treatment center for cancer, diabetes and other life-threatening diseases, CAP/MPT, a medical malpractice provider for physicians in California and medical malpractice insurance for large physician groups and hospitals, and Environmental Diagnostics International, a bio-diagnostics company with focus on the detection of environmental compounds and diseases using monoclonal antibody technology. Ms. Rider holds a B.A. in Psychology from Claremont McKenna College and an M.B.A. from Pepperdine University. The board of directors believes that she is qualified to serve as a director of Inogen because of her extensive executive-level experience with healthcare and life science companies. Family relationships There are no family relationships among any of our directors and executive officers. Board composition and risk oversight Our board of directors is currently composed of six directors. Five of the six directors that comprise our board of directors are independent within the meaning of the independent director guidelines of the NASDAQ Global Select Market. All of the directors other than Benjamin Anderson-Ray, Loren McFarland and Heather Rider were initially elected to our board of directors pursuant to a voting agreement that terminated automatically by its terms upon the completion of our initial public offering in February 2014. The certificate of incorporation and bylaws currently in effect provide that the number of directors shall be at least one and will be fixed from time to time by resolution of our board of directors. During 2014, our board of directors met seven times. 78 Our board of directors is divided into three classes of directors. At each annual meeting of stockholders, a class of directors will be elected for a three-year term to succeed the class whose term is then expiring. The terms of the directors will expire upon the election and qualification of successor directors at the annual meeting of stockholders to be held during the years 2015 for the Class I directors, 2016 for the Class II directors and 2017 for the Class III directors. The Class I directors are Timothy Petersen and Heather Rider. The Class II directors are Loren McFarland and Benjamin Anderson-Ray. The Class III directors are Heath Lukatch, Ph.D. and Raymond Huggenberger. The division of our board of directors into three classes with staggered three-year terms may delay or prevent a change of our management or a change in control. Our board of directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our board of directors is responsible for general oversight of risks and regular review of information regarding our risks, including credit risks, liquidity risks and operational risks. Our compensation, nominating and corporate governance committee is responsible for overseeing the management of risks relating to our executive compensation plans and arrangements and the risks associated with the independence of our board of directors and potential conflicts of interest. Our audit committee is responsible for overseeing the management of our risks relating to accounting matters and financial reporting. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board of directors is regularly informed through discussions from committee members about such risks. Our board of directors believes its administration of its risk oversight function has not affected our board of directors’ leadership structure. Audit Committee Our board of directors has a separately-designated audit committee. The members of our audit committee are Messrs. McFarland (Chairman), Petersen and Anderson-Ray, each of whom is a non-employee member of our Board. The composition of our audit committee meets the requirements for independence under current NASDAQ Stock Market listing standards and SEC rules and regulations. Each member of our audit committee also meets the financial literacy requirements of the NASDAQ Stock Market listing standards. Our audit committee chairman, Mr. McFarland, is our audit committee financial expert, as that term is defined under the SEC rules implementing Section 407 of the Sarbanes-Oxley Act of 2002, and possesses financial sophistication, as defined under the listing standards of the NASDAQ Global Select Market. Our audit committee oversees our corporate accounting and financial reporting process and assists our Board in monitoring our financial systems. Our audit committee also: (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) approves the hiring, discharging and compensation of our independent auditors; oversees the work of our independent auditors; approves engagements of the independent auditors to render any audit or permissible non-audit services; reviews the qualifications, independence and performance of the independent auditors; reviews our financial statements and our critical accounting policies and estimates; reviews the adequacy and effectiveness of our internal controls; and reviews and discusses with management and the independent auditors the results of our annual audit, our annual and quarterly financial statements and our publicly filed reports. Our audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing requirements of NASDAQ Global Select Market. A copy of the charter of our audit committee is available on our website at www.inogen.com in the Corporate Governance section of our Investor Relations webpage. During 2014, our audit committee held eleven meetings. 79 Identifying and Evaluating Nominees for Director The compensation, nominating and governance committee will use the following procedures to identify and evaluate any individual recommended or offered for nomination to the Board: (cid:120) The compensation, nominating and governance committee will consider candidates recommended by stockholders in the same manner as candidates recommended to the Committee from other sources. (cid:120) In its evaluation of director candidates, including the members of the Board eligible for re-election, the compensation, nominating and governance committee will consider the following: (cid:16) The current size and composition of the Board and the needs of the Board and the respective committees of the Board. (cid:16) Such factors as character, integrity, judgment, diversity of experience, independence, area of expertise, corporate experience, length of service, potential conflicts of interest, other commitments and the like. The compensation, nominating and governance committee evaluates these factors, among others, and does not assign any particular weighting or priority to any of these factors. (cid:16) Other factors that the compensation, nominating and governance committee deems appropriate. The compensation, nominating and governance committee also focuses on issues of diversity, such as diversity of gender, race and national origin, education, professional experience and differences in viewpoints and skills. The committee does not have a formal policy with respect to diversity; however, our Board and the compensation, nominating and governance committee believe that it is essential that members of our Board represent diverse viewpoints. (cid:120) The compensation, nominating and governance committee requires the following minimum qualifications to be satisfied by any nominee for a position on the Board: (cid:16) The highest personal and professional ethics and integrity. (cid:16) Proven achievement and competence in the nominee’s field and the ability to exercise sound business judgment. (cid:16) Skills that are complementary to those of the existing Board. (cid:16) The ability to assist and support management and make significant contributions to the Company’s success. (cid:16) An understanding of the fiduciary responsibilities that is required of a member of the Board and the commitment of time and energy necessary to diligently carry out those responsibilities. (cid:120) If the compensation, nominating and governance committee determines that an additional or replacement director is required, the Committee may take such measures that it considers appropriate in connection with its evaluation of a director candidate, including candidate interviews, inquiry of the person or persons making the recommendation or nomination, engagement of an outside search firm to gather additional information, or reliance on the knowledge of the members of the compensation, nominating and governance committee, the Board or management. The compensation, nominating and governance committee may propose to the Board a candidate recommended or offered for nomination by a stockholder as a nominee for election to the Board. Stockholder Recommendations for Nominations to the Board It is the policy of the compensation, nominating and governance committee of the Board to consider recommendations for candidates to the Board from stockholders holding no less than one percent (1%) of the outstanding shares of the Company’s common stock continuously for at least twelve (12) months prior to the date of the submission of the recommendation or nomination. A stockholder that wants to recommend a candidate for election to the Board should direct the recommendation in writing by letter to the Company, attention of the Secretary, at 326 Bollay Drive, Goleta, CA 93117. The recommendation must include the candidate’s name, home and business contact information, detailed biographical data, relevant qualifications, a signed letter from the candidate confirming willingness to serve, information regarding any relationships between the candidate and the Company and evidence of the recommending stockholder’s ownership of Company stock. Such recommendations must also include a statement from the recommending stockholder in support of the candidate, particularly within the context of the criteria for Board membership, including issues of character, integrity, judgment, diversity of experience, independence, area of expertise, corporate experience, length of service, potential conflicts of interest, other commitments and the like and personal references. 80 A stockholder that instead desires to nominate a person directly for election to the Board at an annual meeting of the stockholders must meet the deadlines and other requirements set forth in Section 2.4 of the Company’s Bylaws and the rules and regulations of the Securities and Exchange Commission. Section 2.4 of the Company’s Bylaws requires that a stockholder who seeks to nominate a candidate for director must provide a written notice to the Secretary of the Company not later than the 45th day nor earlier than the 75th day before the one-year anniversary of the date on which the corporation first mailed its proxy materials or a notice of availability of proxy materials (whichever is earlier) for the preceding year’s annual meeting; provided, however, that in the event that no annual meeting was held in the previous year or if the date of the annual meeting is advanced by more than 30 days prior to or delayed by more than 60 days after the one-year anniversary of the date of the previous year’s annual meeting, then notice by the stockholder to be timely must be so received by the Secretary of the Company not earlier than the close of business on the 120th day prior to such annual meeting and not later than the close of business on the later of (i) the 90th day prior to such annual meeting and (ii) the 10th day following the day on which Public Announcement (as defined below) of the date of such annual meeting is first made. That notice must state the information required by Section 2.4 of the Company’s Bylaws, and otherwise must comply with applicable federal and state law. The Secretary of the Company will provide a copy of the Bylaws upon request in writing from a stockholder. “Public Announcement” shall mean disclosure in a press release reported by the Dow Jones News Service, Associated Press or a comparable national news service or in a document publicly filed by the corporation with the Securities and Exchange Commission pursuant to Section 13, 14 or 15(d) of the Securities Exchange Act of 1934, as amended, or any successor thereto. Communications with the Board The Board believes that management speaks for Inogen, Inc. Individual Board members may, from time to time, communicate with various constituencies that are involved with the Company, but it is expected that Board members would do this with knowledge of management and, in most instances, only at the request of management. In cases where stockholders and other interested parties wish to communicate directly with our non-management directors, messages can be sent to our Secretary, at Inogen, Inc., 326 Bollay Drive, Goleta, California 93117, Attn: Secretary. Our Secretary monitors these communications and will provide a summary of all received messages to the Board at each regularly scheduled meeting of the Board. Our Board generally meets on a quarterly basis. Where the nature of a communication warrants, our Secretary may determine, in his or her judgment, to obtain the more immediate attention of the appropriate committee of the Board or non- management director, of independent advisors or of Company management, as our Secretary considers appropriate. Our Secretary may decide in the exercise of his or her judgment whether a response to any stockholder or interested party communication is necessary. This procedure for stockholder and other interest party communications with the non-management directors is administered by the Company’s compensation, nominating and governance committee. This procedure does not apply to (a) communications to non- management directors from officers or directors of the Company who are stockholders, (b) stockholder proposals submitted pursuant to Rule 14a-8 under the Securities and Exchange Act of 1934, as amended, or (c) communications to the Audit Committee pursuant to the Complaint Procedures for Accounting and Auditing Matters. Section 16(a) Beneficial Ownership Reporting Compliance Section 16(a) of the Exchange Act requires our directors, executive officers, and holders of more than 10% of our common stock to file with the SEC reports regarding their ownership and changes in ownership of our securities. Except as set forth below, we believe that our directors, executive officers, and 10% stockholders complied with all Section 16(a) filing requirements in 2014. (cid:120) A late Form 4 report was filed by entities affiliated with Versant Ventures, a beneficial owner of more than 10% of our common stock, on September 12, 2014 to report transactions that occurred on September 9, 2014. (cid:120) A late Form 4 report was filed by Brenton Taylor, an executive officer, on October 2, 2014 to report transactions that occurred on September 25, 2014. (cid:120) A late Form 4 report was filed by entities affiliated with Versant Ventures on December 29, 2014 to report transactions that occurred on December 23, 2014. (cid:120) An amendment to a Form 4 report was filed by entities affiliated with Versant Ventures, a beneficial owner of more than 10% of our common stock, on December 29, 2014 to correct a Form 4 that was originally filed on December 22, 2014. (cid:120) An amendment to a Form 3 report was filed by Brenton Taylor, an executive officer, on December 30, 2014 to correct a Form 3 that was originally filed on February 12, 2014. 81 In making these statements, we have relied upon examination of the filings made with the SEC and the written representations of our directors and executive officers. Code of ethics and conduct We adopted a written code of ethics and conduct that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. A current copy of the code is posted on our website at: http://investor.inogen.com/corporate-governance.cfm. We intend to post any amendments to our code of ethics, and any waivers of the code of ethics for directors and executive officers, on the same website. Item 11. EXECUTIVE COMPENSATION Summary Compensation Table The following table provides information regarding the compensation awarded to, or earned by, our executive officers, including each of our named executive officers, during 2014 and 2013. Name and Principal Position Year Salary ($) Bonus ($) Raymond Huggenberger, ....................... 2014 $ 435,118 — President, Chief Executive Officer and Director .................................................. 2013 346,883 — Stock Awards ($) Option Awards ($)(1) — $1,090,897 $ Non-Equity Incentive Plan Compensation ($)(2) Other Compensation ($)(3) 396,000 $ Total Compensation 1,922,015 — $ — 186,685 260,163 10,236 803,967 Alison Bauerlein, ................................... 2014 $ 267,773 — Executive Vice President, Finance and Chief Financial Officer .......................... 2013 203,542 — — $ 410,887 $ 162,000 $ — $ 840,660 — 140,654 106,860 — 451,056 Scott Wilkinson, ..................................... 2014 $ 256,053 — Executive Vice President, Sales and Marketing ............................................... 2013 215,946 — — $ 321,264 $ 154,800 $ — $ 732,117 — 140,044 113,372 — 469,362 (1) The dollar amounts in this column represent the aggregate grant date fair value of stock option awards. These amounts have been computed in accordance with FASB ASC Topic 718. Pursuant to SEC rules, the amounts shown exclude the impact of estimated forfeitures related to service—based vesting conditions. For a discussion of valuation assumptions, see the notes to our audited financial statements included elsewhere in this Annual Report on Form 10-K (2) Represents the amounts earned and payable under the 2013 Bonus Plan and 2014 Bonus Plan. 2013 Bonus Plan payments were paid in 2014 and 2014 Bonus Plan payments were approved by the compensation, nominating and governance committee and are scheduled to be paid in the second quarter of 2015. (3) Amount represents a housing allowance paid to Mr. Huggenberger. 2014 Non—Equity Incentive Plan Payments For 2014, the target incentive amounts for our named executive officers were the following: Name and principal position Raymond Huggenberger .............................................................................. $ President and Chief Executive Officer ($) 264,000 $ Target award opportunity Actual award amount ($) 396,000 Scott Wilkinson ........................................................................................... 103,200 154,800 Executive Vice President, Sales and Marketing Alison Bauerlein .......................................................................................... 108,000 162,000 Executive Vice President, Finance and Chief Financial Officer 82 Our 2014 incentive compensation plan, or 2014 Bonus Plan, provides our named executive officers with an annual incentive compensation payment, subject to our achievement of our corporate performance goals. For 2014, our corporate-level goals included achieving specified Adjusted EBITDA targets for the year. If our Adjusted EBITDA achievement is at target, each named executive officer would receive 100% of his or her 2014 target award opportunity. Performance above 100% of our Adjusted EBITDA target entitles each named executive officer to an increase to his or her incentive award payment based on the extent of the achievement above target. For our 2014 Bonus Plan, our adjusted EBITDA target was $18.3 million at 100% of our Adjusted EBITDA, and $20.7 million at 150% of our Adjusted EBITDA, excluding expenses incurred in connection with our initial public offering and following on offering costs. The 2014 Bonus Plan reached maximum payout for all executive officers of 150% of target and was approved by the compensation, nominating and governance committee on April 24, 2015 for payment May 1, 2015. 2013 Non—Equity Incentive Plan Payments For 2013, the target incentive amounts for our named executive officers were the following: Name and principal position Raymond Huggenberger .............................................................................. $ President and Chief Executive Officer ($) 173,442 $ Target award opportunity Actual award amount ($) 260,163 Scott Wilkinson ........................................................................................... 75,581 113,372 Executive Vice President, Sales and Marketing Alison Bauerlein .......................................................................................... 71,240 106,860 Vice President, Finance and Chief Financial Officer Our 2013 incentive compensation plan, or 2013 Bonus Plan, provides our named executive officers with an annual incentive compensation payment, subject to our achievement of our corporate performance goals. For 2013, our corporate-level goals included achieving specified Adjusted EBITDA targets for the year. If our Adjusted EBITDA achievement is at target, each named executive officer would receive 100% of his or her 2013 target award opportunity. Performance above 100% of our Adjusted EBITDA target entitles each named executive officer to an increase to his or her incentive award payment based on the extent of the achievement above target. For our 2013 Bonus Plan, our adjusted EBITDA target was $10.5 million, excluding expenses incurred in connection with our initial public offering. The 2013 Bonus Plan reached maximum payout for all executive officers of 150% of target and was approved by the compensation, nominating and governance committee on March 19, 2014 for payment April 11, 2014. Processes and Procedures for Compensation Decisions Our compensation, nominating and governance committee is responsible for the executive compensation programs for our executive officers and reports to our board of directors on its discussions, decisions and other actions. Typically, our Chief Executive Officer makes recommendations to our compensation, nominating and governance committee, often attends committee meetings and is involved in the determination of compensation for the respective executive officers who report to him, except that the Chief Executive Officer does not make recommendations as to his own compensation. Our Chief Executive Officer makes recommendations to our compensation, nominating and governance committees regarding short- and long-term compensation for all executive officers (other than himself) based on our results, an individual executive officer’s contribution toward these results and performance toward individual goal achievement. Our compensation, nominating and governance committee then reviews the recommendations and other data and makes decisions as to total compensation for each executive officer, as well as each individual compensation component. Our compensation, nominating and governance committee reviews and approves, or makes recommendations for approval by the independent members of the Board regarding the compensation of each executive officer, including our Chief Executive Officer. 83 Our compensation, nominating and governance committee is authorized to retain the services of one or more executive compensation advisors, as it sees fit, in connection with the establishment of our compensation programs and related policies. In 2013, our compensation, nominating and governance committee retained Pearl Meyer & Partners, a national compensation consultant, to provide it with information, recommendations and other advice relating to executive compensation on an ongoing basis. Accordingly, Pearl Meyer & Partners now serves at the discretion of our compensation, nominating and governance committee. Our compensation, nominating and governance committee engaged Pearl Meyer & Partners to assist in developing an appropriate group of peer companies to help us determine the appropriate level of overall compensation for our executive officers, as well as assess each separate element of compensation, with a goal of ensuring that the compensation we offer to our executive officers is competitive and fair. Employment Agreements for Executive Officers Raymond Huggenberger We entered into an amended and restated employment agreement with Raymond Huggenberger, our president and chief executive officer, effective October 1, 2013. As of March 1, 2015, Mr. Huggenberger’s current base salary is $475,000 and he is eligible to receive an annual performance bonus of up to 60% of his base salary. Mr. Huggenberger is entitled under his employment agreement to the following severance and change of control benefits upon certain qualifying terminations. If Mr. Huggenberger’s employment is terminated without “cause” (excluding by reason of death or disability) or he resigns for “good reason” (as such terms are defined in the employment agreement), he will be eligible to receive the following benefits if he timely signs and does not revoke a release of claims: (cid:120) (cid:120) if outside the Change in Control Period, continued payment of his base salary for a period of 24 months (collectively, the “CEO Severance Payments”); and throughout the period during which he would be able to obtain COBRA coverage, Mr. Huggenberger and his dependents will only be required to pay the portion of the costs of medical benefits as Mr. Huggenberger was required to pay as of the date of his termination, or Mr. Huggenberger will receive taxable monthly payments for the equivalent period in the event the Company determines that the COBRA subsidy could violate applicable law (the “CEO COBRA Benefits”). The Change in Control Period is the period beginning three months before a change in control, as defined in the employment agreement, and ending 12 months after a change in control. If, during the Change of Control Period, Mr. Huggenberger’s employment is terminated without “cause” (excluding by reason of death or disability) or he resigns for “good reason”, he will be eligible to receive the CEO Severance Payments and CEO COBRA Benefits, however the CEO Severance Payments will continue for a period of 36 months. In the event any of the amounts provided for under this employment agreement or otherwise payable to Mr. Huggenberger would constitute “parachute payments” within the meaning of Section 280G of the Internal Revenue Code and could be subject to the related excise tax, Mr. Huggenberger would be entitled to receive either full payment of benefits under this employment agreement or such lesser amount which would result in no portion of the benefits being subject to the excise tax, whichever results in the greater amount of after-tax benefits to Mr. Huggenberger. The employment agreement does not require us to provide any tax gross-up payments. Scott Wilkinson and Alison Bauerlein We entered into an amended and restated employment agreement with each of Scott Wilkinson, our executive vice president, sales and marketing and Alison Bauerlein, our executive vice president, finance and chief financial officer, treasurer and secretary, effective October 1, 2013. As of March 1, 2015, Mr. Wilkinson’s current base salary is $275,000 and he is eligible to receive an annual performance bonus of up to 40% of his base salary and Ms. Bauerlein’s current base salary is $290,000 and she is eligible to receive an annual performance bonus of up to 40% of her base salary. Each of Mr. Wilkinson and Ms. Bauerlein is entitled under their respective employment agreements to the following severance and change of control benefits upon certain qualifying terminations. 84 If the named executive officer’s employment is terminated without “cause” (excluding by reason of death or disability) or the named executive officer resigns for “good reason” (as such terms are defined in the employment agreement), such named executive officer will be eligible to receive the following benefits if he or she timely signs and does not revoke a release of claims: (cid:120)(cid:3) (cid:120) if outside the Change in Control Period continued payment of his or her base salary for a period of 12 months (the “NEO Severance Payments”); and throughout the period during which he would be able to obtain COBRA coverage, the named executive and his or her eligible dependents will only be required to pay the portion of the costs of medical benefits as he or she was required to pay as of the date of his termination, or he or she will receive taxable monthly payments for the equivalent period in the event the Company determines that the COBRA subsidy could violate applicable law, (the “NEO COBRA Benefits”). If, during the Change of Control Period, the named executive officer’s employment is terminated without cause (excluding by reason of death or disability) or he or she resigns for good reason, he or she will be eligible to receive the NEO Severance Payments and NEO COBRA Benefits, however the NEO Severance Payments will continue for a period of 24 months. In the event any of the amounts provided for under an employment agreement or otherwise payable to the named executive officer would constitute “parachute payments” within the meaning of Section 280G of the Internal Revenue Code and could be subject to the related excise tax, the named executive officer would be entitled to receive either full payment of benefits under the employment agreement or such lesser amount which would result in no portion of the benefits being subject to the excise tax, whichever results in the greater amount of after-tax benefits to the named executive officer. Neither employment agreement requires us to provide any tax gross-up payments. Merger or Change of Control Our 2014 Equity Incentive Plan, or 2014 Plan provides that in the event of a merger or change in control, as defined under the 2014 Plan, each outstanding award will be treated as the administrator determines, except that if a successor corporation or its parent or subsidiary does not assume or substitute an equivalent award for any outstanding award, then such award will fully vest, all restrictions on such award will lapse, all performance goals or other vesting criteria applicable to such award will be deemed achieved at 100% of target levels and such award will become fully exercisable, if applicable, for a specified period prior to the transaction. The award will then terminate upon the expiration of the specified period of time. If the service of an award holder is terminated on or within the 12 months following a change in control, as a result of an involuntary termination as defined in the 2014 Plan, his or her options, restricted stock units and stock appreciation rights, if any, will vest fully and become immediately exercisable, all restrictions on his or her restricted stock will lapse, and all performance goals or other vesting requirements for his or her performance shares and units will be deemed achieved at 100% of target levels, and all other terms and conditions met. In addition, in the event of a change in control, options, stock appreciation rights, restricted stock and restricted stock units held by our outside directors, if any, will vest fully and become immediately exercisable, all restrictions on his or her restricted stock will lapse, and all performance goals or other vesting for his or her performance shares and units will be deemed achieved at one hundred percent (100%) of target levels, and all other terms and conditions met. 401(k) Plan We maintain a tax-qualified retirement plan that provides eligible employees with an opportunity to save for retirement on a tax advantaged basis. All participants’ interests in their deferrals are 100% vested when contributed. In 2014 and 2013, we made no matching contributions into the 401(k) plan. Pre-tax contributions are allocated to each participant’s individual account and are then invested in selected investment alternatives according to the participants’ directions. The 401(k) plan is intended to qualify under Sections 401(a) and 501(a) of the Internal Revenue Code. As a tax-qualified retirement plan, contributions to the 401(k) plan and earnings on those contributions are not taxable to the employees until distributed from the 401(k) plan, and all contributions are deductible by us when made. 85 Outstanding Equity Awards at Fiscal Year-End The following table presents certain information concerning equity awards held by our named executive officers, as of December 31, 2014. Option Awards Stock Awards Number of Securities Underlying Unexercised Options (#) Exercisable Number of Securities Underlying Unexercised Options (#) Unexercisable Option Exercise Price ($) Name Grant Date Raymond Huggenberger ... 2/24/2010 3/28/2012 10/10/2013 4/1/2014 Scott Wilkinson .............. 11/21/2005 3/27/2008 2/24/2010 10/11/2011 3/28/2012 10/10/2013 4/1/2014 Alison Bauerlein ............ 3/27/2008 2/10/2009 2/24/2010 10/11/2011 3/28/2012 10/10/2013 4/1/2014 (cid:3)(cid:3) (cid:3)(cid:3) (cid:3)(cid:3) (cid:3)(cid:3) 223,694 (1) 49,072 (2) 12,961 (8) — (3) 285,727 6,666 (4) 25,000 (5) 40,000 (6) 14,730 (7) 15,989 (2) 9,723 (8) — (3) 112,108 32,798 (5) 20,000 (9) 30,399 (6) — (7) 18,630 (2) 6,127 (8) — (3) — $ 24,537 $ 31,480 $ 173,445 $ 229,462 — $ — $ — $ 2,947 $ 7,995 $ 23,615 $ 51,124 $ 85,681 — $ — $ — $ 1,685 $ 9,316 $ 23,718 $ 65,311 $ 0.60 0.81 8.37 16.62 8.70 2.40 0.60 0.75 0.81 8.37 16.62 2.40 0.60 0.60 0.75 0.81 8.37 16.62 107,954 100,030 Market Value of Shares of Units of Stock that have not Vested ($) Number of Shares or Units of Stock that have not Vested (#) Option Expiration Date 2/23/2020 3/27/2022 10/9/2023 3/31/2021 11/20/2015 3/26/2018 2/23/2020 10/10/2021 3/27/2022 10/9/2023 3/31/2021 3/26/2018 2/9/2019 2/23/2020 10/10/2021 3/27/2022 10/9/2023 3/31/2021 (cid:3)(cid:3)(cid:3)(cid:3) (cid:3)(cid:3)(cid:3)(cid:3) (1) The option fully vested on 12/24/2011. (2) 1/48th of the shares subject to the option vest monthly May 1, 2012 subject to continued service through each vesting date. (3) The option vested with the respect to 25% of the shares subject to the option on April 1, 2015, and 1/36th of the remaining shares subject to the option vest monthly thereafter subject to continued service through each vesting date. (4) The option fully vested on November 21, 2009. (5) The option fully vested on January 1, 2012. (6) The option fully vested on February 24, 2014. (7) (8) (9) The option fully vested on February 10, 2013. 1/48th of the shares subject to the option vest monthly August 1, 2012 subject to continued service through each vesting date. 1/48th of the shares subject to the option vest monthly November 1, 2013 subject to continued service through each vesting date. Director Compensation The table below shows compensation earned by our non-employee directors during 2014. Directors who are also our employees receive no additional compensation for their service as a director. During the year ended December 31, 2014, one director, Mr. Huggenberger, was an employee. Mr. Huggenberger’s compensation is discussed in “Executive Compensation.” 86 Director Compensation Table Name Loren McFarland(3) ......................... (cid:3) $ Benjamin Anderson-Ray(4) ............. (cid:3) Heath Lukatch, Ph.D.(5) .................. (cid:3) Timothy Petersen(6) ......................... (cid:3) Heather Rider(7) ............................... (cid:3) Charles Larsen(8) ............................. (cid:3) Cash Compensation ($)(2)(3) Option Awards ($)(1) Total ($) $ 55,000 35,000 70,000 35,000 14,000 21,000 $ 76,556 76,556 — 76,556 18,529 76,556 131,556 111,556 70,000 111,556 32,529 97,556 (1) Represents the aggregate grant date fair value recognized for financial statement reporting purposes for 2014, calculated in accordance with ASC Topic 718. Such grant-date fair value does not take into account any estimated forfeitures related to service-vesting conditions. See the notes to our audited financial statements elsewhere in this Annual Report on Form 10-K filed for a discussion of assumptions made in determining the grant date fair value and compensation expense of our stock options. (2) Cash fees earned for board and committee service reflect a partial year of service at the amounts discussed in the “Cash compensation” section below. (3) As of December 31, 2014, Mr. McFarland had two options to purchase a total of 15,416 shares consisting of an option to purchase 2,083 and an option to purchase 13,333 shares of our common stock. The first option vested in 12 successive equal monthly installments from grant date of October 1, 2013 and the second option vests in 24 successive equal monthly installments from grant date of April 1, 2014, respectively, subject to continued service through each such date. 2,083 and 4,444 shares of our common stock subject to these options were vested as of December 31, 2014. (4) As of December 31, 2014, Mr. Anderson-Ray had two options to purchase a total of 14,999 shares consisting of an option to purchase 1,666 and an option to purchase 13,333 shares of our common stock. The first option vested in 12 successive equal monthly installments from grant date of October 1, 2013 and the second option vests in 24 successive equal monthly installments from grant date of April 1, 2014, respectively, subject to continued service through each such date. 1,666 and 4,444 shares of our common stock subject to these options were vested as of December 31, 2014. (5) As of December 31, 2014, Dr. Lukatch had no options granted or outstanding. The cash compensation of $70,000 was accrued, but not paid as of December 31, 2014. (6) As of December 31, 2014, Mr. Petersen had one option to purchase a total of 13,333 shares of our common stock. The option vests in 24 successive equal monthly installments from grant date of April 1, 2014, subject to continued service through such date. 4,444 shares of our common stock subject to this option were vested as of December 31, 2014. (7) As of December 31, 2014, Ms. Rider had one option to purchase a total of 2,222 shares of our common stock. The option vests in 24 successive equal monthly installments from grant date of August 15, 2014, subject to continued service through such date. 370 shares of our common stock subject to this option was vested as of December 31, 2014. (8) As of December 31, 2014, Mr. Larsen had no outstanding options to purchase shares of our common stock. Mr Larsen forfeited 2,222 options that had vested during his term on the Board related to the 13,333 options which were granted to him during the year. Mr. Larsen resigned from the Board in the first quarter of 2014. See “Executive Compensation” for information about the compensation of directors who are also our employees. Cash Compensation Following our initial public offering, all non-employee directors are entitled to receive the following cash compensation for their services: (cid:120) (cid:120) (cid:120) (cid:120) $35,000 per year for service as a board member; $20,000 per year for service as chair of the board; $20,000 per year for service as chair of the audit committee; and $15,000 per year for service as chair of the compensation, nominating and governance committee. All cash payments to non-employee directors will be paid quarterly in arrears. 87 Options On the date of each annual meeting of stockholders, each non-employee director will be granted a nonstatutory stock option to purchase 6,666 shares of our common stock, which grant will vest in twelve equal monthly installments beginning with the first monthly anniversary after the grant date, but will vest fully on the date of the next annual meeting held after the date of grant if not fully vested on such date, in each case, subject to the non-employee director continuing to be a service provider through each vesting date. Additionally, on the date of each annual meeting of stockholders, each non-employee director who serves as chairman of our Board or one of its committees will be granted a nonstatutory stock option to purchase: 1,666 shares of our common stock (chairman of the Board), 1,666 shares of our common stock (chairman of the audit committee), and/or 1,666 shares of our common stock (chairman of the compensation, nominating and governance committee). Each of these grants will vest in twelve equal monthly installments beginning with the first monthly anniversary after the grant date, but will vest fully on the date of the next annual meeting held after the date of grant if not fully vested on such date, in each case, subject to the non-employee director continuing to be a service provider through each vesting date. For further information regarding the equity compensation of our non-employee directors, see the section titled “Executive Compensation.” Compensation Committee Interlocks During the past fiscal year, none of the members of our compensation, nominating and governance committee (which includes current members Dr. Lukatch, Mr. Petersen and Ms. Rider, and former member Mr. Anderson-Ray) is or has at any time during the past year been an officer or employee of our company. None of our executive officers currently serves, or in the past year has served, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions) of any entity that has one or more of its executive officers serving on our Board or compensation, nominating and governance committee. Compensation Committee Report The compensation, nominating and governance committee has reviewed and discussed the section captioned “Executive Compensation,” included in this Annual Report on Form 10-K, with management and, based on such review and discussion, the compensation committee has recommended to our board of directors that this “Executive Compensation” section be included in this Annual Report on Form 10-K. Respectfully submitted by the members of the compensation, nominating and governance committee of the board of directors: Heath Lukatch Ph.D., Chairman Timothy Petersen Heather Rider 88 ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS Equity Compensation Plan Information The following table provides information as of December 31, 2014 with respect to shares of our common stock that may be issued under our existing equity compensation plans. (a) Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights (b) Weighted Average Exercise Price of Outstanding Options, Warrants and Rights (1) (c) Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected in Column (a)) Plan Category Equity compensation plans approved by security holders (2)(3) ............................. Equity compensation plans not approved by security holders .................................. Total ........................................................... 2,261,633 $ — 2,261,633 $ 7.31 — 7.31 369,889 — 369,889 (1) The weighted average exercise price is calculated based solely on outstanding stock options. (2) Includes the following plans: 2002 Stock Incentive Plan, 2012 Equity Incentive Plan, 2014 Equity Incentive Plan (“2014 Plan”), and 2014 Employee Stock Purchase Plan (“ESPP”). (3) The number of shares available for issuance under the 2014 Plan also includes an annual increase on the first day of each fiscal year beginning in 2015, equal to the least of: (i) 895,346 shares; (ii) 4% of the outstanding shares of common stock as of the last day of our immediately preceding fiscal year; or (iii) such other amount as our board of directors may determine. Our 2014 Plan had 221,178 options available for issuance as of December 31, 2014. Our ESPP provides for annual increases in the number of shares available for sale under the ESPP on the first day of each fiscal year beginning in 2015, equal to the least of: (i) 179,069 shares; (ii) 1.5% of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or (iii) such other amount as may be determined by the administrator. Our ESPP had 148,711 shares available for sale as of December 31, 2014. On January 1, 2015, the number of shares available for issuance under our 2014 Plan and our ESPP increased by 762,373 shares and 179,069 shares, respectively, pursuant to these provisions. These increases are not reflected in the table above. Principal Stockholders The following table sets forth certain information with respect to the beneficial ownership of our common stock as of April 15, 2015 for: (cid:120) (cid:120) (cid:120) (cid:120) each of our directors; each of our named executive officers; all of our current directors and executive officers as a group; and each person or group who beneficially owned more than 5% of our common stock. We have determined beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where applicable. We have based our calculation of the percentage of beneficial ownership on 19,282,247 shares of our common stock outstanding as of April 15, 2015. We have deemed shares of our common stock subject to stock options that are currently exercisable or exercisable within 60 days of April 15, 2015 to be outstanding and to be beneficially owned by the person holding the stock option for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. 89 Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o Inogen, Inc., 326 Bollay Drive, Goleta, CA 93117. Name of Beneficial Owner+ 5% Stockholders: Novo A/S (1) .............................................................................. Entities affiliated with Versant Ventures (2) .............................. Directors and Executive Officers, including our Named Executive Officers: Raymond Huggenberger (3) ....................................................... Scott Wilkinson (4) .................................................................... Alison Bauerlein (5) ................................................................... Heath Lukatch, Ph.D. ............................................................... Tim Petersen (6) ......................................................................... Benjamin Anderson-Ray (7) ...................................................... Loren McFarland (8) .................................................................. Heather Rider (9) ........................................................................ Number of Shares Beneficially Owned Percentage of Shares Beneficially Owned 3,549,320 1,302,862 18.41% 6.76% 306,435 99,728 150,146 — 826,360 9,443 12,985 3,833 1.56% * * * 4.28% * * * 9.50% All current directors and executive officers as a group (11 persons) (10) ............................................................................... 1,906,176 Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock. * (1) Consists of 3,549,320 shares held by Novo A/S. Novo A/S is a Danish limited liability company. The board of directors of Novo A/S, which consists of Sten Scheibye, Göran Ando, Jørgen Boe, Jeppe Christiansen, Steen Riisgaard and Per Wold-Olsen, has shared investment and voting control with respect to the shares held by Novo A/S and may exercise such control only with the support of a majority of the members of the Novo A/S board of directors. As such, no individual member of the Novo A/S board of directors is deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by Novo A/S. Dr. Lukatch, a member of our board of directors, is employed as a Partner of Novo Ventures (US) Inc. Dr. Lukatch is not deemed a beneficial owner of, and does not have a reportable pecuniary interest in, the shares held by Novo A/S. The address of Novo A/S is Tuborg Havnevej 19, 2900 Hellerup, Denmark. (2) Based solely on a review of Form 4’s filed with the Security and Exchange Commission, consists of (i) 31,334 shares held of record by Versant Affiliates Fund II-A, L.P., a Delaware limited partnership (“VAF II-A”), (ii) 7,812 shares held of record by Versant Side Fund II, L.P., a Delaware limited partnership (“VSF II”), and (iii) 1,263,716 shares held of record by Versant Venture Capital II, L.P., a Delaware limited partnership (“VVC II”). Versant Ventures II, LLC, a Delaware limited liability company (“VV II”) serves as the sole general partner of VAF II-A, VSF II and VVC II own no shares directly. Brian G. Atwood, Samuel D. Colella, Ross A. Jaffe, William J. Link, Ph.D., Donald B. Milder, Rebecca B. Robertson, Bradley J. Bolzon, Charles M. Warden, and Barbara N. Lubash are directors and/or members of VV II and share voting and dispositive power over the shares held by VAF II-A, VSF II and VVC II; however, they disclaim beneficial ownership of the shares held by VAF II-A, VSF II and VVC II except to the extent of their pecuniary interests therein. The address for such entities and persons is c/o Versant Ventures, 3000 Sand Hill Road, Building 4, Suite 210, Menlo Park, California 94025. Includes 6,808 shares held and options to purchase 299,627 shares of common stock that are exercisable within 60 days of April 15, 2015. (3) (4) Consists of options to purchase 99,728 shares of common stock that are exercisable within 60 days of April 15, 2015. (5) Includes 55,575 shares held and options to purchase 94,571 shares of common stock that are exercisable within 60 days of April 15, 2015. (6) Consists of (i) 511,462 shares held of common stock held of record by Arboretum Ventures II, L.P., (ii) 120,106 shares held of common stock held of record by Arboretum Ventures IIa, L.P., (iii) 112,212 shares held of common stock held of record by Arboretum Ventures 1, LLC, and (iv) 74,803 shares of common stock held of record by Arboretum Ventures 1-A, LLC, and options to purchase 7,777 shares of common stock that are exercisable within 60 days of April 15, 2015. Arboretum Investment Manager II, LLC (“AIM II”) serves as the general partner of Arboretum Ventures II, L.P. and serves as the sole manager of Arboretum Investment Manager IIa, LLC, which serves as the general partner of Arboretum Ventures IIa, L.P. Jan Garfinkle and Timothy Petersen are the managing members of AIM II and share the power to vote or dispose of these shares and therefore each of the foregoing managing members may be deemed to have voting and investment power with respect to such shares. Arboretum Investment Manager, LLC (“AIM”) serves as the managing member of Arboretum Ventures 1, LLC and Arboretum 90 Ventures 1-A, LLC. Jan Garfinkle and Timothy Petersen are the managing members of AIM and share the power to vote or dispose of these shares and therefore each of the foregoing managing members may be deemed to have voting and investment power with respect to such shares. The address for such entities and persons is c/o Arboretum Ventures, 303 Detroit Street, Suite 301, Ann Arbor, Michigan 48104. Timothy Petersen is a member of our board of directors. (7) Consists of options to purchase 9,443 shares of common stock that are exercisable within 60 days of April 15, 2015. (8) Includes 3,125 shares held and options to purchase 9,860 shares of common stock that are exercisable within 60 days of April 15, 2015. Includes 3,000 shares held and options to purchase 833 shares of common stock that are exercisable within 60 days of April 15, 2015. (9) (10) Includes 992,395 shares held, and options to purchase 913,781 shares of common stock that are exercisable within 60 days of April 15, 2015. ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE Related Person Transactions In the ordinary course of our business, we have entered into a number of transactions with our officers, directors and 5% or greater stockholders. We believe we have executed all of the transactions set forth below on terms no less favorable to us than we could have obtained from unaffiliated third parties. We have adopted a formal written policy providing that our audit committee will be responsible for reviewing “related party transactions,” which are transactions (i) in which we are or will be a participant, (ii) in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and (iii) in which a related person has or will have a direct or indirect interest. For purposes of this policy, a related person will be defined as a director, nominee for director, executive officer, or greater than 5% beneficial owner of our common stock and their immediate family members. Under this policy, all related party transactions may be consummated or continued only if approved or ratified by our audit committee. We describe below transactions and series of similar transactions, since the beginning of our last fiscal year, to which we were or will be a party, in which: (cid:120) (cid:120) the amounts involved exceeded or will exceed $120,000; and any of our directors, nominees for director, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. Other than as described below, there has not been, nor is there any currently proposed, transactions or series of similar transactions to which we have been or will be a party. Investors’ Rights Agreement We are party to an amended and restated investors’ rights agreement with certain holders of our common stock and warrants to purchase our common stock, including Novo A/S, entities affiliated with Arboretum Ventures, and entities affiliated with Versant Ventures. As of April 15, 2015, the holders of approximately 8.1 million shares of our common stock are entitled to rights with respect to the registration of their shares under the Securities Act. Voting Agreement All of the directors other than Benjamin Anderson-Ray, Loren McFarland and Heather Rider were initially elected to the board of directors pursuant to a voting agreement. Upon the completion of our initial public offering, the obligations of the parties to the voting agreement to vote their shares so as to elect certain nominees terminated and none of our stockholders has any special rights regarding the nomination, election or designation of members of the board of directors. Other Agreements We have entered into separate indemnification agreements with each of our directors and certain of our officers. We have entered into employment agreements with certain of our executive officers that, among other things, provide for certain severance and change of control benefits. For a description of employment agreements with our named executive officers, see “Employment Agreements for Executive Officers.” 91 We have granted stock options to our named executive officers, other executive officers and certain of our directors. Director Independence Our common stock is listed on the NASDAQ Global Select Market. Under the rules of the NASDAQ Global Select Market, independent directors must comprise a majority of a listed company’s board of directors within a specified period after the completion of our initial public offering. In addition, the rules of the NASDAQ Global Select Market require that, subject to specified exceptions, each member of a listed company’s audit and compensation, nominating and governance committee be independent. Under the rules of the NASDAQ Global Select Market, a director will only qualify as an “independent director” if, in the opinion of that company’s board of directors, that person does not have a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. Audit committee members must also satisfy the independence criteria set forth in Rule 10A-3 under the Securities Exchange Act of 1934, as amended, or the Exchange Act. To be considered independent for purposes of Rule 10A-3, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of our audit committee, our Board, or any other board committee: (1) accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2) be an affiliated person of the listed company or any of its subsidiaries. Our Board has undertaken a review of its composition, the composition of its committees and the independence of each of our directors and considered whether any director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our Board has determined that none of Mr. Anderson-Ray, Ms. Rider, Dr. Lukatch, Mr. McFarland, and Mr. Petersen, representing five of our six directors, has a relationship that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is “independent” as that term is defined under the rules of the NASDAQ Global Select Market. Our Board also determined that Messrs. McFarland (chairman), Petersen and Anderson-Ray, who comprise our audit committee, and Dr. Lukatch (chairman), Mr. Petersen and Ms. Rider, who comprise our compensation, nominating and governance committee, satisfy the independence standards for those committees established by applicable Securities and Exchange Commission, or SEC, rules and the listing standards of the NASDAQ Global Select Market. In making this determination, our Board considered the relationships that each non-employee director has with us and all other facts and circumstances our Board deemed relevant in determining independence, including the beneficial ownership of our capital stock by each non-employee director. Board Leadership Structure Dr. Lukatch currently serves as the chairman of our Board. Our Board believes the current board leadership structure provides effective independent oversight of management while allowing our Board and management to benefit from Dr. Lukatch’s leadership and years of experience as a venture capital investor in the biotech industry. Dr. Lukatch is best positioned to identify strategic priorities, lead critical discussion and execute our strategy and business plans. Dr. Lukatch possesses detailed in-depth knowledge of the issues, opportunities, and challenges facing us. Independent directors and management sometimes have different perspectives and roles in strategy development. Our Board believes that Dr. Lukatch’s role enables strong leadership, creates clear accountability, facilitates information flow between management and our Board, and enhances our ability to communicate our message and strategy clearly and consistently to stockholders. Board Meetings and Committees During 2014, our Board held seven meetings (including regularly scheduled and special meetings), and each director attended at least 75% of the aggregate of (i) the total number of meetings of our Board held during the period for which he or she served as a director and (ii) the total number of meetings held by all committees of our Board on which he or she served during the periods that he or she served. It is the policy of our Board to regularly have separate meeting times for independent directors without management. Although we do not have a formal policy regarding attendance by members of our Board at annual meetings of stockholders, we encourage, but do not require, our directors to attend. We have established an audit committee and a compensation, nominating and governance committee. We believe that the composition of these committees meets the criteria for independence under, and the functioning of these committees comply with the requirements of, the Sarbanes-Oxley Act of 2002, the rules of the NASDAQ Global Select Market, and SEC rules and regulations. We 92 intend to comply with the requirements of the NASDAQ Global Select Market with respect to committee composition of independent directors. Each committee has the composition and responsibilities described below. Audit Committee The members of our audit committee are Messrs. McFarland (Chairman), Petersen and Anderson-Ray, each of whom is a non- employee member of our Board. The composition of our audit committee meets the requirements for independence under current NASDAQ Stock Market listing standards and SEC rules and regulations. Each member of our audit committee also meets the financial literacy requirements of the NASDAQ Stock Market listing standards. Our audit committee chairman, Mr. McFarland, is our audit committee financial expert, as that term is defined under the SEC rules implementing Section 407 of the Sarbanes-Oxley Act of 2002, and possesses financial sophistication, as defined under the listing standards of the NASDAQ Global Select Market. Our audit committee oversees our corporate accounting and financial reporting process and assists our Board in monitoring our financial systems. Our audit committee also: (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) approves the hiring, discharging and compensation of our independent auditors; oversees the work of our independent auditors; approves engagements of the independent auditors to render any audit or permissible non-audit services; reviews the qualifications, independence and performance of the independent auditors; reviews our financial statements and our critical accounting policies and estimates; reviews the adequacy and effectiveness of our internal controls; and reviews and discusses with management and the independent auditors the results of our annual audit, our annual and quarterly financial statements and our publicly filed reports. Our audit committee operates under a written charter that satisfies the applicable rules and regulations of the SEC and the listing requirements of NASDAQ Global Select Market. A copy of the charter of our audit committee is available on our website at www.inogen.com in the Corporate Governance section of our Investor Relations webpage. During 2014, our audit committee held eleven meetings. Compensation, Nominating and Governance Committee The members of our compensation, nominating and governance committee are Dr. Lukatch, Mr. Petersen and Ms. Rider. Dr. Lukatch is the chairman of our compensation, nominating and governance committee. The composition of our compensation committee meets the requirements for independence under current NASDAQ Stock Market listing standards and SEC rules and regulations. Each member of the compensation committee is also a non-employee director, as defined pursuant to Rule 16b-3 promulgated under the Exchange Act, and an outside director, as defined pursuant to Section 162(m) of the Internal Revenue Code. Our compensation, nominating and governance committee oversees our compensation policies, plans and benefits programs. Our compensation, nominating and governance committee also: (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) (cid:120) assists the Board in providing oversight of the Company’s overall compensation plans and benefits programs s; reviews and approves, or makes recommendations for approval by the independent members of the Board regarding corporate goals and objectives relevant to compensation of our chief executive officer and other senior officers; evaluates the performance of our officers in light of established goals and objectives; reviews and approves, or make recommendations regarding compensation of our officers based on its evaluations; administers the issuance of stock options and other awards under our stock plans; evaluates and makes recommendations regarding the organization and governance of our Board and its committees; evaluates and proposes nominees for election to our Board; assesses the performance of members of our Board and makes recommendations regarding committee and chair assignments; recommends desired qualifications for board of directors membership and conducts searches for potential members of our Board; and (cid:120) reviews and makes recommendations with respect to our corporate governance guidelines. 93 Our compensation, nominating and governance committee operates under a written charter that satisfies the listing standards of NASDAQ Global Select Market. A copy of the charter of our nominating and governance committee is available on our website at www.inogen.com in the Corporate Governance section of our Investor Relations webpage. During 2014, our compensation, nominating and governance committee held two meetings. ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES The Audit Committee of the Board of Directors selected BDO USA, LLP (“BDO”) to be the Company’s independent registered public accounting firm for the year ended December 31, 2014. Audit Fees The following table presents fees for professional audit services and other services rendered to us by BDO USA, LLP for our fiscal years ended December 31, 2014 and 2013. Audit fees (1) ................................................................... $ Audit-related fees (2) ....................................................... Tax fees (3) ...................................................................... All other fees (4) .............................................................. Total fees .................................................................... $ 2014 2013 631,000 $ — 142,000 — 773,000 $ 643,000 — 97,000 — 740,000 (1) “Audit Fees” consist of fees billed for professional services rendered in connection with the audit of our annual financial statements, review of our quarterly financial statements, and services that are normally provided by BDO USA, LLP in connection with statutory and regulatory filings or engagements for those fiscal years. Fees for 2013 and 2014 also included fees billed for professional services rendered in connection with our Form S-1 and Form S-8 registration statements related to our initial public offering of common stock and follow-on offering of common stock completed in 2014. (2) “Audit-Related Fees” consist of fees billed for professional services for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements and are not reported under “Audit Fees.” BDO USA, LLP did not bill us for any such services for each of the last two fiscal years. (3) “Tax Fees” consist of fees billed for professional services rendered by BDO USA, LLP for tax compliance, tax advice and tax planning. (4) “All Other Fees” consist of fees billed for services other than the services reported in Audit Fees, Audit-Related Fees, and Tax Fees. BDO USA, LLP did not bill us for any such services for each of the last two fiscal years. Auditor Independence In 2014, there were no other professional services provided by BDO USA, LLP that would have required our audit committee to consider their compatibility with maintaining the independence of BDO USA, LLP. Audit Committee Policy on Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm Our audit committee has established a policy governing our use of the services of our independent registered public accounting firm. Under the policy, our audit committee is required to pre-approve all audit and permissible non-audit services performed by our independent registered public accounting firm in order to ensure that the provision of such services does not impair such accounting firm’s independence. All fees paid to BDO USA, LLP for our fiscal years ended December 31, 2014 and 2013 were pre-approved by our audit committee. 94 PART IV ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES (a) The following documents are filed as part of this Annual Report on Form 10-K: 1. Financial Statements The financial statements listed in the accompanying index (page F-1) to the financial statements are filed as part of this Annual Report on Form 10-K. Financial Statement Schedules 2. Schedule II – Valuation and Qualifying Accounts and Reserves All other schedules have been omitted because the information either has been shown in the financial statements or notes thereto, or is not applicable or required under this section. The following exhibits are filed herewith or are incorporated by reference to exhibits previously filed with the U.S. Securities and Exchange Commission. (b) Exhibits Exhibits are filed as part of this Report and are hereby incorporated by reference. Refer to Exhibit Index included herein. 95 [THIS PAGE INTENTIONALLY LEFT BLANK] Inogen, Inc. Index to financial statements Contents Financial statements Report of BDO USA, LLP, independent registered public accounting firm............................................................................... Financial Statements Balance sheets as of December 31, 2014 and 2013 ............................................................................................................................ F-3 Statements of operations for the years ended December 31, 2014, 2013 and 2012 ........................................................................... F-5 Statements of redeemable convertible preferred stock for the years ended December 31, 2014 and 2013 ........................................ F-6 Statements of stockholders’ equity (deficit) for the years ended December 31, 2014 and 2013 ........................................................ F-7 F-8 Statements of cash flows for the years ended December 31, 2014, 2013 and 2012 ........................................................................... Notes to financial statements .............................................................................................................................................................. F-10 F-2 F-1 Report of independent registered public accounting firm Board of Directors and Stockholders Inogen, Inc. Goleta, California We have audited the accompanying balance sheets of Inogen, Inc. (the “Company”) as of December 31, 2014 and December 31, 2013 and the related statements of operations, redeemable convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the three years in the period ended December 31, 2014. In connection with our audits of the financial statements, we have also audited the financial statement schedule listed in the accompanying index. These financial statements and schedule are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements and schedule based on our audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements and schedule. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Inogen, Inc. at December 31, 2014 and 2013, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2014, in conformity with accounting principles generally accepted in the United States of America. Also, in our opinion, the financial statement schedule, when considered in relation to the basic financial statements taken as a whole, presents fairly, in all material respects, the information set forth within. /s/ BDO USA, LLP Los Angeles, California April 26, 2015 F-2 Inogen, Inc. Balance Sheets (amounts in thousands) Assets Current assets Cash and cash equivalents ................................................................................................................ $ Accounts receivable, net of allowances of $3,745 and $3,390 at December 31, 2014 and 2013, respectively .................................................................................................................................... Inventories, net of allowances of $141 and $100 at December 31, 2014 and 2013, respectively ..... Deferred cost of rental revenue ......................................................................................................... Income tax receivable ....................................................................................................................... Deferred tax asset - current ............................................................................................................... Prepaid expenses and other current assets ........................................................................................ Total current assets ................................................................................................................................. Property and equipment Rental equipment, net of allowances of $832 and $157 at December 31, 2014 and 2013, respectively .................................................................................................................................... Manufacturing equipment and tooling .............................................................................................. Computer equipment and software ................................................................................................... Furniture and equipment ................................................................................................................... Leasehold improvements .................................................................................................................. Land and building ............................................................................................................................. Construction in process .................................................................................................................... Total property and equipment ................................................................................................................ Less accumulated depreciation .............................................................................................................. Property and equipment, net .............................................................................................................. Intangible assets, net ............................................................................................................................ Deferred tax asset - noncurrent .......................................................................................................... Other assets ........................................................................................................................................... Total assets ............................................................................................................................................ $ See accompanying notes to financial statements. December 31, 2014 2013 56,836 $ 13,521 19,349 7,616 515 2,129 4,976 1,122 92,543 48,359 3,985 3,699 649 756 126 193 57,767 (25,840) 31,927 270 15,248 97 140,085 $ 10,231 4,248 289 87 3,923 531 32,830 37,573 2,551 2,973 601 887 — 1,093 45,678 (15,956) 29,722 215 17,865 1,765 82,397 F-3 Inogen, Inc. Balance Sheets (continued) (amounts in thousands, except share and per share amounts) Liabilities, redeemable convertible preferred stock and stockholders' equity (deficit) Current liabilities Accounts payable and accrued expenses .......................................................................................... $ Accrued payroll ................................................................................................................................ Current portion of long-term debt ..................................................................................................... Warranty reserve ............................................................................................................................... Deferred revenue .............................................................................................................................. Income tax payable ........................................................................................................................... Total current liabilities ........................................................................................................................... Long-term liabilities Warranty reserve - noncurrent .......................................................................................................... Preferred stock warrant liability ....................................................................................................... Deferred revenue-noncurrent ............................................................................................................ Long-term debt, net of current portion ............................................................................................. Other noncurrent liabilities ............................................................................................................... Total liabilities ....................................................................................................................................... Commitments and contingencies (Note 6) Redeemable convertible preferred stock Preferred stock, $0.001 par value per share; 10,000,000 authorized as of December 31,2013; 0 and 9,541,631 shares issued and outstanding; liquidation preference of $0 and $136,660 at December 31, 2014 and 2013, respectively (Note 7) ..................................................................... Stockholders' equity (deficit) Preferred stock, $0.001 par value per share; 10,000,000 and 100,000 shares authorized; 0 and 66,666 shares issued and outstanding; liquidation preference of $0 and $250 at December 31, 2014 and 2013, respectively (Note 7) ..................................................................... Common stock, $0.001 par value per share; 200,000,000 and 60,000,000 shares authorized; 19,059,364 and 280,974 shares issued and outstanding at December 31, 2014 and 2013, respectively. ................................................................................................................................... Additional paid-in capital ................................................................................................................. Accumulated deficit ............................................................................................................................. Total stockholders' equity (deficit) ..................................................................................................... Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)......... $ See accompanying notes to financial statements. December 31, 2014 2013 11,273 $ 4,066 299 781 2,316 — 18,735 334 — 2,176 315 375 21,935 8,764 2,898 5,258 420 1,487 — 18,827 389 260 776 5,391 455 26,098 — 118,671 — 247 19 174,824 (56,693) 118,150 140,085 $ 1 — (62,620) (62,372) 82,397 F-4 Inogen, Inc. Statements of Operations (amounts in thousands, except share and per share amounts) Revenue Sales revenue .................................................................................................. $ Rental revenue ................................................................................................ Total revenue Cost of revenue (expense) Cost of sales revenue ...................................................................................... Cost of rental revenue, including depreciation of $10,339, $7,132 and $4,056, respectively .............................................................................. Total cost of revenue .......................................................................................... Gross profit ......................................................................................................... Operating expenses Research and development ............................................................................. Sales and marketing ........................................................................................ General and administrative ............................................................................. Total operating expenses ................................................................................... Income from operations ..................................................................................... Other income (expense) Interest expense .............................................................................................. Interest income ............................................................................................... Change in fair value of preferred stock warrant liability ................................ Other income (expense) .................................................................................. Total other expense, net ..................................................................................... Income before provision for income taxes ....................................................... Provision (benefit) for income taxes ................................................................. Net income .......................................................................................................... $ Basic net income (loss) per share attributable to common stockholders....... $ Diluted net income (loss) per share attributable to common stockholders ... $ Weighted-average number of shares used in calculating net income (loss) per share attributable to common stockholders: Years ended December 31, 2014 2013 2012 73,096 $ 39,441 112,537 44,905 $ 30,538 75,443 38,693 24,306 18,327 57,020 55,517 2,977 24,087 17,942 45,006 10,511 (449) 42 36 (88) (459) 10,052 3,226 6,826 $ 12,146 36,452 38,991 2,398 18,375 13,754 34,527 4,464 (562 ) 12 (262 ) 196 (616 ) 3,848 (21,587 ) 25,435 $ 28,704 19,872 48,576 17,384 7,243 24,627 23,949 2,262 12,569 8,289 23,120 829 (493) 88 148 10 (247) 582 18 564 0.33 $ 0.30 $ 0.76 $ 0.68 $ (19.97) (19.97) Basic common shares ..................................................................................... Diluted common shares .................................................................................. 16,182,569 18,037,498 276,535 2,008,156 261,268 261,268 See accompanying notes to financial statements. F-5 . c n I , n e g o n I k c o t S d e r r e f e r P e l b i t r e v n o C e l b a m e e d e R f o s t n e m e t a t S ) s t n u o m a e r a h s t p e c x e , s d n a s u o h t n i s t n u o m a ( l a t o T e l b a m e e d e r e l b i t r e v n o c d e r r e f e r p G s e i r e S e l b a m e e d e r e l b i t r e v n o c F s e i r e S e l b a m e e d e r e l b i t r e v n o c E s e i r e S e l b a m e e d e r e l b i t r e v n o c D s e i r e S e l b a m e e d e r e l b i t r e v n o c C s e i r e S e l b a m e e d e r e l b i t r e v n o c B s e i r e S e l b a m e e d e r e l b i t r e v n o c k c o t s d e r r e f e r p k c o t s d e r r e f e r p k c o t s d e r r e f e r p k c o t s d e r r e f e r p k c o t s d e r r e f e r p k c o t s d e r r e f e r p k c o t s t n u o m A s e r a h S t n u o m A s e r a h S t n u o m A s e r a h S t n u o m A s e r a h S t n u o m A s e r a h S t n u o m A s e r a h S 5 5 2 4 4 2 2 1 , 3 8 1 8 7 , 5 8 4 0 , 2 5 4 3 , 9 0 1 8 7 2 , 7 1 7 6 , 8 1 1 3 9 5 7 8 9 $ — — 5 5 — 9 5 1 , 3 9 5 1 , 3 2 — 7 2 6 , 4 6 8 7 , 7 2 1 4 6 — — — — 2 5 5 , 2 1 $ 7 5 9 , 1 0 7 , 2 5 2 9 , 6 2 $ 4 7 8 , 4 3 6 , 1 1 7 5 , 2 3 $ 5 2 2 , 7 8 4 , 1 8 4 0 , 6 $ 8 4 8 , 3 4 3 6 2 0 , 5 $ 2 8 0 , 3 2 4 . . . . . . . . . . . 1 1 0 2 , 1 3 r e b m e c e D , e c n a l a B — — 3 0 5 , 1 — — — — — 9 1 1 , 1 — — — — — — — — — 2 1 4 5 5 0 , 2 2 0 3 9 2 4 , 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . d e s i c r e x e s t n a r r a W — — — — — — — — . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . s t s o c e l b a m e e d e r n o d n e d i v i d d e m e e D . . . . . . . . . . . k c o t s d e r r e f e r p e l b i t r e v n o c g n i c n a n i f G s e i r e S f o n o i t e r c c A 0 6 2 , 0 4 8 , 2 5 5 0 , 4 1 7 5 9 , 1 0 7 , 2 4 4 0 , 8 2 4 7 8 , 4 3 6 , 1 1 7 5 , 2 3 5 2 2 , 7 8 4 , 1 0 6 4 , 6 3 0 9 , 5 6 3 6 5 0 , 5 1 1 5 , 5 2 4 . . . . . . . . . . . 2 1 0 2 , 1 3 r e b m e c e D , e c n a l a B — — — 5 6 5 , 1 — — — 6 8 0 , 1 — — — — 8 4 0 , 2 1 0 9 , 5 8 — — — — — — — — . . . . . . . . . . . k c o t s d e r r e f e r p e l b i t r e v n o c . . . . . . . . . . . . . . . . . . . . . . . . . . . d e s i c r e x e s t n a r r a W e l b a m e e d e r n o d n e d i v i d d e m e e D 0 6 2 , 0 4 8 , 2 0 2 6 , 5 1 7 5 9 , 1 0 7 , 2 0 3 1 , 9 2 4 7 8 , 4 3 6 , 1 9 1 6 , 4 3 6 2 1 , 3 7 5 , 1 0 6 4 , 6 3 0 9 , 5 6 3 6 5 0 , 5 1 1 5 , 5 2 4 . . . . . . . . . . . 3 1 0 2 , 1 3 r e b m e c e D , e c n a l a B — — — 7 0 2 — — — 9 3 1 — — 4 1 3 5 1 4 , 1 1 9 7 2 4 9 0 , 1 1 — — — — — — — — . . . . . . . . . . . . . . . . . . . . . . . . . . . d e s i c r e x e s t n a r r a W e l b a m e e d e r n o d n e d i v i d d e m e e D . . . . . . . . . . . k c o t s d e r r e f e r p e l b i t r e v n o c o t k c o t s d e r r e f e r p f o n o i s r e v n o C h t i w n o i t c e n n o c n i k c o t s n o m m o c F-6 ) 1 5 2 , 0 2 1 ( ) 7 2 4 , 8 2 ( ) 0 6 2 , 0 4 8 , 2 ( ) 7 2 8 , 5 1 ( ) 7 5 9 , 1 0 7 , 2 ( ) 9 6 2 , 9 2 ( ) 4 7 8 , 4 3 6 , 1 ( ) 3 3 9 , 4 3 ( ) 1 4 5 , 4 8 5 , 1 ( ) 9 3 7 , 6 ( ) 7 9 9 , 6 7 3 ( ) 6 5 0 , 5 ( ) 1 1 5 , 5 2 4 ( . . . . . . . . . . . . . . . . . . . . g n i r e f f o c i l b u p l a i t i n i — $ — $ — — $ — — $ — — $ — — $ — — $ — . . . . . . . . . . . 4 1 0 2 , 1 3 r e b m e c e D , e c n a l a B . s t n e m e t a t s l a i c n a n i f o t s e t o n g n i y n a p m o c c a e e S Inogen, Inc. Statements of Stockholders’ Equity (Deficit) (amounts in thousands, except share amounts) Series A convertible Shares Amount preferred stock Common stock Shares Amount 247 — — — — 250,440 $ — 4,270 17,386 — 1 $ — — — — Additional paid-in capital Total deficit Accumulated stockholders' equity (deficit) (75,566) 60 3 5 (55) (75,814) $ — — — (55) — $ 60 3 5 — — — 1 — — — — — 1 — — 1 — — — 14 (68 ) — — 230 10 1 (241 ) — — 1,363 413 945 61 76 (5,713) 564 (81,018) — — — (7,037) 25,435 (62,620) 88 — — — — (5,781) 564 (80,770) 230 10 1 (7,278) 25,435 (62,372) 1,451 413 946 61 76 — 120,484 (987) — (987) 120,251 3 49,841 — 49,844 — 1,641 — — 19 $ 174,824 $ — 6,826 (56,693) $ 1,641 6,826 118,150 — — 247 — — — — — 272,096 — 8,878 — Balance, December 31, 2011 ............................. 66,666 $ Stock-based compensation ................................. — Stock options exercised ...................................... — Warrants exercised-common .............................. — Accretion of Series G financing costs ................ — Deemed dividend on redeemable convertible preferred stock................................................. — Net income ......................................................... — Balance, December 31, 2012 ............................. 66,666 Stock-based compensation ................................. — Stock options exercised ...................................... — Warrants exercised - preferred ........................... — Deemed dividend on redeemable convertible preferred stock.................................................. — Net income ......................................................... — Balance, December 31, 2013 ............................. 66,666 Stock-based compensation ................................. — Employee stock purchase ................................... — Stock options exercised ...................................... — Warrants exercised - preferred & common ........ — Reclassification of warrant liability ................... — Deemed dividend on redeemable convertible preferred stock................................................. — Conversion of preferred stock ............................ (66,666) Issuance of common stock in connection with initial public offering ...................................... — Excess tax benefits from stock-based compensation arrangements ............................ — — — Net income ......................................................... — Balance, December 31, 2014 ............................. — $ — 19,059,364 $ — 30,358 736,519 222,455 — — — 247 — — — — — — (247) 14,259,647 — 3,529,411 — — 280,974 — — — See accompanying notes to financial statements. F-7 Inogen, Inc. Statements of Cash Flows (amounts in thousands) Years ended December 31, 2013 2014 2012 Cash flows from operating activities Net income .............................................................................................................. $ Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization .......................................................................... Loss on rental units ........................................................................................... Loss on disposal of other fixed assets ............................................................... Provision for sales returns ................................................................................. Provision for doubtful accounts ........................................................................ Provision for rental revenue adjustments .......................................................... Provision for inventory obsolescence ................................................................ Provision for other inventory losses .................................................................. Stock-based compensation expense .................................................................. Increase (decrease) in fair value of preferred stock warrant liability ................ Deferred tax assets ............................................................................................ Excess tax benefits from stock-based compensation arrangements .................. Changes in operating assets and liabilities: Accounts receivable ..................................................................................... Inventories ................................................................................................... Deferred costs of rental revenue .................................................................. Prepaid expenses and other current assets ................................................... Accounts payable and accrued expenses ..................................................... Accrued payroll ........................................................................................... Warranty reserve .......................................................................................... Deferred revenue ......................................................................................... Income tax receivable .................................................................................. Income tax payable ...................................................................................... Deferred tax liabilities ................................................................................. Other noncurrent liabilities .......................................................................... Net cash provided by operating activities .................................................................... Cash flows from investing activities Investment in intangible assets .................................................................... Production of rental equipment .................................................................... Purchases of property and equipment .......................................................... Payment of deposit ...................................................................................... Net cash used in investing activities ............................................................................ See accompanying notes to financial statements. 6,826 $ 25,435 $ 564 12,080 1,895 2 3,451 1,692 7,898 147 55 1,451 (36 ) 1,564 (1,641 ) (22,159 ) (3,570 ) (226 ) (591 ) 3,637 1,168 306 2,229 (401 ) — — (80 ) 15,697 (205 ) (14,481 ) (1,551 ) (17 ) (16,254 ) 8,544 305 16 1,770 2,045 6,613 78 — 230 262 (21,788) — (13,628) (267) (130) (378) 2,150 543 362 1,169 (87) (25) (10) 258 13,467 (37) (15,075) (3,030) — (18,142) 4,984 258 5 627 1,071 3,102 42 — 60 (148) — — (7,462) (2,436) (89) (15) 1,705 893 197 500 — 4 3 139 4,004 (63) (10,361) (2,024) (27) (12,475) F-8 Inogen, Inc. Statements of cash flows (continued) (amounts in thousands) Cash flows from financing activities Net proceeds from issuance of Series G redeemable convertible preferred stock .. Proceeds from borrowings ...................................................................................... Proceeds from redeemable convertible preferred stock warrants and common stock warrants exercised ................................................................. Proceeds from stock options exercised ................................................................... Proceeds from initial public offering ...................................................................... Costs associated with initial public offering ........................................................... Employee stock purchase ....................................................................................... Repayment of debt from investment in intangible assets ....................................... Repayment of borrowings ....................................................................................... Excess tax benefits from stock-based compensation arrangements ........................ Net cash provided by financing activities .................................................................... Net increase (decrease) in cash and cash equivalents.............................................. Cash and cash equivalents, beginning of period ...................................................... Cash and cash equivalents, end of period ................................................................ $ Supplemental disclosures of cash flow information Years ended December 31, 2013 2012 2014 — 6,000 — 6,000 506 946 56,471 (6,031 ) 413 (213 ) (15,861 ) 1,641 43,872 43,315 13,521 56,836 $ 1,883 10 — (597) — (212) (4,000) — 3,084 (1,591) 15,112 13,521 $ 19,945 6,000 422 3 — — — (213) (6,480) — 19,677 11,206 3,906 15,112 462 37 Cash paid during the period for interest .................................................................. $ Cash paid during the period for income taxes ........................................................ 487 $ 2,061 552 $ 311 Non-cash transactions: Deemed dividend on redeemable convertible preferred stock ................................ 987 7,278 5,781 See accompanying notes to financial statements. F-9 Inogen, Inc. Notes to financial statements (amounts in thousands, except share and per share amounts) 1. Nature of business Inogen, Inc. (Company or Inogen) was incorporated in Delaware on November 27, 2001. The Company is a medical technology company that primarily develops, manufactures and markets innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. Traditionally, these patients have relied on stationary oxygen concentrator systems for use in the home and oxygen tanks or cylinders for mobile use, which we call the delivery model. The tanks and cylinders must be delivered regularly and have a finite amount of oxygen, which requires patients to plan activities outside of their homes around delivery schedules and a finite oxygen supply. Additionally, patients must attach long, cumbersome tubing to their stationary concentrators simply to enable mobility within their homes. The Company’s proprietary Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device weighing approximately 4.8 or 7.0 pounds. Our Inogen One G3 and G2 have up to 4.5 and 5 hours of battery life, respectively, with a single battery and can be plugged into an outlet when at home, in a car, or in a public place with outlets available. The Companies Inogen One systems reduce the patient’s reliance on stationary concentrators and scheduled deliveries of tanks with a finite supply of oxygen, thereby improving patient quality of life and fostering mobility. 2. Summary of significant accounting policies Basis of presentation The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP). Accounting estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates used in preparing these financial statements include accounts receivable reserves, inventory reserves, warranty reserves, warrant liability, stock-based compensation expense and income tax provision. Actual results could differ from those estimates and such differences could be material to the financial position and results of operations. Sales revenue The Company generates revenue primarily from sales and rentals of its products. The Company’s products consist of its proprietary line of oxygen concentrators and related accessories. Other revenue comes from service contracts, extended warranty contracts and freight revenue for product shipments. Revenue from product sales is recognized when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred or services have been rendered; (3) the price to the customer is fixed or determinable; and (4) collectability is reasonably assured. Revenue from product sales is recognized upon shipment of the product. Provisions for estimated returns and discounts are made at the time of shipment. Provisions for standard warranty obligations, which are included in cost of sales revenue, are also provided for at the time of shipment. Revenue from the sales of used rental equipment is recognized upon delivery and when collectability is reasonably assured and other revenue recognition criteria are met. When a rental unit is sold, the related cost and accumulated depreciation are removed from their respective accounts, and any gains or losses are included in gross profit. Revenue from the sales of the Company’s services is recognized when no significant obligations remain undelivered and collection of the receivables is reasonably assured. The Company offers extended service contracts on its Inogen One concentrator line for periods ranging from 12 to 24 months after the end of the standard warranty period. Revenue from these extended service contracts is recognized in income on a straight-line basis over the contract period. The Company also offers a lifetime warranty for direct-to-consumer sales. For a fixed price, the Company agrees to provide a fully functional oxygen concentrator for the remaining life of the patient. Lifetime warranties are only offered to patients upon the initial F-10 sale of oxygen equipment by the Company, and are non-transferable. Product sales with lifetime warranties are considered to be multiple element arrangements within the scope of ASC 605-25. There are two deliverables when product that includes a lifetime warranty is sold. The first deliverable is the oxygen concentrator equipment which comes with a standard warranty of three years. The second deliverable is the lifetime warranty that provides for a functional oxygen concentrator for the remaining lifetime of the patient. These two deliverables qualify as separate units of accounting. The revenue is allocated to the two deliverables on a relative selling price method. The Company has vendor-specific objective evidence of selling price for the equipment. To determine the selling price of the lifetime warranty, the company uses its best estimate of the selling price for that deliverable as the lifetime warranty is neither separately priced nor is the selling price available through third-party evidence. To calculate the selling price associated with the lifetime warranties, management considered the profit margins of the overall business, the average estimated cost of lifetime warranties and the price of extended warranties. A significant estimate used to calculate the price and expense of lifetime warranties is the life expectancy of patients. Based on clinical studies, the company estimates that 60% of patients will succumb to their disease within three years. Given the approximate mortality rate of 20% per year, the company estimates on average all patients will succumb to their disease within five years. The Company has taken into consideration that when patients decide to buy an Inogen portable oxygen concentrator with a lifetime warranty, they typically have already been on oxygen for a period of time, which can have a large impact on their life expectancy from the time our product is deployed. After applying the relative selling price method, revenue from equipment sales is recognized when all other revenue recognition criteria for product sales are met. Lifetime warranty revenue is recognized using the straight-line method during the fourth and fifth year after the delivery of the equipment which is the estimated usage period of the contract based on the average patient life expectancy. Shipping and handling costs for sold products and rental assets, shipped to the Company’s customers are included on the statements of operations as part of cost of sales revenue and cost of rental revenue, respectively. The Company’s shipping and handling costs relating to sales revenue and rental revenue were $1,478 and $4,101 respectively, for the year ended December 31, 2014. The Company’s shipping and handling costs relating to sales revenue and rental revenue were $772 and $3,149, respectively, for the year ended December 31, 2013. The Company’s shipping and handling costs relating to sales revenue and rental revenue were $639 and $1,922 respectively, for the year ended December 31, 2012. Income from shipping and handling fees charged to its customers is included in other revenue on the statements of operations. The Company earned $486, $376 and $214 from shipping and handling fees for the years ended December 31, 2014, 2013 and 2012 respectively. Accruals for estimated standard warranty expenses are made at the time that the associated revenue is recognized. The provisions for estimated returns, discounts and warranty obligations are made based on known claims and discount commitments and estimates of additional returns and warranty obligations based on historical data and future expectations. The Company has accrued $1,115 and $809 to provide for future warranty costs at December 31, 2014 and 2013, respectively. Rental revenue The Company recognizes equipment rental revenue over the non-cancelable lease term, which is one month, less estimated adjustments, per ASC 840 — Leases. The Company has separate contracts with each patient that are not subject to a master lease agreement with any payor. The Company evaluates the individual lease contracts at lease inception and the start of each monthly renewal period to determine if there is reasonable assurance that the bargain renewal option associated with the potential capped free rental period would be exercised. Historically, the exercise of such a bargain renewal option is not reasonably assured at lease inception and most subsequent monthly lease renewal periods. If the Company determines that the reasonable assurance threshold for an individual patient is met at lease inception or at a monthly lease renewal period, such determination would impact the bargain renewal period for an individual lease. The Company would first consider the lease classification issue (sales-type lease or operating lease) and then appropriately recognize or defer rental revenue over the lease term, which may include a portion of the capped rental period. To date, the Company has not deferred any amounts associated with the capped rental period. Amounts related to the capped rental period have not been material in the periods presented. The lease term begins on the date products are shipped to patients and are recorded at amounts estimated to be received under reimbursement arrangements with third-party payors, including Medicare, private payors, and Medicaid. Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenue and accounts receivable at their net realizable values. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payors may result in adjustments to amounts originally recorded. Such F-11 adjustments are typically identified and recorded at the point of cash application, claim denial or account review. Accounts receivable are reduced by an allowance for doubtful accounts which provides for those accounts from which payment is not expected to be received, although product was delivered and revenue was earned. Upon determination that an account is uncollectible, it is written- off and charged to the allowance. Amounts billed but not earned due to the timing of the billing cycle are deferred and recognized in income on a straight-line basis over the monthly billing period. For example, if the first day of the billing period does not fall on the first of the month, then a portion of the monthly billing period will fall in the subsequent month and the related revenue and cost would be deferred based on the service days in the following month. Rental revenue is recognized as earned, less estimated adjustments. Revenue not billed at the end of the period are reviewed for the likelihood of collections and accrued. The rental revenue stream is not guaranteed and payment will cease if the patient no longer needs oxygen or returns the equipment. Revenue recognized is at full estimated allowable amounts; transfers to secondary insurances / patient responsibility have no net effect on revenue. Rental revenue is earned for that month if the patient is on service on the first day of the 30-day period commencing on the recurring date of service for a particular claim, regardless if there is a change in condition/death after that date. Included in rental revenue are unbilled amounts for which the revenue recognition criteria had been met as of period-end but were not billed. The estimate of unbilled rental revenue accrual is based on historical trends and estimates of future collectability. Fair value of financial instruments The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable and accrued expenses, debt and warrants. The carrying values of cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair values based on the short-term nature of these financial instruments. The fair value of the Company’s debt approximates carrying value based on the Company’s current incremental borrowing rate for similar types of borrowing arrangements. Imputed interest associated with the Company’s non-interest bearing debt is insignificant. The fair value of the Company’s preferred stock warrant liability is estimated using a Monte Carlo valuation model. Fair value accounting Accounting Standards Codification (ASC) 820, Fair Value Measurements and Disclosures, creates a single definition of fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements. ASC 820 emphasizes that fair value is a market-based measurement, not an entity-specific measurement, and states that a fair value measurement should be determined based on assumptions that market participants would use in pricing the asset or liability. Assets and liabilities adjusted to fair value in the balance sheet are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Level inputs, as defined by ASC 820, are as follows: Level input Input definition Level 1 Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date. Level 2 Level 3 Inputs, other than quoted prices included in Level 1 that are observable for the asset or liability through corroboration with market data at the measurement date. Unobservable inputs that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The following table summarizes fair value measurements by level at December 31, 2013 for the liabilities measured at fair value on a recurring basis: Preferred stock warrant liability ......................................................... $ Total liabilities.................................................................................... $ — $ — $ — $ — $ 260 $ 260 $ 260 260 Level 1 Level 2 Level 3 Total F-12 The following table summarizes the fair value measurements using significant Level 3 inputs, and changes therein, for the years ended December 31, 2014 and 2013: Balance as of December 31, 2012 ........................................................ $ Fair value of preferred stock warrants exercised .................................. Change in fair value ............................................................................. Balance as of December 31, 2013 ........................................................ Fair value of preferred stock warrants exercised .................................. Change in fair value ............................................................................. Reclassification of liability to additional paid in capital ...................... Balance as of December 31, 2014 ........................................................ $ Warrant liability 164 (166 ) 262 260 (148 ) (36 ) (76 ) — The preferred stock warrant liability is marked to market each reporting date until the warrants are settled. The fair value of the preferred stock warrant liability is estimated using a Monte Carlo valuation model, which takes into consideration the market values of comparable public companies, considering among other factors, the use of multiples of earnings, and adjusted to reflect the restrictions on the ability of the Company’s shares to trade in an active market. Cash and cash equivalents Cash equivalents are recorded at cost, which approximates market value. The Company considers all highly liquid investments with original maturities of 90 days or less at the time of purchase to be cash equivalents. Accounts receivable and allowance for bad debts, returns, and adjustments Accounts receivable are customer obligations due under normal sales and rental terms. The Company performs continuing credit evaluations of the customers’ financial condition and generally does not require collateral. The allowance for doubtful accounts is maintained at a level that, in management’s opinion, is adequate to absorb potential losses related to account receivables and is based upon the Company’s continuous evaluation of the collectability of outstanding balances. Management’s evaluation takes into consideration such factors as past bad debt experience, economic conditions and information about specific receivables. The Company’s evaluation also considers the age and composition of the outstanding amounts in determining their net realizable value. The allowance is based on estimates, and ultimate losses may vary from current estimates. As adjustments to these estimates become necessary, they are reported in earnings in the periods that they become known. The allowance is increased by bad debt provisions charged to bad debt expense in operating expense and reduced by direct write-offs, net of recoveries. Provision for sales returns applies to direct to consumer sales only. The Company does not allow returns from providers. This reserve is calculated based on actual historical return rates under our 30-day return program and is applied to the current period’s sales revenue for direct to consumer sales. The Company also records an allowance for rental revenue adjustments and write-offs, which is recorded as a reduction of rental revenue and rental accounts receivable balances. These adjustments and write offs result from contractual adjustments, audit adjustments, untimely claims filings or billings not paid due to another provider performing same or similar functions for the patient in the same period, all of which prevent billed revenue to become realizable. The reserve is based on historical revenue adjustments as a percentage of rental revenue billed during the related period. When recording the allowance for doubtful accounts, the bad debt expense account (general & administrative expense account) is charged, when recording allowance for sales returns, the sales returns account (contra sales revenue account) is charged, and when recording the allowance for adjustments, the rental revenue adjustments account (contra rental revenue account) is charged. At December 31, 2014 and 2013, included in accounts receivable on the balance sheets are earned but unbilled receivables of $3,653 and $1,435 respectively. F-13 Concentration of credit risk Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and accounts receivable. At times, cash account balances may be in excess of the amounts insured by the Federal Deposit Insurance Corporation (FDIC). However, management believes the risk of loss to be minimal. The Company performs periodic evaluations of the relative credit standing of these institutions and has not experienced any losses on its cash and cash equivalents and short-term investments to date. Concentration of customers and vendors The Company sells its products to home medical equipment providers in the United States and in foreign countries on a credit basis. No single customer represented more than 10% of our total revenue for 2013 and 2014. In 2012 one customer accounted for 12% of our total revenue. The Company also rents products directly to patients, which resulted in a customer concentration relating to Medicare’s service reimbursement programs. Medicare’s service reimbursement programs (net of patient co-insurance obligations) accounted for 76%, 73% and 66% of rental revenue in 2014, 2013 and 2012, respectively, and based on total revenue were 27%, 29% and 27% for 2014, 2013 and 2012, respectively. Accounts receivable balances relating to Medicare’s service reimbursement programs amounted to $4,875 or 25% of total accounts receivable at December 31, 2014, $2,560 or 25% of total accounts receivable at December 31, 2013 and $3,043 or 33% of total accounts receivable at December 31, 2012. The Company currently purchases raw materials from a limited number of vendors, which resulted in a concentration of three major vendors that accounted for 19%, 16%, and 10%, respectively, of total raw material purchases in 2014. The three major vendors supply the Company with raw materials used to manufacture the Company’s products. For 2013, the Company’s three major vendors accounted for 17%, 15%, and 8%, respectively, of total raw material purchases. A portion of revenue is earned from sales outside the United States. Non-U.S. revenue is denominated in U.S. dollars. A breakdown of the Company’s revenue from U.S. and non-U.S. sources for the years ended December 31, 2014, 2013 and 2012 is as follows: U.S. revenue .................................................................. $ Non-U.S. revenue .......................................................... Total revenue ................................................................. $ 88,094 $ 24,443 112,537 $ 58,677 $ 16,766 75,443 $ 35,538 13,038 48,576 Years ended December 31, 2013 2014 2012 Inventories Inventories are stated at the lower of cost or market. Cost is determined using a standard cost method, including material, labor and manufacturing overhead, whereby the standard costs are updated at least quarterly to reflect approximate actual costs using the first-in, first out (FIFO) method and market represents the lower of replacement cost or estimated net realizable value. The Company records adjustments at least quarterly to inventory for potentially excess, obsolete, slow-moving or impaired items. Inventories consist of the following: Raw materials and work-in-progress ................................... $ Finished goods ..................................................................... Less: reserves ....................................................................... Inventories ........................................................................... $ 6,774 $ 983 (141) 7,616 $ 3,783 565 (100 ) 4,248 December 31, 2014 2013 F-14 Property and equipment Property and equipment are stated at cost. Depreciation and amortization are calculated using the straight-line method over the assets estimated useful lives as follows: Rental equipment ................................... 1.5-5 years Manufacturing equipment and tooling ... 5 years Computer equipment and software ........ 3 years Furniture and equipment ........................ 3-5 years Leasehold improvements ....................... Shorter of 3-10 years or life of underlying lease Expenditures for additions, improvements and replacements are capitalized and depreciated to a salvage value of zero. Repair and maintenance costs are included in cost of revenue in the statements of operations. Repair and maintenance expense, including both labor and parts, for rental equipment was $1,628 and $1,020 for the years ended December 31, 2014 and 2013, respectively. Depreciation and amortization expense related to property and equipment and rental equipment is summarized below for the years ended December 31, 2014, 2013 and 2012, respectively. Rental equipment ........................................................... $ Other property and equipment ....................................... Total depreciation and amortization .............................. $ 10,339 $ 1,591 11,930 $ 7,132 $ 1,209 8,341 $ 4,056 630 4,686 Years ended December 31, 2013 2014 2012 Accumulated depreciation related to property and equipment and rental equipment is summarized below for the years ended December 31, 2014 and 2013, respectively. Property and equipment Rental equipment, net of allowance ..................................... $ Other property and equipment ............................................. Property and equipment ....................................................... 2014 2013 48,359 $ 9,408 57,767 37,573 8,105 45,678 Years ended December 31, Accumulated depreciation Rental equipment ................................................................. Other property and equipment ............................................. Accumulated depreciation ................................................... Net property and equipment Rental equipment ................................................................. Other property and equipment ............................................. Property and equipment, net ................................................ $ 21,084 4,756 25,840 27,275 4,652 31,927 $ 12,545 3,411 15,956 25,028 4,694 29,722 Long-lived assets The Company accounts for the impairment and disposition of long-lived assets in accordance with ASC 360, Property, Plant, and Equipment. In accordance with ASC 360, long-lived assets to be held are reviewed for events or changes in circumstances that indicate that their carrying value may not be recoverable. The Company periodically reviews the carrying value of long-lived assets to determine whether or not impairment to such value has occurred. No impairments were recorded during the years ended December 31, 2014 and 2013. Deferred rent The Company’s operating leases for its office facilities in California and Texas include a rent abatement period and scheduled rent increases. The Company has accounted for the leases to provide straight-line charges to operations over the life of the leases. F-15 Research and development Research and development costs are expensed as incurred. Advertising costs Advertising costs, which approximated $3,290, $2,840 and $2,503 during the years ended December 31, 2014, 2013 and 2012, respectively, are expensed as incurred, excluding the production costs of direct response commercials. Advertising costs are included in sales and marketing expense in the accompanying statements of operations. Income taxes The Company accounts for income taxes in accordance with ASC 740, Income Taxes. Under ASC 740, income taxes are recognized for the amount of taxes payable or refundable for the current year and deferred tax liabilities and assets are recognized for the future tax consequences of transactions that have been recognized in the Company’s financial statements or tax returns. A valuation allowance is provided when it is more likely than not that some portion, or all, of the deferred tax asset will not be realized. The Company accounts for uncertainties in income tax in accordance with ASC 740-10, Accounting for Uncertainty in Income Taxes. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This accounting standard also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company recognizes interest and penalties on taxes, if any, within operations as income tax expense. No significant interest or penalties were recognized during the periods presented. The Company operates in multiple states. The statute of limitations has expired for all tax years prior to 2011 for federal and 2010 to 2011 for various state tax purposes. However, the net operating loss generated on the federal and state tax returns in prior years may be subject to adjustments by the federal and state tax authorities. We do not anticipate that the amount of our existing unrecognized tax benefits will significantly increase or decrease within the next 12 months. Due to the presence of net operating losses in most jurisdictions, our tax years remain open for examination by taxing authorities back to the inception of the company. Accounting for stock-based compensation The Company accounts for its stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation, which establishes accounting for share-based awards exchanged for employee services and requires companies to expense the estimated fair value of these awards over the requisite employee service period. Share–based compensation cost is determined at the grant date using the Black-Scholes option pricing model. The value of the award that is ultimately expected to vest is recognized as expense on a straight line basis over the employee’s requisite service period. As part of the provisions of ASC 718, the Company is required to estimate potential forfeitures of stock grants and adjust compensation cost recorded accordingly. The estimate of forfeitures will be adjusted over the requisite service period to the extent that actual forfeitures differ, or are expected to differ, from such estimates. Changes in estimated forfeitures will be recognized through a cumulative catch-up adjustment in the period of change and will also impact the amount of stock compensation expense to be recognized in future periods. Business segments The Company operates in only one business segment-manufacturing and marketing and sales of respiratory equipment. Stock Split On November 11, 2013, the Company’s Board of Directors and stockholders approved a 3:1 reverse stock split. This became effective as of November 12, 2013 and the effect of this event has been reflected in all of the share quantities and per share amounts throughout these financial statements. The shares of common stock retained a par value of $0.001. F-16 Reclassifications Certain reclassifications have been made to prior year financial statements to conform to current period financial statement presentation. These revisions increased working capital by $844 at December 31, 2013, but did not impact previously reported total revenue, net income, earnings per share, stockholders’ deficit or cash flows. Earnings per share Earnings per share, or EPS, is computed in accordance with ASC 260, Earnings per Share, and is calculated using the weighted average number of common shares outstanding during each period. Diluted EPS assumes the conversion, exercise or issuance of all potential common stock equivalents unless the effect is to reduce a loss or increase the income per share. For purposes of this calculation, common stock subject to repurchase by the Company, options and warrants are considered to be common stock equivalents and are only included in the calculation of diluted earnings per share when their effect is dilutive. The shares used to compute basic and diluted net income per share represent the weighted-average common shares outstanding, reduced by the weighted-average unvested common shares subject to repurchase. Further, as the Company’s preferred stockholders have the right to participate in any dividend declared on the Company’s common stock, basic and diluted EPS are potentially subject to computation using the two-class method, under which the Company’s undistributed earnings are allocated amongst the common and preferred shareholders. However, as the company recorded a net loss attributable to common stockholders for the year ended December 31, 2012, presentation of EPS using the two class method was not necessary. The Company had net income for the year ended December 31, 2013 and December 31, 2014, and has presented EPS using the two class method. As further discussed in Note 11, on February 20, 2014, the Company completed an initial public offering of 4,411,763 shares of common stock at a price of $16.00 per share. The Company sold 3,529,411 shares of common stock and certain stockholders sold 882,352 shares of common stock. As of March 7, 2014 the underwriters elected to purchase 99,550 additional shares of common stock at the initial public offering price. All preferred stock outstanding as of the IPO automatically converted into 14,259,647 shares of common stock. This IPO transaction has materially altered the number of common shares outstanding. F-17 The computation of EPS is as follows: Years ended December 31, 2013 2014 2012 Numerator—basic: Net income..................................................................... $ Less deemed dividend on redeemable convertible preferred stock ............................................................... Net income (loss) before preferred rights dividend ....... Less preferred rights dividend ....................................... Less: undistributed earnings to preferred stock - basic ... Net income (loss) attributable to common stockholders - basic .................................................. $ Numerator—diluted: Net income..................................................................... $ Less deemed dividend on redeemable convertible preferred stock ............................................................... Net income (loss) before preferred rights dividend ....... Less preferred rights dividend ....................................... Less undistributed earnings to preferred stock - diluted .. Net income (loss) attributable to common stockholders - diluted ............................................... $ Denominator: Weighted-average common shares - basic common stock ............................................................................... Weighted-average common shares - diluted common stock ............................................................................... Net income (loss) per share - basic common stock ........ $ Net income (loss) per share - diluted common stock ..... $ Shares excluded from diluted income (loss) Warrants ................................................................... Preferred convertible stock....................................... Stock options ............................................................ Shares excluded from diluted net income (loss) ... Denominator calculation from basic to diluted: Weighted-average common shares - basic common stock ......................................................................... Warrants ................................................................... Stock Options ........................................................... Weighted-average common shares - diluted common stock ..................................................... 6,826 $ 25,435 $ 564 (987) 5,839 — (567) (7,278 ) 18,157 (7,165 ) (10,781 ) (5,781) (5,217) — — 5,272 $ 211 $ (5,217) 6,826 $ 25,435 $ 564 (987) 5,839 — (514) (7,278 ) 18,157 (7,165 ) (9,625 ) (5,781) (5,217) — — 5,325 $ 1,367 $ (5,217) 16,182,569 276,535 261,268 18,037,498 2,008,156 261,268 0.33 $ 0.30 $ 0.76 $ 0.68 $ (19.97) (19.97) — — 546,142 546,142 — — — — 233,611 14,057,509 1,646,223 15,937,343 16,182,569 128,016 1,726,913 276,535 219,766 1,511,855 261,268 — — 18,037,498 2,008,156 261,268 The computations of diluted net income applicable to common shareholders exclude redeemable convertible preferred stock, warrants and common stock options which were anti-dilutive for the period ended December 31, 2012. Revenue from contracts with customers In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes nearly all existing revenue recognition guidance under U.S. GAAP. The core principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration to which an entity expects to be entitled for those goods or services. ASU 2014-09 defines a five step process to achieve this core principle and, in doing so, more judgment and estimates may be required within the revenue recognition process than are required under existing U.S. GAAP. F-18 The standard is effective for annual periods beginning after December 15, 2016, and interim periods therein, using either of the following transition methods: (i) a full retrospective approach reflecting the application of the standard in each prior reporting period with the option to elect certain practical expedients, or (ii) a retrospective approach with the cumulative effect of initially adopting ASU 2014-09 recognized at the date of adoption (which includes additional footnote disclosures). The Company is currently evaluating the impact of the Company’s pending adoption of ASU 2014-09 on the Company’s financial statements and has not yet determined the method by which the Company will adopt the standard in 2017. 3. Intangible assets During the year ended December 31, 2008, the Company acquired Comfort Life Medical, LLC (Comfort Life). The acquisition resulted in recording an intangible asset in the amount of $92 related to the Medicare license held by the acquired company. The Company amortizes this intangible asset over its estimated useful life of ten years. As of December 31, 2014 and 2013, there were no impairments recorded related to this intangible asset. On April 1, 2009, Comfort Life Medical, LLC merged with Inogen, Inc., and was simultaneously dissolved. During the year ended December 31, 2009, the Company was assigned four patents previously held as an exclusive license from Air Products & Chemicals (APC) in exchange for an increase in a long term liability due to APC of $250. The acquisition of these patents resulted in an intangible asset of $250. During the year ended December 31, 2011, the Company purchased additional patents from APC for a total value of $650. The Company amortizes these intangible assets over an estimated useful life of five years. As of December 31, 2014 and 2013, there were no impairments recorded related to these intangible assets. The Company in 2013 calculated imputed interest on these patents and associated debt over the term of the contractual agreement, and reduced the underlying asset, debt by $177. The company recalculated interest and amortization of the period based on adjusted asset and debt. During the year ended December 31, 2011, the Company acquired Breathe Oxygen Services, LLC. The acquisition resulted in recording an intangible asset in the amount of $66 related to the Medicare license held by the acquired company that allowed them to operate in the state of Tennessee as well as assets of the company. The Company amortizes this intangible asset over its estimated useful life of ten years. As of December 31, 2014 and 2013, there were no impairments recorded related to this intangible asset. On August 29, 2011, Breathe Oxygen Services, LLC merged with Inogen, Inc., and was simultaneously dissolved. The Company also capitalizes costs incurred for the production of direct response advertising commercials and amortizes these intangible assets over a useful life of two years. During the year ended December 31, 2011, the Company paid $95 for its G2 commercial and during the year ended December 31, 2012, the Company paid $63 for its G3 commercial. Amortization expense for intangible assets for the years ended December 31, 2014, 2013 and 2012 was $150 and $203 and $298, respectively. The following tables represent the changes in net carrying values of the intangibles as of the respective dates: December 31, 2014 Licenses .................................................................... Patents and websites ................................................. Commercial .............................................................. Total ......................................................................... December 31, 2013 Licenses .................................................................... Patents ...................................................................... Commercial .............................................................. Total ......................................................................... Average estimated useful lives (in years) 10 5 2 Average estimated useful lives (in years) 10 5 2 $ $ $ $ F-19 Gross carrying amount Accumulated amortization Net amount 104 81 $ 124 749 42 86 270 916 $ 185 $ 873 128 1,186 $ Gross carrying amount Accumulated amortization Net amount 122 63 $ 61 662 32 41 215 766 $ 185 $ 723 73 981 $ Annual estimated amortization expense for each of the succeeding fiscal years is as follows: Years ending December 31, 2015 .......................................................................................... $ 2016 .......................................................................................... 2017 .......................................................................................... 2018 .......................................................................................... 2019 .......................................................................................... Thereafter ................................................................................. $ Intangible amortization 84 65 48 48 25 — 270 4. Long-term debt JP Morgan Chase debt In November 2014, the Company secured a primary banking relationship that provides access to a $15,000 working capital revolving line of credit, and treasury and cash management services through commercial banking with JP Morgan Chase. This agreement is a three year working capital revolving line of credit which replaces the previous loan facility the Company maintained with Comerica. The interest rate on outstanding debt balances will be LIBOR plus 1.25%. The Company is required to maintain a tangible net worth not less than $90,000 and EBITDA of $10,000 for any period of four consecutive quarters commencing with the four-quarter test period ending September 30, 2014. The Company was in compliance as of December 31, 2014, and no outstanding debt balances were outstanding on the credit facility. Comerica debt On October 12, 2012, the Company entered into an amended and restated credit and term loan agreement with its lenders whereby the existing balances and the payback terms were not changed. This transaction did not result in any debt extinguishment losses or gains. The Company did not incur or defer any financing cost directly related to the amendment of the credit and term loan agreement. Due to the completion of the IPO during the term of this facility, a fee equal to 1% of the facility amount of $120, was paid to the lenders in March of 2014, and was included in general and administrative expenses in the Company’s Statements of Operations for the quarter ended March 31, 2014. The amended and restated credit and term loan agreement with the Company’s current lenders provided for new borrowings of up to $12,000 secured by substantially all of the Company’s assets. The amended and restated credit and term loan agreement provided for the existing term loan facility for rental assets amounting to up to $3,000 (Term Loan A), a term loan facility for rental assets amounting to up to $8,000 (Term Loan B), a new term loan facility for rental assets amounting to up to $12,000 (Term Loan C), and an accounts receivable revolving line of credit amounting to up to $1,000 based on 80% of eligible accounts receivable, as defined (AR Revolver). Principal and interest amounts for all the term loans were payable monthly. Each term loan bore interest at the Base Rate, which is a rate equal to the applicable margin plus the greater of (i) the prime rate, (ii) the federal funds effective rate, as defined in the agreement, plus 1% and (iii) the daily adjusting LIBOR rate, plus 1%. The applicable margins for Term Loans A, B, and C were 1.25%, 2.5% and 2.25%, respectively. The Term Loan A facility of $3,000 is presented net of principal payments that began in May 2011. The net balances of this term loan facility were $0 and $417 as of December 31, 2014 and December 31, 2013, respectively. The Term Loan B facility for $8,000 is presented net of principal payments that began in May 2012. The net balances of this term loan facility were $0 and $3,778 as of December 31, 2014 and December 31, 2013, respectively. The Term Loan C facility for $12,000 is presented net of principal payments that began in November 2013. The net balances were $0 and $5,666 as of December 31, 2014 and December 31, 2013, respectively. The AR Revolver expired on October 13, 2013, and was not renewed by the Company. There were no borrowings under the AR Revolver as of and during the year ended December 31, 2014. F-20 The interest rates were 4.5% for Term Loan A, 5.75% for Term Loan B, and 5.5% for Term Loan C at December 31, 2014 and December 31, 2013. As of December 31, 2014 and December 31, 2013, the Company was in compliance with all covenants of the amended and restated credit and term loan agreement. In November 2014, the Company secured a primary banking relationship that provides access to a $15,000 working capital revolving line of credit, and treasury and cash management services through commercial banking with JP Morgan Chase. This agreement is a three year working capital revolving line of credit which replaces the previous loan facility the Company maintained with Comerica. The interest rate on outstanding debt balances will be LIBOR plus 1.25%. The Company is required to maintain a tangible net worth not less than $90,000 and EBITDA of $10,000 for any period of four consecutive quarters commencing with the four-quarter test period ending September 30, 2014. The Company was in compliance as of December 31, 2014, and no outstanding debt balances were outstanding on the credit facility. The Company paid all outstanding balances and accrued interest on the term loan agreements on August 22, 2014 totaling $11,600. As of December 31, 2013 2014 Term Loan A, bearing interest at Base Rate, monthly payments of $83 beginning May 2011 through April 2014 ............................................. $ — $ 417 Term Loan B, bearing interest at Base Rate, monthly payments of $222 beginning May 2012 through April 2015 .................................... Term Loan C bearing interest at Base Rate, monthly payments of $167 beginning November 2013 through May 2014, $367 a month beginning June 2014 through October 2016. ....................................... Contractual obligation, bearing imputed interest at prime plus two, quarterly payments of $53 beginning May 2011 through October 2014 and quarterly payments of $81 beginning January 2015 through October 2016 ........................................................................................ Subtotal ................................................................................................... Less: current maturities ........................................................................... Long-term debt, net of current portion .................................................... $ — 3,778 — 5,666 614 788 614 10,649 (5,258 ) (299 ) 5,391 315 $ As of December 31, 2014, the minimum aggregate payments due under non-cancelable debt are summarized as follows: Years ending December 31, 2015 ...................................................................................... $ 2016 ...................................................................................... 2017 ...................................................................................... Total ..................................................................................... $ 299 315 — 614 5. Income taxes The provision for income taxes consists of the following: Years ended December 31, Current tax expense 2014 2013 2012 Federal ................................................................................ $ State .................................................................................... Total current tax expense ......................................................... Deferred tax benefit (expense) Federal ................................................................................ State .................................................................................... Total deferred tax benefit (expense) ........................................ Plus (less): change in valuation allowance .............................. Total deferred tax benefit (expense), net ................................. Income tax benefit (expense) ................................................... $ (1,139) $ (525) (1,664) (2,782) (3) (2,785) 1,223 (1,562) (3,226) $ (42 ) $ (169 ) (211 ) (798 ) (313 ) (1,111 ) 22,909 21,798 21,587 $ — (15) (15) 523 88 611 (614) (3) (18) F-21 The components of deferred tax assets and liabilities consist of the following: Deferred tax assets (liabilities) NOL and credit carryforward ............................................... $ Accrued expenses ................................................................. Valuation allowance ............................................................. Allowance, reserves and other .............................................. Deferred tax liabilities Property, plant, and equipment ............................................. Other ..................................................................................... Net deferred tax assets (liabilities) ............................................. $ As of December 31, 2014 2013 22,924 $ 3,575 (2,899) 1,965 25,565 (3,674) (1,667) (5,341) 20,224 $ 25,233 2,686 (4,122 ) — 23,797 (1,643 ) (366 ) (2,009 ) 21,788 Reconciliation of the federal statutory income tax rate to the effective income tax rate for the last three years is as follows: Years ended December 31, 2014 2013 2012 U.S. Statutory rate ............................................................. State income taxes (net of federal benefit) ........................ Nondeductible expenses .................................................... Remeasured deferred for state rate change ........................ Change in valuation allowance ......................................... R&D credit (net of reserve) ............................................... Expiration of net operating losses ..................................... Other ................................................................................. Effective income tax rate ........................................................ 34.00% 2.47 1.39 (0.25) (12.16) (3.49) 8.09 2.04 32.09% 34.00 % 5.48 2.54 (8.25 ) (595.34 ) — — 0.58 (560.99 )% 34.00% 4.53 (2.77) (137.26) 105.55 — — (1.02) 3.03% The Company is a C-Corporation for both federal and state income tax purposes. The Company operates in multiple states. The statute of limitations has expired for all tax years prior to 2011 for federal and 2010 to 2011 for various state tax purposes. However, the net operating loss generated on the federal and state tax returns in prior years may be subject to adjustments by the federal and state tax authorities. Income tax provision was $3,226 for the year ended December 31, 2014 compared to income tax benefit of $21,587 for the year ended December 31, 2013. As of December 31, 2014, the Company had $59,319 and $46,434 of federal and state net operating loss carryforwards, respectively, that begin to expire in 2023 and 2015 for federal and state purposes, respectively, if not utilized. As of December 31, 2013, the Company had $57,463 and $52,769 of federal and state net operating loss carryforwards, respectively, that begin to expire in 2023 and 2015 for federal and state purposes, respectively, if not utilized. Our existing net operating losses are subject to limitations arising from a current period ownership change subject to the provisions of Section 382 of the Internal Revenue Code of 1986, as amended, or the Code, and if we undergo one or more future ownership changes our ability to utilize net operating losses could be further limited. In general, under Section 382 of the Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its pre-change net operating losses to offset future taxable income. In general, an “ownership change” occurs if there is a cumulative change in ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period. Even after factoring in the limitations of the current period ownership change, the Company was able to determine that, based upon future projections of income, it is more likely than not that all of its federal net operating losses will be utilized before they expire. However, the Company determined that some of its California net operating losses will expire unused and therefore has a valuation allowance of $2,899 relating to these net operating losses. In the current period, the Company released (or reversed) $1,223 of the California NOLs valuation allowance due to expiration of California F-22 NOLs and changes in estimates of future projections of income, resulting in a determination that is more likely than not that all but $32,796 ($2,899 tax effected) of the California net operating losses will be utilized. Due to overall cumulative losses incurred over the years, the Company maintained a full valuation allowance against its deferred tax assets as of December 31, 2012. As of December 31, 2013 the Company evaluated the current facts and circumstances and concluded that the negative evidence that existed as of December 31, 2012, no longer existed. Accordingly, the Company relied on positive evidence, which included cumulative income in the trailing three years and a forecast of taxable income sufficient to utilize its deferred tax assets including net operating loss carryforwards. During 2013, the Company determined that it was appropriate to release $22,909 of the valuation allowance at December 31, 2013. The Company accounts for uncertainties in income tax in accordance with ASC 740-10, Accounting for Uncertainty in Income Taxes. ASC 740-10 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. This Accounting Standard also provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure, and transition. At December 31, 2014 and 2013, the total unrecognized tax benefits were $577 and $306, respectively. The Company recognizes interest accrued and penalties related to unrecognized tax benefits as income tax expense. No significant interest or penalties were recognized during the periods presented. A reconciliation of the beginning and ending amount of unrecognized tax benefit is as follows: Reconciliation of liability for unrecognized tax benefits Balance at beginning of period ................................................ $ Additions based on tax positions related to current year.......... Additions for tax positions of prior years ................................ Reductions for tax positions of prior years .............................. Settlements ............................................................................... Balance at end of period .......................................................... $ December 31, 2014 2013 306 $ 123 148 — — 577 $ — — 306 — — 306 We do not expect a material increase or decrease in unrecognized tax benefits over the next 12 months. 6. Commitments and contingencies Leases The Company leases its offices and certain equipment under operating leases that expire through December 2019. At December 31, 2014, the minimum aggregate payments due under non-cancelable leases are summarized as follows: December 31, 2014 2015 .......................................................................................... $ 2016 .......................................................................................... 2017 .......................................................................................... 2018 .......................................................................................... 2019 .......................................................................................... Thereafter ................................................................................. $ 870 483 477 457 458 313 3,058 Rent expense of $750, $910 and $806 was included in the accompanying statements of operations for the years ended December 31, 2014, 2013 and 2012, respectively. F-23 Warranty obligation The following table identifies the changes in the Company’s aggregate product warranty liabilities for the year ended December 31, 2014 and 2013: Year ended December 31, 2014 2013 Product warranty liability at beginning of period ........ $ Accruals for warranties issued ..................................... Adjustments related to preexisting warranties (including changes in estimates) ............................... Settlements made (in cash or in kind) .......................... Product warranty liability at end of period .................. $ 809 $ 1,075 406 (1,175) 1,115 $ 447 533 322 (493 ) 809 Legislation and HIPAA The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Government activity has continued with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. The Company believes that it is in compliance with fraud and abuse regulations as well as other applicable government laws and regulations. Compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time. The Health Insurance Portability and Accountability Act (HIPAA) assures health insurance portability, reduces healthcare fraud and abuse, guarantees security and privacy of health information, and enforces standards for health information. The Health Information Technology for Economic and Clinical Health Act (HITECH Act) imposes notification requirements of certain security breaches relating to protected health information. The Company may be subject to significant fines and penalties if found not to be compliant with the provisions outlined in the regulations. Amended & Restated Employment agreements On October 1, 2013, the Company entered into an Employment Agreement with the Chief Executive Officer (CEO) including considerations for salary, bonus awards, and severance and change of control benefits upon certain qualifying terminations up to period of thirty-six months. On October 1, 2013, the Company has entered into employment agreements with certain key employees including considerations for salary, bonus awards, and severance and change of control benefits upon certain qualifying terminations up to period of twenty-four months. Legal proceedings On November 4, 2011, we filed a lawsuit in the United States District Court for the Central District of California against Inova Labs Inc., or Defendant, for infringement of two of our patents. The case, Inogen Inc. v. Inova Labs Inc., Case No. 8:11-cv-01692-JST-AN, or the Lawsuit, involves U.S. Patent Nos. 7,841,343, entitled “Systems and Methods For Delivering Therapeutic Gas to Patients”, or the ’343 patent, and 6,605,136 entitled “Pressure Swing Adsorption Process Operation And Optimization”, or the ’136 patent. We alleged in the Lawsuit that certain of Defendant’s oxygen concentrators infringe various claims of the ’343 and ’136 patents. The Lawsuit seeks damages, injunctive relief, costs and attorney fees. The Defendant has answered the complaint, denying infringement and asserting various sets of defenses including non-infringement, invalidity and unenforceability, patent misuse, unclean hands, laches and estoppel. The Defendant also filed counterclaims against us alleging patent invalidity, non-infringement and inequitable conduct. We denied the allegations in the Defendant’s counterclaims. We have filed a motion to dismiss Defendant’s inequitable conduct counterclaim. F-24 The Defendant filed a request with the U.S. Patent and Trademark Office seeking an inter parties reexamination of the ’343 and ’136 patents. The Defendant also filed a motion to stay the Lawsuit pending outcome of the reexamination. On March 20, 2012, the Court granted the Defendant’s motion to stay the Lawsuit pending outcome of the reexamination and also granted our motion to dismiss the Defendant’s inequitable conduct counterclaim. The Company is party to various other legal proceedings arising in the normal course of business. The Company carries insurance, subject to deductibles under the specified policies, to protect against losses from certain types of legal claims. The Company does not anticipate that any of these proceedings will have a material impact on the Company. Refer to Note 11 for subsequent events for additional information on lawsuits. 7. Convertible preferred stock Prior to the completion of the Company’s initial public offering in February 2014, the Company was authorized to issue common stock and Series A, Series B, Series C, Series D, Series E, Series F, and Series G preferred stock. A summary of the terms of the various types of redeemable convertible preferred stock at December 31, 2013, is as follows: B C Series Shares authorized ............................ 500,000 400,000 Shares issued ................................... 425,511 365,903 Par value.......................................... $ Conversion rate ............................... 1.45108 1.73014 Liquidation preference per share ..... $ 11.880 $ 17.580 $ 8% Dividend rate ................................... 0.001 $ 0.001 $ 5 % D 1,700,000 1,573,126 E 1,700,000 1,634,874 0.001 $ 1.87951 21.900 $ 8% 0.001 $ 2.69244 19.224 $ 8% F Total G 2,800,000 2,900,000 10,000,000 2,701,957 2,840,260 9,541,631 0.001 1.0000 14.083 0.001 $ 1.0000 7.140 $ 8 % 8% Issue date ......................................... July 2003 June 2004 July 2005 to July 2007 February 2009 June 2010 February 2010 to October 2007 to March 2012 Redemption date ............................. January 1, January 1, January 1, 2016 2016 2016 January 1, 2016 January 1, January 1, 2016 2016 A summary of the terms of non-redeemable convertible preferred stock at December 31, 2013 is as follows: Series A Shares authorized ........................................................................ Share issued................................................................................. Par value ...................................................................................... $ Conversion rate ........................................................................... Liquidation preference per share ................................................. $ Dividend rate ............................................................................... Issue date ..................................................................................... May 2002 100,000 66,666 0.001 1.01706 3.750 5 % There was no outstanding convertible preferred stock as of December 31, 2014. Upon closing of the initial public offering on February 20, 2014, all the preferred stockholders converted their shares into 14,259,647 shares of common stock. Common Stock Each share of common stock is entitled to one vote. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the board of directors, subject to the prior rights of holders of other classes of stock outstanding. F-25 Preferred Stock Pursuant to the amended and restated certificate of incorporation filed by the Company in connection with the completion of its initial public offering, the Company’s board of directors is authorized to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in the Company’s control or other corporate action. As of December 31, 2014, no shares of preferred stock were issued or outstanding, and the board of directors has not authorized or designated any rights, preferences, privileges and restrictions for any class of preferred stock. Dividends Prior to our IPO, Series G preferred stockholders were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on all existing series of preferred stock and common stock at the rate of 8% of its original issue price. Prior to our IPO, subject to the prior rights of the holders of Series G preferred stock, Series F preferred stockholders were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on all existing series of preferred stock and common stock at the rate of 8% of its original issue price. Prior to our IPO, subject to the prior rights of the holders of Series G and F preferred stock, the Series E preferred stockholders were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on Series A, B, C, and D preferred stock and common stock at the rate of 8% of its original issue price. Prior to our IPO, subject to the prior rights of the holders of Series G, F, and E preferred stock, the Series D preferred stockholders were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on Series A, B and C preferred stock and common stock at the rate of 8% of its original issue price. Prior to our IPO, subject to the prior rights of the holders of Series G, F, E and D preferred stocks, the Series C preferred stockholders were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on Series A and B preferred stock and common stock at the rate of 8% of its original issue price. Prior to our IPO, subject to the prior rights of the holders of Series G, F, E, D and C preferred stocks, the Series A and B preferred stockholders were entitled to receive dividends prior and in preference to any declaration or payment of any dividend on common stock at the rate of 5% of its original issue price. Dividends were only payable when, as and if declared and were not cumulative for all series. There were no dividends declared during the years ended December 31, 2013 and 2012. Liquidation preferences Prior to our IPO, in the event of any liquidation, including deemed liquidation (as defined in the Company’s Certificate of Incorporation), dissolution or winding up of the Company, the holders of Series G, F and E preferred stock were entitled to be paid out an amount per share of Series G, F and E preferred stock equal to two times the original Series G, F and E issue price, respectively, plus any declared but unpaid dividends before any amounts are paid to both holders of common stock and any other series of preferred stock. All other series of preferred stock were to be redeemed at their original issue price plus any declared, but unpaid dividends. After preferential liquidation proceeds are paid or set aside for payment to all Series of preferred stock, the remaining assets and funds of the Company available for distribution to stockholders were to be distributed ratably among the holders of common and preferred stock on an as-converted to common stock basis. Conversion Prior to our IPO, all series of preferred stock were convertible at any time after issuance, at the option of the holder, into shares of common stock as is determined by dividing the applicable issue price by the applicable conversion price of each as defined in the Company’s Certificate of Incorporation. The conversion rate for all series will initially be one for one, subject to anti-dilution and other customary adjustments (see “Anti-dilution” below). Prior to our IPO, each share of preferred stock was automatically convertible into common stock, at the then applicable conversion rate, upon (i) the election of both the holders of a majority of the then-outstanding Series F preferred stock and Series G preferred stock, voting together as a single class provided, or (ii) the closing of an underwritten initial public offering of the Company’s F-26 common stock pursuant to a registration statement under the Securities Act of 1933, as amended with aggregate proceeds of at least $40 million at an offering price of at least $17.85 per share (as adjusted for stock splits, stock dividends, recapitalizations, etc.). If the Series G preferred shares were converted to common stock in connection with an initial public offering in which shares are sold to the public at a price that was less than $14.0832 per share (as adjusted for stock splits, stock dividends, recapitalizations, etc.), then immediately prior to such conversion, the applicable conversion rate of the Series G preferred stock was to be increased to the extent necessary to make the Series G preferred holders whole as if the initial public offering price to the public had been equal to $14.0832 (as adjusted for stock splits, stock dividends, recapitalizations, etc.). Upon closing of the initial public offering on February 20, 2014, all the preferred stockholders converted their shares into 14,259,647 shares of common stock. Anti-dilution Prior to our IPO, upon each issuance by the Company of any Additional Shares, as defined in the Company’s prior Certificate of Incorporation, without consideration or for consideration less than the Series A to G conversion price in effect immediately prior to the issuance of such additional stock, then the Series A to G conversion price was reduced based on a defined formula. Prior to our IPO, the Series A to D and Series E to G preferred stock was subject to adjustment on a partial ratchet basis and on a full ratchet basis, respectively, if the Company issued additional stock at a price per share less than the then Applicable Conversion Price, except for customary exceptions already set forth in the Company’s prior Certificate of Incorporation. On March 12, 2012, the Company issued and sold an aggregate of 2,840,260 shares of Series G Preferred Stock for $20,000, at a price of $7.0416 per share (March Issuance). Immediately prior to such Issuance, the Series A Conversion Price was $3.687, the Series B Conversion Price was $8.436, the Series C Conversion Price was $10.836, the Series D Conversion Price was $12.651, the Series E Conversion Price was $3.570, and the Series F Conversion Price was $3.570. According to the formula defined in a prior Certificate of Incorporation and simultaneous with the March Issuance, the Series A Conversion Price was not adjusted and remained at $3.687 per share, the Series B Conversion Price was adjusted to $8.187 per share, the Series C Conversion Price was adjusted to $10.161 per share, the Series D Conversion Price was adjusted to $11.652 per share, the Series E Conversion Price was not adjusted and remained at $3.570 per share, and the Series F Conversion Price was not adjusted and remained at $3.570 per share. Voting rights Prior to our IPO, the holder of any share of preferred stock had the right to a number of votes equal to the number of shares of common stock issuable upon conversion of each such share of preferred stock and has full voting rights and powers of the holders of common stock. The preferred stockholders were entitled to vote with the holders of common stock on all matters except as specifically provided in the Certificate of Incorporation or as otherwise prohibited by law. Protective provisions Prior to our IPO, the holders of at least 66 2/3% of preferred stock on an as converted to common stock basis were required to approve certain specified actions as outlined in the Company’s prior Certificate of Incorporation. In addition, the holders of at least 60% of the Series D preferred stock were required to approve certain specified actions as outlined in the Company’s prior Certificate of Incorporation. In addition, the Company could not amend its prior Certificate of Incorporation without the approval of at least 66 2/3% of any series of preferred stock if such amendment would change any of the rights, preferences or privileges of such series. Redemption Prior to our IPO, from and after January 1, 2016, each holder of the Series B, C, D, E, F, and G preferred stock, upon written approval of the holders of at least a majority of the related series shares then outstanding, could, at its option, at any time (and from time to time), require the Company to redeem all or part of the series held by such holder by delivery of a written notice requesting such redemption and the number of shares to be redeemed. The redemption price was equivalent to the liquidation preference for each series of preferred stock. F-27 Prior to our IPO, the redemption provisions of the Series B, C, D, E, F, and G preferred stock were not solely within the control of the Company. Therefore, the Company has presented these series of preferred stock as a component of redeemable convertible preferred stock and not stockholders’ deficit. The Company initially recorded these series of preferred stock at their fair value. As the Series E and F preferred stock have redemption amounts greater than their initial fair value, the Company accretes the carrying value to the redemption value using the interest method. The accretion is treated in the same manner as dividends on nonredeemable stock and are recorded by charges against additional paid-in capital or accumulated deficit. 8. Stock incentive plan The Company has a 2012 Stock Incentive Plan (2012 Plan) under which the Company has reserved 1,216,772 shares of common stock, to be issued in connection with stock options and other equity awards issued under the 2012 Plan. The 2012 Plan provides for option grants at exercise prices not less than 100% of the fair value of common stock on the date of grant. The Company’s 2012 Plan terminated in connection with the Company’s initial public offering, and, accordingly, no shares are available for issuance under this plan. The 2012 Plan will continue to govern outstanding awards granted thereunder. As of December 31, 2014, the combined reserve under the 2012 Plan and the 2002 Plan was 1,531,258 shares of common stock. Previously, the Company had a 2002 Plan, as amended. As of March 12, 2012, the 2002 Plan was terminated and the 2012 Plan was created in its place. On termination, the 2002 Plan had 1,424,540 shares of common stock outstanding. Any shares returned to the 2002 Plan as a result of expiration or termination of equity awards (up to 1,424,646 shares) are added to the 2012 Plan Share reserve. The Company’s board of directors has adopted a 2014 Equity Incentive Plan, or the 2014 Plan, and the Company’s stockholders have approved it. The 2014 Plan became effective immediately prior to the effectiveness of our initial public offering. The Company’s 2014 Plan provides for the grant of incentive stock options, within the meaning of Section 422 of the Internal Revenue Code, to the Company’s employees and any parent and subsidiary corporations’ employees, and for the grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units and performance shares to our employees, directors and consultants and our parent and subsidiary corporations’ employees and consultants. As of December 31, 2014, a total of 895,346 shares of common stock have been reserved for issuance pursuant to the 2014 Plan, of which options to purchase 730,375, shares of the Company’s common stock were outstanding, and 221,178 shares remained available for issuance. In addition, the shares to be reserved for issuance under the Company’s 2014 Plan will also include shares returned to the 2012 Plan and 2002 Plan as the result of expiration or termination of awards (provided that the maximum number of shares that may be added to the 2014 Plan pursuant to such previously granted awards under the 2012 Plan and 2002 Plan is 2,328,569 shares). The number of shares available for issuance under the 2014 Plan also includes an annual increase on the first day of each fiscal year beginning in 2015, equal to the least of: (cid:120) (cid:120) (cid:120) 895,346 shares; 4% of the outstanding shares of common stock as of the last day of our immediately preceding fiscal year; or such other amount as our board of directors may determine. Options typically expire between seven and ten years from the date of grant and vest over one to four year terms. Options have been granted to employees and consultants of the Company at the deemed fair market value, as determined by the Board of Directors, of the shares underlying the options at the date of grant. F-28 The Company’s board of directors adopted a 2014 Employee Stock Purchase Plan, or the 2014 ESPP Plan, and the Company’s stockholders have approved it. The 2014 ESPP Plan became effective immediately prior to the effectiveness of our initial public offering which was filed on February 12, 2014. The Company’s 2014 ESPP Plan provides for the grant to all eligible employees an option to purchase stock under the 2014 ESPP Plan, within the meaning Section 423 of the Internal Revenue Code, and provides for six-month offering periods. Our ESPP Plan permits participants to purchase common stock through payroll deductions of up to 15% of their eligible compensation, which includes a participant’s base straight time gross earnings, incentive compensation, bonuses, overtime and shift premium, but exclusive of payments for equity compensation and other similar compensation. A participant may purchase a maximum of 1,500 shares during a purchase period. Amounts deducted and accumulated by the participant are used to purchase shares of our common stock at the end of each six-month period. The purchase price of the shares will be 85% of the lower of the fair market value of our common stock on the first trading day of each offering period or on the exercise date. The number of shares available for issuance under the 2014 ESPP Plan also includes an annual increase on the first day of each fiscal year beginning in 2015, equal to least of: (cid:120) (cid:120) 179,069 shares 1.5% of the outstanding shares of our common stock on the last day of our immediately preceding fiscal year; or (cid:120) Such other amount as may be determined by the administrator The activity for the 2014 ESPP Stock Plan is as follows: Employee accumulated payroll deductions .............. Total Shares Purchased ............................................ Payroll deductions used to purchase shares ............. Transfer to next offering period ............................... FMV at enrollment date ........................................... $ FMV at purchase date .............................................. $ Purchase price .......................................................... $ *Offering period ends March 2, 2015 First Offering Period Second Offering Period* 414 30,358 413 1 16.00 $ 21.69 13.60 250 — — — 21.69 — — The number of shares available to grant under the 2014 ESPP Plan as of December 31, 2014 was 148,711. Stock-based compensation expense recognized in 2014 for the 2014 ESPP Plan was $134 and is combined with the 2014 Stock Option Plan compensation expense for a total compensation expense of $1,451 for the year ended December 31, 2014. F-29 The activity for stock options under our option plans is as follows: Remaining weighted- average contractual terms (in years) Per share average intrinsic value Weighted- average exercise price Options Price per share Outstanding as of December 31, 2012 ........................ Granted .................................................................. Exercised ............................................................... Forfeited ................................................................ Expired .................................................................. Outstanding as of December 31, 2013 ........................ Vested and exercisable at December 31, 2013 ............ Vested and expected to vest, at December 31, 2013 ..... 1,646,223 $0.60-$8.70 $ 716,326 $1.17-$8.37 $ (8,874) $0.60-$8.70 $ (23,106) $0.60-$8.37 $ (1,894) $0.60-$8.70 $ 2,328,675 $0.60-$8.70 $ 1,524,325 $0.60-$8.70 $ 2,226,738 $0.60-$8.70 $ Outstanding as of December 31, 2013 ........................ Granted .................................................................. Exercised ............................................................... Forfeited ................................................................ Expired .................................................................. Outstanding as of December 31, 2014 ........................ Vested and exercisable at December 31, 2014 ............ Vested and expected to vest, at December 31, 2014 ..... 2,328,675 $0.60-$8.70 $ 754,916 $16.62-$24.52 $ (736,519) $0.60-$16.62 $ (80,640) $0.60-$16.62 $ (4,799) $0.60-$8.37 $ 2,261,633 $0.60-$24.52 $ 1,100,539 $0.60-$18.93 $ 2,144,974 $0.60-$24.52 $ 1.06 3.95 1.35 2.46 1.53 1.94 1.16 1.88 1.94 17.81 1.28 5.81 1.09 7.31 2.02 7.19 6.99 $ 0.41 7.04 $ 5.95 $ 6.95 $ 10.23 11.01 10.29 6.43 $ 5.73 $ 6.38 $ 24.06 29.35 24.18 The number of equity awards available for grant under the 2014 Plan as of December 31, 2014 and under the 2012 Plan for 2013 was 221,178 and 276,839, respectively. The aggregate intrinsic value for options that were exercised for the year ended December 31, 2014, December 31, 2013 and December 31, 2012 was $15,495, $30, and $2, respectively. The following table summarizes information about stock options outstanding at December 31, 2014: Exercise price per share $ 0.60 ......................................................................... $ 0.75 ......................................................................... $ 0.81 ......................................................................... $ 1.17 ......................................................................... $2.40-$6.00 ............................................................... $ 8.37 ......................................................................... $ 8.70 ......................................................................... $ 16.62 ....................................................................... $ 18.93 ....................................................................... $ 24.52 ....................................................................... Shares 515,582 84,724 221,593 293,436 148,490 257,471 9,962 608,153 12,222 110,000 2,261,633 Outstanding Weighted- average life (years) exercise price 5.00 $ 6.75 7.27 8.15 3.22 8.77 1.12 6.25 6.62 6.89 6.43 $ 0.60 0.75 0.81 1.17 2.42 8.37 8.70 16.62 18.93 24.52 7.31 Exercisable Weighted- average exercise price 0.60 0.75 0.81 1.17 2.42 8.37 8.70 16.62 18.93 — 2.02 Shares 515,582 $ 66,276 143,955 109,748 148,490 73,035 9,962 33,121 370 — 1,100,539 $ F-30 The following table summarizes information about stock options outstanding at December 31, 2013: Exercise price per share $ 0.60 ......................................................................... $ 0.75 ......................................................................... $ 0.81 ......................................................................... $ 1.17 ......................................................................... $ 2.10 ......................................................................... $ 2.40 ......................................................................... $ 4.24 ......................................................................... $ 8.37 ......................................................................... $ 8.70 ......................................................................... Shares 920,687 128,845 244,979 427,805 66 316,089 7,461 271,829 10,914 2,328,675 Outstanding Weighted- average life (years) exercise price 5.96 $ 7.75 8.26 9.09 0.09 4.13 0.52 9.77 2.19 7.04 $ 0.60 0.75 0.81 1.17 2.10 2.40 4.50 8.37 8.70 1.94 Exercisable Weighted- average exercise price 0.60 0.75 0.81 1.17 2.10 2.40 4.24 8.37 8.70 1.16 Shares 916,917 $ 76,466 102,329 82,249 66 316,089 7,461 11,834 10,914 1,524,325 $ Employee stock-based compensation expense recognized in 2014 and 2013 was calculated based on awards ultimately expected to vest and has been reduced for estimated forfeitures at a rate of 6.9% and 7.0%, based on the Company’s historical option cancellations. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. For the years ended December 31, 2014, 2013 and 2012, stock-based compensation expense recognized under ASC 718, included in cost of sales, sales and marketing expense, general and administrative expense, and research and development expense, totaled $1,451, $230 and $60, respectively. Valuation assumptions The employee stock-based compensation expense recognized under ASC 718 was determined using the Black-Scholes method. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. The risk-free interest rate is the implied yield currently available on U.S. Treasury zero-coupon issues with a remaining term equal to the expected term. The expected term of the options was based on the simplified method outlined in ASC 718. The volatility factors were based on five peer companies selected from Dow Jones Industry Classification Benchmark (ICB) codes 4535 and 4537. These codes include companies which are the same market categories as the Company, which is the medical equipment and supplies line of business. The peer companies were selected based on similarity of market capitalization, size and certain operating characteristics. The calculated volatility value was established by taking the historical daily closing values prior to grant date, over a period equal to the expected term, for each of the peer companies. When the period of data available was less than the expected term, closing values for the longest period of time available were used. The calculated historical volatility of each of these companies was then averaged to determine the calculated value used by the Company. The value of employee options was estimated on the date of grant using the Black-Scholes option pricing model with the following assumptions used: Expected term (years) ............................................. Risk free interest rate .............................................. Expected dividend yield ......................................... Volatility ................................................................. 2014 4.02-6.99 1.32-2.02% None 42.15-52.73% 2013 5.26-6.03 1.08-1.76% None 50.1-52.77% 2012 5.51-6.07 0.73-1.33% None 48.95-50.52% Under these assumptions, the total weighted average fair value of stock options granted during the years ended December 31, 2014, 2013, and 2012 was $5,329, $1,705, and $95, respectively. F-31 As of December 31, 2014 and December 31, 2013 there was $4,948 and $1,370, respectively of total unrecognized compensation expense related to non-vested share-based compensation granted under the Plan. 9. Warrants In connection with certain of its redeemable convertible preferred stock issuances, convertible debt financings, and other financing arrangements the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock. Such warrants related to its redeemable convertible preferred stock have been recorded as liabilities as a result of non- standard anti-dilution rights and are carried at their estimated fair value using the Monte Carlo valuation model. A summary of outstanding warrants at December 31, 2014 is as follows: Security Common stock .......................................................................... Number of warrants Exercise Expiration price/share date 15,218 $ 0.30 2017-2019 A summary of outstanding warrants at December 31, 2013 is as follows: Security Series C redeemable convertible preferred stock warrants ....... Series D redeemable convertible preferred stock warrants ....... Series E redeemable convertible preferred stock warrants ...... Series E redeemable convertible preferred stock warrants ....... Common stock .......................................................................... Number of warrants Exercise Expiration date price/share 2015 17.580 21.900 2013-2014 2015 9.612 9.612 2016 0.300 2017-2019 14,215 $ 11,415 3,120 1,102 233,611 263,463 A rollforward of warrant activity from January 1, 2013 to December 31, 2014 is as follows: Issued and outstanding Issued and outstanding Series C preferred ................................................... Series D preferred ................................................... Series E preferred ................................................... Common stock........................................................ warrants as of Warrants Warrants warrants as of January 1, 2014 exercised expired December 31, 2014 — — — 15,218 15,218 11,459 11,415 4,222 233,611 218,393 263,463 245,489 2,756 — — — 2,756 14,215 11,415 4,222 Issued and outstanding Issued and outstanding Series C preferred ................................................... Series D preferred ................................................... Series E preferred ................................................... Common stock........................................................ warrants as of Warrants Warrants warrants as of January 1, 2013 exercised expired December 31, 2013 14,215 11,415 4,222 233,611 263,463 14,215 132,169 4,222 233,611 384,217 — 34,859 — — 34,859 — 85,895 — — 85,895 The fair value of the preferred warrant liability was $0 and $260 at December 31, 2014 and 2013, respectively. During the years ended December 31, 2014 and 2013, the Company recorded a gain/(loss) of $36 and ($262), respectively, on the change in fair value of the preferred warrants. F-32 10. Quarterly summary of information (unaudited) Summarized unaudited quarterly financial data are as follows: Quarterly Results 2014 Net sales ............................................................ $ Gross profit ........................................................ Net income ........................................................ $ Net income (loss) per share attributable to Q1 March Q2 June 23,633 $ 11,938 888 $ Q3 September Q4 December 29,118 29,393 $ 13,816 14,649 1,519 2,133 $ 30,393 $ 15,114 2,286 $ common stockholders Basic ............................................................ Diluted ......................................................... (0.01) (0.01) 0.13 0.11 0.12 0.11 0.08 0.07 Quarterly Results 2013 Net sales ............................................................ $ Gross profit ........................................................ Net income ........................................................ $ Net income (loss) per share attributable to Q1 March Q2 June 15,747 $ 8,117 730 $ Q3 September Q4 December 19,762 19,777 $ 10,175 9,642 21,971 774 $ 20,157 $ 11,057 1,960 $ common stockholders Basic ............................................................ Diluted ......................................................... (3.65) (3.65) — — (3.90 ) (3.90 ) 0.91 0.79 Earnings per share is computed independently for each of the quarters presented. Therefore, the sum of the quarterly amounts will not necessarily equal the total for the year. 11. Subsequent events On January 20, 2015, Inogen, Inc. (the “Company”), entered into a Second Amendment to Lease (the “Second Amendment”) amending that certain Multi-Purpose Commercial Building Lease dated February 1, 2010, as amended, (the “Lease”) by and between the Company and Rockbridge Investments, L.P., a California limited partnership, for its principal executive offices consisting of approximately 38,851 rentable square feet located at 326 Bollay Drive, Goleta, California 93117 (collectively, the “Premises”). The original term of the Lease expires on October 31, 2015, and, pursuant to the Second Amendment, the original term of the Lease is extended by an additional five (5) years commencing November 1, 2015 and ending October 31, 2020. The minimum monthly rent under the Lease commencing on November 1, 2015 will be approximately $45 per month, and will increase annually by three percent (3%) each year thereafter during the extended term. The Second Amendment also grants to the Company one option to renew the lease for an additional five (5) years commencing November 1, 2020 at the then prevailing fair market rental rate and otherwise pursuant to the terms and conditions set forth in Exhibit G to the original Lease. Securities Class Action Lawsuit On March 13 and March 19, 2015, plaintiffs Brad Christi and Roger D. Holford each filed, respectively, a lawsuit against Inogen, Raymond Huggenberger, Inogen’s President and Chief Executive Officer, and Alison Bauerlein, Inogen’s Executive Vice President and Chief Financial Officer, in the United States District Court for the Central District of California on behalf of a purported class of purchasers of our securities between November 12, 2014 and March 11, 2015. The complaints allege that Inogen, Mr. Huggenberger and Ms. Bauerlein violated Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, and that Mr. Huggenberger and Ms. Bauerlein violated Section 20(a) of the Securities Exchange Act of 1934. Specifically, the complaints allege that during the purported class period our financial statements and disclosures concerning internal controls over financial reporting were materially false and misleading. The complaints seek compensatory damages in an unspecified amount, costs and expenses, including attorneys’ fees and expert fees, prejudgment and post-judgment interest and such other relief as the court deems proper. The deadline for motions for appointment as lead plaintiff is May 12, 2015. We intend to vigorously defend ourselves against these allegations. We are currently unable to predict the outcome of these lawsuits and therefore cannot determine the likelihood of loss nor estimate a range of possible loss. F-33 On April 15, 2015, the NASDAQ, received a standard notice stating that the Company is not in compliance with NASDAQ Listing Rule 525(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. The April 15, 2015 letter was sent as a result of the Companies delay in filing its Annual Report on Form 10-K for its fiscal year ended December 31, 2014, which the Company announced via a Form 8-K filing on April 14, 2015. The NASDAQ notice has no immediate effect on the listing or trading of Inogen’s common stock on the NASDAQ Global Select market. Under NASDAQ’s listing rules, the Company has 60 calendar days from the date of the letter to submit a plan to regain compliance. By filing year end December 31, 2014 financials on Form 10-K in April of 2015, which resulted in a late filing with the Securities and Exchange Commission, the Company will not be eligible to raise additional capital on Form S-3 for the next twelve months and instead would need to file Form S-1. F-34 Schedule II: Valuation and Qualifying Accounts Balance Beginning of Year Additions Deletions Adjustments End of Year Balance at Year ended December 31, 2014: Allowance for doubtful accounts (1) ................ $ Allowance for sales returns (2) ........................ Allowance for rental revenue adjustments (3) .... Allowance for inventory reserves (4) ............... Allowance for rental asset loss (5) ................... Year ended December 31, 2013: Allowance for doubtful accounts (1) ................ $ Allowance for sales returns (2) ........................ Allowance for rental revenue adjustments (3) .... Allowance for inventory reserves (4) ............... Allowance for rental asset loss (5) ................... Year ended December 31, 2012: Allowance for doubtful accounts (1) ................ $ Allowance for sales returns (2) ........................ Allowance for rental revenue adjustments (3) .... Allowance for inventory reserves (4) ............... Allowance for rental asset loss (5) ................... 1,141 $ 134 2,115 100 157 742 $ 64 1,255 98 77 865 $ 33 984 108 — 1,692 $ 3,451 8,267 201 1,443 2,045 $ 1,770 6,613 78 292 1,071 $ 627 3,102 42 378 1,404 $ 3,412 8,239 160 768 1,284 $ 1,700 6,115 76 212 1,194 $ 596 2,831 52 301 (249) $ — 249 — — (362) $ — 362 — — — $ — — — — 1,180 173 2,392 141 832 1,141 134 2,115 100 157 742 64 1,255 98 77 (1) The additions to the allowance for doubtful accounts represent the estimates of bad debt expense based upon factors for which the company evaluates the collectability of accounts receivable, with actual recoveries netted into additions. Deductions are the actual write-offs of the receivables. (2) The additions to the allowance for sales returns represent estimates of returns based upon historical returns experience for the direct to patient sales channel only. No reserve is recorded for sales to providers. Deductions are the actual returns of products. (3) The additions to the allowance for rental revenue adjustments represent estimates of revenue adjustments that will need to be recorded for billing errors on rental revenue. Deductions are the actual adjustments and write offs of the rental receivables for such revenue adjustments. (4) The inventory allowances are adjusted quarterly for potentially excess, obsolete, slow-moving or impaired items. (5) The allowance for rental asset loss is based on estimated losses of the company’s rental assets that will potentially be lost, stolen or unrecoverable from the patient. Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. SIGNATURES INOGEN, INC. (Registrant) By: /s/ Raymond Huggenberger Raymond Huggenberger President and Chief Executive Officer (Principal Executive Officer) Date: April 27, 2015 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Raymond Huggenberger and Alison Bauerlein, and each of them, as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitutes, may lawfully do or cause to be done by virtue thereof. Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. Signature /s/ Raymond Huggenberger Raymond Huggenberger /s/ Alison Bauerlein Alison Bauerlein /s/ Heath Lukatch, Ph.D. Heath Lukatch, Ph.D. /s/ Benjamin Anderson-Ray Benjamin Anderson-Ray /s/ Heather Rider Heather Rider /s/ Loren McFarland Loren McFarland /s/ Timothy Petersen Timothy Petersen Title President, Chief Executive Officer, and Director (Principal Executive Officer) Chief Financial Officer (Principal Accounting and Financial Officer) Date April 27, 2015 April 27, 2015 Chairman of the Board April 27, 2015 Director Director Director Director April 27, 2015 April 27, 2015 April 27, 2015 April 27, 2015 Incorporated by Reference From Form Incorporated by Reference From Exhibit Number EXHIBIT INDEX Exhibit Number Description 3.1 3.2 4.1 4.2 4.3 4.4 4.5 4.6 4.7 4.8 Thirteenth Amended and Restated Certificate of Incorporation of the Registrant. Amended and Restated Bylaws of the Registrant. Specimen Common Stock Certificate of the Registrant. Ninth Amended and Restated Investors’ Rights Agreement, dated March 12, 2012, by and among the Registrant and the investors named therein, as amended. Form of Warrant to Purchase Common Stock issued in connection with the Registrant’s 2007 convertible note financing. Form of Warrant to Purchase Common Stock issued in connection with the Registrant’s Series E Preferred Stock Financing. Form of Warrant to Purchase Series C Convertible Preferred Stock. Form of Warrant to Purchase Series D Convertible Preferred Stock issued pursuant to the Registrant’s Note and Warrant Purchase Agreement dated July 7, 2006. Form of Warrant to Purchase Series D Convertible Preferred Stock issued in connection with the Registrant’s Note and Warrant Purchase Agreement dated September 1, 2006. Warrant to Purchase Series D Convertible Preferred Stock, dated September 18, 2006, issued to Venture Lending and Leasing IV, LLC. 4.9 Form of Warrant to Purchase Series E Convertible Preferred Stock. 4.10 Form of Second Warrant to Purchase Series E Convertible Preferred Stock. 10.1+ Form of Director and Executive Officer Indemnification Agreement. 10.2+ 2002 Stock Plan, as amended. 10.3+ Form of Notice of Stock Option Grant and Stock Option Agreement under the 2002 Stock Plan, as amended. 10.4+ 2012 Equity Incentive Plan, as amended. 10.5+ Form of Stock Option Agreement under the 2012 Equity Incentive Plan. 10.6+ 2014 Equity Incentive Plan. 10.7+ Form Agreements under the 2014 Equity Incentive Plan. 10.8+ 2014 Employee Stock Purchase Plan. 10.9+ Executive Incentive Compensation Plan. 10.10+ Employment Agreement, dated October 1, 2013, between the Registrant and Raymond Huggenberger. S-1 S-1 S-1/A S-1/A S-1 S-1 S-1 S-1 S-1 S-1 S-1 S-1 S-1 S-1 S-1 S-1 S-1 S-1/A S-1/A S-1/A S-1 S-1/A Date Filed 11/27/13 11/27/13 01/16/14 3.2 3.3 4.1 4.2 01/16/14 4.3 11/27/13 4.4 11/27/13 4.5 4.6 11/27/13 11/27/13 4.7 11/27/13 4.8 11/27/13 4.9 4.10 10.1 10.2 11/27/13 11/27/13 11/27/13 11/27/13 10.3 11/27/13 10.4 10.5 10.6 10.7 10.8 10.9 11/27/13 11/27/13 01/28/14 01/28/14 01/28/14 11/27/13 10.10 12/23/13 10.11+ Employment Agreement, dated October 1, 2013, between the Registrant and Scott Wilkinson. S-1/A 10.11 12/23/13 10.12+ Employment Agreement, dated October 1, 2013, between the Registrant and Alison Bauerlein. S-1/A 10.12 12/23/13 10.13+ Employment Agreement, dated October 1, 2013, between the Registrant and Matt Scribner. S-1/A 10.13 12/23/13 10.14+ Employment Agreement, dated October 1, 2013, between the Registrant and Brenton Taylor. S-1/A 10.14 12/23/13 10.15 Amended and Restated Revolving Credit and Term Loan Agreement, dated October 12, 2012, between the Registrant and Comerica Bank, as amended. S-1/A 10.15 01/16/14 Exhibit Number Description Security Agreement, dated October 12, 2012, between the Registrant and Comerica Bank. Multi-Purpose Commercial Building Lease, dated February 1, 2010, between the Registrant and Rockbridge Investments, L.P., as amended. Lease Agreement, dated May 3, 2012, between the Registrant and Bayview (TX) Holding LLC. Incorporated by Reference From Form Incorporated by Reference From Exhibit Number Date Filed S-1/A 10.16 01/16/14 S-1 S-1 10.17 11/27/13 10.18 11/27/13 License Agreement, dated July 23, 2007, between the Registrant and Air Products and Chemicals, Inc. S-1/A 10.19 12/23/13 Amendment to License Agreement, dated October 23, 2009, between the Registrant and Air Products and Chemicals, Inc. Amendment No. 2 to License Agreement, dated October 4, 2010, between the Registrant and Air Products and Chemicals, Inc. Amendment No. 3 to License Agreement, dated March 22, 2011, between the Registrant and Air Products and Chemicals, Inc. S-1 S-1 S-1 10.20 11/27/13 10.21 11/27/13 10.22 11/27/13 Lease Agreement, dated December 4, 2014, between the Registrant and TCIT Dallas Industrial, Inc. Filed Herewith 10.23 04/27/15 Inogen Continuing Security, dated November 7, 2014 between the Registrant and JPMorgan Chase Bank, N.A. Filed Herewith 10.24 04/27/15 Inogen Credit Agreement, dated November 7, 2014 between the Registrant and JPMorgan Chase Bank, N.A. Filed Herewith 10.25 04/27/15 Inogen LC Note, dated November 7, 2014 between the Registrant and JPMorgan Chase Bank, N.A. Filed Herewith 10.26 04/27/15 Consent of BDO USA, LLP, Independent Registered Public Accounting Firm. Filed Herewith Powers of Attorney (contained in the signature page to this Form 10-K). Filed Herewith 23.1 24.1 04/27/15 04/27/15 Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed Herewith 31.1 04/27/15 Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a 14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Filed Herewith 31.2 04/27/15 Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. File Herewith 32.1 04/27/15 10.16 10.17 10.18 10.19 10.20 10.21 10.22 10.23 10.24 10.25 10.26 23.1 24.1 31.1 31.2 32.1~ 101.INS XBRL Instance Document 101.SCH XBRL Taxonomy Extension Schema Document 101.CAL XBRL Taxonomy Extension Calculation Linkbase Document 101.LAB XBRL Taxonomy Extension Label Linkbase Document 101.PRE XBRL Taxonomy Extension Presentation Linkbase Document 101.DEF XBRL Taxonomy Extension Definition Document Indicates a management contract or compensatory plan. + ~ The certifications attached as Exhibit 32.1 that accompany this Annual Report on Form 10-K, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Inogen, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any general incorporation language contained in such filing. This Page Intentionally Left Blank This Page Intentionally Left Blank BOARD OF DIRECTORS Heath Lukatch, Ph.D. Chairman (cid:70)(cid:87)(cid:104)(cid:106)(cid:100)(cid:91)(cid:104)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:67)(cid:87)(cid:100)(cid:87)(cid:93)(cid:95)(cid:100)(cid:93)(cid:3)(cid:58)(cid:95)(cid:104)(cid:91)(cid:89)(cid:106)(cid:101)(cid:104)(cid:34)(cid:3)(cid:74)(cid:70)(cid:61)(cid:3) Biotechnology Raymond Huggenberger (cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:34)(cid:3)(cid:57)(cid:94)(cid:95)(cid:91)(cid:92)(cid:3)(cid:59)(cid:110)(cid:91)(cid:89)(cid:107)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:69)(cid:92)(cid:211)(cid:89)(cid:91)(cid:104)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3) Director R. Scott Greer (cid:67)(cid:87)(cid:100)(cid:87)(cid:93)(cid:95)(cid:100)(cid:93)(cid:3)(cid:58)(cid:95)(cid:104)(cid:91)(cid:89)(cid:106)(cid:101)(cid:104)(cid:34)(cid:3)(cid:68)(cid:107)(cid:99)(cid:91)(cid:100)(cid:101)(cid:104)(cid:3)(cid:76)(cid:91)(cid:100)(cid:106)(cid:107)(cid:104)(cid:91)(cid:105)(cid:34)(cid:3)(cid:66)(cid:66)(cid:57) Benjamin Anderson-Ray (cid:70)(cid:87)(cid:104)(cid:106)(cid:100)(cid:91)(cid:104)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:55)(cid:90)(cid:108)(cid:95)(cid:105)(cid:101)(cid:104)(cid:34)(cid:3)(cid:74)(cid:104)(cid:95)(cid:100)(cid:95)(cid:106)(cid:87)(cid:105)(cid:3)(cid:55)(cid:90)(cid:108)(cid:95)(cid:105)(cid:101)(cid:104)(cid:105) Loren McFarland (cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:67)(cid:87)(cid:100)(cid:87)(cid:93)(cid:95)(cid:100)(cid:93)(cid:3)(cid:67)(cid:91)(cid:99)(cid:88)(cid:91)(cid:104)(cid:34)(cid:3)(cid:73)(cid:87)(cid:100)(cid:106)(cid:87)(cid:3) (cid:56)(cid:87)(cid:104)(cid:88)(cid:87)(cid:104)(cid:87)(cid:3)(cid:60)(cid:95)(cid:100)(cid:87)(cid:100)(cid:89)(cid:95)(cid:87)(cid:98)(cid:3)(cid:73)(cid:91)(cid:104)(cid:108)(cid:95)(cid:89)(cid:91)(cid:105)(cid:34)(cid:3)(cid:66)(cid:66)(cid:57) Heather Rider (cid:60)(cid:101)(cid:104)(cid:99)(cid:91)(cid:104)(cid:3)(cid:76)(cid:95)(cid:89)(cid:91)(cid:3)(cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:34)(cid:3)(cid:61)(cid:98)(cid:101)(cid:88)(cid:87)(cid:98)(cid:3)(cid:62)(cid:107)(cid:99)(cid:87)(cid:100)(cid:3) Resources, Cymer, Inc. CORPORATE EXECUTIVES Raymond Huggenberger (cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:34)(cid:3)(cid:57)(cid:94)(cid:95)(cid:91)(cid:92)(cid:3)(cid:59)(cid:110)(cid:91)(cid:89)(cid:107)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:69)(cid:92)(cid:211)(cid:89)(cid:91)(cid:104)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3) Director Scott Wilkinson (cid:59)(cid:110)(cid:91)(cid:89)(cid:107)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:76)(cid:95)(cid:89)(cid:91)(cid:3)(cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:34)(cid:3)(cid:73)(cid:87)(cid:98)(cid:91)(cid:105)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3) (cid:67)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106)(cid:95)(cid:100)(cid:93) Alison Bauerlein (cid:59)(cid:110)(cid:91)(cid:89)(cid:107)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:76)(cid:95)(cid:89)(cid:91)(cid:3)(cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:34)(cid:3)(cid:60)(cid:95)(cid:100)(cid:87)(cid:100)(cid:89)(cid:91)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:57)(cid:94)(cid:95)(cid:91)(cid:92)(cid:3) (cid:60)(cid:95)(cid:100)(cid:87)(cid:100)(cid:89)(cid:95)(cid:87)(cid:98)(cid:3)(cid:69)(cid:92)(cid:211)(cid:89)(cid:91)(cid:104)(cid:34)(cid:3)(cid:73)(cid:91)(cid:89)(cid:104)(cid:91)(cid:106)(cid:87)(cid:104)(cid:111)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:74)(cid:104)(cid:91)(cid:87)(cid:105)(cid:107)(cid:104)(cid:91)(cid:104) Matthew Scribner (cid:59)(cid:110)(cid:91)(cid:89)(cid:107)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:76)(cid:95)(cid:89)(cid:91)(cid:3)(cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:34)(cid:3)(cid:69)(cid:102)(cid:91)(cid:104)(cid:87)(cid:106)(cid:95)(cid:101)(cid:100)(cid:105) Brenton Taylor (cid:59)(cid:110)(cid:91)(cid:89)(cid:107)(cid:106)(cid:95)(cid:108)(cid:91)(cid:3)(cid:76)(cid:95)(cid:89)(cid:91)(cid:3)(cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:34)(cid:3)(cid:59)(cid:100)(cid:93)(cid:95)(cid:100)(cid:91)(cid:91)(cid:104)(cid:95)(cid:100)(cid:93) Byron Myers (cid:76)(cid:95)(cid:89)(cid:91)(cid:3)(cid:70)(cid:104)(cid:91)(cid:105)(cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:34)(cid:3)(cid:67)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106)(cid:95)(cid:100)(cid:93) ANNUAL REPORT ON FORM 10-K (cid:73)(cid:106)(cid:101)(cid:89)(cid:97)(cid:94)(cid:101)(cid:98)(cid:90)(cid:91)(cid:104)(cid:105)(cid:3)(cid:99)(cid:87)(cid:111)(cid:3)(cid:104)(cid:91)(cid:89)(cid:91)(cid:95)(cid:108)(cid:91)(cid:3)(cid:87)(cid:3)(cid:89)(cid:101)(cid:102)(cid:111)(cid:3)(cid:101)(cid:92)(cid:3)(cid:101)(cid:107)(cid:104)(cid:3) annual report on Form 10-K, including (cid:106)(cid:94)(cid:91)(cid:3)(cid:211)(cid:100)(cid:87)(cid:100)(cid:89)(cid:95)(cid:87)(cid:98)(cid:3)(cid:105)(cid:106)(cid:87)(cid:106)(cid:91)(cid:99)(cid:91)(cid:100)(cid:106)(cid:105)(cid:3)(cid:87)(cid:100)(cid:90)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:211)(cid:100)(cid:87)(cid:100)(cid:89)(cid:95)(cid:87)(cid:98)(cid:3) statement schedules, free of charge upon (cid:106)(cid:94)(cid:91)(cid:3)(cid:109)(cid:104)(cid:95)(cid:106)(cid:106)(cid:91)(cid:100)(cid:3)(cid:104)(cid:91)(cid:103)(cid:107)(cid:91)(cid:105)(cid:106)(cid:3)(cid:101)(cid:92)(cid:3)(cid:87)(cid:100)(cid:111)(cid:3)(cid:105)(cid:107)(cid:89)(cid:94)(cid:3)(cid:102)(cid:91)(cid:104)(cid:105)(cid:101)(cid:100)(cid:36)(cid:3)(cid:3)(cid:55)(cid:98)(cid:98)(cid:3) (cid:105)(cid:107)(cid:89)(cid:94)(cid:3)(cid:104)(cid:91)(cid:103)(cid:107)(cid:91)(cid:105)(cid:106)(cid:105)(cid:3)(cid:105)(cid:94)(cid:87)(cid:98)(cid:98)(cid:3)(cid:88)(cid:91)(cid:3)(cid:105)(cid:91)(cid:100)(cid:106)(cid:3)(cid:106)(cid:101)(cid:3)(cid:63)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:34)(cid:3)(cid:63)(cid:100)(cid:89)(cid:36)(cid:34)(cid:3) (cid:63)(cid:100)(cid:108)(cid:91)(cid:105)(cid:106)(cid:101)(cid:104)(cid:3)(cid:72)(cid:91)(cid:98)(cid:87)(cid:106)(cid:95)(cid:101)(cid:100)(cid:105)(cid:3)(cid:58)(cid:91)(cid:102)(cid:87)(cid:104)(cid:106)(cid:99)(cid:91)(cid:100)(cid:106)(cid:34)(cid:3)(cid:41)(cid:40)(cid:44)(cid:3)(cid:56)(cid:101)(cid:98)(cid:98)(cid:87)(cid:111)(cid:3) (cid:58)(cid:104)(cid:95)(cid:108)(cid:91)(cid:34)(cid:3)(cid:61)(cid:101)(cid:98)(cid:91)(cid:106)(cid:87)(cid:34)(cid:3)(cid:57)(cid:87)(cid:98)(cid:95)(cid:92)(cid:101)(cid:104)(cid:100)(cid:95)(cid:87)(cid:3)(cid:47)(cid:41)(cid:39)(cid:39)(cid:45)(cid:36)(cid:3) CORPORATE HEADQUARTERS Inogen, Inc. (cid:41)(cid:40)(cid:44)(cid:3)(cid:56)(cid:101)(cid:98)(cid:98)(cid:87)(cid:111)(cid:3)(cid:58)(cid:104)(cid:95)(cid:108)(cid:91)(cid:3) (cid:61)(cid:101)(cid:98)(cid:91)(cid:106)(cid:87)(cid:34)(cid:3)(cid:57)(cid:87)(cid:98)(cid:95)(cid:92)(cid:101)(cid:104)(cid:100)(cid:95)(cid:87)(cid:3)(cid:47)(cid:41)(cid:39)(cid:39)(cid:45) (cid:74)(cid:48)(cid:3)(cid:30)(cid:46)(cid:38)(cid:43)(cid:31)(cid:3)(cid:43)(cid:44)(cid:40)(cid:35)(cid:38)(cid:43)(cid:38)(cid:38) www.inogen.com COMMON STOCK LISTING (cid:68)(cid:55)(cid:73)(cid:58)(cid:55)(cid:71)(cid:3)(cid:61)(cid:98)(cid:101)(cid:88)(cid:87)(cid:98)(cid:3)(cid:73)(cid:91)(cid:98)(cid:91)(cid:89)(cid:106)(cid:3)(cid:67)(cid:87)(cid:104)(cid:97)(cid:91)(cid:106) (cid:74)(cid:95)(cid:89)(cid:97)(cid:91)(cid:104)(cid:3)(cid:73)(cid:111)(cid:99)(cid:88)(cid:101)(cid:98)(cid:48)(cid:3)(cid:63)(cid:68)(cid:61)(cid:68) ANNUAL MEETING OF STOCKHOLDERS (cid:69)(cid:89)(cid:106)(cid:101)(cid:88)(cid:91)(cid:104)(cid:3)(cid:39)(cid:42)(cid:34)(cid:3)(cid:40)(cid:38)(cid:39)(cid:43)(cid:3)(cid:87)(cid:106)(cid:3)(cid:39)(cid:38)(cid:48)(cid:38)(cid:38)(cid:3)(cid:87)(cid:36)(cid:99)(cid:36) Inogen, Inc. (cid:41)(cid:40)(cid:44)(cid:3)(cid:56)(cid:101)(cid:98)(cid:98)(cid:87)(cid:111)(cid:3)(cid:58)(cid:104)(cid:95)(cid:108)(cid:91)(cid:3) (cid:61)(cid:101)(cid:98)(cid:91)(cid:106)(cid:87)(cid:34)(cid:3)(cid:57)(cid:87)(cid:98)(cid:95)(cid:92)(cid:101)(cid:104)(cid:100)(cid:95)(cid:87)(cid:3)(cid:47)(cid:41)(cid:39)(cid:39)(cid:45) REGISTRAR AND TRANSFER AGENT (cid:60)(cid:101)(cid:104)(cid:3)(cid:103)(cid:107)(cid:91)(cid:105)(cid:106)(cid:95)(cid:101)(cid:100)(cid:105)(cid:3)(cid:104)(cid:91)(cid:93)(cid:87)(cid:104)(cid:90)(cid:95)(cid:100)(cid:93)(cid:3)(cid:111)(cid:101)(cid:107)(cid:104)(cid:3)(cid:87)(cid:89)(cid:89)(cid:101)(cid:107)(cid:100)(cid:106)(cid:34)(cid:3) changes of address or the consolidation of (cid:87)(cid:89)(cid:89)(cid:101)(cid:107)(cid:100)(cid:106)(cid:105)(cid:34)(cid:3)(cid:102)(cid:98)(cid:91)(cid:87)(cid:105)(cid:91)(cid:3)(cid:89)(cid:101)(cid:100)(cid:106)(cid:87)(cid:89)(cid:106)(cid:3)(cid:106)(cid:94)(cid:91)(cid:3)(cid:57)(cid:101)(cid:99)(cid:102)(cid:87)(cid:100)(cid:111)(cid:202)(cid:105)(cid:3) transfer agent: (cid:57)(cid:101)(cid:99)(cid:102)(cid:107)(cid:106)(cid:91)(cid:104)(cid:105)(cid:94)(cid:87)(cid:104)(cid:91)(cid:3)(cid:63)(cid:100)(cid:108)(cid:91)(cid:105)(cid:106)(cid:101)(cid:104)(cid:3)(cid:73)(cid:91)(cid:104)(cid:108)(cid:95)(cid:89)(cid:91)(cid:105) (cid:70)(cid:36)(cid:69)(cid:36)(cid:3)(cid:56)(cid:101)(cid:110)(cid:3)(cid:41)(cid:38)(cid:39)(cid:45)(cid:38) (cid:57)(cid:101)(cid:98)(cid:98)(cid:91)(cid:93)(cid:91)(cid:3)(cid:73)(cid:106)(cid:87)(cid:106)(cid:95)(cid:101)(cid:100)(cid:34)(cid:3)(cid:74)(cid:78)(cid:3)(cid:45)(cid:45)(cid:46)(cid:42)(cid:40) (cid:74)(cid:48)(cid:3)(cid:30)(cid:46)(cid:45)(cid:45)(cid:31)(cid:3)(cid:41)(cid:45)(cid:41)(cid:3)(cid:44)(cid:41)(cid:45)(cid:42)(cid:3)(cid:30)(cid:75)(cid:36)(cid:73)(cid:36)(cid:31) (cid:74)(cid:48)(cid:3)(cid:30)(cid:45)(cid:46)(cid:39)(cid:31)(cid:3)(cid:43)(cid:45)(cid:43)(cid:35)(cid:42)(cid:40)(cid:41)(cid:46)(cid:3)(cid:30)(cid:63)(cid:100)(cid:106)(cid:91)(cid:104)(cid:100)(cid:87)(cid:106)(cid:95)(cid:101)(cid:100)(cid:87)(cid:98)(cid:31) (cid:109)(cid:109)(cid:109)(cid:36)(cid:89)(cid:101)(cid:99)(cid:102)(cid:107)(cid:106)(cid:91)(cid:104)(cid:105)(cid:94)(cid:87)(cid:104)(cid:91)(cid:36)(cid:89)(cid:101)(cid:99)(cid:37)(cid:95)(cid:100)(cid:108)(cid:91)(cid:105)(cid:106)(cid:101)(cid:104) LEGAL COUNSEL (cid:77)(cid:95)(cid:98)(cid:105)(cid:101)(cid:100)(cid:3)(cid:73)(cid:101)(cid:100)(cid:105)(cid:95)(cid:100)(cid:95)(cid:3)(cid:61)(cid:101)(cid:101)(cid:90)(cid:104)(cid:95)(cid:89)(cid:94)(cid:3)(cid:28)(cid:3)(cid:72)(cid:101)(cid:105)(cid:87)(cid:106)(cid:95)(cid:34)(cid:3) Professional Corporation San Diego, California INDEPENDENT AUDITORS (cid:58)(cid:91)(cid:98)(cid:101)(cid:95)(cid:106)(cid:106)(cid:91)(cid:3)(cid:28)(cid:3)(cid:74)(cid:101)(cid:107)(cid:89)(cid:94)(cid:91)(cid:3)(cid:66)(cid:66)(cid:70)(cid:3) (cid:66)(cid:101)(cid:105)(cid:3)(cid:55)(cid:100)(cid:93)(cid:91)(cid:98)(cid:91)(cid:105)(cid:34)(cid:3)(cid:57)(cid:87)(cid:98)(cid:95)(cid:92)(cid:101)(cid:104)(cid:100)(cid:95)(cid:87) INVESTOR RELATIONS Inogen, Inc. (cid:63)(cid:100)(cid:108)(cid:91)(cid:105)(cid:106)(cid:101)(cid:104)(cid:3)(cid:72)(cid:91)(cid:98)(cid:87)(cid:106)(cid:95)(cid:101)(cid:100)(cid:105)(cid:3)(cid:58)(cid:91)(cid:102)(cid:87)(cid:104)(cid:106)(cid:99)(cid:91)(cid:100)(cid:106) (cid:41)(cid:40)(cid:44)(cid:3)(cid:56)(cid:101)(cid:98)(cid:98)(cid:87)(cid:111)(cid:3)(cid:58)(cid:104)(cid:95)(cid:108)(cid:91) (cid:61)(cid:101)(cid:98)(cid:91)(cid:106)(cid:87)(cid:34)(cid:3)(cid:57)(cid:87)(cid:98)(cid:95)(cid:92)(cid:101)(cid:104)(cid:100)(cid:95)(cid:87)(cid:3)(cid:47)(cid:41)(cid:39)(cid:39)(cid:45)(cid:3) INTERNET ADDRESS INFORMATION (cid:76)(cid:95)(cid:105)(cid:95)(cid:106)(cid:3)(cid:107)(cid:105)(cid:3)(cid:101)(cid:100)(cid:98)(cid:95)(cid:100)(cid:91)(cid:3)(cid:87)(cid:106)(cid:3)(cid:109)(cid:109)(cid:109)(cid:36)(cid:95)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:36)(cid:89)(cid:101)(cid:99)(cid:3)(cid:92)(cid:101)(cid:104)(cid:3)(cid:99)(cid:101)(cid:104)(cid:91)(cid:3) information about Inogen. The 2014 Annual (cid:72)(cid:91)(cid:102)(cid:101)(cid:104)(cid:106)(cid:3)(cid:95)(cid:105)(cid:3)(cid:87)(cid:108)(cid:87)(cid:95)(cid:98)(cid:87)(cid:88)(cid:98)(cid:91)(cid:3)(cid:101)(cid:100)(cid:98)(cid:95)(cid:100)(cid:91)(cid:3)(cid:88)(cid:111)(cid:3)(cid:108)(cid:95)(cid:105)(cid:95)(cid:106)(cid:95)(cid:100)(cid:93)(cid:3)(cid:94)(cid:106)(cid:106)(cid:102)(cid:48)(cid:37)(cid:37) (cid:95)(cid:100)(cid:108)(cid:91)(cid:105)(cid:106)(cid:101)(cid:104)(cid:36)(cid:95)(cid:100)(cid:101)(cid:93)(cid:91)(cid:100)(cid:36)(cid:89)(cid:101)(cid:99)(cid:37)(cid:105)(cid:91)(cid:89)(cid:36)(cid:89)(cid:92)(cid:99) Special Note Regarding Forward-Looking Statements This 2014 Annual Report contains forward- looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. The forward-looking statements are contained principally in the sections entitled “Business” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements include information concerning our possible or assumed future results of operations, (cid:88)(cid:107)(cid:105)(cid:95)(cid:100)(cid:91)(cid:105)(cid:105)(cid:3)(cid:105)(cid:106)(cid:104)(cid:87)(cid:106)(cid:91)(cid:93)(cid:95)(cid:91)(cid:105)(cid:34)(cid:3)(cid:211)(cid:100)(cid:87)(cid:100)(cid:89)(cid:95)(cid:100)(cid:93)(cid:3)(cid:102)(cid:98)(cid:87)(cid:100)(cid:105)(cid:34)(cid:3) competitive position, industry environment, potential growth opportunities and market growth expectations, new product launches, and the effects of competition. Forward- looking statements include statements that are not historical facts and can be (cid:95)(cid:90)(cid:91)(cid:100)(cid:106)(cid:95)(cid:211)(cid:91)(cid:90)(cid:3)(cid:88)(cid:111)(cid:3)(cid:106)(cid:91)(cid:104)(cid:99)(cid:105)(cid:3)(cid:105)(cid:107)(cid:89)(cid:94)(cid:3)(cid:87)(cid:105)(cid:3)(cid:199)(cid:87)(cid:100)(cid:106)(cid:95)(cid:89)(cid:95)(cid:102)(cid:87)(cid:106)(cid:91)(cid:105)(cid:34)(cid:200)(cid:3) “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Given these uncertainties, you should not place undue reliance on any forward-looking statements. In particular, Inogen, Inc. (“Inogen”) cannot predict its future revenues or operating results or its future rates of revenue growth, if any. Inogen’s business, revenues, and operating results as well as its rate of revenue growth, if any, will be subject to numerous risks and uncertainties, including (among others) risks arising from the possibility that Inogen will not realize anticipated revenue; the impact of reduced reimbursement rates, including in connection with the implementation of the competitive bidding and the newly released Center for Medicare and Medicaid Services (CMS) rules; the possible loss of key employees, customers, or suppliers; intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products; and risks relating to a recently (cid:211)(cid:98)(cid:91)(cid:90)(cid:3)(cid:105)(cid:91)(cid:89)(cid:107)(cid:104)(cid:95)(cid:106)(cid:95)(cid:91)(cid:105)(cid:3)(cid:89)(cid:98)(cid:87)(cid:105)(cid:105)(cid:3)(cid:87)(cid:89)(cid:106)(cid:95)(cid:101)(cid:100)(cid:3)(cid:98)(cid:87)(cid:109)(cid:105)(cid:107)(cid:95)(cid:106)(cid:3)(cid:87)(cid:93)(cid:87)(cid:95)(cid:100)(cid:105)(cid:106)(cid:3) us and certain members of our executive management team in United States District Court for the Central District of California. In addition, Inogen’s business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; its ability to successfully launch new products and applications; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. In addition, investors in Inogen should review the more detailed discussions of risks and uncertainties affecting our business described under the caption “Risk factors” in (cid:101)(cid:107)(cid:104)(cid:3)(cid:55)(cid:100)(cid:100)(cid:107)(cid:87)(cid:98)(cid:3)(cid:72)(cid:91)(cid:102)(cid:101)(cid:104)(cid:106)(cid:3)(cid:101)(cid:100)(cid:3)(cid:60)(cid:101)(cid:104)(cid:99)(cid:3)(cid:39)(cid:38)(cid:35)(cid:65)(cid:3)(cid:211)(cid:98)(cid:91)(cid:90)(cid:3)(cid:109)(cid:95)(cid:106)(cid:94)(cid:3) the Securities and Exchange Commission on April 27, 2014 and supplemented in our subsequent Quarterly Reports on Form 10-Q. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Inogen, Inc. 326 Bollay Dr Goleta, CA 93117 www.inogen.com

Continue reading text version or see original annual report in PDF format above